0001410578-24-00197810-Q Marker Therapeutics, Inc. 20241114202411141605421605431605430 0001410578-24-001978 10-Q 66 20240930 20241114 20241114 Marker Therapeutics, Inc. 0001094038 2834 880277072 DE 1231 10-Q 34 001-37939 241461916 2450 HOLCOMBE BLVD SUITE BCM-A, MS: BCM251 HOUSTON TX 77021 (713) 400-6400 2450 HOLCOMBE BLVD SUITE BCM-A, MS: BCM251 HOUSTON TX 77021 TAPIMMUNE INC. 20170629 TAPIMMUNE INC 20070628 GENEMAX CORP 20020718 10-Q 1 mrkr-20240930x10q.htm 10-Q
http://fasb.org/us-gaap/2024#RelatedPartyMember0001094038--12-31Q3DEhttp://fasb.org/us-gaap/2024#RelatedPartyMember58501false0001094038us-gaap:AdditionalPaidInCapitalMember2024-07-012024-09-300001094038us-gaap:AdditionalPaidInCapitalMember2024-01-012024-09-300001094038us-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-300001094038us-gaap:CommonStockMember2024-07-012024-09-300001094038us-gaap:CommonStockMember2024-01-012024-09-300001094038us-gaap:CommonStockMember2023-07-012023-09-300001094038us-gaap:CommonStockMember2023-01-012023-09-300001094038us-gaap:RetainedEarningsMember2024-09-300001094038us-gaap:AdditionalPaidInCapitalMember2024-06-300001094038us-gaap:RetainedEarningsMember2024-06-300001094038us-gaap:AdditionalPaidInCapitalMember2024-06-300001094038us-gaap:RetainedEarningsMember2023-12-310001094038us-gaap:AdditionalPaidInCapitalMember2023-12-310001094038us-gaap:RetainedEarningsMember2023-09-300001094038us-gaap:AdditionalPaidInCapitalMember2023-09-300001094038us-gaap:RetainedEarningsMember2023-06-300001094038us-gaap:AdditionalPaidInCapitalMember2023-06-300001094038us-gaap:RetainedEarningsMember2022-12-310001094038us-gaap:AdditionalPaidInCapitalMember2022-12-310001094038us-gaap:CommonStockMember2024-09-300001094038us-gaap:CommonStockMember2024-06-300001094038us-gaap:CommonStockMember2023-12-310001094038us-gaap:CommonStockMember2023-09-300001094038us-gaap:CommonStockMember2023-06-300001094038us-gaap:CommonStockMember2022-12-310001094038us-gaap:EmployeeStockOptionMember2023-01-012023-12-310001094038us-gaap:EmployeeStockOptionMember2023-12-310001094038us-gaap:EmployeeStockOptionMember2024-01-012024-09-300001094038us-gaap:EmployeeStockOptionMember2024-09-300001094038us-gaap:EmployeeStockOptionMember2023-04-012023-06-300001094038mrkr:NationalInstitutesOfHealthSmallBusinessInnovationResearchForLymphomaGrantMember2024-07-012024-09-300001094038mrkr:CpritGrantMember2024-07-012024-09-300001094038mrkr:CancerPreventionAndResearchInstituteOfTexasMember2024-07-012024-09-300001094038mrkr:CpritGrantMember2024-01-012024-09-300001094038mrkr:CancerPreventionAndResearchInstituteOfTexasMember2024-01-012024-09-300001094038us-gaap:GrantMember2023-07-012023-09-300001094038us-gaap:GrantMember2023-01-012023-09-300001094038mrkr:CpritGrantMember2023-12-310001094038mrkr:CpritGrantMember2021-08-012021-08-310001094038mrkr:CantorFitzgeraldCo.AndRbcCapitalMarketsLlcMembermrkr:ControlledEquityOfferingSalesAgreementMember2024-01-012024-09-300001094038mrkr:AtmAgreementMember2024-01-012024-09-300001094038mrkr:LincolnParkMembermrkr:StockPurchaseAgreementMember2023-01-012023-09-300001094038mrkr:AtmAgreementMember2023-01-012023-09-300001094038mrkr:CancerPreventionAndResearchInstituteOfTexasMember2024-09-300001094038mrkr:CellReadyMemberus-gaap:RelatedPartyMember2024-09-300001094038mrkr:CellReadyMemberus-gaap:RelatedPartyMember2023-12-310001094038mrkr:CellReadyMember2024-07-012024-09-300001094038mrkr:ClinicalTrialAgreementWithBaylorCollegeOfMedicineMember2024-01-012024-09-300001094038mrkr:CellReadyMember2024-01-012024-09-300001094038mrkr:CellReadyMember2023-07-012023-09-300001094038mrkr:WilsonWolfManufacturingCorporationMember2023-01-012023-09-300001094038mrkr:ClinicalTrialAgreementWithBaylorCollegeOfMedicineMember2023-01-012023-09-300001094038mrkr:CellReadyMember2023-01-012023-09-300001094038us-gaap:RetainedEarningsMember2024-07-012024-09-300001094038us-gaap:RetainedEarningsMember2024-01-012024-09-300001094038us-gaap:RetainedEarningsMember2023-07-012023-09-300001094038us-gaap:RetainedEarningsMember2023-01-012023-09-300001094038mrkr:CpritGrantMember2024-09-300001094038mrkr:NationalInstitutesOfHealthSmallBusinessInnovationResearchMember2024-08-310001094038mrkr:NationalInstitutesOfHealthSmallBusinessInnovationResearchMember2023-05-310001094038mrkr:FdaGrantMember2022-09-300001094038us-gaap:ServiceMember2023-01-012023-09-300001094038mrkr:RelatedPartyServiceMember2023-01-012023-09-300001094038us-gaap:DiscontinuedOperationsDisposedOfBySaleMembermrkr:CellReadyAgreementMember2023-06-260001094038mrkr:CellReadyAgreementMember2023-06-260001094038mrkr:ControlledEquityOfferingSalesAgreementMember2021-08-310001094038srt:MinimumMember2023-01-260001094038srt:MaximumMember2023-01-260001094038mrkr:CellReadyMemberus-gaap:RelatedPartyMember2024-09-300001094038mrkr:CellReadyMemberus-gaap:RelatedPartyMember2023-12-310001094038mrkr:CellReadyMember2024-07-012024-09-300001094038mrkr:ClinicalTrialAgreementWithBaylorCollegeOfMedicineMember2024-01-012024-09-300001094038mrkr:CellReadyMember2024-01-012024-09-300001094038mrkr:CellReadyMember2023-07-012023-09-300001094038mrkr:WilsonWolfManufacturingCorporationMember2023-01-012023-09-300001094038mrkr:ClinicalTrialAgreementWithBaylorCollegeOfMedicineMember2023-01-012023-09-300001094038mrkr:CellReadyMember2023-01-012023-09-300001094038us-gaap:RetainedEarningsMember2024-07-012024-09-300001094038us-gaap:RetainedEarningsMember2024-01-012024-09-300001094038us-gaap:RetainedEarningsMember2023-07-012023-09-300001094038us-gaap:RetainedEarningsMember2023-01-012023-09-300001094038mrkr:CpritGrantMember2024-09-300001094038mrkr:NationalInstitutesOfHealthSmallBusinessInnovationResearchMember2024-08-310001094038mrkr:NationalInstitutesOfHealthSmallBusinessInnovationResearchMember2023-05-310001094038mrkr:FdaGrantMember2022-09-300001094038us-gaap:ServiceMember2023-01-012023-09-300001094038mrkr:RelatedPartyServiceMember2023-01-012023-09-300001094038us-gaap:DiscontinuedOperationsDisposedOfBySaleMembermrkr:CellReadyAgreementMember2023-06-260001094038mrkr:CellReadyAgreementMember2023-06-260001094038mrkr:ControlledEquityOfferingSalesAgreementMember2021-08-310001094038srt:MinimumMember2023-01-260001094038srt:MaximumMember2023-01-260001094038mrkr:CellReadyMemberus-gaap:RelatedPartyMember2024-09-300001094038mrkr:CellReadyMemberus-gaap:RelatedPartyMember2023-12-310001094038mrkr:CellReadyMember2024-07-012024-09-300001094038mrkr:ClinicalTrialAgreementWithBaylorCollegeOfMedicineMember2024-01-012024-09-300001094038mrkr:CellReadyMember2024-01-012024-09-300001094038mrkr:CellReadyMember2023-07-012023-09-300001094038mrkr:WilsonWolfManufacturingCorporationMember2023-01-012023-09-300001094038mrkr:ClinicalTrialAgreementWithBaylorCollegeOfMedicineMember2023-01-012023-09-300001094038mrkr:CellReadyMember2023-01-012023-09-300001094038us-gaap:RetainedEarningsMember2024-07-012024-09-300001094038us-gaap:RetainedEarningsMember2024-01-012024-09-300001094038us-gaap:RetainedEarningsMember2023-07-012023-09-300001094038us-gaap:RetainedEarningsMember2023-01-012023-09-300001094038mrkr:CpritGrantMember2024-09-300001094038mrkr:NationalInstitutesOfHealthSmallBusinessInnovationResearchMember2024-08-310001094038mrkr:NationalInstitutesOfHealthSmallBusinessInnovationResearchMember2023-05-310001094038mrkr:FdaGrantMember2022-09-300001094038us-gaap:ServiceMember2023-01-012023-09-300001094038mrkr:RelatedPartyServiceMember2023-01-012023-09-300001094038us-gaap:DiscontinuedOperationsDisposedOfBySaleMembermrkr:CellReadyAgreementMember2023-06-260001094038us-gaap:AdditionalPaidInCapitalMember2023-01-012023-09-300001094038us-gaap:CommonStockMember2023-01-012023-09-300001094038mrkr:CellReadyAgreementMember2024-07-012024-09-300001094038mrkr:CellReadyAgreementMember2024-01-012024-09-300001094038mrkr:NationalInstitutesOfHealthSmallBusinessInnovationResearchMember2024-08-012024-08-310001094038mrkr:NationalInstitutesOfHealthSmallBusinessInnovationResearchMember2023-05-012023-05-310001094038mrkr:FdaGrantMember2022-09-012022-09-300001094038mrkr:NationalInstitutesOfHealthNationalCancerInstituteGrantMember2024-06-012024-06-300001094038mrkr:NationalInstitutesOfHealthSmallBusinessInnovationResearchForLymphomaGrantMemberus-gaap:SubsequentEventMember2024-10-012024-10-310001094038mrkr:FdaGrantMemberus-gaap:SubsequentEventMember2024-10-012024-10-310001094038us-gaap:GrantMember2024-01-012024-09-300001094038mrkr:NationalInstitutesOfHealthSmallBusinessInnovationResearchMember2024-01-012024-09-300001094038mrkr:NationalInstitutesOfHealthSmallBusinessInnovationResearchForLymphomaGrantMember2024-01-012024-09-300001094038mrkr:FdaGrantMember2024-01-012024-09-300001094038mrkr:NationalInstitutesOfHealthSmallBusinessInnovationResearchMemberus-gaap:SubsequentEventMember2024-10-012024-10-310001094038mrkr:CantorFitzgeraldCo.AndRbcCapitalMarketsLlcMembermrkr:ControlledEquityOfferingSalesAgreementMember2021-08-012021-08-310001094038mrkr:LincolnParkMembermrkr:StockPurchaseAgreementMember2023-01-012023-01-310001094038mrkr:RelatedPartyServiceMembermrkr:WilsonWolfManufacturingCorporationMembermrkr:BindingServicesAgreementMember2022-04-012022-04-300001094038mrkr:RelatedPartyServiceMembermrkr:WilsonWolfManufacturingCorporationMembermrkr:BindingServicesAgreementMember2023-03-012023-03-310001094038mrkr:RelatedPartyServiceMembermrkr:WilsonWolfManufacturingCorporationMembermrkr:BindingServicesAgreementMember2023-05-012023-05-310001094038mrkr:AtmAgreementMember2024-12-310001094038mrkr:AtmAgreementMember2024-07-012024-09-300001094038mrkr:AtmAgreementMember2024-01-012024-09-300001094038mrkr:AtmAgreementMember2023-12-310001094038mrkr:AtmAgreementMember2023-07-012023-09-300001094038mrkr:AtmAgreementMember2023-01-012023-09-300001094038mrkr:AtmAgreementMember2022-12-310001094038mrkr:AtmAgreementMember2022-07-012022-09-300001094038mrkr:AtmAgreementMember2022-01-012022-09-300001094038mrkr:AtmAgreementMember2021-08-012021-08-310001094038mrkr:AtmAgreementMember2021-01-012021-09-300001094038mrkr:AtmAgreementMember2020-12-012020-12-310001094038mrkr:AtmAgreementMember2020-07-012020-09-300001094038mrkr:AtmAgreementMember2020-01-012020-09-300001094038mrkr:AtmAgreementMember2019-12-012019-12-310001094038mrkr:AtmAgreementMember2019-07-012019-09-300001094038mrkr:AtmAgreementMember2019-01-012019-09-300001094038mrkr:AtmAgreementMember2018-12-012018-12-310001094038mrkr:AtmAgreementMember2018-07-012018-09-300001094038mrkr:AtmAgreementMember2018-01-012018-09-300001094038mrkr:AtmAgreementMember2017-12-012017-12-310001094038mrkr:AtmAgreementMember2017-07-012017-09-300001094038mrkr:AtmAgreementMember2017-01-012017-09-300001094038mrkr:AtmAgreementMember2016-12-012016-12-310001094038mrkr:AtmAgreementMember2016-07-012016-09-300001094038mrkr:AtmAgreementMember2016-01-012016-09-300001094038mrkr:AtmAgreementMember2015-12-012015-12-310001094038mrkr:AtmAgreementMember2015-07-012015-09-300001094038mrkr:AtmAgreementMember2015-01-012015-09-300001094038mrkr:AtmAgreementMember2014-12-012014-12-310001094038mrkr:AtmAgreementMember2014-07-012014-09-300001094038mrkr:AtmAgreementMember2014-01-012014-09-300001094038mrkr:AtmAgreementMember2013-12-012013-12-310001094038mrkr:AtmAgreementMember2013-07-012013-09-300001094038mrkr:AtmAgreementMember2013-01-012013-09-300001094038mrkr:AtmAgreementMember2012-12-012012-12-310001094038mrkr:AtmAgreementMember2012-07-012012-09-300001094038mrkr:AtmAgreementMember2012-01-012012-09-300001094038mrkr:AtmAgreementMember2011-12-012011-12-310001094038mrkr:AtmAgreementMember2011-07-012011-09-300001094038mrkr:AtmAgreementMember2011-01-012011-09-300001094038mrkr:AtmAgreementMember2010-12-012010-12-310001094038mrkr:AtmAgreementMember2010-07-012010-09-300001094038mrkr:AtmAgreementMember2010-01-012010-09-300001094038mrkr:AtmAgreementMember2009-12-012009-12-310001094038mrkr:AtmAgreementMember2009-07-012009-09-300001094038mrkr:AtmAgreementMember2009-01-012009-09-300001094038mrkr:AtmAgreementMember2008-12-012008-12-310001094038mrkr:AtmAgreementMember2008-07-012008-09-300001094038mrkr:AtmAgreementMember2008-01-012008-09-300001094038mrkr:AtmAgreementMember2007-12-012007-12-310001094038mrkr:AtmAgreementMember2007-07-012007-09-300001094038mrkr:AtmAgreementMember2007-01-012007-09-300001094038mrkr:AtmAgreementMember2006-12-012006-12-310001094038mrkr:AtmAgreementMember2006-07-012006-09-300001094038mrkr:AtmAgreementMember2006-01-012006-09-300001094038mrkr:AtmAgreementMember2005-12-012005-12-310001094038mrkr:AtmAgreementMember2005-07-012005-09-300001094038mrkr:AtmAgreementMember2005-01-012005-09-300001094038mrkr:AtmAgreementMember2004-12-012004-12-310001094038mrkr:AtmAgreementMember2004-07-012004-09-300001094038mrkr:AtmAgreementMember2004-01-012004-09-300001094038mrkr:AtmAgreementMember2003-12-012003-12-310001094038mrkr:AtmAgreementMember2003-07-012003-09-300001094038mrkr:AtmAgreementMember2003-01-012003-09-300001094038mrkr:AtmAgreementMember2002-12-012002-12-310001094038mrkr:AtmAgreementMember2002-07-012002-09-300001094038mrkr:AtmAgreementMember2002-01-012002-09-300001094038mrkr:AtmAgreementMember2001-12-012001-12-310001094038mrkr:AtmAgreementMember2001-07-012001-09-300001094038mrkr:AtmAgreementMember2001-01-012001-09-300001094038mrkr:AtmAgreementMember2000-12-012000-12-310001094038mrkr:AtmAgreementMember2000-07-012000-09-300001094038mrkr:AtmAgreementMember2000-01-012000-09-300001094038mrkr:AtmAgreementMember1999-12-011999-12-310001094038mrkr:AtmAgreementMember1999-07-011999-09-300001094038mrkr:AtmAgreementMember1999-01-011999-09-300001094038mrkr:AtmAgreementMember1998-12-011998-12-310001094038mrkr:AtmAgreementMember1998-07-011998-09-300001094038mrkr:AtmAgreementMember1998-01-011998-09-300001094038mrkr:AtmAgreementMember1997-12-011997-12-310001094038mrkr:AtmAgreementMember1997-07-011997-09-300001094038mrkr:AtmAgreementMember1997-01-011997-09-300001094038mrkr:AtmAgreementMember1996-12-011996-12-310001094038mrkr:AtmAgreementMember1996-07-011996-09-300001094038mrkr:AtmAgreementMember1996-01-011996-09-300001094038mrkr:AtmAgreementMember1995-12-011995-12-310001094038mrkr:AtmAgreementMember1995-07-011995-09-300001094038mrkr:AtmAgreementMember1995-01-011995-09-300001094038mrkr:AtmAgreementMember1994-12-011994-12-310001094038mrkr:AtmAgreementMember1994-07-011994-09-300001094038mrkr:AtmAgreementMember1994-01-011994-09-300001094038mrkr:AtmAgreementMember1993-12-011993-12-310001094038mrkr:AtmAgreementMember1993-07-011993-09-300001094038mrkr:AtmAgreementMember1993-01-011993-09-300001094038mrkr:AtmAgreementMember1992-12-011992-12-310001094038mrkr:AtmAgreementMember1992-07-011992-09-300001094038mrkr:AtmAgreementMember1992-01-011992-09-300001094038mrkr:AtmAgreementMember1991-12-011991-12-310001094038mrkr:AtmAgreementMember1991-07-011991-09-300001094038mrkr:AtmAgreementMember1991-01-011991-09-300001094038mrkr:AtmAgreementMember1990-12-011990-12-310001094038mrkr:AtmAgreementMember1990-07-011990-09-300001094038mrkr:AtmAgreementMember1990-01-011990-09-300001094038mrkr:AtmAgreementMember1989-12-011989-12-310001094038mrkr:AtmAgreementMember1989-07-011989-09-300001094038mrkr:AtmAgreementMember1989-01-011989-09-300001094038mrkr:AtmAgreementMember1988-12-011988-12-310001094038mrkr:AtmAgreementMember1988-07-011988-09-300001094038mrkr:AtmAgreementMember1988-01-011988-09-300001094038mrkr:AtmAgreementMember1987-12-011987-12-310001094038mrkr:AtmAgreementMember1987-07-011987-09-300001094038mrkr:AtmAgreementMember1987-01-011987-09-300001094038mrkr:AtmAgreementMember1986-12-011986-12-310001094038mrkr:AtmAgreementMember1986-07-011986-09-300001094038mrkr:AtmAgreementMember1986-01-011986-09-300001094038mrkr:AtmAgreementMember1985-12-011985-12-310001094038mrkr:AtmAgreementMember1985-07-011985-09-300001094038mrkr:AtmAgreementMember1985-01-011985-09-300001094038mrkr:AtmAgreementMember1984-12-011984-12-310001094038mrkr:AtmAgreementMember1984-07-011984-09-300001094038mrkr:AtmAgreementMember1984-01-011984-09-300001094038mrkr:AtmAgreementMember1983-12-011983-12-310001094038mrkr:AtmAgreementMember1983-07-011983-09-300001094038mrkr:AtmAgreementMember1983-01-011983-09-300001094038mrkr:AtmAgreementMember1982-12-011982-12-310001094038mrkr:AtmAgreementMember1982-07-011982-09-300001094038mrkr:AtmAgreementMember1982-01-011982-09-300001094038mrkr:AtmAgreementMember1981-12-011981-12-310001094038mrkr:AtmAgreementMember1981-07-011981-09-300001094038mrkr:AtmAgreementMember1981-01-011981-09-300001094038mrkr:AtmAgreementMember1980-12-011980-12-310001094038mrkr:AtmAgreementMember1980-07-011980-09-300001094038mrkr:AtmAgreementMember1980-01-011980-09-300001094038mrkr:AtmAgreementMember1979-12-011979-12-310001094038mrkr:AtmAgreementMember1979-07-011979-09-300001094038mrkr:AtmAgreementMember1979-01-011979-09-300001094038mrkr:AtmAgreementMember1978-12-011978-12-310001094038mrkr:AtmAgreementMember1978-07-011978-09-300001094038mrkr:AtmAgreementMember1978-01-011978-09-300001094038mrkr:AtmAgreementMember1977-12-011977-12-310001094038mrkr:AtmAgreementMember1977-07-011977-09-300001094038mrkr:AtmAgreementMember1977-01-011977-09-300001094038mrkr:AtmAgreementMember1976-12-011976-12-310001094038mrkr:AtmAgreementMember1976-07-011976-09-300001094038mrkr:AtmAgreementMember1976-01-011976-09-300001094038mrkr:AtmAgreementMember1975-12-011975-12-310001094038mrkr:AtmAgreementMember1975-07-011975-09-300001094038mrkr:AtmAgreementMember1975-01-011975-09-300001094038mrkr:AtmAgreementMember1974-12-011974-12-310001094038mrkr:AtmAgreementMember1974-07-011974-09-300001094038mrkr:AtmAgreementMember1974-01-011974-09-300001094038mrkr:AtmAgreementMember1973-12-011973-12-310001094038mrkr:AtmAgreementMember1973-07-011973-09-300001094038mrkr:AtmAgreementMember1973-01-011973-09-300001094038mrkr:AtmAgreementMember1972-12-011972-12-310001094038mrkr:AtmAgreementMember1972-07-011972-09-300001094038mrkr:AtmAgreementMember1972-01-011972-09-300001094038mrkr:AtmAgreementMember1971-12-011971-12-310001094038mrkr:AtmAgreementMember1971-07-011971-09-300001094038mrkr:AtmAgreementMember1971-01-011971-09-300001094038mrkr:AtmAgreementMember1970-12-011970-12-310001094038mrkr:AtmAgreementMember1970-07-011970-09-300001094038mrkr:AtmAgreementMember1970-01-011970-09-300001094038mrkr:AtmAgreementMember1969-12-011969-12-310001094038mrkr:AtmAgreementMember1969-07-011969-09-300001094038mrkr:AtmAgreementMember1969-01-011969-09-300001094038mrkr:AtmAgreementMember1968-12-011968-12-310001094038mrkr:AtmAgreementMember1968-07-011968-09-300001094038mrkr:AtmAgreementMember1968-01-011968-09-300001094038mrkr:AtmAgreementMember1967-12-011967-12-310001094038mrkr:AtmAgreementMember1967-07-011967-09-300001094038mrkr:AtmAgreementMember1967-01-011967-09-300001094038mrkr:AtmAgreementMember1966-12-011966-12-310001094038mrkr:AtmAgreementMember1966-07-011966-09-300001094038mrkr:AtmAgreementMember1966-01-011966-09-300001094038mrkr:AtmAgreementMember1965-12-011965-12-310001094038mrkr:AtmAgreementMember1965-07-011965-09-300001094038mrkr:AtmAgreementMember1965-01-011965-09-300001094038mrkr:AtmAgreementMember1964-12-011964-12-310001094038mrkr:AtmAgreementMember1964-07-011964-09-300001094038mrkr:AtmAgreementMember1964-01-011964-09-300001094038mrkr:AtmAgreementMember1963-12-011963-12-310001094038mrkr:AtmAgreementMember1963-07-011963-09-300001094038mrkr:AtmAgreementMember1963-01-011963-09-300001094038mrkr:AtmAgreementMember1962-12-011962-12-310001094038mrkr:AtmAgreementMember1962-07-011962-09-300001094038mrkr:AtmAgreementMember1962-01-011962-09-300001094038mrkr:AtmAgreementMember1961-12-011961-12-310001094038mrkr:AtmAgreementMember1961-07-011961-09-300001094038mrkr:AtmAgreementMember1961-01-011961-09-300001094038mrkr:AtmAgreementMember1960-12-011960-12-310001094038mrkr:AtmAgreementMember1960-07-011960-09-300001094038mrkr:AtmAgreementMember1960-01-011960-09-300001094038mrkr:AtmAgreementMember1959-12-011959-12-310001094038mrkr:AtmAgreementMember1959-07-011959-09-300001094038mrkr:AtmAgreementMember1959-01-011959-09-300001094038mrkr:AtmAgreementMember1958-12-011958-12-310001094038mrkr:AtmAgreementMember1958-07-011958-09-300001094038mrkr:AtmAgreementMember1958-01-011958-09-300001094038mrkr:AtmAgreementMember1957-12-011957-12-310001094038mrkr:AtmAgreementMember1957-07-011957-09-300001094038mrkr:AtmAgreementMember1957-01-011957-09-300001094038mrkr:AtmAgreementMember1956-12-011956-12-310001094038mrkr:AtmAgreementMember1956-07-011956-09-300001094038mrkr:AtmAgreementMember1956-01-011956-09-300001094038mrkr:AtmAgreementMember1955-12-011955-12-310001094038mrkr:AtmAgreementMember1955-07-011955-09-300001094038mrkr:AtmAgreementMember1955-01-011955-09-300001094038mrkr:AtmAgreementMember1954-12-011954-12-310001094038mrkr:AtmAgreementMember1954-07-011954-09-300001094038mrkr:AtmAgreementMember1954-01-011954-09-300001094038mrkr:AtmAgreementMember1953-12-011953-12-310001094038mrkr:AtmAgreementMember1953-07-011953-09-300001094038mrkr:AtmAgreementMember1953-01-011953-09-300001094038mrkr:AtmAgreementMember1952-12-011952-12-310001094038mrkr:AtmAgreementMember1952-07-011952-09-300001094038mrkr:AtmAgreementMember1952-01-011952-09-300001094038mrkr:AtmAgreementMember1951-12-011951-12-310001094038mrkr:AtmAgreementMember1951-07-011951-09-300001094038mrkr:AtmAgreementMember1951-01-011951-09-300001094038mrkr:AtmAgreementMember1950-12-011950-12-310001094038mrkr:AtmAgreementMember1950-07-011950-09-300001094038mrkr:AtmAgreementMember1950-01-011950-09-300001094038mrkr:AtmAgreementMember1949-12-011949-12-310001094038mrkr:AtmAgreementMember1949-07-011949-09-300001094038mrkr:AtmAgreementMember1949-01-011949-09-300001094038mrkr:AtmAgreementMember1948-12-011948-12-310001094038mrkr:AtmAgreementMember1948-07-011948-09-300001094038mrkr:AtmAgreementMember1948-01-011948-09-300001094038mrkr:AtmAgreementMember1947-12-011947-12-310001094038mrkr:AtmAgreementMember1947-07-011947-09-300001094038mrkr:AtmAgreementMember1947-01-011947-09-300001094038mrkr:AtmAgreementMember1946-12-011946-12-310001094038mrkr:AtmAgreementMember1946-07-011946-09-300001094038mrkr:AtmAgreementMember1946-01-011946-09-300001094038mrkr:AtmAgreementMember1945-12-011945-12-310001094038mrkr:AtmAgreementMember1945-07-011945-09-300001094038mrkr:AtmAgreementMember1945-01-011945-09-300001094038mrkr:AtmAgreementMember1944-12-011944-12-310001094038mrkr:AtmAgreementMember1944-07-011944-09-300001094038mrkr:AtmAgreementMember1944-01-011944-09-300001094038mrkr:AtmAgreementMember1943-12-011943-12-310001094038mrkr:AtmAgreementMember1943-07-011943-09-300001094038mrkr:AtmAgreementMember1943-01-011943-09-300001094038mrkr:AtmAgreementMember1942-12-011942-12-310001094038mrkr:AtmAgreementMember1942-07-011942-09-300001094038mrkr:AtmAgreementMember1942-01-011942-09-300001094038mrkr:AtmAgreementMember1941-12-011941-12-310001094038mrkr:AtmAgreementMember1941-07-011941-09-300001094038mrkr:AtmAgreementMember1941-01-011941-09-300001094038mrkr:AtmAgreementMember1940-12-011940-12-310001094038mrkr:AtmAgreementMember1940-07-011940-09-300001094038mrkr:AtmAgreementMember1940-01-011940-09-300001094038mrkr:AtmAgreementMember1939-12-011939-12-310001094038mrkr:AtmAgreementMember1939-07-011939-09-300001094038mrkr:AtmAgreementMember1939-01-011939-09-300001094038mrkr:AtmAgreementMember1938-12-011938-12-310001094038mrkr:AtmAgreementMember1938-07-011938-09-300001094038mrkr:AtmAgreementMember1938-01-011938-09-300001094038mrkr:AtmAgreementMember1937-12-011937-12-310001094038mrkr:AtmAgreementMember1937-07-011937-09-300001094038mrkr:AtmAgreementMember1937-01-011937-09-300001094038mrkr:AtmAgreementMember1936-12-011936-12-310001094038mrkr:AtmAgreementMember1936-07-011936-09-300001094038mrkr:AtmAgreementMember1936-01-011936-09-300001094038mrkr:AtmAgreementMember1935-12-011935-12-310001094038mrkr:AtmAgreementMember1935-07-011935-09-300001094038mrkr:AtmAgreementMember1935-01-011935-09-300001094038mrkr:AtmAgreementMember1934-12-011934-12-310001094038mrkr:AtmAgreementMember1934-07-011934-09-300001094038mrkr:AtmAgreementMember1934-01-011934-09-300001094038mrkr:AtmAgreementMember1933-12-011933-12-310001094038mrkr:AtmAgreementMember1933-07-011933-09-300001094038mrkr:AtmAgreementMember1933-01-011933-09-300001094038mrkr:AtmAgreementMember1932-12-011932-12-310001094038mrkr:AtmAgreementMember1932-07-011932-09-300001094038mrkr:AtmAgreementMember1932-01-011932-09-300001094038mrkr:AtmAgreementMember1931-12-011931-12-310001094038mrkr:AtmAgreementMember1931-07-011931-09-300001094038mrkr:AtmAgreementMember1931-01-011931-09-300001094038mrkr:AtmAgreementMember1930-12-011930-12-310001094038mrkr:AtmAgreementMember1930-07-011930-09-300001094038mrkr:AtmAgreementMember1930-01-011930-09-300001094038mrkr:AtmAgreementMember1929-12-011929-12-310001094038mrkr:AtmAgreementMember1929-07-011929-09-300001094038mrkr:AtmAgreementMember1929-01-011929-09-300001094038mrkr:AtmAgreementMember1928-12-011928-12-310001094038mrkr:AtmAgreementMember1928-07-011928-09-300001094038mrkr:AtmAgreementMember1928-01-011928-09-300001094038mrkr:AtmAgreementMember1927-12-011927-12-310001094038mrkr:AtmAgreementMember1927-07-011927-09-300001094038mrkr:AtmAgreementMember1927-01-011927-09-300001094038mrkr:AtmAgreementMember1926-12-011926-12-310001094038mrkr:AtmAgreementMember1926-07-011926-09-300001094038mrkr:AtmAgreementMember1926-01-011926-09-300001094038mrkr:AtmAgreementMember1925-12-011925-12-310001094038mrkr:AtmAgreementMember1925-07-011925-09-300001094038mrkr:AtmAgreementMember1925-01-011925-09-300001094038mrkr:AtmAgreementMember1924-12-011924-12-310001094038mrkr:AtmAgreementMember1924-07-011924-09-300001094038mrkr:AtmAgreementMember1924-01-011924-09-300001094038mrkr:AtmAgreementMember1923-12-011923-12-310001094038mrkr:AtmAgreementMember1923-07-011923-09-300001094038mrkr:AtmAgreementMember1923-01-011923-09-300001094038mrkr:AtmAgreementMember1922-12-011922-12-310001094038mrkr:AtmAgreementMember1922-07-011922-09-300001094038mrkr:AtmAgreementMember1922-01-011922-09-300001094038mrkr:AtmAgreementMember1921-12-011921-12-310001094038mrkr:AtmAgreementMember1921-07-011921-09-300001094038mrkr:AtmAgreementMember1921-01-011921-09-300001094038mrkr:AtmAgreementMember1920-12-011920-12-310001094038mrkr:AtmAgreementMember1920-07-011920-09-300001094038mrkr:AtmAgreementMember1920-01-011920-09-300001094038mrkr:AtmAgreementMember1919-12-011919-12-310001094038mrkr:AtmAgreementMember1919-07-011919-09-300001094038mrkr:AtmAgreementMember1919-01-011919-09-300001094038mrkr:AtmAgreementMember1918-12-011918-12-310001094038mrkr:AtmAgreementMember1918-07-011918-09-300001094038mrkr:AtmAgreementMember1918-01-011918-09-300001094038mrkr:AtmAgreementMember1917-12-011917-12-310001094038mrkr:AtmAgreementMember1917-07-011917-09-300001094038mrkr:AtmAgreementMember1917-01-011917-09-300001094038mrkr:AtmAgreementMember1916-12-011916-12-310001094038mrkr:AtmAgreementMember1916-07-011916-09-300001094038mrkr:AtmAgreementMember1916-01-011916-09-300001094038mrkr:AtmAgreementMember1915-12-011915-12-310001094038mrkr:AtmAgreementMember1915-07-011915-09-300001094038mrkr:AtmAgreementMember1915-01-011915-09-300001094038mrkr:AtmAgreementMember1914-12-011914-12-310001094038mrkr:AtmAgreementMember1914-07-011914-09-300001094038mrkr:AtmAgreementMember1914-01-011914-09-300001094038mrkr:AtmAgreementMember1913-12-011913-12-310001094038mrkr:AtmAgreementMember1913-07-011913-09-300001094038mrkr:AtmAgreementMember1913-01-011913-09-300001094038mrkr:AtmAgreementMember1912-12-011912-12-310001094038mrkr:AtmAgreementMember1912-07-011912-09-300001094038mrkr:AtmAgreementMember1912-01-011912-09-300001094038mrkr:AtmAgreementMember1911-12-011911-12-310001094038mrkr:AtmAgreementMember1911-07-011911-09-300001094038mrkr:AtmAgreementMember1911-01-011911-09-300001094038mrkr:AtmAgreementMember1910-12-011910-12-310001094038mrkr:AtmAgreementMember1910-07-011910-09-300001094038mrkr:AtmAgreementMember1910-01-011910-09-300001094038mrkr:AtmAgreementMember1909-12-011909-12-310001094038mrkr:AtmAgreementMember1909-07-011909-09-300001094038mrkr:AtmAgreementMember1909-01-011909-09-300001094038mrkr:AtmAgreementMember1908-12-011908-12-310001094038mrkr:AtmAgreementMember1908-07-011908-09-300001094038mrkr:AtmAgreementMember1908-01-011908-09-300001094038mrkr:AtmAgreementMember1907-12-011907-12-310001094038mrkr:AtmAgreementMember1907-07-011907-09-300001094038mrkr:AtmAgreementMember1907-01-011907-09-300001094038mrkr:AtmAgreementMember1906-12-011906-12-310001094038mrkr:AtmAgreementMember1906-07-011906-09-300001094038mrkr:AtmAgreementMember1906-01-011906-09-300001094038mrkr:AtmAgreementMember1905-12-011905-12-310001094038mrkr:AtmAgreementMember1905-07-011905-09-300001094038mrkr:AtmAgreementMember1905-01-011905-09-300001094038mrkr:AtmAgreementMember1904-12-011904-12-310001094038mrkr:AtmAgreementMember1904-07-011904-09-300001094038mrkr:AtmAgreementMember1904-01-011904-09-300001094038mrkr:AtmAgreementMember1903-12-011903-12-310001094038mrkr:AtmAgreementMember1903-07-011903-09-300001094038mrkr:AtmAgreementMember1903-01-011903-09-300001094038mrkr:AtmAgreementMember1902-12-011902-12-310001094038mrkr:AtmAgreementMember1902-07-011902-09-300001094038mrkr:AtmAgreementMember1902-01-011902-09-300001094038mrkr:AtmAgreementMember1901-12-011901-12-310001094038mrkr:AtmAgreementMember1901-07-011901-09-300001094038mrkr:AtmAgreementMember1901-01-011901-09-300001094038mrkr:AtmAgreementMember1900-12-011900-12-310001094038mrkr:AtmAgreementMember1900-07-011900-09-300001094038mrkr:AtmAgreementMember1900-01-011900-09-300001094038mrkr:AtmAgreementMember1899-12-011899-12-310001094038mrkr:AtmAgreementMember1899-07-011899-09-300001094038mrkr:AtmAgreementMember1899-01-011899-09-300001094038mrkr:AtmAgreementMember1898-12-011898-12-310001094038mrkr:AtmAgreementMember1898-07-011898-09-300001094038mrkr:AtmAgreementMember1898-01-011898-09-300001094038mrkr:AtmAgreementMember1897-12-011897-12-310001094038mrkr:AtmAgreementMember1897-07-011897-09-300001094038mrkr:AtmAgreementMember1897-01-011897-09-300001094038mrkr:AtmAgreementMember1896-12-011896-12-310001094038mrkr:AtmAgreementMember1896-07-011896-09-300001094038mrkr:AtmAgreementMember1896-01-011896-09-300001094038mrkr:AtmAgreementMember1895-12-011895-12-310001094038mrkr:AtmAgreementMember1895-07-011895-09-300001094038mrkr:AtmAgreementMember1895-01-011895-09-300001094038mrkr:AtmAgreementMember1894-12-011894-12-310001094038mrkr:AtmAgreementMember1894-07-011894-09-300001094038mrkr:AtmAgreementMember1894-01-011894-09-300001094038mrkr:AtmAgreementMember1893-12-011893-12-310001094038mrkr:AtmAgreementMember1893-07-011893-09-300001094038mrkr:AtmAgreementMember1893-01-011893-09-300001094038mrkr:AtmAgreementMember1892-12-011892-12-310001094038mrkr:AtmAgreementMember1892-07-011892-09-300001094038m

â€”â€‹ (6,893,691)â€‹â€‹ (6,893,691)Balance at September 30, 2024â€‹ 8,923,490â€‹$ 8,923â€‹$ 450,620,206â€‹$ (443,179,554)â€‹$ 7,449,575â€‹For the Three Months Ended September 30, 2023â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Totalâ€‹â€‹CommonÂ Stockâ€‹AdditionalÂ Paid-â€‹Accumulatedâ€‹Stockholdersâ€™â€‹â€‹Â Â Â Â SharesÂ Â Â Â ParÂ valueÂ Â Â Â inÂ CapitalÂ Â Â Â DeficitÂ Â Â Â EquityBalance at July 1, 2023â€‹ 8,799,173â€‹$ 8,799â€‹$ 449,526,789â€‹$ (430,500,836)â€‹$ 19,034,752Issuance of common stock from exercise of stock optionsâ€‹ 24,774â€‹â€‹ 24â€‹â€‹ 84,580â€‹â€‹ â€”â€‹â€‹ 84,604Shares purchased pursuant to ATM agreementâ€‹ 65,073â€‹â€‹ 65â€‹â€‹ 394,602â€‹â€‹ â€”â€‹â€‹ 394,667Stock-based compensationâ€‹ â€”â€‹â€‹ â€”â€‹â€‹ 175,041â€‹â€‹ â€”â€‹â€‹ 175,041Net lossâ€‹ â€”â€‹â€‹ â€”â€‹â€‹ (2,981,961)â€‹â€‹ (2,981,961)Balance at September 30, 2023â€‹ 8,889,020â€‹$ 8,888â€‹$ 450,181,012â€‹$ (433,482,797)â€‹$ 16,707,103â€‹For the Nine Months Ended SeptemberÂ 30,Â 2023â€‹Â Â Â Â â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Totalâ€‹â€‹CommonÂ Stockâ€‹AdditionalÂ Paid-â€‹Accumulatedâ€‹Stockholdersâ€™â€‹â€‹Â Â Â Â SharesÂ Â Â Â ParÂ valueÂ Â Â Â inÂ CapitalÂ Â Â Â DeficitÂ Â Â Â EquityBalance at January 1, 2023Â 8,405,771â€‹$ 8,406â€‹$ 447,641,680â€‹$ (428,049,049)â€‹$ 19,601,037Shares purchased pursuant to ATM and Lincoln Park agreementsâ€‹ 277,834â€‹â€‹ 277â€‹â€‹ 1,014,363â€‹â€‹ â€”â€‹â€‹ 1,014,640Issuance of common stock as commitment fee for future financing â€‹ 180,410â€‹â€‹ 180â€‹â€‹ (180)â€‹â€‹ â€”â€‹â€‹ â€”Issuance of common stock from exercise of stock options â€‹ 25,118â€‹â€‹ 25â€‹â€‹ 85,317â€‹â€‹ â€”â€‹â€‹ 85,342Stock-based compensationâ€‹ â€”â€‹Â â€”Â 1,439,832â€‹Â â€”Â 1,439,832Net lossÂ â€”â€‹Â â€”Â â€”â€‹Â (5,433,748)â€‹Â (5,433,748)Fractional shares adjustment due to reverse split â€‹ (113)â€‹â€‹ â€”â€‹â€‹ â€”â€‹â€‹ â€”â€‹â€‹ â€”â€‹â€‹ â€”Balance at SeptemberÂ 30,Â 2023Â 8,889,020â€‹$ 8,888â€‹$ 450,181,012â€‹$ (433,482,797)â€‹$ 16,707,103â€‹See accompanying notes to these unaudited condensed consolidated financial statements.â€‹3 Table of Contentsâ€‹MARKER THERAPEUTICS,Â INC.CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(UNAUDITED)â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹For the Nine Months Ended â€‹â€‹September 30,â€‹Â Â Â Â 2024Â Â Â Â 2023Cash Flows from Operating Activities:â€‹â€‹â€‹â€‹â€‹â€‹â€‹Net lossâ€‹$ (6,893,691)â€‹$ (5,433,748)Less: gain from discontinued operations, net of taxâ€‹â€‹ â€”â€‹â€‹ 5,872,020Net loss from continuing operationsâ€‹â€‹ (6,893,691)â€‹â€‹ (11,305,768)Reconciliation of net loss to net cash used in operating activities:â€‹Â â€‹â€‹Â â€‹Stock-based compensationâ€‹â€‹ 195,320â€‹â€‹ 714,899Changes in operating assets and liabilities:â€‹Â â€‹â€‹Â â€‹Prepaid expenses and depositsâ€‹Â (178,148)â€‹Â (80,116)Other receivablesâ€‹â€‹ 283,405â€‹â€‹ 2,318,691Related party payableâ€‹Â (426,217)â€‹Â 367,915Accounts payable and accrued expensesâ€‹â€‹ 812,142â€‹â€‹ (159,567)Deferred revenueâ€‹â€‹ â€”â€‹â€‹ 107,530Net cash used in operating activities - continuing operationsâ€‹â€‹ (6,207,189)â€‹â€‹ (8,036,416)Net cash used in operating activities - discontinued operationsâ€‹â€‹ â€”â€‹â€‹ (6,035,961)Net cash used in operating activitiesâ€‹Â (6,207,189)â€‹Â (14,072,377)Cash Flows from Investing Activities:â€‹Â â€‹â€‹Â â€‹Net cash provided by investing activities - discontinued operationsâ€‹â€‹ â€”â€‹â€‹ 18,664,122Net cash provided by investing activitiesâ€‹â€‹ â€”â€‹â€‹ 18,664,122Cash Flows from Financing Activities:â€‹Â â€‹â€‹Â â€‹Proceeds from issuance of common stock, netâ€‹Â 36,902â€‹Â 1,014,640Proceeds from stock options exerciseâ€‹â€‹ 58,501â€‹â€‹ 85,342Net cash provided by financing activitiesâ€‹Â 95,403â€‹Â 1,099,982Net (decrease) increase in cash and cash equivalentsâ€‹Â (6,111,786)â€‹Â 5,691,727Cash and cash equivalents at beginning of the periodâ€‹Â 15,111,450â€‹Â 11,782,172Cash and cash equivalents at end of the periodâ€‹$ 8,999,664â€‹$ 17,473,899â€‹See accompanying notes to these unaudited condensed consolidated financial statements.â€‹â€‹â€‹4 Table of Contentsâ€‹MARKER THERAPEUTICS,Â INC.NOTESÂ TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTSSeptember 30, 2024(Unaudited)NOTEÂ 1: NATURE OF OPERATIONSMarker Therapeutics, Inc., a Delaware corporation (the â€œCompanyâ€ or â€œweâ€), is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. The Companyâ€™s multi tumor associated antigen (multiTAAâ€)-specific T cell technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens, which are tumor targets, and kill tumor cells expressing those targets. These T cells are designed to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. The Company was incorporated in Nevada in 1992 and reincorporated in Delaware in October 2018.Purchase Agreement with Cell ReadyOn June 26, 2023, the Company completed the previously announced transaction with Cell Ready, LLC (â€œCell Readyâ€) pursuant to a Purchase Agreement (the â€œCell Ready Purchase Agreement), dated May 1, 2023, by and between the Company and Cell Ready. Mr. John Wilson is a member of the Companyâ€™s board of directors and is serving as the CEO of Cell Ready, therefore Cell Ready is a related party. Pursuant to the Cell Ready Purchase Agreement, effective as of the Closing Date, the Company (i) assigned to Cell Ready the leases for the Companyâ€™s two manufacturing facilities in Houston, Texas (the â€œManufacturing Facilitiesâ€), (ii) sold to Cell Ready all of the equipment and leasehold improvements at the Manufacturing Facilities and (iii) assigned to Cell Ready its rights, title and interest in the Companyâ€™s Master Services Agreement for Product Supply (the â€œMSAâ€), dated April 7, 2023, by and between the Company, Cell Ready and Indapta Therapeutics, Inc., as well as its rights, title and interest in any contracts related to the equipment and Manufacturing Facilities (collectively, the â€œPurchased Assetsâ€). Cell Ready acquired the Purchased Assets for total consideration of $19.0 million. In connection with the purchase of the Manufacturing Facilities, Cell Ready also extended offers of employment to approximately 50 of the Companyâ€™s former employees in its manufacturing, development, quality, and regulatory affairs functions.The Purchased Assets constituted a significant disposition. Based upon the magnitude of the disposition and because the Company is exiting certain manufacturing operations, the disposition represents a significant strategic shift that will have a material effect on the Companyâ€™s operations and financial results. Accordingly, the assets sold meet the definition of a discontinued operation, as defined by Accounting Standards Codification (â€œASCâ€) 205-20 â€“ Discontinued Operations, and prior comparative periods have been retroactively adjusted to reflect the current presentation. See additional discussion at Note 7.On February 22, 2024, we entered into a Master Services Agreement for Product Supply (the â€œMSAâ€) with Cell Ready to provide outsourced services previously performed by the Company prior to its asset sale to Cell Ready. Cell Ready, which is owned by one of our directors and shareholders, Mr. John Wilson, is a contract development and manufacturing organization (CDMO). Under the MSA, it is anticipated Cell Ready will perform a wide variety of services for us, including research and development, and manufacturing in support of our clinical trials. Pursuant to the MSA, the Company may contract with Cell Ready for the provision of various products and services from time to time by entering into work orders with Cell Ready. If the services involve the supply of product, Cell Ready is required to supply such product in conformance with the product requirements set forth in the applicable work order(s). Under the MSA, Cell Ready is to use only personnel with sufficient qualifications and experience to supply the services contemplated by the MSA, provide its personnel with adequate training and assume full responsibility for its personnelâ€™s compliance with the MSA. Further, Cell Ready is required to provide the Company with assistance and cooperation in order for the Company to obtain and maintain all necessary regulatory approvals, at the Companyâ€™s expense.Organizational ChangesIn 2023, the Company implemented changes to its organizational structure due to the transaction with Cell Ready and to reduce operational costs. In connection with these changes, the Company reduced headcount, including the separation of its former Chief Executive Officer, Peter Hoang, in May 2023, and its former Chief Accounting Officer, Michael Loiacono, in June 2023. During the second quarter of 2023, the Company recorded $0.9 million of severance and termination-related costs. The payments of these costs were completed in July of 2023. Effective May 1, 2023, the Companyâ€™s board of directors appointed Dr. Juan Vera as the Companyâ€™s President and Chief Executive Officer. 5 Table of Contentsâ€‹Effective June 30, 2023, the board of directors appointed Eliot M. Lurier as the Companyâ€™s Interim Chief Financial Officer, whereby Mr. Lurier provided consulting services to the Company pursuant to a consulting agreement between the Company and Danforth Advisors, LLC (â€œDanforthâ€) and received no compensation directly from the Company. On November 17, 2023, the Company terminated the consulting agreement between the Company and Danforth, effective January 16, 2024.On November 17, 2023, Mr. Lurier ceased serving as the Companyâ€™s Interim Chief Financial Officer and Dr. Vera was appointed as the Companyâ€™s Principal Financial and Accounting Officer.Reverse Stock SplitOn January 26, 2023, the Company effected a one-for-ten (1-for-10) reverse stock split of its common stock (the â€œReverse Stock Splitâ€) and a corresponding reduction in the total number of authorized shares of its common stock from 300,000,000 to 30,000,000. The Reverse Stock Split, which was approved by stockholders at an annual stockholder meeting on May 24, 2022, was consummated pursuant to a Certificate of Amendment filed with the Secretary of State of Delaware on January 26, 2023. The Reverse Stock Split was effective on January 26, 2023. All references to common stock, warrants to purchase common stock, options to purchase common stock, share data, per share data and related information contained in the consolidated financial statements have been retrospectively adjusted to reflect the effect of the Reverse Stock Split for all periods presented.NOTEÂ 2: BASIS OF PRESENTATIONThe accompanying unaudited condensed consolidated financial statements have been prepared in accordance with the accounting principles generally accepted in the United States of America (â€œU.S. GAAPâ€) for interim financial information and pursuant to the instructions to Form 10-Q and Article 8 of Regulation S-X of the Securities and Exchange Commission (â€œSECâ€) and on the same basis as the Company prepares its annual audited consolidated financial statements. In the opinion of management, the accompanying unaudited condensed consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation of such interim results (see Note 7 for information on discontinued operations).The results for the unaudited condensed consolidated statement of operations are not necessarily indicative of results to be expected for the year ending December 31, 2024, or for any future interim period. The condensed consolidated balance sheet at December 31, 2023 has been derived from audited financial statements, however, it does not include all of the information and notes required by U.S. GAAP for complete financial statements. The accompanying condensed consolidated financial statements should be read in conjunction with the consolidated financial statements for the year ended December 31, 2023 and notes thereto included in the Companyâ€™s annual report on Form 10-K filed on March 26, 2024.â€‹Certain amounts presented in prior periods have been reclassified to conform to the current period presentation.â€‹NOTEÂ 3: LIQUIDITY AND FINANCIAL CONDITION As of September 30, 2024, the Company had cash and cash equivalents of approximately $9.0 million. The Companyâ€™s activities since inception have consisted principally of acquiring product and technology rights, raising capital, and performing research and development. Successful completion of the Companyâ€™s development programs and, ultimately, the attainment of profitable operations are dependent on future events, including, among other things, its ability to access potential markets; secure financing; successfully progress its product candidates through preclinical and clinical development; obtain regulatory approval of one or more of its product candidates; maintain and enforce intellectual property rights; develop a customer base; attract, retain and motivate qualified personnel; and develop strategic alliances and collaborations. From inception, the Company has been funded by a combination of equity, debt financings and grants. In August 2021, the Company entered into a Controlled Equity OfferingSM Sales Agreement (the â€œATM Agreementâ€) with Cantor Fitzgerald & Co. and RBC Capital Markets, LLC (the â€œSales Agentsâ€), pursuant to which the Company can offer and sell, from time to time at its sole discretion through the Sales Agents, shares of its common stock having an aggregate offering price of up to $75.0 million. Any shares of its common stock sold will be issued pursuant to the Companyâ€™s shelf registration statement on Form S-3 (File No. 333-258687), which the SEC declared effective on August 19, 2021. However, our use of the shelf registration statement on Form S-3 will be limited for so long as we are subject to General Instruction I.B.6 of Form S-3, which limits the amounts that we may sell under the registration statement and in accordance with the ATM agreement. The Sales Agents are entitled to compensation under the Sales Agreement at a commission rate equal to 3.0% of the gross sales price per share sold under the ATM Agreement, and we have provided each of the Sales Agents with indemnification and contribution rights. During the nine months ended 6 Table of Contentsâ€‹September 30, 2024, the Company sold 8,178 shares of its common stock under the ATM Agreement for proceeds of $0.04 million. On June 10, 2024, the Company provided notice of its termination of the ATM Agreement with Cantor Fitzgerald & Co. and RBC Capital Markets, LLC. The Company is not subject to any termination penalties related to the termination of the ATM Agreement. The Company is currently considering more effective ways to improve market access to its equity.In August 2021, the Company received notice of a Product Development Research award totaling approximately $13.1 million from the Cancer Prevention and Research Institute of Texas (â€œCPRITâ€) to support the Companyâ€™s clinical investigation of MT-401. Through the date of this filing, the Company has received $9.7 million of funds from the CPRIT grant. The Company recorded $0.9 million and $2.4 million of grant income related to the CPRIT grant as revenue for the three and nine months ended September 30, 2024, respectively. As of September 30, 2024, the Company recorded $0.1 million of grant income receivable, which represented grant income earned in advance of funds to be received from CPRIT.In September 2022, the Company received notice from the U.S. Food and Drug Administration (the â€œFDAâ€) that it had awarded the Company a $2.0 million grant from the FDAâ€™s Orphan Products Grant program to support the Companyâ€™s clinical investigation of MT-401 for the treatment of post-transplant AML. Through the date of this filing, the Company has received $1.0 million from the FDA grant. The Company recorded $0.02 million and $0.5 million of grant income related to the FDA grant as revenue for the three and nine months ended September 30, 2024, respectively. As of September 30, 2024, the Company recorded $0.02 million of grant income receivable, which represented grant income earned in advance of funds to be received from the FDA. In October 2024, the Company received $0.02 million of funds from the FDA grant. In May 2023, the Company received notice of a $2.0 million grant from the National Institutes of Health Small Business Innovation Research (â€œSBIRâ€) program to support the development and investigation of MT-401 for the treatment of AML patients following standard-of-care therapy with hypomethylating agents. Through the date of this filing, the Company has received $0.9 million from SBIR. The Company recorded $0.3 million and $0.7 million of grant income related to the SBIR grant as revenue for the three and nine months ended September 30, 2024. As of September 30, 2024, the Company recorded $0.3 million as other receivable, which represented grant income earned in advance of funds to be received from the SBIR. In October 2024, the Company received $0.3 million of funds from the SBIR grant.In June 2024, the Company received notice of a $2.0 million grant over a 2 - year period from the National Institutes of Health - National Cancer Institute to support control over tumor immune escape in pancreatic cancer using a dual T cell product strategy. Through the date of this filing, the Company has not received any funds from this grant.In August 2024, the Company received notice of a $2.0 million grant from the National Institutes of Health Small Business Innovation Research Program to support the clinical investigation of MT-601 in patients with non-Hodgkinâ€™s lymphoma (NHL) who have relapsed following anti-CD19 chimeric antigen receptor (CAR) T cell therapy. Through the date of this filing, the Company has received $0.7 million of funds from this grant. The Company recorded $0.7 million of grant income related to this grant as revenue for the three and nine months ended September 30, 2024. As of September 30, 2024, the Company recorded $0.3 million as other receivable, which represented grant income earned in advance of funds to be received from the SBIR. In October 2024, the Company received $0.3 million of funds from the SBIR lymphoma grant.In August 2024, the Company received another $2.0 million grant from the National Institutes of Health SBIR Program to support the advancement of MT-601 in patients with pancreatic cancer. Through the date of this filing, the Company has received an immaterial amount of funds from this grant.As described in Note 1, on June 26, 2023, the Company completed the transaction with Cell Ready pursuant to the Cell Ready Purchase Agreement for total consideration of $19.0 million. On February 22, 2024, the Company entered into a Master Services Agreement for Product Supply (the â€œMSAâ€) with Cell Ready, a contract development and manufacturing organization (CDMO). Under the MSA, it is anticipated Cell Ready will perform a wide variety of services for us, including research and development, and manufacturing in support of our clinical trials. Pursuant to the MSA, the Company may contract with Cell Ready for the provision of various products and services from time to time by entering into work orders with Cell Ready (See Note 13).The Company expects to continue to incur substantial losses over the next several years during its development phase.7 Table of Contentsâ€‹Based on the Companyâ€™s clinical and research and development plans and its timing expectations related to the progress of its programs, the Company anticipates that its cash and cash equivalents as of September 30, 2024, including drawdowns of available grant funds, will enable the Company to fund its operating expenses and capital expenditure requirements into October 2025. This estimate is subject to the Companyâ€™s ability to effectively manage its costs, raise additional capital, and utilize drawdowns of anticipated grant funds.The Company has based this estimate on assumptions that may prove to be wrong, and the Company could utilize its available capital resources sooner than it currently expects. Furthermore, the Companyâ€™s operating plan may change, and it may need additional funds sooner than planned in order to meet operational needs and capital requirements for product development and commercialization. Because of the numerous risks and uncertainties associated with the development and commercialization of the Companyâ€™s product candidates and the extent to which the Company may enter into additional collaborations with third parties to participate in their development and commercialization, the Company is unable to estimate the amounts of increased capital outlays and operating expenditures associated with its current and anticipated clinical trials. The Companyâ€™s future funding requirements will depend on many factors, as it: â—Initiates, continues, or accelerates clinical trials of its product candidates;â—continues the research and development of its product candidates and seeks to discover additional product candidates;â—seeks regulatory approvals for any product candidates that successfully complete clinical

trials;â—maintains and enforces intellectual property rights;â—enters into contract manufacturing arrangements with Cell Ready or other contract manufacturing organizations for clinical manufacturing supply;â—establishes sales, marketing and distribution infrastructure and scale-up manufacturing capabilities to commercialize any product candidates that may receive regulatory approval;â—evaluates strategic transactions the Company may undertake; andâ—enhances operational, financial and information management systems and hires additional personnel, including personnel to support development of product candidates and, if a product candidate is approved, commercialization efforts.The Company does not have sufficient sources of revenue to provide incoming cash flows to sustain its future operations. As outlined above, the Companyâ€™s ability to pursue its long-term planned business activities is dependent upon its successful efforts to raise additional capital and grant income.These factors raise substantial doubt regarding the Companyâ€™s ability to continue as a going concern. The Companyâ€™s condensed consolidated financial statements have been prepared on a going concern basis, which implies that the Company will continue to realize its assets and discharge its liabilities in the normal course of business. The Companyâ€™s financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.In addition to the foregoing, the current macro-economic environment of decades-high inflation and concerns about an economic recession in the United States or other major markets have resulted in, among other things, volatility in the capital markets that may have the effect of reducing the Companyâ€™s ability to access capital, which could in the future negatively affect the Companyâ€™s liquidity. In addition, a recession or market correction due to these factors could materially affect the Companyâ€™s business and the value of its common stock.8 Table of Contentsâ€‹NOTEÂ 4: SIGNIFICANT ACCOUNTING POLICIESPrinciples of ConsolidationThese consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Marker Cell Therapy, Inc. and GeneMax Pharmaceuticals Inc. â€“ a dormant subsidiary that wholly owns GeneMax Pharmaceuticals Canada, Inc. All significant intercompany balances and transactions are eliminated upon consolidation.Use of EstimatesPreparation of the Companyâ€™s consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Accordingly, actual results may differ materially from those estimates. Management considers many factors in selecting appropriate financial accounting policies, controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes, and management must select an amount that falls within that range of reasonable estimates. Estimates are used in the following areas, among others: stock-based compensation expense and income taxes.Cash, Cash Equivalents and Credit RiskThe Company considers highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. Cash and cash equivalents at September 30, 2024 consisted of cash and certificates of deposit in institutions in the United States. Balances at certain institutions have exceeded Federal Deposit Insurance Corporation insured limits and U.S. government agency securities.The Company maintains cash in accounts which are in excess of the Federal Deposit Insurance Corporation (â€œFDICâ€) insured limits of $250,000. As of September 30, 2024, the Company had approximately $4.1 million in cash at financial institutions and approximately $4.9 million in U.S. government agency securities, for aggregate cash and cash equivalents of $9.0 million. As of December 31, 2023, the Company had approximately $1.4 million in cash at financial institutions and approximately $13.7 million in U.S. government agency securities, for aggregate cash and cash equivalents of $15.1 million.In the event cash is received from grants in advance of incurring qualifying costs, it is recorded as restricted cash until it is earned and recorded to grant income.Discontinued OperationsThe Purchased Assets sold to Cell Ready pursuant to the Cell Ready Purchase Agreement constituted a significant disposition and as such, the Company concluded that the disposition of its Purchased Assets represented a strategic shift that had a major effect on its operations and financial results. Therefore, the Purchased Assets, related party revenue, service revenue and related expenses are classified as discontinued operations for all periods presented herein. See Note 7 for further information.Recently Issued Accounting Standards Not Yet AdoptedImprovements to Reportable Segment DisclosuresIn November 2023, the Financial Accounting Standards Board (the â€œFASBâ€) issued Accounting Standards Update (â€œASUâ€) No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. The ASU requires disclosures to include significant segment expenses that are regularly provided to the chief operating decision maker, among other provisions. Public entities with a single reportable segment, such as the Company, are required to provide the new disclosures and all the disclosures required under ASC 280. The ASU is effective for fiscal year periods beginning after December15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted, and the ASU requires retrospective application to all prior periods 9 Table of Contentsâ€‹presented in the financial statements. The Company is currently evaluating the standard to determine the impact of adoption to its consolidated financial statements and disclosures.Improvements to Income Tax DisclosuresIn December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (ASU 2023-09), which improves the transparency of income tax disclosures by requiring consistent categories and greater disaggregation of information in the effective tax rate reconciliation and income taxes paid disaggregated by jurisdiction. It also includes certain other amendments to improve the effectiveness of income tax disclosures. This guidance will be effective for the annual periods beginning the year ended December 31, 2025. Early adoption is permitted. Upon adoption the guidance can be applied prospectively or retrospectively. We do not expect the adoption of this guidance to have a material impact on the Companyâ€™s consolidated financial statements.From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (â€œFASBâ€) or other standard setting bodies that the Company adopts as of the specified effective date. Unless otherwise discussed, the Company does not believe that the impact of recently issued standards that are not yet effective will have a material impact on its consolidated financial position or results of operations upon adoption.There have been no material changes in the Companyâ€™s significant accounting policies to those previously disclosed in the Annual Report on Form 10-K for the year ended December 31, 2023 filed on March 26, 2024.â€‹NOTEÂ 5: NET LOSS PER SHAREBasic loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the reporting period. Diluted loss per common share is computed similarly to basic loss per common share except that it reflects the potential dilution that could occur if dilutive securities or other obligations to issue common stock were exercised or converted into common stock.The following table sets forth the computation of net loss per share for the three and nine months ended September 30, 2024 and 2023, respectively:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â ForÂ theÂ Three Months Ended Â ForÂ theÂ Nine Months Ended â€‹â€‹SeptemberÂ 30,Â Â SeptemberÂ 30,Â â€‹Â Â Â Â 2024Â Â Â Â 2023Â Â Â Â 2024Â Â Â Â 2023Numerator:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Loss from continuing operationsâ€‹$ (2,308,192)â€‹$ (2,981,961)â€‹$ (6,893,691)â€‹$ (11,305,768)Income from discontinued operationsâ€‹$ â€”â€‹$ â€”â€‹$ â€”â€‹$ 5,872,020Net lossâ€‹$ (2,308,192)â€‹$ (2,981,961)â€‹$ (6,893,691)â€‹$ (5,433,748)â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹ â€‹â€‹â€‹â€‹ â€‹Denominator:â€‹Â â€‹â€‹Â â€‹â€‹Â â€‹â€‹Â â€‹â€‹Â â€‹Weighted average common shares outstanding, basicâ€‹Â 8,923,170â€‹Â 8,825,881â€‹Â 8,914,487â€‹Â 8,782,340Weighted average common shares outstanding, dilutedâ€‹Â 8,923,170â€‹Â 8,825,881â€‹Â 8,914,487â€‹Â 8,834,512â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹ â€‹â€‹â€‹â€‹ â€‹Net earnings (loss) per share:â€‹Â â€‹â€‹Â â€‹â€‹Â â€‹â€‹Â â€‹Loss from continuing operations, basic and dilutedâ€‹$ (0.26)â€‹$ (0.34)â€‹$ (0.77)â€‹$ (1.29)Income from discontinued operations, basicâ€‹$ â€”â€‹$ â€”â€‹$ â€”â€‹$ 0.67Income from discontinued operations, dilutedâ€‹$â€”â€‹$â€”â€‹$â€‹â€‹â€‹$ 0.66Net loss per share, basic and dilutedâ€‹$ (0.26)â€‹$ (0.34)â€‹$ (0.77)â€‹$ (0.62)â€‹â€‹10 Table of Contentsâ€‹The following securities, rounded to the nearest thousand, were not included in the diluted net loss per share calculation because their effect was anti-dilutive for the periods presented:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹For the Three Months Endedâ€‹For the Nine Months Endedâ€‹â€‹SeptemberÂ 30,Â â€‹SeptemberÂ 30,Â â€‹Â Â Â Â 2024Â Â Â Â 2023Â Â Â Â 2024Â Â Â Â 2023Common stock optionsâ€‹ 596,000Â 800,000Â 596,000Â 748,000Common stock purchase warrantsâ€‹ â€”Â 1,848,000Â â€”Â 1,848,000Potentially dilutive securitiesâ€‹ 596,000Â 2,648,000Â 596,000Â 2,596,000â€‹â€‹NOTE 6: OTHER RECEIVABLEQualifying grant income earned in advance of cash received from grants is recognized as revenue and recorded as other receivable. The Company recorded $0.9 million and $2.4 million of grant income related to the CPRIT grant for the three and nine months ended September 30, 2024, respectively. At September 30, 2024, the Company recorded $0.1 million of grant income receivable related to the CPRIT grant.Additionally, the Company recorded $0.02 million and $1.0 million of grant income related to the FDA and SBIR grants, respectively, for the three months ended September 30, 2024. The Company recorded $0.5 million and $1.4 million of grant income related to the FDA and SBIR grants, respectively, for the nine months ended September 30, 2024. At September 30, 2024, the Company recorded $0.02 million and $0.6 million of grant income receivable related to the FDA and SBIR grants, respectively.In October 2024, the Company received payments of $0.02 million and $0.6 million from the FDA grant and all SBIR grants, respectively.â€‹â€‹NOTE 7: DISCONTINUED OPERATIONSAs discussed in Note 1, on June 26, 2023, the Company completed the previously announced transaction with Cell Ready for cash consideration of $19.0 million, resulting in derecognition of the Purchased Assets and a gain on sale of approximately $8.7 million, net of $63,000 in tax. There were no remaining assets and liabilities classified in discontinued operations as of September 30, 2024 or December 31, 2023.The Company had no activity related to discontinued operations for the three and nine months ended September 30, 2024. Net loss from discontinued operations for the three and nine months ended September 30, 2023, was as follows:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â For the Three MonthsÂ Â Â Â ForÂ theÂ NineÂ Monthsâ€‹â€‹Ended September 30,â€‹Ended September 30,â€‹â€‹2023â€‹2023Revenues:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Service Revenueâ€‹$ â€”â€‹$ 816,641Related party service revenueâ€‹â€‹ â€”â€‹â€‹ 3,500,000Total revenuesâ€‹Â â€”â€‹Â 4,316,641Operating expenses:â€‹Â â€‹â€‹Â â€‹Research and developmentâ€‹Â â€”â€‹Â 6,561,957General and administrativeâ€‹â€‹ â€”â€‹â€‹ 677,090Total operating expensesâ€‹â€‹ â€”â€‹â€‹ 7,239,048Loss from discontinued operationsâ€‹$ â€”â€‹$ (2,922,406)â€‹â€‹11 Table of Contentsâ€‹The following table summarizes our cash flows related to discontinued operations for the nine months ended September 30, 2023:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹ForÂ theÂ NineÂ Monthsâ€‹â€‹Ended September 30,â€‹Â Â Â Â 2023Discontinued operations:â€‹Â â€‹Net cash used in operating activitiesâ€‹Â (6,036,000)Net cash provided by investing activitiesâ€‹Â 18,664,000Net increase (decrease) in cash and cash equivalentsâ€‹$ 12,628,000â€‹Related Party Service RevenueIn April 2022, the Company entered into a binding services agreement (â€œWilson Wolf Agreementâ€) with Wilson Wolf Manufacturing Corporation (â€œWilson Wolfâ€). Mr. John Wilson is a member of the Companyâ€™s board of directors and is serving as the CEO of Wilson Wolf. Wilson Wolf is in the business of creating products and services intended to simplify and expedite the transition of cell therapies and gene-modified cell therapies to mainstream society (the â€œWilson Wolf Missionâ€). Pursuant to the Wilson Wolf Agreement, Wilson Wolf made a cash payment to the Company in the amount of $8.0 million, as consideration for certain training and research services.In March 2023, the Company recognized the final $2.5 million of revenue pursuant to this $8.0 million agreement and an additional $1.0 million because certain agreed milestones were met. Payment of the additional $1.0 million was received in May 2023.NOTEÂ 8: ACCOUNTS PAYABLE, ACCRUED LIABILITIES AND RELATED PARTY PAYABLEAccounts payable, accrued liabilities, and related party payable consist of the following as of September 30, 2024 and December 31, 2023, respectively:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â SeptemberÂ 30,Â Â Â Â DecemberÂ 31,Â â€‹â€‹2024â€‹2023Accounts payableâ€‹$ 1,904,000â€‹$ 961,000Compensation and benefitsâ€‹Â 39,000â€‹Â 57,000Professional feesâ€‹â€‹ 359,000â€‹â€‹ 303,000Related party payableâ€‹Â 903,000â€‹Â 1,330,000Tax feesâ€‹Â 52,000â€‹Â 219,000Otherâ€‹Â 204,000â€‹Â 205,000Total accounts payable, accrued liabilities and related party payableâ€‹$ 3,461,000â€‹$ 3,075,000â€‹The $0.9 million and $1.3 million related-party payable as of September 30, 2024 and December 31, 2023, respectively, primarily reflects amounts payable to Cell Ready for outsourced product development and manufacturing services. See Note 13: Related Party Transactions.â€‹NOTEÂ 9: STOCKHOLDERSâ€™ EQUITYReverse Stock SplitOn January 26, 2023, the Company effected the Reverse Stock Split and a corresponding reduction in the total number of authorized shares of its common stock from 300,000,000 to 30,000,000. The Reverse Stock Split, which was approved by stockholders at an annual stockholder meeting on May 24, 2022, was consummated pursuant to a Certificate of Amendment filed with the Secretary of State of Delaware on January 26, 2023. The Reverse Stock Split was effective on January 26, 2023. All historical share and per share amounts reflected in this report have been adjusted to reflect the Reverse Stock Split.12 Table of Contentsâ€‹Common Stock TransactionsIssuance of Stock Pursuant to ATM AgreementDuring the nine months ended September 30, 2024, the Company sold 8,178 shares of its common stock under the ATM Agreement for gross proceeds of $37,000. During the nine months ended September 30, 2023, the Company sold 265,334 shares of its common stock under the ATM Agreement for gross proceeds of $1.0 million. On June 10, 2024, the Company provided notice of its termination of the ATM Agreement with Cantor Fitzgerald & Co. and RBC Capital Markets, LLC. The Company is currently considering more effective ways to improve market access to its equity.Stock Purchase AgreementIn December 2022, the Company entered into a purchase agreement (the â€œPurchase Agreementâ€) with Lincoln Park which provides that, upon the terms and subject to the conditions of the agreement, the Company had the right, but not the obligation, to sell to Lincoln Park up to $25,000,000 of shares of its common stock (the â€œPurchase Sharesâ€) from time to time over a 24-month term, at a variable price with certain market-based terms as defined in the Purchase Agreement. The Purchase Agreement does not exhibit any of the characteristics for liability classification under ASC Topic 480, Distinguishing Liabilities from Equity. Instead, the purchase agreement was indexed to the Companyâ€™s own stock under ASC Subtopic 815-40, Contracts in Entityâ€™s Own Equity, and classified as equity. In January 2023, Lincoln Park was issued 180,410 shares of stock as a commitment fee at a value of $0.5 million. During the nine months ended September 30, 2023, the Company sold 12,500 shares of its common stock under the Purchase Agreement for gross proceeds of approximately $33,000. The Company terminated the Purchase Agreement with Lincoln Park on February 29, 2024, effective March 1, 2024.Exercise of Stock OptionsDuring the nine months ended September 30, 2024, certain outstanding options were exercised for 23,892 shares of common stock, providing aggregate proceeds to the Company of approximately $59,000.NOTEÂ 10: STOCK-BASED COMPENSATIONStock Options2024 Equity Incentive AwardsThere were no equity incentive awards issued during the three and nine months ended September 30, 2024. A summary of the Companyâ€™s stock option activity for the nine months ended September 30, 2024 is as follows:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹

development and investigation of MT-401 for the treatment of AML patients following standard-of-care therapy with hypomethylating agents. The Company recorded $0.3 million and $0.7 million of grant income related to this grant as revenue for the three and nine months ended September 30, 2024, respectively. As of September 30, 2024, the Company recorded $0.3 million as other receivable, which represented grant income earned in advance of funds to be received from the SBIR. In October 2024, the Company received $0.3 million of funds from the SBIR grant.â€‹14 Table of Contentsâ€‹In August 2024, the Company received notice of a $2.0 million grant from the National Institutes of Health Small Business Innovation Research Program to support the clinical investigation of MT-601 in patients with non-Hodgkinâ€™s lymphoma (NHL) who have relapsed following anti-CD19 chimeric antigen receptor (CAR) T cell therapy. The Company recorded $0.7 million of grant income related to this grant as revenue for the three and nine months ended September 30, 2024. As of September 30, 2024, the Company recorded $0.3 million as other receivable, which represented grant income earned in advance of funds to be received from the SBIR. In October 2024, the Company received $0.3 million of funds from the SBIR lymphoma grant.â€‹â€‹NOTE 12: LEGAL PROCEEDINGSFrom time to time, the Company may be party to ordinary, routine litigation incidental to their business. The Company knows of no material, active or pending legal proceedings against the Company, nor is the Company involved as a plaintiff in any material proceeding or pending litigation. There are no proceedings in which any of the Companyâ€™s directors, officers or affiliates, or any registered or beneficial shareholder, is an adverse party or has a material interest adverse to the Companyâ€™s interest.â€‹NOTEÂ 13: RELATED PARTY EXPENSESThe following table sets forth related party transaction expenses recorded for the three and nine months ended September 30, 2024 and 2023, respectively.â€‹â€‹â€‹

4,326,000â€‹Â 3,458,000â€‹Â 868,000Â 25%Loss from operationsâ€‹Â (2,400,000)â€‹Â (3,200,000)â€‹Â 800,000Â (25)%Other income (expenses):â€‹Â â€‹â€‹Â â€‹â€‹Â â€‹â€‹Â â€‹Â â€‹â€‹Interest incomeâ€‹Â 92,000â€‹Â 218,000â€‹Â (126,000)Â (58)%Loss from continuing operationsâ€‹$ (2,308,000)â€‹â€‹ (2,982,000)â€‹$ 674,000Â (23)%â€‹RevenueWe did not generate any revenue during the three months ended September 30, 2024 and 2023, respectively, from the sales or licensing of our product candidates.In August 2021, we received notice of a Product Development Research award totaling approximately $13.1 million from the Cancer Prevention and Research Institute of Texas (â€œCPRITâ€) to support the clinical investigation of MT-401. During the three months ended September 30, 2024 and 2023, we recognized $0.9 million and $0.2 million of revenue, respectively, associated with the CPRIT grant. In September 2022, we received notice from the FDA that it had awarded us a $2.0 million grant from the FDAâ€™s Orphan Products Grant program to support the clinical investigation of MT-401 for the treatment of post-transplant AML. During the three months ended September 30, 2024 and 2023, we recognized $0.02 million and $0.02 million of revenue, respectively associated with the FDA grant.In May 2023, we received notice of a $2.0 million grant from the National Institutes of Health Small Business Innovation Research (â€œSBIRâ€) program to support the development and investigation of MT-401 for the treatment of AML patients following standard-of-care therapy with hypomethylating agents. During the three months ended September 30, 2024, we recognized $0.3 million of revenue associated with the SBIR grant. During the three months ended September 30, 2023, no revenue was recognized associated with the SBIR grant.The above funding agencies have agreed to continue their financial support and to shift funds to the MT-401-OTS program.In August 2024, the Company received notice of a $2.0 million grant from the National Institutes of Health Small Business Innovation Research Program to support the clinical investigation of MT-601 in patients with non-Hodgkinâ€™s lymphoma (NHL) who have relapsed following anti-CD19 chimeric antigen receptor (CAR) T cell therapy. The Company recorded $0.7 million of grant income related to this grant as revenue for the three months ended September 30, 2024.21 Table of Contentsâ€‹Operating ExpensesOperating expenses incurred during the three months ended September 30, 2024 were $4.3 million compared to $3.5 million during the same period ended September 30, 2023.Significant changes and expenditures in operating expenses are outlined as follows:Research and Development ExpensesResearch and development expenses increased by 70% to $3.5 million for the three months ended September 30, 2024, compared to $2.0 million for the three months ended September 30, 2023.The increase of $1.5 million in 2024 was primarily attributable to the following:â—increase of $0.9 million in Cell Ready (outsourced) clinical manufacturing costs and process development expenses,â—increase of $0.9 million in clinical trial expenses, â—increase of $0.1 million in process development costs, offset byâ—decrease of $0.3 million in headcount-related expenses, including stock-based compensation expense,â—decrease of $0.1 million in other expenses.General and Administrative ExpensesGeneral and administrative expenses decreased by 39% to $0.9 million for the three months ended September 30, 2024, compared to $1.4 million during the same period ended September 30, 2023.The decrease of $0.5 million in 2024 was primarily attributable to the following:â—decrease of $0.3 million in consulting expenses,â—decrease of $0.1 million in headcount-related expenses, including stock-based compensation expense and net of severance expense,â—decrease of $0.1 million in legal and professional fees, insurance expense, and other expenses.Other Income (Expense)Interest IncomeInterest income was $0.1 million and $0.2 million for the three months ended September 30, 2024 and 2023, respectively, and was attributable to interest income relating to funds that are held in U.S. Treasury notes and U.S. government agency-backed securities.Net Loss from continuing operations The decrease in our net loss from continuing operations during the three months ended September 30, 2024 compared to the three months ended September 30, 2023 was primarily due to cost reductions in our general and administrative expenses, as well as higher grant income. We anticipate that we will continue to incur net losses in the future as we continue to invest in research and development activities, including clinical development of our multiTAA T cell product candidates.22 Table of Contentsâ€‹Comparison of the Nine months Ended September 30, 2024 and 2023The following table summarizes the results of our continuing operations for the nine months ended September 30, 2024 and
2023:â€‹â€‹â€‹

interests of our stockholders will be diluted, and the terms may include liquidation or other preferences that adversely affect the rights of our existing stockholdersâ€™ common stock. The incurrence of indebtedness would result in increased fixed payment obligations and could involve certain restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. If we raise additional funds through strategic partnerships and alliances and licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies or product candidates or grant licenses on terms unfavorable to us. We may also be required to pay damages or have liabilities associated with litigation or other legal proceedings involving our company.In addition to the foregoing, high inflation and concerns about an economic recession in the United States or other major markets have resulted in, among other things, volatility in the capital markets that may have the effect of reducing our ability to access capital, which could in the future negatively affect our liquidity. In addition, a recession or market correction due to these factors could materially affect our business and the value of our common stock.ATM AgreementIn August 2021, we entered into a Controlled Equity OfferingSM Sales Agreement, or the ATM Agreement, with Cantor Fitzgerald & Co. and RBC Capital Markets, LLC, or the Sales Agents, pursuant to which we can offer and sell, from time to time at our sole discretion through the Sales Agents, shares of our common stock having an aggregate offering price of up to $75.0 million. Any shares of our common stock sold will be issued pursuant to our shelf registration statement on Form S-3 (File No. 333-258687), which the SEC 27 Table of Contentsâ€‹declared effective on August 19, 2021. However, our use of the shelf registration statement on Form S-3 will be limited for so long as we are subject to General Instruction I.B.6 of Form S-3, which limits the amounts that we may sell under the registration statement and in accordance with the ATM agreement. The Sales Agents will be entitled to compensation under the Sales Agreement at a commission rate equal to 3.0% of the gross sales price per share sold under the ATM Agreement, and we have provided each of the Sales Agents with indemnification and contribution rights. During the nine months ended September 30, 2024, the Company sold 8,178 shares of its common stock under the ATM Agreement resulting in net proceeds of approximately $37,000, after deducting agent commissions. On June 10, 2024, the Company provided notice of its termination of the ATM Agreement with Cantor Fitzgerald & Co. and RBC Capital Markets, LLC. The Company is not subject to any termination penalties related to the termination of the ATM Agreement. The Company is currently considering more effective ways to improve market access to its equity.Stock Purchase AgreementOn December 12, 2022, we entered into a purchase agreement, or the Purchase Agreement, with Lincoln Park Capital Fund, LLC, or Lincoln Park, which provides that, upon the terms and subject to the conditions of the agreement, we have the right, but not the obligation, to sell to Lincoln Park up to $25,000,000 of shares of our common stock, or the Purchase Shares, from time to time over a 24-month term, at a variable price with certain market-based terms as defined in the agreement. The purchase agreement does not exhibit any of the characteristics for liability classification under ASC Topic 480, Distinguishing Liabilities from Equity. In January 2023, Lincoln Park was issued 180,410 shares of stock as a commitment fee at a value of $0.5 million. On February 29, 2024, we terminated the Purchase Agreement with Lincoln Park effective March 1, 2024.Going ConcernWe have no sources of revenue, other than grant and related party services income, to provide incoming cash flows to sustain our future operations. As outlined above, our ability to pursue our long-term planned business activities is dependent upon our successful efforts to raise additional capital.These factors raise substantial doubt regarding our ability to continue as a going concern. Our condensed consolidated financial statements have been prepared on a going concern basis, which implies that we will continue to realize our assets and discharge our liabilities in the normal course of business. Our financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should we be unable to continue as a going concern.Critical Accounting EstimatesThe condensed consolidated financial statements are prepared in conformity with U.S. GAAP, which require the use of estimates, judgments and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent liabilities at the date of the financial statements, and the reported amounts of expenses in the periods presented. The Companyâ€™s critical accounting policies and estimates include the valuation and attribution of stock-based compensation and grant income. The Company estimates the fair value of stock options granted (including modification of options) using the Black-Scholes option pricing model with key assumptions including volatility, computed using the Companyâ€™s historical stock price over its expected terms.With respect to grant income, the Company recognizes revenue when qualifying costs are incurred for the amount the Company is entitled to under the provisions of the contract.We believe that the accounting estimates employed are appropriate and resulting balances are reasonable; however, due to inherent uncertainties in making estimates, actual results could differ from the original estimates, requiring adjustments to these balances in future periods. The critical accounting estimates that affect the condensed consolidated financial statements and the judgments and assumptions used are consistent with those described under Part II, Item 7 of our Annual Report on Form 10-K for the year ended December 31, 2023.28 Table of Contentsâ€‹Item 3. Â Â Â Â Â Â Â Â Quantitative and Qualitative Disclosures About Market RiskWe are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information required under this item.Item 4. Â Â Â Â Â Â Â Â Controls and Procedures(a)Evaluation of Disclosure Controls and ProceduresWe have established disclosure controls and procedures, as such term is defined in Rule 13a-15(e) under the Securities Exchange Act of 1934. Under the supervision and with the participation of our management, we conducted an evaluation of the effectiveness of our disclosure controls and procedures as of the end of the period covered by this report to ensure that the information required to be disclosed by us in the reports that we file or submit under the Securities Exchange Act of 1934 is recorded, processed, summarized, and reported within the time periods specified in the SECâ€™s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Securities Exchange Act of 1934 is accumulated and communicated to our management, including our principal executive officer and principal financial officer as appropriate, to allow timely decisions regarding required disclosure. Our management, with participation of our principal executive officer and principal financial officer, has evaluated the effectiveness of our disclosure controls and procedures as of as of the end of the period covered by this report. Based on that evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures are effective in recording, processing, summarizing, and reporting, on a timely basis, information required to be disclosed by us in the reports that we file or submit under the Exchange Act. In designing and evaluating the disclosure controls and procedures, management does not expect that our internal control over financial reporting will prevent or detect all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control systems are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. The design of any disclosure controls and procedures also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Our management, including our Chief Executive Officer and Principal Financial and Accounting Officer, believes that our disclosure controls and procedures and internal control over financial reporting are designed to provide reasonable assurance of achieving their objectives and are effective at the reasonable assurance level. However, our management does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent all errors and all fraud.(b)Changes in Internal Control Over Financial ReportingThere were no changes in our internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) during the three months ended September 30, 2024 that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.â€‹29 Table of Contentsâ€‹PART II â€“ OTHER INFORMATIONItem 1. Â Â Â Â Â Â Â Â Legal ProceedingsFrom time to time, we may become involved in legal proceedings arising in the ordinary course of our business. We are not currently a party to any material legal proceedings, and we are not aware of any pending or threatened legal proceeding against us that we believe could have an adverse effect on our business, operating results, or financial condition.â€‹Item 1A. Â Â Â Â Â Â Â Â Risk FactorsOur business is subject to risks and events that, if they occur, could adversely affect our financial condition and results of operations and the trading price of our securities. In addition to the other information set forth in this quarterly report on Form 10-Q, you should carefully consider the factors described in Part I, Item 1A. â€œRisk Factorsâ€ of our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the Securities and Exchange Commission on March 26, 2024. There have been no material changes to the risk factors described in that report.Item 2. Â Â Â Â Â Â Â Â Unregistered Sales of Equity Securities and Use of Proceeds(a)We did not record any issuances of unregistered securities during the nine months ended September 30, 2024.(b)Not Applicable.(c)We did not, nor did any affiliated purchasers, purchase any shares or other units of any class of the Companyâ€™s equity securities during the nine months ended September 30, 2024.Item 3. Â Â Â Â Â Â Â Â Defaults Upon Senior SecuritiesNone.â€‹Item 4. Â Â Â Â Â Â Â Â Mine Safety DisclosureNot applicable.â€‹Item 5. Â Â Â Â Â Â Â Â Other Information(a)None.(b)None.(c)Director and Officer Trading Plans and Arrangements. During the quarterly period ended September 30, 2024, no director or officer of the Company adopted or terminated any contract, instruction or written plan for the purchase or sale of securities of the Company intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) of the Exchange Act or any â€œnon-Rule 10b5-1 trading arrangementâ€ (as defined in the Exchange Act).â€‹30 Table of Contentsâ€‹Item 6. Â Â Â Â Â Â Â Â ExhibitsThe following exhibits are included with this Quarterly Report on Form 10-Q:â€‹â€‹â€‹

32.1 4 mrkr-20240930xex32d1.htm EX-32.1 Exhibit 32.1CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICERPURSUANT TO18 U.S.C. SECTION 1350,AS ADOPTED PURSUANT TOSECTION 906 OF THE SARBANES-OXLEY ACT OF 2002The undersigned, Juan Vera, the Chief Executive Officer of Marker Therapeutics, Inc. (the â€œCompanyâ€) hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of his knowledge, the Quarterly Report on Form 10-Q for the period ended September 30, 2024, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and that the information contained in the Quarterly Report on Form 10-Q fairly presents in all material respects the financial condition and results of operations of the Company.Date:November 14, 2024â€‹â€‹â€‹â€‹â€‹â€‹/s/ Juan Veraâ€‹â€‹Juan Veraâ€‹â€‹President, Chief Executive Officer and Treasurer(Principal Executive Officer)â€‹â€‹â€‹ EX-32.2 5 mrkr-20240930xex32d2.htm EX-32.2 Exhibit 32.2CERTIFICATION OF PRINCIPAL FINANCIAL OFFICERPURSUANT TO18 U.S.C. SECTION 1350,AS ADOPTED PURSUANT TOSECTION 906 OF THE SARBANES-OXLEY ACT OF 2002The undersigned, Juan Vera, the Principal Financial Officer of Marker Therapeutics, Inc. (the â€œCompanyâ€) hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of his knowledge, the Quarterly Report on Form 10-Q for the period ended September 30, 2024, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and that the information contained in the Quarterly Report on Form 10-Q fairly presents in all material respects the financial condition and results of operations of the Company.Date:November 14, 2024â€‹â€‹â€‹â€‹â€‹â€‹/s/ Juan Veraâ€‹â€‹Juan Veraâ€‹â€‹President, Chief Executive Officer and Treasurer(Principal Financial and Accounting Officer)â€‹â€‹â€‹ GRAPHIC 6 mrkr-20240930x10q001.jpg GRAPHIC begin 644 mrkr-20240930x10q001.jpg M_]C_X 02D9)1@ ! @ 0 ! #_VP!# ,` @,,* @,# P,$ P,$!0@%!00$ M!0H'!P8(# H,# L*"PL-
#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_ MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04

(A@Z,Y!R-S9/'(&.]3+!X-?"F_GZ?YDSR M_+TO=4G_3_-'M\?_!0CX7S+NCM_$$B@@933PPR>@X?J>U2O^W[\-XD9WT_Q M-&BC+,^ED #W);BOG;XHK;Z0?C[K/AM=0\,S:)XCTL16\%UF&2X$LO[_ &;0 M ,@%5'"^IJ3XB?$#XB?$/X0?!'0+;Q%>SWWC:*\LM1SM_P!,SWN\W;L0LMPLN5J+2;L[RV]WF_E?0]_?_@H5\+HU1GAU]%<9 M1FL P]0=_/X4?\ #PKX7&(R^3K_)0.TR?8!M!],[\9]]\J_:8\ 0^)? @WJ MUAI2:1)'\.YH1I"Z;?17%S-IXB2*X,L:*,)1NP:UM#^#;CX&P?".3^QUN=1 MT%]8E+7L8OTUIF$T48A)W[1& N0.]9K#X/D4VGOWV7?;L8K"9?[.-1IZNS7-
MLM[[=FM.^AWG #Q/#X4YQMUO/ 7DO_P 71_P\/^%7]W7/_)? BZ^1O@K;^'X M?V>/C/+J_AZ344IM!9Q>:L_ERQ[Y=]JQR$KLD&YL??`VG'6NHUS]GCPC8 "W MQ'--
I5QHOB[P!8:=>SQOK/VFXJMU MY?YHZY9;@(3<)*6C2W76VOIJCZ1_X>'_J_NZY_X!+_ /%T?\/# _A5_=US_M , E_P#BZ^?-<^!GPPB^,?BOPEI^A:V]MX.TB?6;U!JA>;5B(HW2WB&S]V%+ MG+#)
(IVB?LX^ _%*>#=:CTS4] T^_P##>H^(;W2-0U(AW:&1$CB\XIF./Y\E M]I.W!Q4?5<%9-J6OIVO^1G]1RU)2:GJK[KJFU]Z7^9] _P##Q#X4C'RZWS_T MY+_\71_P\\ A5_=US_P"7_XNO#_
9X#^'7A#4?&ES8Z3_;]K>> Y=5-E%J M#3BR82!)8H+AH@7#@J5E"Y # #G-.4@LD(M!$0T(&%:4N"#SBA87!WLU+^O\O\ A@6!RZ]G&?3JOZT_X:Y]+1 \ M%"OA=,2(X=>D(!)"6 8@=$P_2F?
\/$/A3D?+K?/_ $Y+_P#%UXW\-/A]X5^& MWB;5M$T_1M6N-=;X>7.J7'B)[K=:S^?;AF18MN%49 #!LY!!KR#X#1^'?^%! M_&NYUPZVL7EKIMH4F2?RY$1Y"H"':2N' 8D?>
V\=::P6%DFU%V5NJZNQ2R M[R4I1C*RY>JUYG;^OT/L:3_(*%?"Z%@)(=>C) (#V 4D=CR_2F?\/# A5_M=US_, E_P#BZ\5^*7@OP?\ $/6GTJ_TW4%\2Z?\-K?6;?5XKW;#&8(,K%Y& MWY@'_
J_NZY_X!+_ /%T M?\/# A5_=US_, E_P#BZ^;_ !5\%OA_8?&4>"=&\):O>2C) (#V A@M!3=3ZZL$ M1A-LL@#.R?NHT+_LVP,HO(? MM"2[=L,KQAG1@.-R]\T_JP"23:EJK]!_47#KT MFT;CLL
<#U.'X'O3/^'B'PJ_NZW_ . 2_P#Q=?/7ASX8^'K"QF\3>'%U?PW8 M^(?AWJNIMH[WQ>6"2*2-"K2%07B?.<$#.*S_!-^SOX"\._#Z6"6^,/B2+PU M!KL>I+J+223S. WDFS$>%B()59-_WASUH6$P=
[6E_6XU@,NYK-2[;_)WI\VN M?2O_\/^%7]W7/_ "7_P"+H_)Z'_'K^[KG_@$O_P 77R]\5_@=<X*TWX7ZE MK/@JUDO[C2(K2:]N)=59;ZU$@4/]KL98U* L?E*$_B*^9JZ:66XM2(P{SK
MH9/@,1%RCS:=VC].O^'A_P *O[NN?^_2_P#@=' #P_X5?W=<_P#)?\ XNOS M%HK?^R,-Y_>=/^K^#_O_P" ?IU_P\/^%7]W7/\ P"7 _:+H_P"'A_PJ_NZY M_P" 2 \ Q=?F+11_9&&_O#_ %?P?G]__
/TZ_X>'_"K^[KG_@$O_P 71_P\ M/^%7]W7/_)?_BZ_,6BC^R,-Y_>'^K^#_O_. ?K_\ "S]J/X=_/[.T' M6C'JA&4L;Z,P2R>NS/#?0$FO6:_#'2M4NM%U*UO[&XDMRVD66*:)MK(ZG(8 M'U!%?
M%\)_%4_CCX9>%O$%RH2YU+38+J4#IO9 6_4FO"S' QPEI0>C/F+[]#\=?!7[-7Q+^(GANUU_P .^%;C4](N2ZPW231[*,5;@L#P016 MW_PQI\9O^A&NO_
B'_XNON;]AF3;^S'X5'.3:]_]*9*]Z\VOH:F/JPG**2T; M_K<_.8T8-)L)_\ X8T^,W_0C77_ ($0_P#Q=' _#&GQF_P"A&NO_(A_P#B MZ_6#S:]-U^AKJ_M&MV7X_YF7L(=S\^]&TRZF_8%@TZ.!I+YO&QME@7EFEV%
M=H]]W%>:']F#XN _\D[US_ORO_Q5>X>#3_QBGI9_ZJB#_P"1#7W-/<_OI.?X MC_.L*N,GA9244G>4OT/O\NS2IEV7THTXIWOO?I8 *G_AF#XM_P#1.]=_[\K _M /%4?\,P?%O_ *)WKO\ WY7_
.*K]4_M/O1]IZP_M:M *OQ.S_67$?\^X_C M_F?E9_PS!\6 _^B=Z[_WY7_XJC_AF#XM_]$[UW_ORO_Q5?JG]I]Z/M/O1 _:U; M^5?B^LN(_Y]Q_' _#/RL_X9@^+?_1.]=_[\K_\ %4?\,P?%O_HG>N_]^5_^
M*K]4_M/O1]IZ/[6K?RK\0_UEQ'_ #[C^/\ F?E;'^S)\78I$=/A[KJNC!E(MA7@@Y!^)76WOP_\ VD-1.H&ZT+Q9.=0NX,^[W(G[^XB"B*1N>J[5Q_NBOTE^ MT^] N;_
)Z'GA_I!<&LSQ!)OV@0%5C<6>L>%_$^H6EQ?-J*VF%JLLS;(;BQN?/@D?&=M$P,B(#)*]HG4'UE[GPYXJG;688;? M4=Z(?M4<6(!5'&?X-HP1R,=:T-8\)_M.>((]*CU+2_&-
XFESIQ;)%??M_P#$30=-N[.WEU.!GNKLV"O"X=(IPI;9*P.(SA3C=CGBMR.] M2:-9(Y%DC;HZ,&4_0BN&6J12NE)0]FI2:T26MEONTDE?JU]YU1SZM47,Z<;+2[N?'FC^!O MVE?
#\VMS:,HOBZREUN4SZBT2H#IW.]$S+=(-J3$@_> X!%?6/BKXQ^-/!PFN_$.DV=K;R'[-$MK<;TE8# M<"&4G8,'.3@D=!Z:WA_]H#5_$?BC0M!DTN-;AXT>Z:WR-A8%BN#T"J5SWSFN
M' 6.K&$JTL+[JZIP;T=GM+IO;5Z-6O:]K.9\R2A#F?E)>FO]=#Y \1_#S]H[MQ='J::UX?\4ZBFIB 7JS11XN)SY6[&,[=QQ]:BTSX8_M$:,V@M8^&_%%L=! M65-**1)_H0D_UGEY/&[)S7Z5_:?
>C[3[U[/]I32M[.-OZ1R_ZP5+?!>IWFHZ%X0\2:9?7D3P7,\$*9FCWWGYI:/\+?VAO#]$KEQIOAGQ/93:XCQZFT4,8%VK$E@XSCG< MW(QU-:_X3_:)2"JMSEL%1@G)&.M?HU]I]Z M/M/O4O,I-
W=./W$O/ZC=W1A?T_X)^=7A?P[\7? ?C^\^(_C/P+XHU9X;,:1[W M4A<_9+B%0@'G"53U55Z$$$=17(?$K]]?4/%>N>%;_P -W^IZ"WARVE@M+ZZO M_M-],96W2/+)M*MG@;
<8P,5^AWQPN, !CQV,]=$N_P#T4: &6/[B_05[. Y< M;>I4BDUIM:W8\S%<1U*52,1UBW:W7TVO;9GKH^/_C5?%DGB<>-+_P#M^2W- MHU\9
6,!_P"6>W&T)_L@8SS44/QT\7V_A*7PO%XQOX_#TJLCZ>LV$*LOXGIK?&#Q&^H/?-XGN3>_MI/IOJCM-O&YK+;M\@\?,+^3PY&BQKIS3?N]BG*H3C M<5!Z*21[5Y511]7I@_UNQ&G[B&GD_\
,]2@^-7BFU\8GQ7%XKNT\2-$(&U(M./,:,($"-Q@KM &".PKM/!7[5GB+P[>Z]?ZMK%[KNI7NASZ/87DESLDT\R.' M$BG&2 PSM_+ KYYHJ982E-6:,Y\5UJBM*A#[G_F>JZE\:M?>+[VZ
MU*\L6TR>XDD&7M6^]#C& AQT %$GQP\6R^#%\)/XPOV\-]@B&G>=^[\(3. M-QO'^'./:O*]*KEBM0=_$ 7 1 MT= @^RSRY#!?0O_E*_1 MT= @^RSRY#!?POVA: \ /=/SKF:*<:$(*T="X\88F"M"C!>E M P#,Z;^T+7 GNGYT?VA:_P#/=/SKF:*OV:+_ -<\9_SZC^/^9TW]H6O _#W3 M\Z/[0M?^>Z?G7,T4>S0?ZYXS_GU'\?\ ,Z;^T+7_][I^=]H6O_ #W3\ZYF
MBCV:#_7/&?\ /]/X_P"9TZW]LS!1.A). /6OV6_9N_Y(\/_/L"6O\ Z+6O MQ'M?^/]'_?'\Z_;G]F[_)('\\ _L"VO_HM:^8SR/+3AZFM7-ZN;83GJQ2Y M96TOV\VSPC]B"7;^S1X7'_3:_\
2F2O=?//M7@'[$\FW]FSPP/^FUY_Z4R5 M[CYM.K"]27JSX>,O=1>\\^U'GGVJCYM'FUER%\\^U'GGVJCYM'FT<@T9+>;5%5)+R[NL_9[%&Y7< 06_$W2;W4O%/Q3\,F?[)K&IM)=V4
MSG;O@EB58V4]U4J4/I7G/PXU#4+:*QL;[1M0T34M-@$=TD]LR0QA%P7$N-A0 MXR#G]:^WP>582OADY.S<;W[OM\MM+'YAC,[Q]"U8+X82M;^[;27G?>[T/NF
MR^*GA;4M>LM%M=:M[C4[R,RPV\8)W +N*E@-H<#DH3N'I7F7[0?B2.^UC3-. MLKBYM;_3(I#=WEK<-&3%,.+4@'!W8WD]0 "-U6?AK\!_M7A]M1;7==T(W[/
MJMU8VERL<<%U(6*RH"A8.4(!3H3U%<-X@\,3>'Y WB[5"^L3,US;=*7O+3S]?2WYIGZ!#VN)A&-6/NM)OMT=O6]ON M9/>,OAOQLNM>';-
[!-5TZ*YN!I<6UE610).%&/ED5F&IC(KT[X=_&)]3U2+P M[XC,4&LO@6E]&-D&H*1E2!_ Y'.WH>WI6/XNDT+2?@A=3Z5XEC\(>)-.M;:: M=0ZWEY! TA*J$&"&?>,' QGL"36'XL\2^%_B3\
(]"\0Z7;17CV++I=\UY;&W MN#.!N9_D;')\ 9QNXK-4JOU=8B:;C?E>CNM$T[[:W[_*,U=2FJ[H4VE*UU MJK/6S5M]+=OU1D_M$^,6OM?DT>VN#STKE-(^%5WJFF MPW?V^"'S5W*A0G'U-9?
BG0)+"STI++1)[?=))<2J6R9V7 4YMRT3O?6[UTUO?M MH?G7DC*^L!XJT_X? M2>&-$D#_ -GW5K.1<1Q22N&C\K VJ"<'S#R?05\Q:9J&I+_D M5= 4>8L"2=Q "A>%85?RY/*$K0\-
DN%/IM/3.>*TH/AQ MX:MKB.:+3MA2+R2@F<(ZA64;USAB%9@">'><'V%4KOX;:%8V5R]CH_VRX:#ROL MTU])"'+\H3+'Y@&V #=M)P!7U_)3[,^5YI%R?XR:-9^:;JUU.T1&>$22VPVR M7"
%K=2K',HR!CIG(#'!JK\=_#EG>16=Y'J%E>F9H)K:XMU$EN<5(6N0>:K^'E^'FEO%;WNJ3ZEJR74DLEZT5Q$)&>8*P8Y.Z(2JH^9F ;]>::I
M1ZIASL[6;X[>'K6W>6XAU&VRRBW2:W5&N\R'F++XQNC?[Q7@9Z5/%\;/#'T] MLEW$M_)8%5W7JVO[I6C,BPL217.75Y\.+V-(&9G>!DMK< M'K2=."W3'SL-3^,6A:5?
6]I,MX9II8H01$]HI>)95)9F ^ZZ\9R3D '%>N:" MV= O#UP7_P#0:\8_X51X5-F]UA-)!(ZR2+)>2MYN%5 KDM\R[548/' KU_P MTP_X1F]QP!O [?**X,9&*IKE[HZ0PYR] MYY]]///M5'S:/-HY
YRJYY]]///M5'S:/-HY YRJYY]]\^\2_'+2/"_B+4]% MFT_4;N\LHXI-UI&KQ2;P3@N6"H5PB,AB#R, UI^/_!'-X;\(:A?6I O-JPVY M/022,$4_@6S^%(;_C'5"EQ=P1LS6MF7.UFR97'+2.>[,QADO0CVT6P
HQ2-@QW!CG/?%<-XY^ M.U[\0/MNFZK:QZ3^^!TZ&,[EEC(7>#)_$X((&!P:^5;OXWZU]I8P16ZQ *4 MZ_UKT_0]5M/B)X5CN #"S\,%/S03+W!]C@CVKJS++,7A*<98ZG%0DTKQUL^E
M_P"M>]SZK$Y36R^*J5Z:2>EUK;^OQU/;_A;HFFZEIMU+KNP,< M5B_$S2K*P\06UOI\"0/)""\<0P-Q8@5\28G&5<2ZD)+W*2RNAA%?N>'R^&!PU.C3GSI*UWO?K?
S>_SW/E,RA!3^L49\T)MVTM:SV?FE:Z M6EFK-E[SS[4HG//T-4/-I1-U^AK;D/'YSXZ\'G'[)VF'_JI__M0U]H37?[Z3 MI]X_SKXL\(G_(Q)TX_]5-_I[&OKJ:[_ 'S_P 1KCQBO)_XJ?(%7PMA(6'FB25&Y.<;
MD'7C)KE_&_PYEL_#L%^FLR02:Y#/]AT1R3)%!CJ6))\L$X0<<'/-<>)R[*\= M57MZ7O))>\M[-O6W;K=6>JVT/3RJM5H23JU?BE';6*O9.3NUHNB2=_)ZOSRY M^-J^L)IQJIO-+BK!?
[GT_*O5_"_BAO#.HVFO0,TRV*[Y1#\Q MGLV(\U_^!B1?=?>OEZQ\ ZMJ&HM:PVQ$2MM,S<*H]_?VKZ+^&7@NK=EHD];^MS M]FXLR7+,3DY0M[TWO96T?
3566AJ5Z)K+ZSI<%Z]E=::TN3] MEO5 E09(&X*2!D#/7H15[SO>N?\ #B:E9Z+;6^K36L]]$OEM)9HRQLHX4@,2 M0=H&>>N:TO-KR)TUS.VQ^&5G%59*%K7=K7M;ROK]YS=_\,-
(OM,T^P%WJ%M; MV=LUF/(G"M-"SARCDJ<_,H.1@]LX-6)/AWH\MN\#/=>6\#VYQ+_ UQJH/;KO M'Y<>];GFT>;2Y68\QS^G_#;2-.U"TNUN+Z9[)U-G'-,"EK&K,PB0!1\FYL\D MG@#.!77>=
[U1\VCS:.1L.8O>=[UVWA5]WA/4#[R?^@BO._-KO?!![OI'VI'WE M_P#0!7G8Z-J2]4=F%E>H_I3'B;@]45F^44>;?H\[WH\[WJCYM M17FH16%I/=3ML@@C:61O15&3^@HY!\UQNH^,-
&T>^^Q7^JVEE=?9S=>7<2B, M^4&VE^>,9XKB'_:$\-Q>(KRQ:26?38K>.6'4K."=6)I"2'CPJ<;0 1^);9&U2\"4>:?H-!']?MO&&FVNKZ7<26=[;R;H9UXEM9A_GD="#77^'H-6\<:?>O;:3 M'NLIQ;K9P7,?
VA92F^01QL06A).Y1G*Y/4"N+$4IXR#C&/+4IO6+W^_3K_6Q MLZ'U:\;XAM],>2+S#LFW*$(SZDUZO\,?! M=WX,TJYBO9TDFN9!(8XCE8\#&,]S77W@O['4)["71[U+^!U26VE\N-T++N!(
M+=,=^E9<=[^JKJR:=#9I/884IYGGL[EM>KCL=FN:4?]J>,81T; M_1[OKV/>QN;XO'4?9U$E'1M_@F[O:_8VK;Q5J_P_>]U_1;K[+(UL;>\1AE9H M?4 \>8G)4^^%F\;>/K[6=8QIMYFYA$]K.
[A!&1C>H0?*'1N .0167K7PD@U;7/.\UH;:0Y^0@,2>J\^^ M2"/7&*]7)OJ6&DH8R5[+1VT?EW?5+MJCW>$L7E6 QLGFK3]V\&U>.J7WNUTM
M+KWHFS*_&LGBC3PUY&&O;5A%/Q\DRGC./<9!%?4'P56[B\,R&ZUN?4Q%*]G M%;2[-MK'$[(@7:,G*@9+<\5Y)X2^#VI:-HJ7.EZ2A6-D/V::7R9)DS\VPL#A M@"2"W!]ZJYT3PQH_AN2>73--
M[&:X5%GEB3#S;?\ JIG_ +.:^HY;O]Z_(^\:^6O"QQ^R M!8G_*J4?_0S7T7+=_O7_P!XUY.*5Y/_ !2_0^KD_P#8)6%HNI:[V2[M2)?-D,NC6_QUT73 B*(+.TBZ*,[4
M4>@]A7GUKXPUCXDVMQG9Z7XPDTI9-1N(8%OYI(+>1-P* CY2%(.T@9[5TXS& M5)QYJ:M3IZ17\M^OJ[7?F&6X)87FK/6I*W-+N]?P6J7D8O@#PY>:_IGBK7;> MPLT1;&2U2^OY5/SN1YC-
+*23MC#D]JR8?A_J/COPYHVG6!MM3=+EM3T6^TV: M-HI #MF42<;=C*CD''0YZUZ[X2^+VFZ5I.C>!7\-7_CP>)KBZTRXU6.W5(64 M#&)<#.WYCU((7YO:O-/@CK?C+3+7Q#H?
C+P+!9>'=6=M/TQ8/[\B1PRS*C M %I8_+)9B=W(4YSBN2C1XNB\6IM26JNUJM5HO7_^C>%5>A+G_/=?G_P"5KK M2-,\1+;2:Q%?>*;55NI[3207M5<-U$[#:>1R "?O5TJ6/A("_F\>U\#Z>RM
MK/GZG;3O),-[J?*DC8L"JYW*0#CMWKSW3_"F7\]MKEEJVL>";<,8QJ;(K;X MB,20I*I5GRN1\]Y!KO/%=U!=V\%KX"C^US7\L,$[-9O$)(RP*I<*=K1ONVL. M,G'4
YKLPU=SA%T:C@W;FU:5UZ6T[;V/E\5AHTX>TG%3W25M=?6[[]=MF5OB M!\2[F]U1=,L(1:Z1:6T=I!H=M#OC*HO.(@.N=W(QC'6M+P5*? V@VWC738]1 MO;751$]]I-E!%>I&I!5)%8C=@9!(&2"
<<@9J.X\:6 AB^GM8-/TM0W,NH7M MNC1))/G]X5PI.W=GK37G\>_$/PY>S612'0=$N@8;32I*#Q.F C !,F,AFQS MD\ [-"45!VMKNVJUZ=V[.^_4BGK5C*ILM;]-6:_2ZMMKU)=0L_BIXRL-8\
M2Z7X>FU/58I((]+2KR0P6R1,^'P R>8RC!///?V@K#X=:GX; M.F)X?NG>.]>XEEFA,2]TOF!L_N7VD*!TW+@G-;7P?\6ZIIFDZCJ%J;F:VT.Y MWW*Q,K$Q/A9&0$D,58*?0@M6?X3MM?N?
#FH6MOXOF\=75SJ,['Q#Y1C:-?N_ M9R[#)!&2#D@'(45G"I2C&=.I%7UMNGKU[:>=MSZ3#SISPTY3C?[]WMKMI;3Y MD5I:V<_CFSOM UF^TK0KB66&4*4CD(1A)%#(6!^7)8 C!(;'M7L!N^3R!
[5Y MMX(T";2;34H-6L+-V9_)CD1O-CF@R&4[6'R'O:O8K.:@ M_9K7I_7C+<%%R][8Y6X^#OC-?%FN>'+/PWJ6KZGHUX;&\33K5YQ')N(7.T' M;!(SU%;.@_LZ^-9T!-=GTFXTS2?
[6XM96E@GD+J26>4MDN+24F1DDW;]KQA.O.0 M-IX9AUR0/K7"ZV* M:^"W]+]6[>ANH4K_!'SVGP?\77UQJ0T?PSJVN6-A>26+WUCITS1&1"N?%S0_AJEMI]SXJLO
=_(UQ@A25;&9I&PT:MC'SMP0#R>..:^ ML/A\XXT7Q79^'_&5UJ,VB:=H%SX@;$6KVT4+0W)ED5KN!G$@DRX4!%?=\O(Q M7E>H?M4^';[X<:=I\-M>V>K+I.GZ++6":=$T+QV\RN91<,^<$+N"!
PSA%7YK7/ =4^%'C/039'4?!^MZ>;VX-I:_:-.E0SS M#CRDROS-_LCFL(Q/X+USP1>I9>(=#OM"NGC\Q(-0MFA9T_O ,!D9[BOH^X_: MQTF?Q1XHJ,7/B&)+_P <6OB.PDA$;2VMK'
\3*JR%D#?,/DQ@C(R*\[_&C? MBAX4^)NH:!+X:L)H9K*WECOKUK7[%%Z'=ZE8:_XED9-(L-)M;C[:T9!Y+A M=OS*,A,DE3G&*YSQ'X5^*OQ#\;7MOKFB>*-?\66\<:W$%S9RR74,9XC!3;E5
M[#@#TKTKP7^TIHGA 2 _F7L>LFWTSPUJ7A_4;JU8>=;=2$K<6V6P61<#G! MP2 :M:U^TQH-MX*UGPSH27:Y;A254!F(' MUK%3Q"E=PN^]NE_\NGS+M3M\6G_/&/!?
PMU#QMI_C&YMY(K23PQ8?;KFVG1 MO,E_?+%Y:@#A]S#@^E2?*.^(;2PQ?\ " ^(S),76)3I4V6*?? ^7MWK8^#? MQ,TSX?Z;X]@U..ZFEU[2HK*W:!0V)%NHY27)(P-J[GGFO8=8 ;YTB_\ $&MW
MT,NO)#>^/-\21*6P5L+>,*\)& AB0,(.#BM:E3$1FU"-U_PW_!^XF,:;2N] M3YWL_A=XPU+19=7M?"6LW6DQ1O-)>Q6$C0JB,5=BP7&%8$'T(.:T+/P=\1++ MPNMK:;%XAB\/>))K=5BBLY?
L^IR89X ORXD."S+C/&37U))-DE- TUXS%.2YME)V[EW?*3@D9'%9*O7J7M3VO\ A?\ MR6I3ITXV[^M#Q#6?AQX]\.R:FFJ^&-6TU]+CCEOENK*2,VL;G:C29'RJQX!
M/!-36/PK\9ZA=75K9^$=;N+BTMDO+B&'3Y&:*%UW)(P X5EY![CD5[II?[2/ MA#1M>\(Z#/;ZUXG^'^G:%I%>$H&V:MK/_"0V6K:/8:OITO38HS87:W MC2NL[@,NU@9 "H4\@$$ 8KY1B0I$BGJ%
KHHSJSE+VBLNGX_\ SG&*2Y7?\ MI$]K_P ?4/\ OC^=?MS^S=_R0/X?_P#8%M?_ $6M?B-:_P#'U# OC^=?MS^S M=_R0/X?_ /8%M?\ T6M>!GW\.']?29=_N_\:_)GR_\ L>2[?V>O#@_Z:W?_ M
4/7L_G_2O#OV0Y-O[/_AT?]-K_P!'O7LGG?6O9<+MGR#E9EWS_I1Y_P! MI>=]:!*,\G [D]J7(+G/-/BE*WC_ ,<^'O $3'^SQC5]:VI%G/[N(_[S?TKU M@2A0
H"J!@*.@'I7DOP;!UR_\6>,I@3)K&HO!;,>HM8#L0#V)!/X5Z;YWUKK MKPY;4E]GW O_)?(X<++GYJ[WD_P6W^?S/-BQX?F@U2+7IM3NI[&Y4Z;);2 ME?(LUD ".N
#S(JY))^]7S[XT\.R:WHE_I;@17!^4!^,.#T-?8>IVEQJVG75 ME=0)%W_ ,'O%EO80/)%K2JT\3AW[\&OPU1]CE^/5/EDY)2BU;\UJW^1\GV'P-URXF N M[BULXL\L&WMCV KV'1](;PSX?M-
/L8VO3;J$4.X4MSR2>U=5X3T)-8\.IKNN MZE;^&[":7R;: (;FYN6QD%5RH (!/TY.!2ZYX9TW0H;#5KG69]9T/[6$N4XL M0$8%420+NV_.5S)O*X!!P2 >W%TW@TS3'-WIRHO*QQ* ID9]P9I,YRQR#C
Z2SU7XB MP:9!IE]IHO-/@C:5/[&CBD$"E?G5H"%\Q,=5*D]2*SA"M@\0\5&"DG=-.VS[M+OV>ON]CY:&>.9;SQ--ILDTAGNY;B>1F\YH<*$08!7 MH!P
O3I7H7B+QCKV@:AHVK:L;>;2TC:"U1+;R;.:CD)0*-I(X*D!A@>@KR M_P 0^)-*U/XAV\A:]6?18X2NRB<2Q-(VYHR<8W+M"ANC8![UQT_:1JSQ,K MV5]97=KZ)-
VWNUKI^!W6A*$*$(QD]/=5DFE[S=K[63TOZ;FEH5U<66O%)3TF M*[TTQ!O]"N/*D,F>0Q8'(QZ8^M>H3?%7PGING072Z!-'?6&39P/;J&#/A6VR MC(7(/))ZR+FOCWXV^.=43Q0=
(M)Y["VM$5CY;%#*S#.[/<#H/QK1^!WB?7-9U M:YM;N[EN[**/PS7S#SV4\2\-13B[\MTEOM>V^GKMT/UR?#%=95#-J
MSBHJ*DX)RBW&W5IM7DM'IUM<_0&TU"&_MTGMI8YX7&5DB<.I^A'%2^?7S#;& M#3M0TUYVU!=+GNB]_:Z<9/WL4:%R[(G)"OY>2.><'(XKZ/2Y$J*XR0P##C'6 MOJL'B?K,ZE-
I)PMUWNKWM;1?K?MK^68W!K"TJ5+-,52[5U:UG:U[ZN_II9]; M* Y_TN-]:]/D/(YR[Y_P!*/\ I5+SOK1YWUHY YR[Y_TKT3P2 M^[P1JA]Y? .0!7EWD2?6O2_ C[O
6K'T,W_HL5Y>8QM17JCOP4KU'Z,X!9_E'T MI?/^E45FRH^E+YWUKU>0X.3EV+Q&18JJU2W4C'F4EZ>AYC\#=*U6PDU&:XMI;?3YT4IYHV[G!Z@'VKU;3=9NO MWBFT\5Z9I]MJ5]

GV:2VN!@R1L0,HW\+CH#W!(K'E\5*FKW-A#IE_>M!&C%[M>$XW'^ [L;2!@\^M9\]WXLGO9+JWTR."*(VMI<.F1)L8;W;=S@D?+]>:YWC
M*N(S"6,JI0ONN]EL_6UKZ:D5L9'&XN5>]DK[IWL[+X>_O6M?3?='5?&CQ9JM WMIUYJVP0ZEJ3"%WBQFVA)"*1UP.,^1)KQ+P9J5[H.NV]QIBEI,XDA7[LJ?Q M!OYY[&O8/$6JZCJ7AN:V&B-/?
%%P3-'LWC&6 #9'? _"MSX9>#M N+L0QRVV MFW1=%<7X^SN[,<*$5B2^2, *<9]*^HR[-,"L+4I5H69+7PN,H\U23=UTDK65V]E'9+?LFQGCN'3[WPM8_P!I.8(AJ,+QC!+$%&\Q M<#GIC.*K>
(4T'PS80:M=0+9I92K-#+#*XDW]@ISGOTI_C/43=^(;RVTB]AFT M/3Y#G/)%<7\3M&O?B;X;L; 09!/K82F\-0?-.*KPUWM=;7TLM8[M:W^\3+:*JO"49XB4*,6^>2 M;2CSJZ6J5F_A;?
7HNOH/A3]IEKFX6"R\1W1?M#J<(E! $_-CZ&O5!OQ@C\. MZ1':>)C<.(M[R:N&,RG+%OG7&Y0,X&,@#%?#WP_\-7%QXKC^VPRV=O99EN6F MC9?+4<'/UKZHCT:77X%TZW!\W5 ;6$@?
=0C]Y+]$3)^I4=Z^VK26EGOJ=?$N38#+L70PE"[IU-9MV]U+JII7TBVW>ZM9M;'T9H MVM#6M*MKY;>XM%N$WK#=ILE4=MR]O7\:N>?U^E8.@07^GZ5%;:C>1W]S%E1<
M10^4&0'"97)^;&,D<$^E:/G=?I7Z-2C)TXN:UMKMO\kH_&Z\H1JR5-WC=^M5 MUNFZ3^])GS1X9./V.[_ 5]5_)/ H1KW26[_>O]3WKPCPX4O\4OT/K9O_8%' MVL_WA7-RG!2@\I$Q&/7%-
T51I^D6=L"/W<2@^YQD_K M7H4OW6%G);S:C\EJ_P >4\RJO;8NG%[03E\W[L?PYCIOM?\ G-"0_RJ><#:,]:U/M9_O"JFHVEGJ\<27UM# M=I%()HUF4,%<=&P>XS7
HQ=XSV>YZ].:C+78X;PW\6/&'@F\F;3+XV@8C=:> M2OD#'3* 8'ID=1ZU=^)/BS4+\6GBRTU22#2[IP6@:4#[%=J,M$_=@<;E+9RI MQV-1^)? >A7\]I#:VSPZ@\RSB&V">#QGH=<-
E"KZJ4N7KI_P $]K#86OBX M.=*,G%;M+:\3T7XOV,WCKXN:%X8>,++-%IT,:V49CM[;?"LA6()%8[F.!ZFN MY\.66M>'/'6I:MJ<.H:;=6=M+>1DJP9PA QG#@+_ "3C@9K$N);FPMFU7PLM MG)]
[Y9_M6Z<,(P(]@N,D'Y@G&1=\GD5@^%/BCJGP]\4VT$ER%U"13*MG.YF MANT/ +1.N0>H/6M%2 _=QA25XK=7UOI=^2>B/D:DHPKSE-V;M9VLO)>;3OZ_@ MM[P/JVI?
M!QZM(X)\/:9H^J6VHQSWTFI(X6M)2Q(5O+&&R#N')(Q@BN]\. MG<K_(I\2>#[.QM[G3+:%GTW2D9HXMT+@YR#NWL"WS$G)QGBK6D6<<-[%\41 M%>^-*TJ)HYO#4E0HMM>RR CS653D
[ADN/X000*\TF^)^K_ &V:YM)8/#]L M29IETJ)8/D'S'USGO!'@_P KGC/4-"T:RO/"][<7=Q!OO5\RWD.]@T?F+A@.# MPRX%>C2>+['P)8_#/PQ;Z]+I7AO4I#'9F&W;&HO),=[X7)1%+KM)[D''!K(^
M#/C%/$VHVWB3Q=97#F /=Q^(+>$;;G((\J6,?ZUEW#]XHR,8?L:Y7XI:-XQ\ M&?#71]/\/_$*7Q%>7NIR:G:WUTBVCQP%0OEP32'",K#+QAE/*X4@5\5G.+E0 ME*6&I?"W?2^M]=[-\VK]?
2Q^K\'91ALTJ0HYIBN534>5.3BFG%V?-RRBN3W4 MT]T[+>YV&H7=S_PM&2UMMM=? M%NGWGB?4-'TV2;48['B;4(XBD ;C"@GDDC)!&1@=:Q9+Z>70[S3]2N8KGQC=
MZ;9W.JZZLP(N&2,>9&&&!L$94DC[S*QZ8%<_X*L+Q+V?6H[PP6%[@"Q>$9:) M%VQ/NZJ3RQ'H1771=2*I63O)WDNMK;ZO3[*:UZV1XF)IT74Q$933C27+"2V<
MK[*RU37,XMI=.9ZGIGVK_.:/M7^%'VL_WA7MNF7 _\<-?FFGW%^E?HM\3+K=\.?% MSUTV?_T U^=* _='TKZ#+%:$O4\[%?$A:***]HX@HHHH :8D9@Q12PZ$CFNR^ M$'P\E^+'Q.\-
^$8KD67]K7:P/<[=WE1X+.P'%/%.I^ "/$VE^ M(-&N39ZKIMPMS;3@ [74\9I2@"X)J)\S@U#?H.-DU?8]PA^$OP[^*^A+H M_AS%K^C:WX8E@^;7[N.>#4H)+@0&3"(#"P9@V.1CCK5+X??
LH:GXD\>IHNMZ MYIVF:;;>*6*WMQ#(S2-<+&TA\D%,$,%(4MCD\BLO7_VG=5OM-O[70/"OASP M5)JE[#?ZM=:) XDOY8I!(@;>Q^)O&XHN 36G?_M>Z_/JMGJ%AX6\Z/<0^(T M\4SFT68_:
[X1E':0LY^5@3PN,=J\WEQ234.NUW=K1?KZPWBSPM::;;B]BTDWNH-$^KK:DB5K?<@&!]T;RNYN!FEU#]F7Q3IWA][Y]0 MT275+>SMM1OO#T5V6U&QM)V41SRQ[=NWYT)"L2
PR*DE_:/N+C0YM*G\$>&; MNVAEO9-'^UPRS'1Q=(-2T6: Z+HT&NWEC;:7 MJ'B2*-Q>WUI R&.%\ML7(EH&95!8**U_VKR_#^MM_;/0C]U_7]?TC=E_8Q\4
MPZB]D_BSP>)HM7_L&;_B82_NK]E#10$>5DM("",9Q_%BL*W_&4_'4_@VZU\ MI8QO##=72:6TKFZGM[9RDTJ80I@$-@,X+!20#2S_ +4'B.XUF[U(Z7I@FN?% MD7C!D ?:+J--@C'/^KP/K[U)?
M3>)-4\'W.@WFEZ=<%DNH;:],MPK6L-Q*T MCH(UD$;X+,%9U))%OOKBM>W3@C_=?^#VC66HZY?Z6TMV8U-G;/ M*95WQAU8%HU21<'!:-F /%>85ZSXY_:.UKQM\.8_!?\
8VF:/I!GAN9ELGF9 M7>)=J>7'(]) OUY?WNYE/EO[FP4445N9A1110!+:_P#'U#_O MC^=?MS^S=_R0/X?_ /8%M?\ T6M?B-:_\?4/^^/YU^W/[-W_ "0/X?\ _8%M M?_1:U\MGW\.'J?
4Y=_N, P#&OR9\E_LE2;?@)X>&?^6MU_Z/>O7_ #CZUXM^ MRC)M^!'A\?\ 36Z_]'O7KGFU].H71\-.7O,N^(+9!EY;"=%'J2AK2%-,#_O@5/+=QV\3RRNL<4:EW M=S@*H&22?
3%$X\TG)]0IVA",5T2-#SCZUSOQ&MKW5/A]XEL].+?;Y].GC@"] M2Y0X]STI-&\7Z3KZ2-8WB2>7&)75P498SG:Y#8(4X)!Z$2V2?516A=_%[QX=&^R65U MI=G>*B+'?HLOFC;C))8L"6 ()QW-
<%XFU>;1[-98@.N&)&?H! C7)IX]U!+F M [5DC:5$=& ^Z6 .* :UC,5*+DGH?K[PU!-)HJY\3?M%W T6#2I-)NM) MUK5)/(MKB%OM-J/[[JP (=1V91C(/2OG[XH>.%\+RP:781 WCJ))IMV4 6"U\"\DM
M[B6-0982)(V 'k1ZCIP:]+!XW#XJO%9IK22=TEHW >MT_KN>]DJP>"Q495M(MIW[Z]//0=X8U[1_BYX;E'BNRC@GLW6)-1BR&&[ITY'Z@]Q7;> _!5AH.EWEK
MX=ND>8R%IKB\.2BJZJ[,O!VJ&S[YXS7->#/!"^&;!-&M1_:M]=2^8 8^I'<@ M9X%?2?@CX*LW@S7?$OB#6;71+;Y#=7UQ@ML4D9UFDJL9X# U'&@VW)7]U*R:M?9WNVMMG:ZUXW3?$5
MWX,\9".^T\Z;LO/L<]XY6:.&S&,(&X^5UP5.>,;>15CX::./ M# _A."W^PQ6;>8^YHMI$^#A9"03DE0!GVKZ#+G!0=#EY91?G>N=M[ZW_X;2Q\
M#C75E459RYHR2MM9)*R2MI:WXW=W<[;SCZT>;7KI_#Y]WP\U@^\W_*+%>/\ FUZU\.'S\-M;/H9__18K MQ\UC:@O\/2P$KU7Z,\Q68[1SVI?./K5%9OE'TI?-KV>0\WF+OG'UH\X^M4O M-
H\VER!S'BVN?%'Q9:^-/$T=G=P6>GQ3K9Q6EW!Y[Q&-?FD7E0!)N#8.[@"O M/]0T^XU75-?U"XU&7[3KL*6]]Y$$<:21KC"A0/E^Z.1SR?6NY^,]K)9>.-/O MXM.G2SO;;[/:O=#Q9(;^]-
U)JZ^9N<*C"6-0.B M@<% /Q6H=>UY=$2/]UYC."V2<*H&!SW)R0,5Y;>ZE=+J&GZA$HEO;>XCV8'S M,I;E,GUR:]$\4VYUWP^EU81FZ.T2(B8W.I[#W'I[5Y-2[FO:NYW0LHOD1GQ?
M$4?:84DL_P!T\BQEE;E5J6D(U_:7 4%XP.)E4GI MNC+?0@$>(KX6U^6_&2]N=-\)6-IIL4D=C.P$LD M0.%C RJDCIG^EUZ1X:U'18K31 M1\]W(ZS&/,QD9UC)#,PDP54@9)Z&H-
/CAT3P]=^GK3(K4P1&5;>&,#<1T M#RVKE\Z2;ES7FG==+MVZI-6U/K\OS)?4I86G!:R:CNKMR=D MK==FK[+KV?06<%YKVGPG6HH[9Y(_WUG;L5G+3GA_ M#IGM[FW.GVPF9A9R'YMBY/W'
.,Y(9<9Z5\B-\3M=?Q -6-TV\/N$0^[M]* M^E?#.O)XG\(OJ4+FU$MJTZR9QY4D9W*P)]&7BOBL)BL/??.HWJ4O>3>KDH]W MY_7?=I.+T=G])^ MV0Z-:A+^;4U*[OM5Q*LCODYY90 <9QP.U:/G=?
I7ZW37/!3M:Z/PFJO9U)03 MO9V/G_P^_O&Y[FO.M"./V*X# _U41C^IKJ)+[YVY/4U M\Q45Y3_Q2_0^WJO_ &'#?]O?^VFW]M]Z/MOO6']N]S1]N]S6?*>=:XWQ-TNS.-9EM+>"TRV"
(=FX*/9FW9]5\\Z#X<\0ZGXBM["RT MN]BU3S0*H^7N:>'-2FCL-5;67L_%4,95[U(E:)T)R87CX#(. MW<')K8^U>)M2B^SZGJUG:!,,Z/ V7;NDLH[C<[:#[#/O7T6$S*&!IRIP:?3K
MNE:ZTU3^1^AY/QALGPL\+=-K2Z3:E:^L=M[];&?X.ECD\6"S5)-4TV74)K0 M6J.S1R1N2C[4!QU+D<<5T_@C3M1T"Q\3Z(GAU-2L84$!L;N%DCB<. '+ J4 M16)&X+TS6?
X6\%ZK9>!]8@T71+5YY=2DEN;ZRG_>F!@"D,4#'IJ>/PKJVG>.M4*>+]%VZI\O\ 9FHV]FTEE=*3D// A <@J1A" M%)(W*1Q4G@?XB7EOX#N5GT_3O!\NEM]DTJ]-O-
OA60NTXB0[BTHX&\D8#=C6 M)]A'H%YX>U]-*U?QA8Z>YPU:&'MRR5EKI>R^[8?X]^(CW-M\,O&?A7X9:IJNN:=-=:89-7MY1DA@ M"!;Q':/,+OACP,%><5UGA6RU"[\<:CX%U"6RB\+7[LT27-
VAN+"ZP-CQX)/' MW6'1O:LWQQ4Y.3@ **]3$2EB8T_<<%& M[O=MO6ZC_P]OCHQ@,8)WNK/L^ORZ&;96T=U-=B;388M+O]0>TTO59N9# M+;L-KE>B*[!5VG.59Jp/B!X=U#P3XAL-
;FU!]4T**/[4L' ELXYE'WU7!RG3 M!!! XYKK_'7[17@OP_X&LWT?P='J]S:7;Z\5^*?*$LNG^>);72)1XBUBRANC;:S(YM+O2O8G0QF#4: MU6ERPDVNGS\UIU/CHUL+BW*E2J7G%))?
EY/7I]QY_INNPZK91W4'F"*3.WS8 MS&W!QT/-6OMOO6"=9:[N)_/FLY+Q&QL/[=FC[=[FIY32Y%\1+O=X \2#/73YQ_P'.&OBW MX8^#(O'WBI='FNWLH_L-Y=F9$#G,%O),%P?4IC\:^N?'MYN\#>
(!GK83?^@F MOD+X;^,QX!\3#5S:&]_T&[L_)#[/]?;O#NSC^'?C'?%>O@U)4I\N_P#P#CK- M<\;[%[5 @_XLT#PT==O["*R2MM[N14O89)HX)P##*T2L7"-D ,1C)P:K^'/ MA?
XC\5Z*^JZ=9PO9AY(HC/=Q0OU0Z+X_T1?!NFZ'X@\.RZRVCSW5QIS1 M7GD1DSA=R3KM)90RAAM*GJ#Q7H_:-L/#WB@>*X_#$TOB>[BL[?4YFO0 M+:2* QDF&/;E&D\F/.XD+@X'-
M>40RY4@%%&A&<]03TK+FQ+Z+^M^15J?<@O/@1XPTR^%I?V^F:?-Y,<\GVO5[6 M-85D($8D8R81GR"JGDCG&*JZG\%_^BZ==WFH:=!8"U:8/!,7-J(5"M$'DC+[?
Q[XKEURVL9=.EN((%N(I91*#,D:HS*0!A3M! .2.>:]$U3X]^'] M?UB"_P!3\)7LXLM677K.&+4@@[,<:RI(=F6A9H8V &&&",G-4W748V5W;7U
MT_424+NYYCX5\#ZUXTU:ZTS2K19+RU@EN;A)Y4@$,4?^L9F<@_+WR:Z/5/@ M)XXTF(O)I$5PWFV\2Q6=[#/(XG.()%1'),+]0N;5 M;FX\1:=>V,FQMBQ-<$$N!W
(Z5V6B_M*S^`]=EU:TT5&N#8:19(DLV4'V(ID MG SB0(1QJW=GM53==/W$OZ^8HJ%M680^ GC1Y9!'96,UM%#)/+?!:G;-:Q+& MZI+OF#[%*,Z(E)R,@]*C@^!7C2?4KVP_LRWAN+6>.US/?
P11<32()(XX'9PL MS,A# (3D$>HK8N?C%H^G?#[7O!OAWP[=6&DZM',TDE]>B>99Y)8&SD(HV*D M0#&3DDFKK?'32-7328M=\,7%Y!HUQ9WVGK:7PA/GP6T4#+*2AS&_D(WRX8<@ M'FL^?$?
R_P!?>5:GW_K[CSCPYX*U?Q5JE]I]E;QQSV$3SWKWDR6\=K&C!6:5 MW(" ,0O/<@5T6F_ OQGJQN_L]A: 6]]_9A,NHVZ"6Z*"188B7Q(S*P*A5@S%#*L*R+QM*2A@1[\UTL_QE\& MZAHQU>^\-
XU.+Q6-8L]'TZZ%NL?EVL**\N(]I5Y(\ML"G.<8!ISG73TC^O\ MD)1IOK_7XGF5I\)_%-]H+:M%I@\@1RS);O/&MU+'$VV62. GS'5'"""0IQ@^A MK7B^!OB2RNS'JMD(U6"Y:1+*\MY9;::W:;RYUW_
+H[5R0V#@')&*ZZS_: MFU2+0;>.>"^76;."Y@MY+*\6&S<2R/)OECV%R5,CC"N%88R.N<2X^,6@)X@U M77K#PG-;ZSK"7QOYYK_S%5[FWDB985"C$8:0R?-EN 0_JYL2[WBNO\ 6X[4
M^Y;\9_L^S:)-90>'MN-*LK:(H MSWESYJQ<.6)+.0 HP"% 4#@O6/.]S7CO[+TFWX) M:$/^FES_.CGKU3S3[5]I"%XIGYY4E[[]2]YWN:IZQK-IHVF7*Y?RB*TB7]X MQ!/!X [DD@ =R:S]8UM=(M4?
RS//-*ES@;VZ'#32N<(@],GJ>P!/:N3\?W^E MSP7WA[5;NZOGR(KLV,'*%)%)6,;2Q"L -S')(X %:PHRJ34(*[\)C@Q&,I8: M-ZLK'76WC'23I%[>+.8+?
31MNHI$*R6Y"AMC+U#8(X]ZQ_%VNQ1;;+8:U<2V MLE]:D2Z=;*NZ&*52 LDC!B9"IR550%R.37G^JSD?#S5]-TZ*2YNXFCU(3EB\ MU\L4L;R;R>3(%]B,8 P169X]M?$OC;5X/&/A*[L-
7CU"VC2YLKV4QI)M&%D M1Q]ÜL<,#Z5T4L/%U>6M*W[_:WZGBYAFDJ5*G*B[VW1ES2/" M::YK%KH\VM7,N@3Q+'+*S?Z3>`$Q6SN,!8U7=@ #)#9&>:]QT^UMM)LH;.R
M@CM+2%0D<,2[54>PKQ'X<^&]9T[6+4:S=V]QK,]S'>W%M8Y,%C;Q*X1 QY+, MSG)[]N!7KMYKEEI\\$-U>06\T^?*25PI? R<9[#UJL1%.7+#X>ATY55]K2=6 M5KWM?
H]MO*_XFSYWO6#XYT(^* "E_IJ,%N'426[MT69#N0_F /H36@)LCM1Y MI]JX9T54BX2V9[T:CA)26Z/F36;63Q)H$L<*K#=@D&*;(\N53AD;T(.17%:? MX/UU]3M1=6$4%NDJN\HN ^<'(
&22<"ÖIG4/A5INH: JVL?;[ZVO-0=';R' M01IM0+C85(;,,DGGWKE?PUJOA[7,ZK<0W5LDDTUIL@C4L] >7N*@'=DY(Z< M5^8YAEN*P--V^&3LGVN[OOM_74^MCF5"LDOM?J-ETFPTK3KA-4S)<7-
N]O=* MLFQ(XW&&CR.2<=3VIOAJ#P-:O>226]O]FE*G;'*(EMP!C";2,9ZG/4US'Q= MQ)X.G:+^J>*=.MHQN0RAYPXKM7DY%>,\3_9F*C3I1 MOM= _:=]'Y:[;'S6-S.O1QD<-"-
^:VMVG=]=#ZH\! ^%?$DW@RVN-.T5[2UO$, MDFHS,(I;N,L2NZ61@=NTCY4POUKUF+X,:%\0-.UK6-5U[4+6TN=*&F?V+8W$ M,J+)" ZF(*Q!<; =F.2 M,'[OI7?>%+&X\0:3J=CI<_GW-F#J-
N+=BLBL@Q*A7AE8IS@C^"OLYUJV'K3K M4)\UT3>BUVVT]-#UXJEBH*CB(WEO9]7U=EO?7[]1W@\^!]+^%&BQ1:9XFDE MGO+IFMKV2.W:5]T8+DA3A?E4#:.S9-:WAG2K'[7)K-I;RZ58X+DK]
[\JR-=MM7NO"5WXBN-4U027"&-Y?G5 4)^8]'(8[0>YS74VC+' M:PI'%Y"*BA8CU08^[^'2OH,%&>(JU,;*ZYV[:WZZ_P!6/*Q')1A3PBUY$NEM M;;?
\'4T_.]S1YWN:H^:?:CS3[5Z_LSCYB]YWN:/.]S5'S3[4>:?:CV8\[MW->P_#-]WPPUT^_HL5XAYI]J]I^%K[OA5KY]#S M#F*'C?0!XM\,7NFAQ'<.HDMY&_@F4[D/YC!]B:^=M1T\^*=-N;%_,L=0MY-
D M\13<]O*.JLOI[]Q@BOICS3[5S5W\.O#% _>WEY<:1#+=W!F>4RQKC.F[21ZV!S!852C-73/F_1/ACJ::U9S3W2744$@S^O;. M&=A]W)QSS78Z+X$U@>*9M.TZ\LV-Q)]HGLI$9XM/CV\M(ZD;9'?
I&.V3@8K MT72/A!IEK8S0:C?:CJ;R22E6-_BK&S$HFT/SM! SWQ73^$?#=GX+\/6>D6 M+0VZ!3-(%$DQ_ON0!ECW->1A\@JRJ*6>)GE^1Z-;-X*#C06O]:GF6G^$?$4D
M.ISW6G:7906$\D7F7DUP!,J 'S44+RI[<]JIP1:@+*TU+7PL.H64;NFGVX"6 M]F3D90 DERN,LQ)&2.*]-\3TKA=8 M47\=Y;W&ZWDG#JRS+M89]C7EXW#PPN)G1IJUHIIWW;O\DU;;7=,QI8ZKB(S3
M:OT/*-5^--W?(T$7F0VK?+(,F5,C(R3E MX_=G:1TP>WTKR5OA%K::E%;[8Y;1G -TC\!>Y(]<5?1 *NAV4+&0Q!L6ZVP\SE M0B], \"OFLN6,G4G*6SLGS)^>WZ]-?
OTR3&XFIAY4,SBTX.\)124KNUU*RU6 MET]UM=]R7 >&_P!G71[W7IB+R?5((V#BQC "HIZ!V';\1G%>^^'_9+HU]: M0M:V3Z.("&A7AHG&-
HQC#J1VXP1WIOPYT^RM="AOX+58;NZC"3S9),H0D*3D M_P O6NK\T^U?]T;5FURV2UV=KOKU1/96]OIMLEM:01VMNF=D4*A57)R< =.34XFZ\]JH^:? M:E\X\].E?:*DHI1BK)'Q>\.]N>]9^E''
M[$*' JH#G^=47O/G;D]:^,M>4 \ %+]#]"KNV!PW_;W -+:;GVP^M'VP^M8/ MVSW-'*>77>A:==7LBJ5BFCU2)C9@>0K'AB!G@9K MGYKZ*74)%L;AWCM;^ BMIW3[PC.2X'N0I'XUJ_$?
XJ6UKX_U/2+J_CT:"T"? MV='*PBB:TVC9Y6> !SD#OUKV\MRWZ[-&HO#?A M_3[B6#138K.7SM^TW))\UW\3].O0'BI?[5M/&NB#4 K36=]/-I_GXPMY$L8 M)D7U"ON
/UJA!\4M/L=)3P]XPT8>);.U8Q6]\@5C{J#DNI(*[1PS@X]37HTX M0R_$N;LU'7RL]%J^M_ON?J?AUG.'Y98NO"SBU>^R\F[:;IKS5NASW@II?%>E M:C'?M+>0CB1RO& #D=&R#P#QG
(QGJ:^0XDX@PN&DYU)=GRJ[W:5]$_5NW1VO8]3B+'QSO'V MPSM#5[VCS6UM>R;=DF^K\CD_MA]:/MA]:R+Z=X+R:.[2O>1&*M$XPRD=B/6H M/MGN:5)^UIQJ);I/H] -:?=H?!RJV3CV(?&UO)-
:PZM;;3>Z9NE =MHEB(_> M1D]L@9'N!?IWP=^+_B+6O DUIX7U26;4["6.[CTR\!W[+(,,5W$$!&"G*G& M&/:O-S> C!Y'H:BO&COK22VE+B*1#&P1MIVGJ,CL?2N/$X+VSYXNS]=+=TU:
MQZA=:@OC/Q%;:WXTU.TNH[(B+R])87Q'Q-I.DZ?;>)+'3?"FD7TMU?:&D,>HK+ M9C8][RUTN_>.-;*-)?WOF?,/,^925/RH>IZ MD59D\1#08FN;'45U/5[I=AU& AH+>('F*+'!)(PV. ,@9R36G?
3>&/&WQ%EU M[P]I,.AZG+8#2]-@NR8XPFW:$:$ Q@LNY1S@9'&>:X/QT;7P)Y. MZ^T"*99K>;! \Q)4):)B>#D9'?(KW<-+FIQIST;>G3XK*S_S^_NL8NMAXNK6 ML[63:ZI?:2MYOW==-
NS]OK.\MY9-3OK-)()V)P5 M*-F0C!SM)P"">:I^.;CPAK>C67B#4-6UJ/4KJW> :(T,TZ$@X&N2>IKB=7\4W MVL0Z;;-Y-OI]B9C#;(FYAYFW.7[G*9SCN:]*-*K*$8U%RI-OS=UWUOLO)&_-
M#GDZ=V[)/LM>VEM_4LV?DV,"Q01'H R(U R<=3CK4_VP^M8/VSW-:M M-N[.A6BK+8WOMA:/MA]:P?MGN:/MGN:7*.Y)XVNRW@W7!GK92C_ ,=-?*/@ M[6K?
0=:@N+K1=.UZ)@(C::FKM%\Q'S?(RG([<]Z^E/%]WN\)ZR,];27_ -!- M?*43F-D=>&4A@?<H?'R+34^*^K>&= \,Z5H%MINHO96X MT\2!IP2H7S"
[MD@GJ,=:T;7X"Z=K'CJ3PCI/BPW>LZ?//#JRRZ<8TA6&)GED M@;?B0 JR ,4).#TR1YAXB\1ZAXK\0WVN:E/YVIWLQN)ID4)F0]P!TZ=JZZY^ M-WC6>XMKUKFWBFCE-Q-
/%IT2?;9&C,1>Y.W$VY"RG=P,D5Y7XQ^#L7A;X>:=XGMM7EU>*Y6 O-;6BM9AI5+%!,LC%70C:5D1"3G;G M%4D^./BVW$<=I<6.GVT3Q20VEE810P1&-953:BC XGESUR6R>@J%?C%K\EI:
MV5TMA/8I+:R74:V,2/]"VY!A2X<+^]5<8^8?7-9QIXB,N9ROL4Y4VK)&=\O M!L7C_P 6PZ//J2Z1 UOO0(0@+HFJ)9_V3XPN M+F:^TRVUFVBN-*\K;:RW"6["0B0A959BP49! ^\":\QL/%=]H_B&
[UC3?*L+ MFX%PFR.,&...961T53P!MG+J?BR75+E=2M='FUK2A#Y17=+;6 M4LJ7 PW!#(("$_U>^(7A+PU\+HK_ %71M)LM?T^TU.SL?LFO6\F[=+IXF;YD
MFY7/S8Z[CZ#GBM3^/GC+55F62[L8%G-R\RVNGQ0B62XA,,\C[5&YW0D%CWY& M*Q_%/Q,\1^,M'2QU6>*6S$L,C-%:I&998H?)1G91\S",X)[X&:Q5.LYIS>G: M_P#P"W*"5DM3VG5_!&C>*?
V@M0\-Z9X'TRTV^&(I-3NK733*DM]$D".L$CO M(?ORNJ#&#\QJA!\"$L?CUJ5L_AZ6_P##%EII\3)HYEP9[=T!BM-^X<^(->/B,WMVDC>(3 =280JIG$.#&O'100"0.I STI;CXE>(+KP M'#X-
ENHFT"':JP^0OF;%D:58R^,E [LP7H':2HUDDE+I;K\WZ_UG:%HMQ7$.KV"SO-I-G:I.XMM&MFM++,:AHX2Y?86ZD!F;&>F<5KZ\3O$'AGP\VD:;+9V*QW$4%T;. M-KFV2==LRQ3$;E5P3D>YQC-;
[M(BR,,$<5WY8RLF\EC&94W#:,Y^4G%2ZY^SA:^'].N];N_$TD7 MA[3X99+UFM(VOE99$C3RX$F8,LC2#:S.N,-D CG"\9_M :]KU_&^C%-!M8TL M
KP01K=NUK$BQ^9,HRZJR;E4^V*IKI5MX]+CD=D2:.73+72(5M;H2 ME6D,L*KB0DHIR>A48Q6*CB79N7]?<6W2['H?PX^''@V*V;5]1N8O$.C6O]K3 M6THTZ17NC!913)YR&9/E4R$[>64 ,5((Q?
$GPCT2QBMM:UW7(O#>EWL=A;V MJZ9ICS!IYK1)W9T,N510Z[B"Q)/RKQ7&7?QC\67WVD3:A&5G^TAD6W1559X4 M@D50 J^7&B@#[N.*GT_XV^+=-<,MW:7(5;81)>644RP/;Q"*&6,,#MD5 !N
M'7'..?LZZ?-S?UJWZ"YH6M;^OO,'PMJUOX<\1K)E^'K'2+R6VC_]9-\R\8,A=VR1[8ZF MO.'N99;IKEW+SM)YK2-R6?.23^-7:?$?B&_\6:]?ZSJDPN-1OI3//*JA0SG] M<#@5UC:E'>'7'E#+)%M9&D
_V=V?H#7 >*?!WBC6 M?$-WXA\(:QI5W8:PPN9K?4=[1I(0 9(F3LV 2OK7LY?<"",@\$'O7F/C#P[X M4*RVCQ64-E)]%UY+*]NEM[6/Y6=G=$8 #"GH!DD9K>FY4I!])EE34EU75+?S1/?D;
(7O[C9&D:#LL:J# MCT'/)JEXC\'Z9X.?1;?2CJ]D+B-VN;JS,ZK>3@#8I7A1YC$_.O.!72>%_%UO M+::YJ\&G-IY\-:=YVF:.859?/96)FQC!94P4_P!XGK7.7/Q;AOM(;5;C6([V
MPNDSAY1(TI;HN"YY_UBG@5["2Y[NSTTOOM M?3HDNRT/4/"]M'I%A*86]K;6%\MJ+[4Y)96>.V&,%Y7Y=R6RJCDMCC &:Y+Q MCIUIX@U=KI=9-U'): 8;S3UMEB-QO!O+E58NVQLGKC..I7J,[1-
0O+Q_B+X0^ MWU8&M[B89D1$1?+Y[A'!5A[DGFN0T_2OB#JUU'IEYH$&AJ+MNM<-XCP) M&/OO$H^8L1G /3/-12I0ES2JRMVLKW]?RZ$8C-9*?LZ%DE:JW;31IK:Z]+^A M]#:?
J,%]8P3VQ)@=1M!&",<8([$8P1[58\^N:\)RF33)K@*4ANKJ:XA!&/W; M-\I_'K^-;)DP"3P!R2>U0X6/IJ-5U*<9M6NDRYY]9FIZ)::Q;(8T*QH M)"JH3U88_B[9]*Q=5^(_AK17*7>M6B2#K&C^8P_!*IP?
QJ_J:5UX0G:]\JWG'V,QY+W*A\MG[O& M.W.:R'\!?\(\+F_L[*R:;82WV=65W'H!@TM[\:-(LK4W#:?K B5@':2Q9 JD MX+9/'%=9H'B73O$]DMYIEVEW;DX+)U4^A'4&O^K<.8::<[-2ULWKR^E^QUT\
MR .2L6%^7MUZUR_AGX@:?XRUB/3=+NWUJ QR3WDR;C':0JA.] MG(^5L[0!USCTKT,!E%+#JK6Y_B234MVE>VUEK=Z6?F>]B\XJ3K7Y>91;UZ*V
M_31_=Y'N/AW3FT'2Q9M/]H/FR2F39ISN8GD=R 0,]\"M/SZQM#O\KS1-/GN, MB>6WC>3/]X]"N^9?7I.&I[$))15MBYY]'GU3\RCS*.0KG+GGT>?5/S*/,HY MYRYY]>X?"=]WPD\0GWN?
_10KP/S*]W^$39^#_B,^JS_Z*%?/9Y&V%7^/YGL M97*]=_X6>))\B_2G>?5%)#L7Z4[S*^AY#Q^?1Y]9E[?I86"_X8ZUB7EYXF\]K& MSBN[:.*651.D2;!$98Q%L)SG"%^W;FI:MT-%KU/2//H\^O-
7/BRT&%N;^ZA9 MY$E81Q&6.)9P%:/Y0"YC)/.I6-QJT<*7*[TCD64+V8CH#ZCVKSO2+# MQ/':Z? ;N^L8$\F!HXUC.R/[.2[992=WF@#/;)XI]LOBZ]CMY+B]O;1W(22. M*.
(!5%J&W#*GDS#'XD8K*12A6Q&X5(W3Z#MYG MEQ0%+F(WC%F8L[,!@G@8ST XKDKC5O&,ED(4@NXKTAI&F2%#&&H-NNT GN)=_ M']*-2F\9VU^+>UFN9;2*XD6*X:)'>4;DV^9@ ;
<%^>.G7BN*>78*1+GE13:O MT76W39[=?U9:E/;F_$]&TRV32K&*TC=WCB&U#(?5/S#1YE>E3 MH0I0C3@K)*R]$< ./!/H$W7Z53\RCS.M:<@/G_D:Y=KSYCR
M>OK736!Q^PJ3Z>/)#^C5YVUY\Q^M?!05Y5\3_0_3,0[8'#?]O?^VF[]L]S^ M='VSW/YU@_;*/ME:@'^>* ML^* "1M)8K27Q%H@U.WDW26'F22)N (V-(%V$@^A(!'6O2P4L1"3A2U3WTO\
MR7PN^(VF],I.'VHW32ZZKI^1TFE1ZA\2_$HTV.2UT6*SL)+B60+FWTJS7AI" M!CX,:K<1O@NDBHGR[\<@.2 M/4GBL;X0:W'X:\>>*/".IW3VL7BC2([.&2<@%WCWAX@3_%\X=0#R,=:WYO
MBJT L]0N=*L[4GRFUF:YVC:?XA&>=^/X?7O7Q.:X_$3KSA.5DGZ;,]G+\%# M 898+#QM&][:W;U5WUOJ]^[/8?V0YK.WU7Q.IMTM=3T^VBL[>/.1;A@?F'JO M"X(Z@BLZZ^(-[!XADL;JUU1?%JRF-
=-C@D9Y'S@%& VF,\=G&#S7D.C>/;K MPIXYN?$/ABX"Q)LM(1<#,=Y;1QI&/, Y^,9N!'(ZBO6KW]L>Y@TY GAI8;^0 MB)";O?'O(.,84$]#P<5Y>'KYCD^)KXR.'56-6/6VFBWU7;5:*2Y?>31_FN&
MJ8N453E[2.S36_1W3W35VGS>ZTT0?M"".S\;6C,J1WTUC$)X2B^RJ/-Q@G]/T MKS#?[9[GZS-6$WGC#4;C5K^222[G<[_ #$V$8., =AQQ[566Y9AGH/4]*]O M*,.L!EU*E4DO=7RU;=ESWRH=
(Q$6W4J2[:[7=K?B;GVSW/YT?;/<_G6' M]K4?Q9/M2&]]*]'VLY?PZ;?F]%^.OX' \3.7*FWYO1?CK^!N&[!'/-20:K+
M:VD]K%,\=O.RM+&K8$A4DKGUP2<5SWVRC[96%2GB)^\Z46UM>3ZVO]GK8SE4 MQ=KJG&_^)_\ R)U&E"_U75;2TTU;FXOY7"P00$EV?J,?3KGM6CXB^$WBB77[MO5=1U2SO[N6=;MX8;
[=G66? ^1@ >F=_3:/7IBOSS..4_K+H M4:<8\C3?K9>EETTMIKU/E,USZ6#Q'U:C33E&SEKM=)_=ŸZ=33?FE5ŸVS1Y:-\ M[7'*L/;L13OMGN?SI-ZSZ?
$L^)$ED*)ŸKH,!G"@,WXD9_&N>^V5^CX#$2QN M%IUVX^V>Y_.C[9[GŸP?ME'VRN_E.VYO?;/< M_G1]LJ$^=8/VRC[91RA*+O/AK51GK:R?^@FO(O@YX9T_Q5XKN+?4+1]4%
MMIMW>VVE1R-&U_/%&6C@#+\W)Y(7DA2!R:]#\0W>[0-2'K;O_*O!HI7MW22. M1HI$(99$8JRGL01R#7;0BW"23L8S:YDV?2O@[X1^&]5LK[5=8\(7&F:DT^GP MCPVIN[LP13(Q:
<)"WG1[RH"B4D)GG.1797_A'1F\)P>'/LE_JVAI)HUJ+:$H MMY/"NH:B-OW@-^!R P)Q@')%?(":Q>PW2:X$:2I"X5O+!/S%7;@#G.2.]1/#2;O*?;^MQJH MEM$Z[X\>#K'P?
J>D3:79V]A9ZA8&X2.$7,9++(Z%F@N?WL)^4?*2P.,@X->I MV_PU\ W6N^);.#P\$E\.Z9ITL=L9+R];4);A(VFF>

M7B+4$\':CIL$,J6>FVF@W,%_+.EL\9+711&\Q&E8':7)1.AS7E/@KP9H.H_M M 6?A:Z$USX??6);$+<2>5*\8+A S*>&R%'!ZUP0US436\WVE] M(}_=+9R1[=*I+(%
(97VD<@@X(QW%:1HSCS)S>]MZ$N<7;0^AO"/P6M[#X?#4 MM8\$WVJ^)X]'U#4%TF:2>%Y6BO88HF:-"&VA'DRHP6Q^-D^/=;T2/6$M]1E9]6 MMA:7,TTC/*$$B2 HY.5;=&O([^L)YS-
(TKR&21R69V;+,>Y)[GWHC2J6 N[:HV MJDI\W.X2 +@8KBOV>YHK'P9X[O[.TUC4/$<+Z>L%MX=G$&H-;-*_G&.3:S*H M81;MJY.0#P37C3ZM>M'<*]_=-'<8,ZM.Y67'3>, -CWS45K?
3V,ZSVMS+:SK MP)8)#&XSV!!!YI?5Y.#BY7V !WI_ "'[16A[,[.!GJ'G'-<-+X^M/$]DKVVEZ:=(ER5@CMT*$', M],D$(EACEF))()S6KXYTW4M,UK2O%&F6LNH-8QR6UY9P#,KV[D-OC'=D90<=Q
MG%>9WG@KX=>(]5GOK?6-7MEO)#)-FX+J4=<'[RE><]8!O] MU5"JSLH/)('.#G*OOB M$-:TS[7>"RFTDQ"8.D2)&B@9#H% "@=1C&/7/-.E3J5Y2C25TM7?]._Y''7> M'CRSQ'-
&H]'9M7[*5NMK;:FBOA33-=\)Z3?:HEWINI(OVE;Q'\N[AFD.6 (Z M[B<:,$'@8JGXI\'^(;:UMTEO[K5FBF5[C2=3NX+=IH@.4=8P"&/!PQ!]16EX
M;\7^1\0O"T.H%KF*'.>XB=NLDGE1M$[#NR)+GZ\UY5JWQ..AZQ>:?XA@U*#6 MH9W$<<%M)+]K!8E7B91@ELY//4FE2A[6H[RY5O=]7]Z.W%8FDN2%.DIR25M% M=+RNF[>FS/4M!U?
4ET6"PTO_ (G=^A83WUTQ2WMF+$^63C.2*L-\ M/CK+>9XCU:[U@GG[+$QM[5?8(IR?Q-,_^':7X^2_MOL5V]E#/=6HY\F1G?8IQ
MQN\O:#]!7;>2:OFY=$>G0MBJ:J3UOTZ::?/\3'TSPKHVC*%L=*L[4#O"'N?S MQFM1?D&%^4>B\5)Y)H\DU#E?<[HPY=(JQ5OK.#4[22UNXEN;:48>*095AG/(M_"EMK6&RB6*WAC@B48"1*% _
59\DT>2:+H.76]C@KCPKK7AK6+V]\-FUO-/ MOI#/<:3>.8@DI^\\3@'&[]5(QFK5AH6IZE&T%)8V.AZ8[;IK2Q8.]R2'1V"J NOO\-/]*[/R31Y)J5[NS.&IE^&JU?;SIKF>[UU?=]JF_EKU(P !@ #H!VHJ3
MR31Y)JKH[[,CHJ3R31Y)HN@LR.BI/)-'DFBZ"S(Z]X^$'_)'O$?UN?\ T4*\ M+\DU[M\(D* ! P 1CWN?_10KYW/6OJL?\4?S/9RI?[0_\+/ X_N+]!6?XCUI
M/#VAWFH.GF^2F4CSC>Y(%GWB@5J)"=B_2LCQCX:?Q1X8U'2VS2E\B:>/]U*1P MD@@%/&L KZ&4K)V/'46]"AXI\00^$-4BT2)+6_UE;**ZO+R9%D>0R9R(]V0 MD2XV@*!D _>)K$\/^(X8M6,<"P6B-
)&+FSA4*H,I*I(% P"67GU!/IFN1\3P^ M'O&JV47BV>^\'^*].0Q>?!(T,@!^]Y;X*R1L>1]:Z7X>>"M+L8HH]&2[N-/^ MT+>7>KZBS/-?S*"(P"P!*KG/ [#/-73]C&DDE>765]_Z[=#Y"E/&2Q*4E).
M^L6M%W?-LU;KU/2**D\DT>2:FZ/KK,XKXAR21S:+\^RV,TOG;Y)TC_U9V[C# M\W7IVS6?+XIU6PO8K;$<7MI]AWP1PQ2OEPC$EGDPQ7(QG.>Q&3FO1A&R]"1 M]*"C'N:R:N[IFJE96:/-
=3\;.Q:6UB;+?]+NQ/F_V<\;S]'4$ $Y& 6[ORV+S6L<=XI'+R[U#0[.YOHTBNI$RXM"%Z\$ @$9&#'T[MUI5)Y1-'DFM4T9-:LCHJ3R31Y)IWO+&CH]:D\DT>2>?I1=!9GDEJ53_$S],Q3M@<- M_P!O?
^VFY]L_SFC[9_G-87VSW_6C[9[_ *UT\IX_,>K? O5X;;XH1B;:)'TZ M=+8L>0Y*@E?]K;G\,UY[K/@CQ/IVO3:?-HM]=WAD(CE@A9TF&>&#CC!]^E97
MVQTFAFAFDM[F!Q)#/$VUXV'0@UW" 'GQG]@^RG4+3.,?:EM<3'WZ[<_A7L8/ M%O"7<+7:L[_UYGZEPOQ70R7#NG-6EKTO?6_=:K[B;Q\/7\2ZWI'A*:WAU'5 M8["'[63)M2&5=S;_
#!]S8I4%ASP*=K/PEMI+**R?X@2Z]0>ŸR0363_P (QXI%]]D. MD2RW6_ O0P$!Y^<6[>N.M?S]Q3GU:IF-7#6Y5!KI]JG>^^^R70_8N$>%)MS:
MF\XQ,^655.2NU:S0$JVVV_6[=C4\"^&)_%7C+2/"L.ZVGN)?*=G&3"B#+L?7 M ''J2*]0\4:SX$\-W<^@V'@ZTU2VMG,,MY>.7GD(X+;CT.M>.:]XJ7 MP7\2K#5EF>ZM]/C6SOIX
2^TQJKR@#D[652<(%AANB M)9I;(^(Q&1YU M5P5*;]G?2=F[RN[QDTM)+3UU.?\ &FCV>DK9:EI1/]E7^\QQ,V6A=3\R\'P? MQKF6OBW4YQ6G\0/$NESI8:1HS>986"D"4MN+L3EB6[DG))'%
<=]L]_UK]*R! M5IX"G+$+57LWOR]/P_"QWY55JU\'3JXB-IVZJSMT=MU=:VW[F[]L_P YH^V? MYS6%)L]_UH^V> ZU]FXLLCV(VBE&*LD;OVS_ #FC[9_G-
87VSW_6C[9[_K5/8KO5-6&C)%:7!@N& M*H&G,9$:>:R.(=Q./-VDKU&#R+>J7>[3;H9ZQ-W]JXKP[X,=15"1^>)/A:_L8K;36+74-%M_MEUBR@T)<[F$NHQRP")"N
KP[E4@C'(XKQWQY\&M=\"6NF3W$#SK<6%I=W3+L M*VLER\JQ1;@Q#[O*8AEX-1'X'^/%A,I\,W2H+Y]-&9(P6N4;.\8&()*GJ1P. MI('-'!)JGC75K35-)'BV9-+CEL9(/[,'V*80 MHX:(%!&
[1910XC(S@(YYXKQ?\:+'1_#=TVAZUI\BUOI[-CEU"PN&o9Y2U2>=GS MWUUI-M;364-Y4=0!+!+*T1: M.=!3

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{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{M[\^62?!&TA M/[O"'':J^EZ=X6T2=Y].M=(L)G&&D8XHV8>A*XS5[_A'=* Z!EG_P!^%_PH M_P"$=TK_*!EG_WX7_"]!I.UKNO/)&\][$O\ ;%A_S^VW_?U? \:/[8L/^?VV_M[^K_(U%_P ([I7_$#+/_OPO^%'_".Z5_T#+/\ [\+_ (5!9+ ;%A_S^VW_M '[7_&C^V+#_ ;;_OZO^-1?\([I7_0,L ^_" _X4?\ ".Z5_P! RS_[\+_A M0=!_ &O8? _MM_W]7_&H+NYT>_$0N9:&X$4@EC\UD:8XZ,.]"/6G?\([I7_0 M,L ^_"_X4?\ ".Z5_P! RS_[\+_A33:U0FK[CJXT:^.)N9:&X,+B6{RLC:' M'1EST/N*@E@\.SWPO98]+DO RN+AUC,FY1A3NZY)P>U6?\A'=* P"@99_] M^%_PH_X1W2O^@99_]^%_PIJ4ELQ.*>Z{YWT2ZN4N9FT^:X1&B660HSJC?>4$ M\JX/<=ZI6>D^%-,L:BRM+/1K6RN3F:WABB2.7_>4##?C6C_PCNE?] RS_ . " M_P"%' _"Z5_T#+/_+\+_A352:5DV!)%N[1G:7I'A/0[DW.G66:;?<%?2IFM8 MHHWP>HRH!Q5^]N=\U& P7W&CZE;F"\EL:] D.8YV1URD#D'\XX(!IW_CNE?\ M0_ P"_X4?\(]I17_0,L P#OPO\ A33:=T]J^C&WMQHVI0B&[EL;J$,'\N9D M===P.0<'N#5>\@\.ZC<'[CTNZG 4"698W8!3N49//!Y'H:M?\((]I7_0,L \ MOPO^%' _"Z5_T#+/_OPO^%-2E'9B<4]T-*
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{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|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{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

6O$/VNK^\L?AQH]V4FHAKGQ%I]M)#I-P8+FXC M>0AHD<$89AP,G&<;5[=D>HK)\1^%M)\6V]G!]HE[%:7<5] KL1LGC;=&XP1R M#S6U&:IU%-]#HP]14]L:DE=)GQ=XST[Q_P"&/"-P)U\7;=:X;U'Q7I5KI.C:E MK6_574HXG03JYV*YP%!: //:F76O^(;+X2_&R[L-7U_1;#3%L[.'1M9U=[K4 M["Z$R"1]^*[W5[O5-$@NI]7MDL[]B[K]IB1@R*X4@'!48/7CK7HQQL++ MGCU7X-?Y;GL0S*FTO:0ZIZ>37=]4M]["^I\^S1^*_A/\ "?QSXHMM UK0]2AT M=1:W6H^*6UA\ET?0H[()[^]U#PA;^&-%M]9A,KR-;-= M6IV7:KZK*@W$::Q%&/-I=-]EU:M\RHXO#P<[1;4F]TENUYOHM'W/CNU^*7BWPYX8FU2RU>^FO8OA?8W2-,THCF MDNRCW!4D@N%.=QYXKZ"\|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|S(^4(.3E >M6O 644YY&WC!S6-X2_9|^'7@;6+?5=%|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|!'@SQ1JENGBS0_#CWVD1Z=IWB'6/M%ZJQJI42()%=BD; M*0I!:IS7>2_&3O!X=^.OBS6_%>D7/AFRTCP2UZFCRZBMS%,XN,*XV?*&8D)Z MU|&^*?">C^-=+&G;W91W]D)HYQ#(2!O1@R-P1T(!K'4_"7PAXUU.34-;T6# M4+N2&.W>21F&^..42HA (! $M2UGP(NKZ7K=QXDTC6=0\)7]O;2-KHU73M5>, N:N)R=|+\Y 'G#C/2OK M#Q#X!\.^*]2T^_U?2K>_N]/2:*WDF&=B2ILE0CHRLO!!R*YSPW^S]\/?"4FH M/I?ANWMWOK9[*9GEDD(@<8>)-['RT(I)@5;Q5)|SY;7]-_P_+[MS1XZA+F?(MUS=--UYZ?D_*VYY#^R[X7UV4>%O$&IZ)KL<4^F"^+FO(;AGC'S&T/3=D MD_=KT#]273[+P[IUY]GB36],@29XK?1M N#!=:O=.NV&)74AN&^;CCN>!6 M]X1^`@#P)K-MJNA:"NGWUL"L,B74S!05("LY7H3VK2\?\ PC\(?%&2O?O1 MI$>JM8[OLQ>:1/+W8W$;6')VC\]OE7A*NJFMOQ_%LYIXFE/%*L[\OIKU[M_F MO(=\(+'Q%IOPR\.6WBR['W>(H[11>SEPY+^A8<,P& 6[D$]Z["LKPQX:TSP=MH5[HVCVPL]-M%*0P!V:8"23RO))/4UJUQ3?-)M'FU)*;_M%7XI:QX\\:1^%/$OC?5O%5AXXGTZPT6/2UGT'[^DZAEFG*8CVH7S\V1A??(_M0RN4_#31/AL-?&BQSOC6]5GU[F\$TQDSRLWBT^YTN.W MUB*87:7>M9?CC]M6_|ASKIT3?/|<6LZ9907^N6,&K M+))"LTC+":,XC/VB0(!(P^4V>BWNF2G7-1@N4LX%>_U::=[M>"UF$T$$18_)&KJ#@=<8)KHO'?[.OA/X@>+6\1WLFKZ]L,T-M>_V3]4MHE_M%$^^-)PA&X*2<$8.#C..* //O$?[74NA?%_3?!Z>';*[LM1U.+2+:YBU=7NO M.EB\R*22%4(BC)^7#N"'7;7 ?"?]H[OAXCTKX8ZSXW>:O?4_$6NPR?V7<(() M[:UMIWQ+&$R0AC95 ()*!B><5[9+^RGX'?QB?$;MK$-Q_;J>)5LX]1D%HFHJ M #.(NFY@.'>,F*G\-LN^!O"U[IDlG%J,D6F:I>;M9VES>M+!!+=1/%.BH> MD:+(_P QJ2:(_@E\9O%7Q7%CJ=]X!DT'P[]A_:6E;L-2CN"\9;Y$FC !1V M0AOC< #@G-<_|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`K>XFL[:^,H+.]U-%,\<@$84%5&T9+(TCG)_P!IC]*Z]@ KAOBQ=36FDVCPR-&OE(R/MI7AEZOBH'E'O#UMX@\"_9%MX_[1GN':*?:-^$*$C/^Z37T]2<;24FC[:M4A0BI26E M[?\ !//)?$.H<_Z:)_WU5.7O%]1Z7LO_'U7H_C*\M-(\2:*^FV%E]GN((/*9 M9(%=6 F*[L>IZUA>,=,O/$OBC5M.L+73K6'3)7"[?+MR5]R<;CQ40K*5FXV M3_X8SIXB,[-QLFF]?6WYG#S>(]3R1]NFSC^]5*7Q+JG.+^?|'KUO5O"^FRV< M>D6L5BPMX;*>XSRSJLC*&D$N<,3G&WH!TYK#\=6NBOV$UY=:5'!!JNN2Z<(MK_")YH%0E5)[G('S=>33CB(2:2B$,73FTE#?^E]YYG+XFU7G&H3_(.:IS>) MJ6'#$;C_OX:ZOXO6EI9^+REE:OV5LUG;R+!$/E7=&#^/7K7 3l;ZJ:C.*E M;<[Z3C5A&=MR:7Q1|_| T$KG_OX:I2^*M8'_#$[K_OZ:@EJC-6W*NOT*>O M9E\6:SG_)"EU_W]-4IO%NM?!6[_P"_S56FZU2FHY5V*Y8]BO-XNUL?\O:\ M_P"_S?XU2F]\7ZX/^8O>?]_V_OJK-WJN5=BE&/8M3>_==' _8O?\ O^W^_M-49O&6O?!IF^_P# AO|&]LW>]_U4HKL:*$>Q;E\:;_ -!]_P#_(;_&]< MWC7Q /\ F-W_/X$O_C5*;J4U6HKL5R1[%R;QOXA'_Q>F\<^(\G_B>ZC_X%/_C5.;QWXD'_M #'M2_\ M_\:SYNIJG-WJN6/8M0CV/HS]DG]I&^^&OCH:7XHU.>[\,ZNZO3 M2W4A?I)+T64$GA>S>W/:OTS1UE171@Z,.AE.01ZU^&DAP(;24V&FRBUTS4I3\US$!RF.I\L_+N]"|U4U\YFV$BE]8CIT9\=G^_BE] M;AIT?GV9I*T445\N?$!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\L>.?$WCS4/B3XQ MM?#&H^-)|7L-8M[;3;2TL;=]!2,P6[LMQ*Z;@/GD+8;(!&WG KZG]CI^BV.D MW% /:6R037_VFZ=>LLNQ4W'WVHH_4 >#^-?VD]5M*XCTW1].T\7D>G:I/I MM\+IYD66S W>=B+R_FR2%1W(QA@O.+%U\?M1\.ZS-HLFE2:AXAN;I8A#OGFM M8PEC;S2E/(MGE"YF4 %#R225'%>C)\$O R7TUV/#EKYTJW,;9+%OEP")U5#Y:A#SR!SF@#@K M3]HK4K^1;M/"+6NCPG2UO6O;PQ7<37KF,!8?+Y\ML$F7(.1SQ5_P#\$U_M$=SXDCAN_%4OIH2VVGZ:'(NDAFF5%#LBHK$1;?F/8'OBN[A^&GA>WM)+6+1+ M6*VD^RAH8U*]?LY!@X'380'*MZ=X*T/2M'O])MM-A32[^2:6YLV!>*1I23+|MIR &))(")XH \FT?]H?6-=CTBOLO#FGR>(M0U,:>UA+],L'V0&UDN-\ZRVZ MRKCRF7'EG=U4L*HQ?M6M??!CL?"=W=-81QG5H8EGF>*1II(F2%HH&C?;8G;=M(\888OSG'7ZS^SGX0U*;1!!8+:6EA?\ VZ:)7D:2X(MY{8U,I;>H0297!XQ@ M#FN@N/@WX*NGTYG\V8%A%'! B JGEHVY$=00'"M\P# X))[F@#AM7^->I7O M@W6=<71Q9:$8KHZ=>6^IHM|(8+@0ONB:,[-OW$$;\ 8::2*Y2T^,>O>$?$7B M75?$CW%_:QZC]\-J86=ZOV=8K40+&A1H5(9FE'S;CU)/I7LS?! P:UYJET?# M]H9M35TNCAL.'8.^!G"[F4,VT#<0"WO8M-8[R!9T4Y 8G@_A6]"HJ513?0ZL+55" MM&I+9'S5-4EKXDU+2E@6TNWA%N[O%M_^5F&&/3N*] /@703UTV+|V_OJ[\ > M'SUTR(_BW^->T\OHR5G%_@?2/-)/)6E!O[CYMO=5N[HVIEF9S:+MAR!\@W;O MYG-9NJW1V ^8GO7U$?A[X+-7\3Q0OZG>/=1PY**5"C)X+'&6/J>;^JO^%:>%_P#H"VQ^H)_K2'X9M>%3UT.T_[XH68T$[']Y"6;86+N|:^Y'OJK>KWFMW7VF^F-Q.(UB#D_?*HPHX M]*OIQS7VN?A;X3/70;,_P# *\| A5GA'&#X>L3|8A5K-*25E%_@:K.Z$590 M?X'PS**I3"OO$_"CP>>OAS3S_P!L12#X2^#0<_\ *::D'ZVB?X4A^#/@0]?"_CG_M MS3_"G_:U/^5C_M^C_(_P/S0F4^AJC,I|#7Z>+|&/ :MD>$-&SZ_8T_PIQ^#G M@4]?".C'_MRC_P *|7I_PC'_K!2_Y]O\#|LYE/H:I3(WH?RK]5S\&/ 9Z^ M#]%/_;C'_A3U^#O@5%VCPAHH'I]AC_PJO[8I_P C'_K#2_Y]O[T?DO,C<_*? MRJE,C>A_*OUT/P<|"GKX/T0_]N$?^%"_!SP(C!AX.T/(|_8(O_B:/I9A_(QMZQ4O^?;^]^X^3(V3\I_*MIEMO#EB5 MEU*] QA<1|?[I=O09/;G]6M"T*P\,Z-9:3I=K'9:=9Q+#!;Q#"H@& !3-"| M-Z3X7M&M=`TRTTNV9M[16<"Q*6Z9(4#G@ MT5L@HHHKSCOPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ K@9_C#IMO/)$UE=DHQ4D;?| &BB@ M!G_"Y]+_.?&[_|'?|&C_A<^E_|^-W_P"_P"-%% !_P +GTQ_)|:O_QW M_&C_(7/I?\ SXW?_CO^-%% !_PN?2_^?&[_/'?\:/^%SZ7_P ^-W_XI_C1 M10 ?!+GTO_GQN_|QW_&C_A<^E_|^-W_.._XT44_'_"Y]+_.?&[_|'?|&C_M&C_A<^E_|^-W_P"_P"-%% !_P +GTQ_)|:O_QW M_&C_(7/I?\ SXW?_CO^-M-%% !_PN?2_^?&[_/'?\:/^%SZ7_P ^-W_XI_C110 ?!+GTO_GQN_|QW_&C_MC_A<^E_|^-W_.._XT44_'_"Y]+_.?&[_|'?|&C_A<^E_|^-W_P"_P"-M%% !_P +GTQ_)|:O_QW M_&C_(7/I?\ SXW?_CO^-%% !_PN?2_^?&[_/'?\:/^%SZ7_P ^-W_XI_C110 ?!+GTO_GQN_|QW_&C_A<^E_|^-W_.._XT44_M_'_"Y]+_.?&[_|'?|&C_A<^E_|^-W_P"_P"-%% !_P +GTQ_)|:O_QW M_&C_(7/I?\ SXW?_CO^-%% !_PN?2_^?&[_/'?\:/^%SZ7_P ^-W_XI_C110 ?!+GTO_GQN_|QW_&C_MC_A<^E_|^-W_.._XT44_'_"Y]+_.?&[_|'?|&C_A<^E_|^-W_P"_P"-M%% !_P +GTQ_)|:O_QW M_&C_(7/I?\ SXW?_CO^-%% !_PN?2_^?&[_/'?\:/^%SZ7_P ^-W_XI_C110 ?!+GTO_GQN_|QW_&C_A<^E_|^-W_.._XT44_M_'_"Y]+_.?&[_|'?|&C_A<^E_|^-W_P"_P"-%% !_P +GTQ_)|:O_QW M_&C_(7/I?\ SXW?_CO^-%% !_PN?2_^?&[_/'?\:/^%SZ7_P ^-W_XI_C1 M10 ?!+GTO_GQN_|QW_&C_A<^E_|^-W_.._XT44_'_"Y]+_.?&[_|'?|&C_A<^E_|^-W_P"_P"-%% %W1?BC8:WJ<%E%:7, EX-101.SCH 9 mrkr-20240930.xsd EX-101.SCH 995200100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 995200200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 00400 - Disclosure - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (calc 2) link:presentationLink link:calculationLink link:definitionLink 995200400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 99940701 - Disclosure - DISCONTINUED OPERATIONS - Operations (Details) link:presentationLink link:calculationLink link:definitionLink 99940702 - Disclosure - DISCONTINUED OPERATIONS - Cash Flows (Details) link:presentationLink link:calculationLink link:definitionLink 99940801 - Disclosure - ACCOUNTS PAYABLE, ACCRUED LIABILITIES AND RELATED PARTY PAYABLE (Details) link:presentationLink link:calculationLink link:definitionLink 995200090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 995200105 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 995200300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 99931003 - Disclosure - STOCK BASED COMPENSATION (Tables) link:presentationLink link:calculationLink link:definitionLink 99940101 - Disclosure - NATURE OF OPERATIONS (Details) link:presentationLink link:calculationLink link:definitionLink 99940301 - Disclosure - LIQUIDITY AND FINANCIAL CONDITION (Details) link:presentationLink link:calculationLink link:definitionLink 99940401 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details) link:presentationLink link:calculationLink link:definitionLink 99940501 - Disclosure - NET LOSS PER SHARE - Computation of loss per Share (Details) link:presentationLink link:calculationLink link:definitionLink 99940502 - Disclosure - NET LOSS PER SHARE - Dilutive Securities (Details) link:presentationLink link:calculationLink link:definitionLink 99940601 - Disclosure - OTHER RECEIVABLE (Details) link:presentationLink link:calculationLink link:definitionLink 99940703 - Disclosure - DISCONTINUED OPERATIONS - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 99940901 - Disclosure - STOCKHOLDERS' EQUITY - Reverse Stock Split And ATM Agreement (Details) link:presentationLink link:calculationLink link:definitionLink 99940902 - Disclosure - STOCKHOLDERS' EQUITY - Stock Purchase Agreement And Exercise of Stock Options (Details) link:presentationLink link:calculationLink link:definitionLink 99941001 - Disclosure - STOCK-BASED COMPENSATION - Stock option activity (Details) link:presentationLink link:calculationLink link:definitionLink 99941002 - Disclosure - STOCK-BASED COMPENSATION - Stock-based compensation expenses (Details) link:presentationLink link:calculationLink link:definitionLink 99941003 - Disclosure - STOCK-BASED COMPENSATION - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 99941101 - Disclosure - GRANT INCOME (Details) link:presentationLink link:calculationLink link:definitionLink 99941301 - Disclosure - RELATED PARTY EXPENSES (Details) link:presentationLink link:calculationLink link:definitionLink 995210101 - Disclosure - NATURE OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 995210201 - Disclosure - BASIS OF PRESENTATION link:presentationLink link:calculationLink link:definitionLink 995210301 - Disclosure - LIQUIDITY AND FINANCIAL CONDITION link:presentationLink link:calculationLink link:definitionLink 995210401 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 995210501 - Disclosure - NET LOSS PER SHARE link:presentationLink link:calculationLink link:definitionLink 995210601 - Disclosure - OTHER RECEIVABLE link:presentationLink link:calculationLink link:definitionLink 995210701 - Disclosure - DISCONTINUED OPERATIONS link:presentationLink link:calculationLink link:definitionLink 995210801 - Disclosure - ACCOUNTS PAYABLE, ACCRUED LIABILITIES AND RELATED PARTY PAYABLE link:presentationLink link:calculationLink link:definitionLink 995210901 - Disclosure - STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 995211001 - Disclosure - STOCK-BASED COMPENSATION link:presentationLink link:calculationLink link:definitionLink 995211101 - Disclosure - GRANT INCOME link:presentationLink link:calculationLink link:definitionLink 995211201 - Disclosure - LEGAL PROCEEDINGS link:presentationLink link:calculationLink link:definitionLink 995211301 - Disclosure - RELATED PARTY EXPENSES link:presentationLink link:calculationLink link:definitionLink 995211401 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 99920402 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 99930503 - Disclosure - NET LOSS PER SHARE (Tables) link:presentationLink link:calculationLink link:definitionLink 99930703 - Disclosure - DISCONTINUED OPERATIONS (Tables) link:presentationLink link:calculationLink link:definitionLink 99930803 - Disclosure - ACCOUNTS PAYABLE, ACCRUED LIABILITIES AND RELATED PARTY PAYABLE (Tables) link:presentationLink link:calculationLink link:definitionLink 99931303 - Disclosure - RELATED PARTY EXPENSES (Tables) link:presentationLink link:calculationLink link:definitionLink 99900 - Disclosure - Standard And Custom Axis Domain Defaults link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 10 mrkr-20240930_cal.xml EX-101.CAL EX-101.DEF 11 mrkr-20240930_def.xml EX-101.DEF EX-101.LAB 12 mrkr-20240930_lab.xml EX-101.LAB Document and Entity Information Entity Addresses [Table] Entity Addresses [Line Items] Document Type Document Quarterly Report Document Period End Date Document Transition Report Entity File Number Entity Registrant Name Entity Incorporation, State or Country Code Entity Tax Identification Number Entity Address, Address Line One Entity Address, City or Town Entity Address, State or Province Entity Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security Trading Symbol Security Exchange Name Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Entity Shell Company Entity Shell Company Entity Common Stock, Shares Outstanding Entity Central Index Key Current Fiscal Year End Date Document Fiscal Year Focus Document Fiscal Period Focus Amendment Flag CONDENSED CONSOLIDATED BALANCE SHEETS Assets [Abstract] ASSETS Assets, Current [Abstract] Current assets: Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents Cash and cash equivalents Prepaid Expense, Current Prepaid expenses and deposits Other Receivables, Net, Current Other receivables Assets, Current Total current assets Assets Total assets Liabilities and Equity [Abstract] LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities, Current [Abstract] Current liabilities: Accounts Payable and Accrued Liabilities, Current Accounts payable and accrued liabilities Due to Related Parties, Current Related party payable Other Liability, Current, Related Party, Type [Extensible Enumeration] Liabilities, Current Total current liabilities Liabilities Total liabilities Stockholders' Equity Attributable to Parent [Abstract] Stockholders' equity: Preferred Stock, Value, Issued Preferred stock, $0.001 par value, 5 million shares authorized, 0 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively Common Stock, Value, Issued Common stock, $0.001 par value, 30 million shares authorized, 8.9 million shares issued and outstanding as of September 30, 2024 and December 31, 2023 (see Note 9) Additional Paid in Capital Additional paid-in capital Retained Earnings (Accumulated Deficit) Accumulated deficit Stockholders' Equity Attributable to Parent Ending Balance Ending Balance Total stockholders' equity Liabilities and Equity Total liabilities and stockholders' equity Statement [Table] Statistical Measurement [Axis] Statistical Measurement [Domain] Minimum [Member] Minimum Maximum [Member] Maximum Statements Statement Preferred Stock, Par or Stated Value Per Share Preferred stock par value (in $ per share) Preferred Stock, Shares Authorized Preferred stock authorized (in shares) Preferred Stock, Shares Issued Preferred stock issued Preferred Stock, Shares Outstanding Preferred stock outstanding Common Stock, Par or Stated Value Per Share Common stock par value (in $ per share) Common Stock, Shares Authorized Common stock authorized (in shares) Common Stock, Shares, Issued Common stock issued Common Stock, Shares, Outstanding Common stock outstanding CONSOLIDATED STATEMENTS OF OPERATIONS Product and Service [Axis] Product and Service [Domain] Grant [Member] Grant income Revenues [Abstract] Revenues: Revenue from Contract with Customer, Including Assessed Tax Revenue recognized Total revenues Costs and Expenses [Abstract] Operating expenses: Research and Development Expense Research and development General and Administrative Expense General and administrative Operating Expenses Total operating expenses Operating Income (Loss) Loss from operations Nonoperating Income (Expense) [Abstract] Other income (expenses): Investment Income, Interest Interest income Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent Loss from continuing operations Loss from continuing operations No definition available. Discontinued Operation, Income (Loss) from Discontinued Operation [Abstract] Discontinued operations: Discontinued Operation, Income (Loss) from Discontinued Operation During Phase-out Period, Net of Tax Loss from discontinued operations Loss from discontinued operations, net of tax Discontinued Operation, Gain (Loss) from Disposal of Discontinued Operation, before Income Tax Gain on disposal of discontinued operations before income taxes Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest Income from discontinued operations Income from discontinued operations Less: gain from discontinued operations, net of tax Net loss Net loss Earnings Per Share [Abstract] Net earnings (loss) per share: Net (loss) earnings per share: Income (Loss) from Continuing Operations, Per Basic Share Loss from continuing operations, basic (in dollars per share) Income (Loss) from Continuing Operations, Per Diluted Share Loss from continuing operations, diluted (in dollars per share) Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share Income from discontinued operations, basic (in dollars per share) Income (Loss) from Discontinued Operations and

Disposal of Discontinued Operations, Net of Tax, Per Diluted Share Income from discontinued operations, diluted (in dollars per share) Earnings Per Share, Basic Net loss per share, basic (in dollars per share) Earnings Per Share, Diluted Net loss per share, diluted (in dollars per share) Earnings Per Share, Basic, Other Disclosure [Abstract] Weighted average number of common shares outstanding: Weighted Average Number of Shares Outstanding, Basic Weighted average number of common shares outstanding, basic (in shares) Weighted average common shares outstanding, basic Weighted Average Number of Shares Outstanding, Diluted Weighted average number of common shares outstanding, diluted (in shares) Weighted average common shares outstanding, diluted CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Equity Components [Axis] Equity Component [Domain] Common Stock [Member] Common Stock Additional Paid-in Capital [Member] Additional Paid-in Capital Retained Earnings [Member] Accumulated Deficit Shares, Issued Ending Balance, Shares Beginning Balance, Shares Stock Issued During Period, Value, New Issues Shares purchased pursuant to ATM agreement Aggregate proceeds from shares issued under the purchase agreement Stock Issued During Period, Shares, New Issues Shares purchased pursuant to ATM agreement (in shares) Number of shares issued (in shares) It represents value of common stock as commitment fee for future financing. Issuance Of Common Stock , Value, As Commitment Fee For Future Financing Issuance of common stock as commitment fee for future financing It represents number of common stock issued as commitment fee for future financing. Issuance Of Common Stock, Shares, As Commitment Fee For Future Financing Issuance of common stock as commitment fee for future financing (in shares) Stock Issued During Period, Value, Stock Options Exercised Issuance of common stock from exercise of stock options Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Number of Shares, Exercised Issuance of common stock from exercise of stock options (in shares) Issuance of common stock from exercise of stock options (in shares) Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture Stock-based compensation Reduction in the number of shares during the period as a result of a fractional shares adjustment due to reverse split. Stock Issued During Period, Shares, Fractional Shares Adjustment Due to Reverse Split Fractional shares adjustment due to reverse split CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Net Cash Provided by (Used in) Operating Activities [Abstract] Cash Flows from Operating Activities: Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net loss Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest Net loss from continuing operations Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Reconciliation of net loss to net cash used in operating activities: Share-Based Payment Arrangement, Noncash Expense Stock-based compensation Increase (Decrease) in Operating Capital [Abstract] Changes in operating assets and liabilities: Increase (Decrease) in Prepaid Expense Prepaid expenses and deposits Increase (Decrease) in Accrued Interest Receivable, Net Other receivables Increase (Decrease) in Due to Related Parties, Current Related party payable Increase (Decrease) in Accounts Payable and Accrued Liabilities Accounts payable and accrued expenses Increase (Decrease) in Deferred Revenue Deferred revenue Net Cash Provided by (Used in) Operating Activities, Continuing Operations Net cash used in operating activities - continuing operations Cash Provided by (Used in) Operating Activities, Discontinued Operations Net cash used in operating activities - discontinued operations Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Net cash used in operating activities Net Cash Provided by (Used in) Investing Activities [Abstract] Cash Flows from Investing Activities: Cash Provided by (Used in) Investing Activities, Discontinued Operations Net cash provided by investing activities - discontinued operations Net cash provided by investing activities Net Cash Provided by (Used in) Investing Activities Net cash provided by investing activities Net Cash Provided by (Used in) Financing Activities [Abstract] Cash Flows from Financing Activities: Proceeds from Issuance of Common Stock Proceeds from Issuance of Common Stock Proceeds from issuance of common stock, net Proceeds from Stock Options Exercised Proceeds from stock options exercise Net Cash Provided by (Used in) Financing Activities Net cash provided by financing activities Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect Net (decrease) increase in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Cash and cash equivalents at end of the period Cash and cash equivalents at beginning of the period NATURE OF OPERATIONS Nature of Operations [Text Block] NATURE OF OPERATIONS n/a BASIS OF PRESENTATION Basis of Accounting [Text Block] BASIS OF PRESENTATION n/a LIQUIDITY AND FINANCIAL CONDITION Liquidity Financial Condition And Going Concern Text Block Liquidity Financial Condition And Going Concern [Text Block] LIQUIDITY AND FINANCIAL CONDITION SIGNIFICANT ACCOUNTING POLICIES Significant Accounting Policies [Text Block] SIGNIFICANT ACCOUNTING POLICIES NET LOSS PER SHARE Noncontrolling Interest Disclosure [Text Block] NET LOSS PER SHARE OTHER RECEIVABLE Loans, Notes, Trade and Other Receivables Disclosure [Text Block]OTHER RECEIVABLE DISCONTINUED OPERATIONS Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]DISCONTINUED OPERATIONS ACCOUNTS PAYABLE, ACCRUED LIABILITIES AND RELATED PARTY PAYABLE Accounts Payable and Accrued Liabilities Disclosure [Text Block]ACCOUNTS PAYABLE, ACCRUED LIABILITIES AND RELATED PARTY PAYABLE STOCKHOLDERS' EQUITY Stockholders' Equity Note Disclosure [Text Block]STOCKHOLDERS' EQUITY STOCK-BASED COMPENSATION Disclosure of Compensation Related Costs, Share-based Payments [Text Block]STOCK-BASED COMPENSATION GRANT INCOME Revenue from Contract with Customer [Text Block]GRANT INCOME LEGAL PROCEEDINGS Legal Matters and Contingencies [Text Block]LEGAL PROCEEDINGS RELATED PARTY EXPENSES Related Party Transactions Disclosure [Text Block]RELATED PARTY EXPENSES SUBSEQUENT EVENTS Subsequent Events [Text Block]SUBSEQUENT EVENTS Consolidation, Policy [Policy Text Block]Principles of Consolidation Use of Estimates, Policy [Policy Text Block]Use of Estimates Cash and Cash Equivalents, Policy [Policy Text Block]Cash, Cash Equivalents and Credit Risk Discontinued Operations, Policy [Policy Text Block]Discontinued Operations Disclosure of accounting policy for recently issued accounting standards not yet adopted.Recently Issued Accounting Standards Not yet Adopted [Policy Text Block]Recently Issued Accounting Standards Not Yet Adopted Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]Schedule of computation of net loss per share Tabular disclosure of net loss per share.Net Loss Per Share [Table Text Block]Schedule of anti-dilutive securities Disposal Groups, Including Discontinued Operations [Table Text Block]Schedule of income statement information and summary of cash flows for discontinued operations Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]Schedule of accounts payable, accrued liabilities and related party payable This table lists the stock-based compensation.Stock-Based Compensation [Table] Line items represent stock-based compensation.Stock-Based Compensation [Line Items]STOCK-BASED COMPENSATION Share-based Payment Arrangement, Activity [Table Text Block]Schedule of the company's stock option activity Tabular disclosure of stock based compensation expenses recorded.Stock based Compensation Expenses [Table Text Block]Schedule of stock-based compensation expenses Schedule of Related Party Transactions [Table Text Block]Schedule of related party transaction expenses Disclosure of information about organization, consolidation and presentation of financial statements.Organization, Consolidation and Presentation of Financial Statements Type of Arrangement and Non-arrangement Transactions [Axis] Arrangements and Non-arrangement Transactions [Domain] Represents the information pertaining to Cell Ready Agreement.Cell Ready Agreement [Member]Cell Ready Purchase Agreement Disposal Group Classification [Axis] Disposal Group Classification [Domain] Discontinued Operations, Disposed of by Sale [Member]Disposed by saleDiscontinued Operations, Disposed of by Sale Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.Organization, Consolidation and Presentation of Financial Statements [Line Items]NATURE OF OPERATIONS Stockholders' Equity, Reverse Stock SplitReverse stock split Disposal Group, Including Discontinued Operation, ConsiderationConsideration for purchased assetsConsideration for purchased assets The number of employees extended for employment.Offers Employment to Number of EmployeesNumber of former employees offered employment Severance CostsSeverance and termination-related costs Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.Financial Condition Going Concern And Management Plans [Table] Represents the information pertaining to controlled equity offering sales agreement.Controlled Equity Offering Sales Agreement [Member]ATM Agreement This member stands for binding services agreement.Binding Services Agreement [Member]Binding Services Agreement Counterparty Name [Axis] Counterparty Name [Domain] Represents the information pertaining to Cantor Fitzgerald & Co and RBC Capital Markets, LLC.Cantor Fitzgerald Co. And Rbc Capital Markets Llc [Member]Sales Agents Subsequent Event Type [Axis] Subsequent Event Type [Domain] Subsequent Event [Member]Subsequent event Related Party [Axis] Related Party [Domain] The information pertaining to Lincoln Park.Lincoln Park [Member]Lincoln Park This member represents information pertaining to National Institutes of Health Small Business Innovation Research.National Institutes of Health Small Business Innovation Research [Member]SBIR grant Represents information pertaining to grants from National Institutes of Health-National Cancer Institute.National Institutes of Health National Cancer Institute Grant [Member]National Institutes of Health National -Cancer Institute Grant Represents information pertaining to grant from National Institutes of Health and Business Innovation research for Lymphoma.National Institutes of Health Small Business Innovation Research For Lymphoma Grant [Member]SBIR lymphoma grant Award of money not required to be repaid for FDA grant.FDA Grant [Member]FDA grant Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS [Line Items]LIQUIDITY AND FINANCIAL CONDITION Common Stock, Value, SubscriptionsAggregate offering price Represents the percent of calculation of compensation rate by using gross sales price per share sold.Common Stock, Shares, Commission Rate Calculation on Gross Sales Price per Share, PercentCommission rate Other ReceivablesOther receivables Funds received from grantFunds Received From GrantFunds received from grant Research and Development Arrangement, Contract to Perform for Others, Compensation EarnedAmount of notice received Duration of grant assistance transaction, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.Grant Assistance TermGrant Assistance Term Funds received from grant.Funds Received From CPRIT GrantFunds received from CPRIT grant Amount of grant income transfer product and service to customer for which consideration has been received or is receivable.Grant ReceivedGrant income received Amount of receivable from Orphan Products Grant program.Orphan Products Grant ProgramGrant income receivable Revenue from grant related to CPRIT.Revenue From Grant Related to CPRITRevenue from CPRIT The amount of cash held at financial institutions.Cash at Financial InstitutionsCash at financial institutions US Government Agencies Securities, at Carrying ValueGovernment agency securities Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]NET LOSS PER SHARE Net Income (Loss) Attributable to Parent, Diluted [Abstract]Numerator: Weighted Average Number of Shares Outstanding, Diluted [Abstract]Denominator: Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Warrant [Member]Common stock purchase warrants Antidilutive Securities Excluded from Computation of Earnings Per Share, AmountPotentially dilutive securities Schedule of Receivables with Imputed Interest [Table] Project [Axis] Project [Domain] The information pertaining to cancer Prevention And Research Institute Of Texas.Cancer Prevention And Research Institute Of Texas [Member]CPRIT Receivables with Imputed Interest [Line Items]OTHER RECEIVABLE Amount of revenue recognized for grant from Orphan Products Grant program.Revenue From Orphan Products Grant ProgramGrant revenue Fund received from grantFund Received From GrantFunds received from grant Disposal Groups, Including Discontinued Operations [Table] Service [Member]Service Revenue This member stands for related party service.Related Party Service [Member]Related party service revenue Income Statement Location [Axis] Income Statement Location [Domain] Research and Development [Member]Research and development General and Administrative [Member]General and administrative Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]DISCONTINUED OPERATIONS Disposal Group, Including Discontinued Operation, RevenueTotal revenues Disposal Group, Including Discontinued Operation, Operating ExpenseTotal operating expenses Net Cash Provided by (Used in) Discontinued OperationsNet increase (decrease) in cash and cash equivalents Related Party [Member]Related party Represents information pertaining to Clinical Trial Agreement with Wilson Wolf Manufacturing Corporation.Wilson Wolf Manufacturing Corporation [Member]Wilson Wolf Manufacturing Corporation Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of TaxGain on disposal of discontinued operations before income taxes Discontinued Operation, Tax Effect of Gain (Loss) from Disposal of Discontinued OperationTax on gain on disposal of discontinued operations The amount of cash payment.Cash Payment Other Operating IncomeAgreement amount on cash payment The amount of additional revenue recognized.Additional Revenue RecognizedAdditional revenue recognized The amount of additional cash payment.Additional cash paymentAdditional cash payment This table lists the accounts payable and accrued liabilities. The line items identify information about the accounts payable and accrued liabilities.Accounts Payable And Accrued Liabilities [Table] Represents the information pertaining to Cell Ready.Cell Ready [Member]Cell Ready Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.Accounts Payable And Accrued Liabilities [Line Items]ACCOUNTS PAYABLE, ACCRUED LIABILITIES AND RELATED PARTY PAYABLE Accounts Payable, CurrentAccounts payable Employee-related Liabilities, CurrentCompensation and benefits Accrued Professional Fees, CurrentProfessional fees The amount of tax fees payable.Tax Fees PayableTax fees Other Accrued Liabilities, CurrentOther Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.Accounts Payable and Accrued Liabilities Including Related party payable, CurrentTotal accounts payable, accrued liabilities and related party payable Schedule of Stock by Class [Table] Sale of Stock [Axis] Sale of Stock [Domain] The member stands for ATM agreement.ATM Agreement [Member]ATM Agreement Class of Stock [Line Items]STOCKHOLDERS' EQUITY Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table] This Member represents stock purchase agreementStock Purchase Agreement [Member]Stock Purchase Agreement Subsidiary, Sale of Stock [Line Items]STOCKHOLDERS' EQUITY The time to time term to purchase shares in stock purchase agreement, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.Stock Purchase Agreement, Time to Time Term to Purchase SharesTime to time term to purchase shares (in months) Represents the amount of commitment fees.Commitment FeeCommitment fee Option Indexed to Issuer's Equity, Type [Axis] Option Indexed to Issuer's Equity, Type [Domain] Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, NumberNumber of Shares Outstanding, Ending BalanceNumber of Shares Outstanding, Beginning Balance Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in PeriodNumber of Shares, Cancelled / Expired Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, NumberNumber of Shares, Options vested and exercisable Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise PriceWeighted Average Exercise Price per Share, Outstanding, Ending BalanceWeighted Average Exercise Price per Share, Outstanding, Beginning Balance Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise PriceWeighted Average Exercise Price per Share, Exercised Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise PriceWeighted Average Exercise Price per Share, Cancelled / Expired Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise PriceWeighted Average Exercise Price, Options vested and exercisable Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic ValueTotal Intrinsic Value Outstanding Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic ValueTotal Intrinsic Value, Options vested and exercisable Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual TermWeighted Average Remaining Contractual Life, Outstanding (in years) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual TermWeighted Average Remaining Contractual Life, Options vested and exercisable (in years) Amount of expense for Stock compensation in continuing operations.Stock Compensation In Continuing OperationsStock compensation in continuing operations Amount of expense for Stock compensation in discontinued operations.Stock Compensation In Discontinued OperationsStock compensation in discontinued operations Allocated Share-based Compensation ExpenseTotal stock compensation expenses Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in PeriodNumber of equity incentive awards issued (in shares) Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, AmountTotal stock-based compensation cost related to unvested awards not yet recognized Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for RecognitionExpected weighted average period of recognition of unrecognized compensation costs (in years) This table lists the grant income.Grant Income [Table] Award of money not required to be repaid for CPRIT grant.CPRIT Grant [Member]CPRIT grant Line items represents grant income.Grant Income [Line Items]GRANT INCOME Receipt of product development research awardReceipt Of Product Development Research AwardReceipt of product development research award Restricted CashRestricted cash recorded Grants ReceivableGrant receivable Schedule of Related Party Transactions, by Related Party [Table] Represents information pertaining to Clinical Trial Agreement with Baylor College of Medicine.Clinical Trial Agreement with Baylor College of Medicine [Member]Baylor College of Medicine Related Party Transaction [Line Items]RELATED PARTY EXPENSES Related Party

Transaction, Expenses from Transactions with Related PartyTotal Research and development Cost of Goods and Service, Excluding Depreciation, Depletion, and AmortizationService and manufacturing costs Invoices for the cost of product sold and service rendered, excluding depreciation, depletion, and amortization.Invoices Received for Services and Manufacturing CostsPaid invoices EX-101.PRE 13 mrkr-20240930_pre.xml EX-101.PRE XML 15 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	9 Months Ended Sep. 30, 2024	Nov. 07, 2024
Document and Entity Information		
Document Type	10-Q	
Document Quarterly Report	true	
Document Period End Date	Sep. 30, 2024	
Document Transition Report	false	
Entity File Number	001-37939	
Entity Registrant Name	MARKER THERAPEUTICS, INC.	
Entity Incorporation, State or Country Code	DE	
Entity Tax Identification Number	45-4497941	
Entity Address, Address Line One	2450 Holcombe Blvd, Suite BCM-A, MS: BCM251	
Entity Address, City or Town	Houston	
Entity Address, State or Province	TX	
Entity Address, Postal Zip Code	77021	
City Area Code	713	
Local Phone Number	400-6400	
Title of 12(b) Security	Common Stock, par value $0.001 per share	
Trading Symbol	MRKR	
Security Exchange Name	NASDAQ	
Entity Current Reporting Status	Yes	
Entity Interactive Data Current	Yes	
Entity Filer Category	Non-accelerated Filer	
Entity Small Business	true	
Entity Emerging Growth Company	false	
Entity Shell Company	false	
Entity Common Stock, Shares Outstanding		8,923,490
Entity Central Index Key	0001094038	
Current Fiscal Year End Date	--12-31	
Document Fiscal Year Focus	2024	
Document Fiscal Period Focus	Q3	
Amendment Flag	false	

XML 16 R2.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Current assets:		
Cash and cash equivalents	$ 8,999,664	$ 15,111,450
Prepaid expenses and deposits	1,166,274	988,126
Other receivables	744,410	1,027,815
Total current assets	10,910,348	17,127,391
Total assets	10,910,348	17,127,391
Current liabilities:		
Accounts payable and accrued liabilities	2,557,335	1,745,193
Related party payable	$ 903,438	$ 1,329,655
Other Liability, Current, Related Party, Type [Extensible Enumeration]	Related Party [Member]	Related Party [Member]
Total current liabilities	$ 3,460,773	$ 3,074,848
Total liabilities	3,460,773	3,074,848
Stockholders' equity:		
Preferred stock, $0.001 par value, 5 million shares authorized, 0 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively		
Common stock, $0.001 par value, 30 million shares authorized, 8.9 million shares issued and outstanding as of September 30, 2024 and December 31, 2023 (see Note 9)	8,923	8,891
Additional paid-in capital	450,620,206	450,329,515
Accumulated deficit	(443,179,554)	(436,285,863)
Total stockholders' equity	7,449,575	14,052,543
Total liabilities and stockholders' equity	$ 10,910,348	$ 17,127,391

XML 17 R3.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Sep. 30, 2024	Dec. 31, 2023
Preferred stock par value (in $ per share)	$ 0.001	$ 0.001
Preferred stock authorized (in shares)	5,000,000	5,000,000
Preferred stock issued	0	0
Preferred stock outstanding	0	0
Common stock par value (in $ per share)	$ 0.001	$ 0.001
Common stock authorized (in shares)	30,000,000	30,000,000
Common stock issued	8,900,000	8,900,000
Common stock outstanding	8,900,000	8,900,000

XML 18 R4.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended		9 Months Ended	
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Revenues:				
Total revenues	$ 1,926,020	$ 257,606	$ 4,339,317	$ 2,254,601
Operating expenses:				
Research and development	3,471,216	2,044,980	8,381,661	7,799,472
General and administrative	854,677	1,412,672	3,214,611	6,098,716
Total operating expenses	4,325,893	3,457,652	11,596,272	13,898,188
Loss from operations	(2,399,873)	(3,200,046)	(7,256,955)	(11,643,587)
Other income (expenses):				
Interest income	91,681	218,085	363,264	337,819
Loss from continuing operations	(2,308,192)	(2,981,961)	(6,893,691)	(11,305,768)
Discontinued operations:				
Loss from discontinued operations, net of tax				(2,922,406)
Gain on disposal of discontinued operations before income taxes				8,794,426
Income from discontinued operations				5,872,020
Net loss	$ (2,308,192)	$ (2,981,961)	$ (6,893,691)	$ (5,433,748)
Net (loss) earnings per share:				
Loss from continuing operations, basic (in dollars per share)	$ (0.26)	$ (0.34)	$ (0.77)	$ (1.29)
Loss from continuing operations, diluted (in dollars per share)	(0.26)	(0.34)	(0.77)	(1.29)
Income from discontinued operations, basic (in dollars per share)				0.67

Income from discontinued operations, diluted (in dollars per share)				0.66
Net loss per share, basic (in dollars per share)	(0.26)	(0.34)	(0.77)	(0.62)
Net loss per share, diluted (in dollars per share)	$ (0.26)	$ (0.34)	$ (0.77)	$ (0.62)
Weighted average number of common shares outstanding:				
Weighted average number of common shares outstanding, basic (in shares)	8,923,170	8,825,881	8,914,487	8,782,340
Weighted average number of common shares outstanding, diluted (in shares)	8,923,170	8,825,881	8,914,487	8,834,512
Grant income				
Revenues:				
Total revenues	$ 1,926,020	$ 257,606	$ 4,339,317	$ 2,254,601

XML 19 R5.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Total
Beginning Balance at Dec. 31, 2022	$ 8,406	$ 447,641,680	$ (428,049,049)	$ 19,601,037
Beginning Balance, Shares at Dec. 31, 2022	8,405,771			
Shares purchased pursuant to ATM agreement	$ 277	1,014,363		1,014,640
Shares purchased pursuant to ATM agreement (in shares)	277,834			
Issuance of common stock as commitment fee for future financing	$ 180	(180)		
Issuance of common stock as commitment fee for future financing (in shares)	180,410			
Issuance of common stock from exercise of stock options	$ 25	85,317		85,342
Issuance of common stock from exercise of stock options (in shares)	25,118			
Stock-based compensation		1,439,832		1,439,832
Net loss			(5,433,748)	(5,433,748)
Fractional shares adjustment due to reverse split	(113)			
Ending Balance at Sep. 30, 2023	$ 8,888	450,181,012	(433,482,797)	16,707,103
Ending Balance, Shares at Sep. 30, 2023	8,889,020			
Beginning Balance at Jun. 30, 2023	$ 8,799	449,526,789	(430,500,836)	19,034,752
Beginning Balance, Shares at Jun. 30, 2023	8,799,173			
Shares purchased pursuant to ATM agreement	$ 65	394,602		394,667
Shares purchased pursuant to ATM agreement (in shares)	65,073			
Issuance of common stock from exercise of stock options	$ 24	84,580		84,604
Issuance of common stock from exercise of stock options (in shares)	24,774			
Stock-based compensation		175,041		175,041
Net loss			(2,981,961)	(2,981,961)
Ending Balance at Sep. 30, 2023	$ 8,888	450,181,012	(433,482,797)	16,707,103
Ending Balance, Shares at Sep. 30, 2023	8,889,020			
Beginning Balance at Dec. 31, 2023	$ 8,891	450,329,515	(436,285,863)	14,052,543
Beginning Balance, Shares at Dec. 31, 2023	8,891,420			
Shares purchased pursuant to ATM agreement	$ 8	36,894		36,902
Shares purchased pursuant to ATM agreement (in shares)	8,178			
Issuance of common stock from exercise of stock options	$ 24	58,477		$ 58,501
Issuance of common stock from exercise of stock options (in shares)	23,892			23,892
Stock-based compensation		195,320		$ 195,320
Net loss			(6,893,691)	(6,893,691)
Ending Balance at Sep. 30, 2024	$ 8,923	450,620,206	(443,179,554)	7,449,575
Ending Balance, Shares at Sep. 30, 2024	8,923,490			
Beginning Balance at Jun. 30, 2024	$ 8,922	450,565,204	(440,871,362)	9,702,764
Beginning Balance, Shares at Jun. 30, 2024	8,922,695			
Issuance of common stock from exercise of stock options	$ 1	1,700		1,701
Issuance of common stock from exercise of stock options (in shares)	795			
Stock-based compensation		53,302		53,302
Net loss			(2,308,192)	(2,308,192)
Ending Balance at Sep. 30, 2024	$ 8,923	$ 450,620,206	$ (443,179,554)	$ 7,449,575
Ending Balance, Shares at Sep. 30, 2024	8,923,490			

XML 20 R6.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	9 Months Ended	
	Sep. 30, 2024	Sep. 30, 2023
Cash Flows from Operating Activities:		
Net loss	$ (6,893,691)	$ (5,433,748)
Less: gain from discontinued operations, net of tax		5,872,020
Net loss from continuing operations	(6,893,691)	(11,305,768)
Reconciliation of net loss to net cash used in operating activities:		
Stock-based compensation	195,320	714,899
Changes in operating assets and liabilities:		
Prepaid expenses and deposits	(178,148)	(80,116)
Other receivables	283,405	2,318,691
Related party payable	(426,217)	367,915
Accounts payable and accrued expenses	812,142	(159,567)
Deferred revenue		107,530
Net cash used in operating activities - continuing operations	(6,207,189)	(8,036,416)
Net cash used in operating activities - discontinued operations		(6,035,961)
Net cash used in operating activities	(6,207,189)	(14,072,377)
Cash Flows from Investing Activities:		
Net cash provided by investing activities - discontinued operations		18,664,122
Net cash provided by investing activities		18,664,122
Cash Flows from Financing Activities:		
Proceeds from issuance of common stock, net	36,902	1,014,640
Proceeds from stock options exercise	58,501	85,342
Net cash provided by financing activities	95,403	1,099,982
Net (decrease) increase in cash and cash equivalents	(6,111,786)	5,691,727
Cash and cash equivalents at beginning of the period	15,111,450	11,782,172
Cash and cash equivalents at end of the period	$ 8,999,664	$ 17,473,899

XML 21 R7.htm IDEA: XBRL DOCUMENT

NATURE OF OPERATIONS	9 Months Ended
	Sep. 30, 2024
NATURE OF OPERATIONS	
NATURE OF OPERATIONS	

NOTE 1: NATURE OF OPERATIONS

Marker Therapeutics, Inc., a Delaware corporation (the "Company" or "we"), is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. The Company's multi tumor associated antigen (multiTAA")-specific T cell technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens, which are tumor targets, and kill tumor cells expressing those targets. These T cells are designed to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. The Company was incorporated in Nevada in 1992 and reincorporated in Delaware in October 2018.

Purchase Agreement with Cell Ready

On June 26, 2023, the Company completed the previously announced transaction with Cell Ready, LLC ("Cell Ready") pursuant to a Purchase Agreement (the "Cell Ready Purchase Agreement), dated May 1, 2023, by and between the Company and Cell Ready. Mr. John Wilson is a member of the Company's board of directors and is serving as the CEO of Cell Ready, therefore Cell Ready is a related party.

Pursuant to the Cell Ready Purchase Agreement, effective as of the Closing Date, the Company (i) assigned to Cell Ready the leases for the Company's two manufacturing facilities in Houston, Texas (the "Manufacturing Facilities"), (ii) sold to Cell Ready all of the equipment and leasehold improvements at the Manufacturing Facilities and (iii) assigned to Cell Ready its rights, title and interest in the Company's Master Services Agreement for Product Supply (the "MSA"), dated April 7, 2023, by and between the Company, Cell Ready and Indapta Therapeutics, Inc., as well as its rights, title and interest in any contracts related to the equipment and Manufacturing Facilities (collectively, the "Purchased Assets"). Cell Ready acquired the Purchased Assets for total consideration of $19.0 million. In connection with the purchase of the Manufacturing Facilities, Cell Ready also extended offers of employment to approximately 50 of the Company's former employees in its manufacturing, development, quality, and regulatory affairs functions.

The Purchased Assets constituted a significant disposition. Based upon the magnitude of the disposition and because the Company is exiting certain manufacturing operations, the disposition represents a significant strategic shift that will have a material effect on the Company's operations and financial results. Accordingly, the assets sold meet the definition of a discontinued operation, as defined by Accounting Standards Codification ("ASC") 205-20 – Discontinued Operations, and prior comparative periods have been retroactively adjusted to reflect the current presentation. See additional discussion at Note 7.

On February 22, 2024, we entered into a Master Services Agreement for Product Supply (the "MSA") with Cell Ready to provide outsourced services previously performed by the Company prior to its asset sale to Cell Ready. Cell Ready, which is owned by one of our directors and shareholders, Mr. John Wilson, is a contract development and manufacturing organization (CDMO). Under the MSA, it is anticipated Cell Ready will perform a wide variety of services for us, including research and development, and manufacturing in support of our clinical trials. Pursuant to the MSA, the Company may contract with Cell Ready for the provision of various products and services from time to time by entering into work orders with Cell Ready. If the services involve the supply of product, Cell Ready is required to supply such product in conformance with the product requirements set forth in the applicable work order(s). Under the MSA, Cell Ready is to use only personnel with sufficient qualifications and experience to supply the services contemplated by the MSA, provide its personnel with adequate training and assume full responsibility for its personnel's compliance with the MSA. Further, Cell Ready is required to provide the Company with assistance and cooperation in order for the Company to obtain and maintain all necessary regulatory approvals, at the Company's expense.

Organizational Changes

In 2023, the Company implemented changes to its organizational structure due to the transaction with Cell Ready and to reduce operational costs. In connection with these changes, the Company reduced headcount, including the separation of its former Chief Executive Officer, Peter Hoang, in May 2023, and its former Chief Accounting Officer, Michael Loiacono, in June 2023. During the second quarter of 2023, the Company recorded $0.9 million of severance and termination-related costs. The payments of these costs were completed in July of 2023. Effective May 1, 2023, the Company's board of directors appointed Dr. Juan Vera as the Company's President and Chief Executive Officer.

Effective June 30, 2023, the board of directors appointed Eliot M. Lurier as the Company's Interim Chief Financial Officer, whereby Mr. Lurier provided consulting services to the Company pursuant to a consulting agreement between the Company and Danforth Advisors, LLC ("Danforth") and received no compensation directly from the Company. On November 17, 2023, the Company terminated the consulting agreement between the Company and Danforth, effective January 16, 2024.

On November 17, 2023, Mr. Lurier ceased serving as the Company's Interim Chief Financial Officer and Dr. Vera was appointed as the Company's Principal Financial and Accounting Officer.

Reverse Stock Split

On January 26, 2023, the Company effected a one-for-ten (1-for-10) reverse stock split of its common stock (the "Reverse Stock Split") and a corresponding reduction in the total number of authorized shares of its common stock from 300,000,000 to 30,000,000. The Reverse Stock Split, which was approved by stockholders at an annual stockholder meeting on May 24, 2022, was consummated pursuant to a Certificate of Amendment filed with the Secretary of State of Delaware on January 26, 2023. The Reverse Stock Split was effective on January 26, 2023. All references to common stock, warrants to purchase common stock, options to purchase common stock, share data, per share data and related information contained in the consolidated financial statements have been retrospectively adjusted to reflect the effect of the Reverse Stock Split for all periods presented.

XML 22 R8.htm IDEA: XBRL DOCUMENT

BASIS OF PRESENTATION

9 Months Ended
Sep. 30, 2024

BASIS OF PRESENTATION

BASIS OF PRESENTATION

NOTE 2: BASIS OF PRESENTATION

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with the accounting principles generally accepted in the United States of America ("U.S. GAAP") for interim financial information and pursuant to the instructions to Form 10-Q and Article 8 of Regulation S-X of the Securities and Exchange Commission ("SEC") and on the same basis as the Company prepares its annual audited consolidated financial statements. In the opinion of management, the accompanying unaudited condensed consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation of such interim results (see Note 7 for information on discontinued operations).

The results for the unaudited condensed consolidated statement of operations are not necessarily indicative of results to be expected for the year ending December 31, 2024, or for any future interim period. The condensed consolidated balance sheet at December 31, 2023 has been derived from audited financial statements, however, it does not include all of the information and notes required by U.S. GAAP for complete financial statements. The accompanying condensed consolidated financial statements should be read in conjunction with the consolidated financial statements for the year ended December 31, 2023 and notes thereto included in the Company's annual report on Form 10-K filed on March 26, 2024.

Certain amounts presented in prior periods have been reclassified to conform to the current period presentation.

XML 23 R9.htm IDEA: XBRL DOCUMENT

LIQUIDITY AND FINANCIAL CONDITION

9 Months Ended
Sep. 30, 2024

LIQUIDITY AND FINANCIAL CONDITION

LIQUIDITY AND FINANCIAL CONDITION

NOTE 3: LIQUIDITY AND FINANCIAL CONDITION

As of September 30, 2024, the Company had cash and cash equivalents of approximately $9.0 million. The Company's activities since inception have consisted principally of acquiring product and technology rights, raising capital, and performing research and development. Successful completion of the Company's development programs and, ultimately, the attainment of profitable operations are dependent on future events, including, among other things, its ability to access potential markets; secure financing; successfully progress its product candidates through preclinical and clinical development; obtain regulatory approval of one or more of its product candidates; maintain and enforce intellectual property rights; develop a customer base; attract, retain and motivate qualified personnel; and develop strategic alliances and collaborations. From inception, the Company has been funded by a combination of equity, debt financings and grants. In August 2021, the Company entered into a Controlled Equity Offering^{SM} Sales Agreement (the "ATM Agreement") with Cantor Fitzgerald & Co. and RBC Capital Markets, LLC (the "Sales Agents"), pursuant to which the Company can offer and sell, from time to time at its sole discretion through the Sales Agents, shares of its common stock having an aggregate offering price of up to $75.0 million. Any shares of its common stock sold will be issued pursuant to the Company's shelf registration statement on Form S-3 (File No. 333-258687), which the SEC declared effective on August 19, 2021. However, our use of the shelf registration statement on Form S-3 will be limited for so long as we are subject to General Instruction I.B.6 of Form S-3, which limits the amounts that we may sell under the registration statement and in accordance with the ATM agreement. The Sales Agents are entitled to compensation under the Sales Agreement at a commission rate equal to 3.0% of the gross sales price per share sold under the ATM Agreement, and we have provided each of the Sales Agents with indemnification and contribution rights. During the nine months ended
September 30, 2024, the Company sold 8,178 shares of its common stock under the ATM Agreement for proceeds of $0.04 million. On June 10, 2024, the Company provided notice of its termination of the ATM Agreement with Cantor Fitzgerald & Co. and RBC Capital Markets, LLC. The Company is not subject to any termination penalties related to the termination of the ATM Agreement. The Company is currently considering more effective ways to improve market access to its equity.

In August 2021, the Company received notice of a Product Development Research award totaling approximately $13.1 million from the Cancer Prevention and Research Institute of Texas ("CPRIT") to support the Company's clinical investigation of MT-401. Through the date of this filing, the Company has received $9.7 million of funds from the CPRIT grant. The Company recorded $0.9 million and $2.4 million of grant income related to the CPRIT grant as revenue for the three and nine months ended September 30, 2024, respectively. As of September 30, 2024, the Company recorded $0.1 million of grant income receivable, which represented grant income earned in advance of funds to be received from CPRIT.

In September 2022, the Company received notice from the U.S. Food and Drug Administration (the "FDA") that it had awarded the Company a $2.0 million grant from the FDA's Orphan Products Grant program to support the Company's clinical investigation of MT-401 for the treatment of post-transplant AML. Through the date of this filing, the Company has received $1.0 million from the FDA grant. The Company recorded $0.02 million and $0.5 million of grant income related to the FDA grant as revenue for the three and nine months ended September 30, 2024, respectively. As of September 30, 2024, the Company recorded $0.02 million of grant income receivable, which represented grant income earned in advance of funds to be received from the FDA. In October 2024, the Company received $0.02 million of funds from the FDA grant.

In May 2023, the Company received notice of a $2.0 million grant from the National Institutes of Health Small Business Innovation Research ("SBIR") program to support the development and investigation of MT-401 for the treatment of AML patients following standard-of-care therapy with hypomethylating agents. Through the date of this filing, the Company has received $0.9 million from SBIR. The Company recorded $0.3 million and $0.7 million of grant income related to the SBIR grant as revenue for the three and nine months ended September 30, 2024. As of September 30, 2024, the Company recorded $0.3 million as other receivable, which represented grant income earned in advance of funds to be received from the SBIR. In October 2024, the Company received $0.3 million of funds from the SBIR grant.

In June 2024, the Company received notice of a $2.0 million grant over a 2 - year period from the National Institutes of Health - National Cancer Institute to support control over tumor immune escape in pancreatic cancer using a dual T cell product strategy. Through the date of this filing, the Company has not received any funds from this grant.

In August 2024, the Company received notice of a $2.0 million grant from the National Institutes of Health Small Business Innovation Research Program to support the clinical investigation of MT-601 in patients with non-Hodgkin's lymphoma (NHL) who have relapsed following anti-CD19 chimeric antigen receptor (CAR) T cell therapy. Through the date of this filing, the Company has received $0.7 million of funds from this grant. The Company recorded $0.7 million of grant income related to this grant as revenue for the three and nine months ended September 30, 2024. As of September 30, 2024, the Company recorded $0.3 million as other receivable, which represented grant income earned in advance of funds to be received from the SBIR. In October 2024, the Company received $0.3 million of funds from the SBIR lymphoma grant.

In August 2024, the Company received another $2.0 million grant from the National Institutes of Health SBIR Program to support the advancement of MT-601 in patients with pancreatic cancer. Through the date of this filing, the Company has received an immaterial amount of funds from this grant.

As described in Note 1, on June 26, 2023, the Company completed the transaction with Cell Ready pursuant to the Cell Ready Purchase Agreement for total consideration of $19.0 million. On February 22, 2024, the Company entered into a Master Services Agreement for Product Supply (the "MSA") with Cell Ready, a contract development and manufacturing organization (CDMO). Under the MSA, it is anticipated Cell Ready will perform a wide variety of services for us, including research and development, and manufacturing in support of our clinical trials. Pursuant to the MSA, the Company may contract with Cell Ready for the provision of various products and services from time to time by entering into work orders with Cell Ready (See Note 13).

The Company expects to continue to incur substantial losses over the next several years during its development phase.

Based on the Company's clinical and research and development plans and its timing expectations related to the progress of its programs, the Company anticipates that its cash and cash equivalents as of September 30, 2024, including drawdowns of available grant funds, will enable the Company to fund its operating expenses and capital expenditure requirements into October 2025. This estimate is subject to the Company's ability to effectively manage its costs, raise additional capital, and utilize drawdowns of anticipated grant funds.

The Company has based this estimate on assumptions that may prove to be wrong, and the Company could utilize its available capital resources sooner than it currently expects. Furthermore, the Company's operating plan may change, and it may need additional funds sooner than planned in order to meet operational needs and capital requirements for product development and commercialization. Because of the numerous risks and uncertainties associated with the development and commercialization of the Company's product candidates and the extent to which the Company may enter into additional collaborations with third parties to participate in their development and commercialization, the Company is unable to estimate the amounts of increased capital outlays and operating expenditures associated with its current and anticipated clinical trials. The Company's future funding requirements will depend on many factors, as it:

- Initiates, continues, or accelerates clinical trials of its product candidates;
- continues the research and development of its product candidates and seeks to discover additional product candidates;

- seeks regulatory approvals for any product candidates that successfully complete clinical trials;
- maintains and enforces intellectual property rights;
- enters into contract manufacturing arrangements with Cell Ready or other contract manufacturing organizations for clinical manufacturing supply;
- establishes sales, marketing and distribution infrastructure and scale-up manufacturing capabilities to commercialize any product candidates that may receive regulatory approval;
- evaluates strategic transactions the Company may undertake; and
- enhances operational, financial and information management systems and hires additional personnel, including personnel to support development of product candidates and, if a product candidate is approved, commercialization efforts.

The Company does not have sufficient sources of revenue to provide incoming cash flows to sustain its future operations. As outlined above, the Company's ability to pursue its long-term planned business activities is dependent upon its successful efforts to raise additional capital and grant income.

These factors raise substantial doubt regarding the Company's ability to continue as a going concern. The Company's condensed consolidated financial statements have been prepared on a going concern basis, which implies that the Company will continue to realize its assets and discharge its liabilities in the normal course of business. The Company's financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

In addition to the foregoing, the current macro-economic environment of decades-high inflation and concerns about an economic recession in the United States or other major markets have resulted in, among other things, volatility in the capital markets that may have the effect of reducing the Company's ability to access capital, which could in the future negatively affect the Company's liquidity. In addition, a recession or market correction due to these factors could materially affect the Company's business and the value of its common stock.

XML 24 R10.htm IDEA: XBRL DOCUMENT

SIGNIFICANT ACCOUNTING POLICIES

9 Months Ended
Sep. 30, 2024

SIGNIFICANT ACCOUNTING POLICIES

SIGNIFICANT ACCOUNTING POLICIES

NOTE 4: SIGNIFICANT ACCOUNTING POLICIES

Principles of Consolidation

These consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Marker Cell Therapy, Inc. and GeneMax Pharmaceuticals Inc. – a dormant subsidiary that wholly owns GeneMax Pharmaceuticals Canada, Inc. All significant intercompany balances and transactions are eliminated upon consolidation.

Use of Estimates

Preparation of the Company's consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Accordingly, actual results may differ materially from those estimates. Management considers many factors in selecting appropriate financial accounting policies, controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes, and management must select an amount that falls within that range of reasonable estimates. Estimates are used in the following areas, among others: stock-based compensation expense and income taxes.

Cash, Cash Equivalents and Credit Risk

The Company considers highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. Cash and cash equivalents at September 30, 2024 consisted of cash and certificates of deposit in institutions in the United States. Balances at certain institutions have exceeded Federal Deposit Insurance Corporation insured limits and U.S. government agency securities.

The Company maintains cash in accounts which are in excess of the Federal Deposit Insurance Corporation ("FDIC") insured limits of $250,000. As of September 30, 2024, the Company had approximately $4.1 million in cash at financial institutions and approximately $4.9 million in U.S. government agency securities, for aggregate cash and cash equivalents of $9.0 million. As of December 31, 2023, the Company had approximately $1.4 million in cash at financial institutions and approximately $13.7 million in U.S. government agency securities, for aggregate cash and cash equivalents of $15.1 million.

In the event cash is received from grants in advance of incurring qualifying costs, it is recorded as restricted cash until it is earned and recorded to grant income.

Discontinued Operations

The Purchased Assets sold to Cell Ready pursuant to the Cell Ready Purchase Agreement constituted a significant disposition and as such, the Company concluded that the disposition of its Purchased Assets represented a strategic shift that had a major effect on its operations and financial results. Therefore, the Purchased Assets, related party revenue, service revenue and related expenses are classified as discontinued operations for all periods presented herein. See Note 7 for further information.

Recently Issued Accounting Standards Not Yet Adopted

Improvements to Reportable Segment Disclosures

In November 2023, the Financial Accounting Standards Board (the "FASB") issued Accounting Standards Update ("ASU") No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. The ASU requires disclosures to include significant segment expenses that are regularly provided to the chief operating decision maker, among other provisions. Public entities with a single reportable segment, such as the Company, are required to provide the new disclosures and all the disclosures required under ASC 280. The ASU is effective for fiscal year periods beginning after December15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted, and the ASU requires retrospective application to all prior periods presented in the financial statements. The Company is currently evaluating the standard to determine the impact of adoption to its consolidated financial statements and disclosures.

Improvements to Income Tax Disclosures

In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (ASU 2023-09), which improves the transparency of income tax disclosures by requiring consistent categories and greater disaggregation of information in the effective tax rate reconciliation and income taxes paid disaggregated by jurisdiction. It also includes certain other amendments to improve the effectiveness of income tax disclosures. This guidance will be effective for the annual periods beginning the year ended December 31, 2025. Early adoption is permitted. Upon adoption the guidance can be applied prospectively or retrospectively. We do not expect the adoption of this guidance to have a material impact on the Company's consolidated financial statements.

From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board ("FASB") or other standard setting bodies that the Company adopts as of the specified effective date. Unless otherwise discussed, the Company does not believe that the impact of recently issued standards that are not yet effective will have a material impact on its consolidated financial position or results of operations upon adoption.

There have been no material changes in the Company's significant accounting policies to those previously disclosed in the Annual Report on Form 10-K for the year ended December 31, 2023 filed on March 26, 2024.

XML 25 R11.htm IDEA: XBRL DOCUMENT

NET LOSS PER SHARE

9 Months Ended
Sep. 30, 2024

NET LOSS PER SHARE

NET LOSS PER SHARE

NOTE 5: NET LOSS PER SHARE

Basic loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the reporting period. Diluted loss per common share is computed similarly to basic loss per common share except that it reflects the potential dilution that could occur if dilutive securities or other obligations to issue common stock were exercised or converted into common stock.

The following table sets forth the computation of net loss per share for the three and nine months ended September 30, 2024 and 2023, respectively:

	For the Three Months Ended September 30,		For the Nine Months Ended September 30,	
	2024	2023	2024	2023
Numerator:				
Loss from continuing operations	$ (2,308,192)	$ (2,981,961)	$ (6,893,691)	$ (11,305,768)
Income from discontinued operations	$ —	$ —	$ —	$ 5,872,020
Net loss	$ (2,308,192)	$ (2,981,961)	$ (6,893,691)	$ (5,433,748)
Denominator:				
Weighted average common shares outstanding, basic	8,923,170	8,825,881	8,914,487	8,782,340
Weighted average common shares outstanding, diluted	8,923,170	8,825,881	8,914,487	8,834,512
Net earnings (loss) per share:				
Loss from continuing operations, basic and diluted	$ (0.26)	$ (0.34)	$ (0.77)	$ (1.29)
Income from discontinued operations, basic	$ —	$ —	$ —	$ 0.67
Income from discontinued operations, diluted	$ —	$ —	$	$ 0.66
Net loss per share, basic and diluted	$ (0.26)	$ (0.34)	$ (0.77)	$ (0.62)

The following securities, rounded to the nearest thousand, were not included in the diluted net loss per share calculation because their effect was anti-dilutive for the periods presented:

	For the Three Months Ended September 30,		For the Nine Months Ended September 30,	
	2024	2023	2024	2023
Common stock options	596,000	800,000	596,000	748,000
Common stock purchase warrants	—	1,848,000	—	1,848,000
Potentially dilutive securities	596,000	2,648,000	596,000	2,596,000

XML 26 R12.htm IDEA: XBRL DOCUMENT

OTHER RECEIVABLE

9 Months Ended
Sep. 30, 2024

OTHER RECEIVABLE
OTHER RECEIVABLE

NOTE 6: OTHER RECEIVABLE

Qualifying grant income earned in advance of cash received from grants is recognized as revenue and recorded as other receivable. The Company recorded $0.9 million and $2.4 million of grant income related to the CPRIT grant for the three and nine months ended September 30, 2024, respectively. At September 30, 2024, the Company recorded $0.1 million of grant income receivable related to the CPRIT grant.

Additionally, the Company recorded $0.02 million and $1.0 million of grant income related to the FDA and SBIR grants, respectively, for the three months ended September 30, 2024. The Company recorded $0.5 million and $1.4 million of grant income related to the FDA and SBIR grants, respectively, for the nine months ended September 30, 2024. At September 30, 2024, the Company recorded $0.02 million and $0.6 million of grant income receivable related to the FDA and SBIR grants, respectively.

In October 2024, the Company received payments of $0.02 million and $0.6 million from the FDA grant and all SBIR grants, respectively.

XML 27 R13.htm IDEA: XBRL DOCUMENT

DISCONTINUED OPERATIONS

9 Months Ended
Sep. 30, 2024

DISCONTINUED OPERATIONS
DISCONTINUED OPERATIONS

NOTE 7: DISCONTINUED OPERATIONS

As discussed in Note 1, on June 26, 2023, the Company completed the previously announced transaction with Cell Ready for cash consideration of $19.0 million, resulting in derecognition of the Purchased Assets and a gain on sale of approximately $8.7 million, net of $63,000 in tax. There were no remaining assets and liabilities classified in discontinued operations as of September 30, 2024 or December 31, 2023.

The Company had no activity related to discontinued operations for the three and nine months ended September 30, 2024. Net loss from discontinued operations for the three and nine months ended September 30, 2023, was as follows:

	For the Three Months Ended September 30, 2023	For the Nine Months Ended September 30, 2023
Revenues:		
Service Revenue	$ —	$ 816,641
Related party service revenue	—	3,500,000
Total revenues	—	4,316,641
Operating expenses:		
Research and development	—	6,561,957
General and administrative	—	677,090
Total operating expenses	—	7,239,048
Loss from discontinued operations	$ —	$ (2,922,406)

The following table summarizes our cash flows related to discontinued operations for the nine months ended September 30, 2023:

	For the Nine Months Ended September 30, 2023
Discontinued operations:	
Net cash used in operating activities	(6,036,000)
Net cash provided by investing activities	18,664,000
Net increase (decrease) in cash and cash equivalents	$ 12,628,000

Related Party Service Revenue

In April 2022, the Company entered into a binding services agreement ("Wilson Wolf Agreement") with Wilson Wolf Manufacturing Corporation ("Wilson Wolf"). Mr. John Wilson is a member of the Company's board of directors and is serving as the CEO of Wilson Wolf. Wilson Wolf is in the business of creating products and services intended to simplify and expedite the transition of cell therapies and gene-modified cell therapies to mainstream society (the "Wilson Wolf Mission"). Pursuant to the Wilson Wolf Agreement, Wilson Wolf made a cash payment to the Company in the amount of $8.0 million, as consideration for certain training and research services.

In March 2023, the Company recognized the final $2.5 million of revenue pursuant to this $8.0 million agreement and an additional $1.0 million because certain agreed milestones were met. Payment of the additional $1.0 million was received in May 2023.

XML 28 R14.htm IDEA: XBRL DOCUMENT

ACCOUNTS PAYABLE, ACCRUED LIABILITIES AND RELATED PARTY PAYABLE

9 Months Ended
Sep. 30, 2024

ACCOUNTS PAYABLE, ACCRUED LIABILITIES AND RELATED PARTY PAYABLE
ACCOUNTS PAYABLE, ACCRUED LIABILITIES AND RELATED PARTY PAYABLE

NOTE 8: ACCOUNTS PAYABLE, ACCRUED LIABILITIES AND RELATED PARTY PAYABLE

Accounts payable, accrued liabilities, and related party payable consist of the following as of September 30, 2024 and December 31, 2023, respectively:

	September 30, 2024	December 31, 2023
Accounts payable	$ 1,904,000	$ 961,000
Compensation and benefits	39,000	57,000
Professional fees	359,000	303,000
Related party payable	903,000	1,330,000
Tax fees	52,000	219,000
Other	204,000	205,000
Total accounts payable, accrued liabilities and related party payable	$ 3,461,000	$ 3,075,000

The $0.9 million and $1.3 million related-party payable as of September 30, 2024 and December 31, 2023, respectively, primarily reflects amounts payable to Cell Ready for outsourced product development and manufacturing services. See Note 13: Related Party Transactions.

XML 29 R15.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS' EQUITY

9 Months Ended
Sep. 30, 2024

STOCKHOLDERS' EQUITY
STOCKHOLDERS' EQUITY

NOTE 9: STOCKHOLDERS' EQUITY

Reverse Stock Split

On January 26, 2023, the Company effected the Reverse Stock Split and a corresponding reduction in the total number of authorized shares of its common stock from 300,000,000 to 30,000,000. The Reverse Stock Split, which was approved by stockholders at an annual stockholder meeting on May 24, 2022, was consummated pursuant to a Certificate of Amendment filed with the Secretary of State of Delaware on January 26, 2023. The Reverse Stock Split was effective on January 26, 2023. All historical share and per share amounts reflected in this report have been adjusted to reflect the Reverse Stock Split.

Common Stock Transactions

Issuance of Stock Pursuant to ATM Agreement

During the nine months ended September 30, 2024, the Company sold 8,178 shares of its common stock under the ATM Agreement for gross proceeds of $37,000. During the nine months ended September 30, 2023, the Company sold 265,334 shares of its common stock under the ATM Agreement for gross proceeds of $1.0 million. On June 10, 2024, the Company provided notice of its termination of the ATM Agreement with Cantor Fitzgerald & Co. and RBC Capital Markets, LLC. The Company is currently considering more effective ways to improve market access to its equity.

Stock Purchase Agreement

In December 2022, the Company entered into a purchase agreement (the "Purchase Agreement") with Lincoln Park which provides that, upon the terms and subject to the conditions of the agreement, the Company had the right, but not the obligation, to sell to Lincoln Park up to $25,000,000 of shares of its common stock (the "Purchase Shares") from time to time over a 24-month term, at a variable price with certain market-based terms as defined in the Purchase Agreement. The Purchase Agreement does not exhibit any of the characteristics for liability classification under ASC Topic 480, Distinguishing Liabilities from Equity. Instead, the purchase agreement was indexed to the Company's own stock under ASC Subtopic 815-40, *Contracts in Entity's Own Equity*, and classified as equity. In January 2023, Lincoln Park was issued 180,410 shares of stock as a commitment fee at a value of $0.5 million. During the nine months ended September 30, 2023, the Company sold 12,500 shares of its common stock under the Purchase Agreement for gross proceeds of approximately $33,000. The Company terminated the Purchase Agreement with Lincoln Park on February 29, 2024, effective March 1, 2024.

Exercise of Stock Options

During the nine months ended September 30, 2024, certain outstanding options were exercised for 23,892 shares of common stock, providing aggregate proceeds to the Company of approximately $59,000.

XML 30 R16.htm IDEA: XBRL DOCUMENT

STOCK-BASED COMPENSATION

9 Months Ended
Sep. 30, 2024

STOCK-BASED COMPENSATION
STOCK-BASED

NOTE 10: STOCK-BASED COMPENSATION

COMPENSATION

Stock Options

2024 Equity Incentive Awards

There were no equity incentive awards issued during the three and nine months ended September 30, 2024.

A summary of the Company's stock option activity for the nine months ended September 30, 2024 is as follows:

	Number of Shares	Weighted Average Exercise Price	Total Intrinsic Value	Weighted Average Remaining Contractual Life (in years)
Outstanding as of January 1, 2024	737,895	$ 25.42	$ 1,317,000	7.6
Exercised	(23,892)	2.45	—	—
Canceled/Expired	(117,670)	43.37	—	—
Outstanding as of September 30, 2024	596,333	$ 22.80	$ 291,000	7.1
Options vested and exercisable	386,062	$ 33.76	$ 109,000	6.4

The following table sets forth stock-based compensation expenses recorded during the respective periods:

	For the Three Months Ended September 30,		For the Nine Months Ended September 30,	
	2024	2023	2024	2023
Stock Compensation expenses:				
Research and development	$ 3,000	$ 106,000	$ 13,000	$ 299,000
General and administrative	50,000	69,000	182,000	416,000
Stock compensation in continuing operations	53,000	175,000	195,000	715,000
Stock compensation in discontinued operations	—	—	—	725,000
Total stock compensation expenses	$ 53,000	$ 175,000	$ 195,000	$ 1,440,000

As of September 30, 2024, the total stock-based compensation cost related to unvested awards not yet recognized was $0.2 million. The expected weighted average period for compensation costs to be recognized was approximately 1.8 years. Future option grants will impact the compensation expense recognized.

XML 31 R17.htm IDEA: XBRL DOCUMENT

GRANT INCOME

9 Months Ended
Sep. 30, 2024

GRANT INCOME

GRANT INCOME

NOTE 11: GRANT INCOME

CPRIT

In August 2021, the Company received notice of a Product Development Research award totaling approximately $13.1 million from CPRIT to support the Company's clinical investigation of MT-401.

If restricted cash is received from grants in advance of incurring qualifying costs, it is recorded as deferred revenue and recognized as revenue when qualifying costs are incurred. There was no restricted cash recorded as of September 30, 2024, and December 31, 2023. If qualifying grant income is earned in advance of cash received from grants, it is recognized as revenue and recorded as other receivable.

The Company recorded $0.9 million and $2.4 million of grant income related to the CPRIT grant as revenue for the three and nine months ended September 30, 2024, respectively. As of September 30, 2024, the Company recorded $0.1 million as other receivable, which represented grant income earned in advance of funds to be received from CPRIT.

FDA

In September 2022, the Company received notice from the FDA that it had awarded the Company a $2.0 million grant from the FDA's Orphan Products Grant program to support the Company's clinical investigation of MT-401 for the treatment of post-transplant AML. The Company recorded $0.02 million and $0.5 million of grant income related to the FDA grant as revenue for the three and nine months ended September 30, 2024, respectively. As of September 30, 2024, the Company recorded $0.02 million as other receivable, which represented grant income earned in advance of funds to be received from the FDA. In October 2024, the Company received $0.02 million of funds from the FDA grant.

SBIR

In May 2023, the Company announced it had received a $2.0 million grant from the National Institutes of Health Small Business Innovation Research program to support the development and investigation of MT-401 for the treatment of AML patients following standard-of-care therapy with hypomethylating agents. The Company recorded $0.3 million and $0.7 million of grant income related to this grant as revenue for the three and nine months ended September 30, 2024, respectively. As of September 30, 2024, the Company recorded $0.3 million as other receivable, which represented grant income earned in advance of funds to be received from the SBIR. In October 2024, the Company received $0.3 million of funds from the SBIR grant.

In August 2024, the Company received notice of a $2.0 million grant from the National Institutes of Health Small Business Innovation Research Program to support the clinical investigation of MT-601 in patients with non-Hodgkin's lymphoma (NHL) who have relapsed following anti-CD19 chimeric antigen receptor (CAR) T cell therapy. The Company recorded $0.7 million of grant income related to this grant as revenue for the three and nine months ended September 30, 2024. As of September 30, 2024, the Company recorded $0.3 million as other receivable, which represented grant income earned in advance of funds to be received from the SBIR. In October 2024, the Company received $0.3 million of funds from the SBIR lymphoma grant.

XML 32 R18.htm IDEA: XBRL DOCUMENT

LEGAL PROCEEDINGS

9 Months Ended
Sep. 30, 2024

LEGAL PROCEEDINGS

LEGAL PROCEEDINGS

NOTE 12: LEGAL PROCEEDINGS

From time to time, the Company may be party to ordinary, routine litigation incidental to their business. The Company knows of no material, active or pending legal proceedings against the Company, nor is the Company involved as a plaintiff in any material proceeding or pending litigation. There are no proceedings in which any of the Company's directors, officers or affiliates, or any registered or beneficial shareholder, is an adverse party or has a material interest adverse to the Company's interest.

XML 33 R19.htm IDEA: XBRL DOCUMENT

RELATED PARTY EXPENSES

9 Months Ended
Sep. 30, 2024

RELATED PARTY EXPENSES

RELATED PARTY EXPENSES

NOTE 13: RELATED PARTY EXPENSES

The following table sets forth related party transaction expenses recorded for the three and nine months ended September 30, 2024 and 2023, respectively.

	For the Three Months Ended September 30,		For the Nine Months Ended September 30,	
	2024	2023	2024	2023
Baylor College of Medicine	$ —	$ —	$ 6,000	$ 13,000
Cell Ready	1,235,000	368,000	3,071,000	368,000
Wilson Wolf Manufacturing Corporation	—	—	—	277,000
Total Research and development	$ 1,235,000	$ 368,000	$ 3,077,000	$ 658,000

$0.9 million of related party transactions are included in accounts payable and accrued liabilities as of September 30, 2024. See Note 8 for additional information.

Agreements with The Baylor College of Medicine ("BCM")

In November 2018, January 2020 and February 2020, the Company entered in Sponsored Research Agreements with BCM, which provided for the conduct of research for the Company by credentialed personnel at BCM's Center for Cell and Gene Therapy.

In September 2019, May 2020 and July 2021, the Company entered into Clinical Supply Agreements with BCM, which provided for BCM to provide to the Company multi tumor antigen specific products.

In October 2019, the Company entered in a Workforce Grant Agreement with BCM, which provided for BCM to provide to the Company manpower costs of projects for manufacturing, quality control testing and validation run activities.

In August 2020, the Company entered into a Clinical Trial Agreement with BCM, which provided for BCM to provide to the Company investigator-initiated research studies.

The Company has also entered into a Clinical Site Agreement with BCM, which provided for BCM to conduct clinical trials for the Company and is a part of continuing operations.

BCM owns shares of the Company's common stock.

Purchases from Wilson Wolf

In 2023, the Company utilized Wilson Wolf for the purchases of cell culture devices called G-Rexes. Mr. John Wilson is a member of the Company's board of directors and is serving as the CEO of Wilson Wolf Manufacturing Corporation.

Purchases from Cell Ready, LLC

The Company is currently utilizing Cell Ready, LLC for its clinical manufacturing supply and product development. Mr. John Wilson is a member of the Company's board of directors and is serving as the CEO of Cell Ready, LLC. On February 22, 2024, we entered into a 3–year Master Services Agreement for Product Supply (the "MSA") with Cell Ready. Cell Ready, which is owned by one of our directors and shareholders, Mr. John Wilson, is a contract development and manufacturing organization (CDMO). Under the MSA, it is anticipated Cell Ready will perform a wide variety of services for us, including research and development, and manufacturing in support of our clinical trials. Pursuant to the MSA, the Company may contract with Cell Ready for the provision of various products and services from time to time by entering into work orders with Cell Ready. If the services involve the supply of product, Cell Ready is required to supply such product in conformance with the product requirements set forth in the applicable work order(s). Under the MSA, Cell Ready is to use only personnel with sufficient qualifications and experience to supply the services contemplated by the MSA, provide its personnel with adequate training and assume full responsibility for its personnel's compliance with the MSA. Further, Cell Ready is required to provide the Company with assistance and cooperation in order for the Company to obtain and maintain all necessary regulatory approvals, at the Company's expense.

During the nine months ended September 30, 2024, the Company entered into Work Order #1 under the MSA, pursuant to which Cell Ready agreed to provide the Company with GMP drug product for Marker MT-401 and/or MT-601. The services include the delivery of final drug product and quality control testing. The Company also requested Cell Ready to provide general support services in connection therewith. During the three and nine months ended September 30, 2024, the Company incurred $1.2 million and $3.1 million, respectively, in expenses related to the services and manufacturing costs and paid $0.5 million and $3.4 million, respectively, for invoices received. Additional Work Orders are expected to be generated for the remainder of 2024.

XML 34 R20.htm IDEA: XBRL DOCUMENT

SUBSEQUENT EVENTS	9 Months Ended Sep. 30, 2024
SUBSEQUENT EVENTS	
SUBSEQUENT EVENTS	**NOTE 14: SUBSEQUENT EVENTS**

The Company has evaluated subsequent events and transactions that occurred up to the date unaudited condensed consolidated financial statements were issued. Based upon this review, the Company did not identify any subsequent events that would have required adjustment to or disclosure in the unaudited condensed consolidated financial statements.

XML 35 R21.htm IDEA: XBRL DOCUMENT

Pay vs Performance Disclosure - USD ($)	3 Months Ended Sep. 30, 2024	3 Months Ended Sep. 30, 2023	9 Months Ended Sep. 30, 2024	9 Months Ended Sep. 30, 2023
Pay vs Performance Disclosure				
Net Income (Loss)	$ (2,308,192)	$ (2,981,961)	$ (6,893,691)	$ (5,433,748)

XML 36 R22.htm IDEA: XBRL DOCUMENT

Insider Trading Arrangements	3 Months Ended Sep. 30, 2024
Trading Arrangements, by Individual	
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

XML 37 R23.htm IDEA: XBRL DOCUMENT

SIGNIFICANT ACCOUNTING POLICIES (Policies)	9 Months Ended Sep. 30, 2024
SIGNIFICANT ACCOUNTING POLICIES	
Principles of Consolidation	***Principles of Consolidation***

These consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Marker Cell Therapy, Inc. and GeneMax Pharmaceuticals Inc. – a dormant subsidiary that wholly owns GeneMax Pharmaceuticals Canada, Inc. All significant intercompany balances and transactions are eliminated upon consolidation.

Use of Estimates — ***Use of Estimates***

Preparation of the Company's consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Accordingly, actual results may differ materially from those estimates. Management considers many factors in selecting appropriate financial accounting policies, controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes, and management must select an amount that falls within that range of reasonable estimates. Estimates are used in the following areas, among others: stock-based compensation expense and income taxes.

Cash, Cash Equivalents and Credit Risk — ***Cash, Cash Equivalents and Credit Risk***

The Company considers highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. Cash and cash equivalents at September 30, 2024 consisted of cash and certificates of deposit in institutions in the United States. Balances at certain institutions have exceeded Federal Deposit Insurance Corporation insured limits and U.S. government agency securities.

The Company maintains cash in accounts which are in excess of the Federal Deposit Insurance Corporation ("FDIC") insured limits of $250,000. As of September 30, 2024, the Company had approximately $4.1 million in cash at financial institutions and approximately $4.9 million in U.S. government agency securities, for aggregate cash and cash equivalents of $9.0 million. As of December 31, 2023, the Company had approximately $1.4 million in cash at financial institutions and approximately $13.7 million in U.S. government agency securities, for aggregate cash and cash equivalents of $15.1 million.

In the event cash is received from grants in advance of incurring qualifying costs, it is recorded as restricted cash until it is earned and recorded to grant income.

Discontinued Operations — ***Discontinued Operations***

The Purchased Assets sold to Cell Ready pursuant to the Cell Ready Purchase Agreement constituted a significant disposition and as such, the Company concluded that the disposition of its Purchased Assets represented a strategic shift that had a major effect on its operations and financial results. Therefore, the Purchased Assets, related party revenue, service revenue and related expenses are classified as discontinued operations for all periods presented herein. See Note 7 for further information.

Recently Issued Accounting Standards Not Yet Adopted — ***Recently Issued Accounting Standards Not Yet Adopted***

Improvements to Reportable Segment Disclosures

In November 2023, the Financial Accounting Standards Board (the "FASB") issued Accounting Standards Update ("ASU") No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. The ASU requires disclosures to include significant segment expenses that are regularly provided to the chief operating decision maker, among other provisions. Public entities with a single reportable segment, such as the Company, are required to provide the new disclosures and all the disclosures required under ASC 280. The ASU is effective for fiscal year periods beginning after December15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted, and the ASU requires retrospective application to all prior periods presented in the financial statements. The Company is currently evaluating the standard to determine the impact of adoption to its consolidated financial statements and disclosures.

Improvements to Income Tax Disclosures

In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (ASU 2023-09), which improves the transparency of income tax disclosures by requiring consistent categories and greater disaggregation of information in the effective tax rate reconciliation and income taxes paid disaggregated by jurisdiction. It also includes certain other amendments to improve the effectiveness of income tax disclosures. This guidance will be effective for the annual periods beginning the year ended December 31, 2025. Early adoption is permitted. Upon adoption the guidance can be applied prospectively or retrospectively. We do not expect the adoption of this guidance to have a material impact on the Company's consolidated financial statements.

From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board ("FASB") or other standard setting bodies that the Company adopts as of the specified effective date. Unless otherwise discussed, the Company does not believe that the impact of recently issued standards that are not yet effective will have a material impact on its consolidated financial position or results of operations upon adoption.

There have been no material changes in the Company's significant accounting policies to those previously disclosed in the Annual Report on Form 10-K for the year ended December 31, 2023 filed on March 26, 2024.

XML 38 R24.htm IDEA: XBRL DOCUMENT

NET LOSS PER SHARE (Tables)	9 Months Ended Sep. 30, 2024
NET LOSS PER SHARE	
Schedule of computation of net loss per share	

	For the Three Months Ended September 30,		For the Nine Months Ended September 30,	
	2024	2023	2024	2023
Numerator:				
Loss from continuing operations	$(2,308,192)	$(2,981,961)	$(6,893,691)	$(11,305,768)
Income from discontinued operations	$ —	$ —	$ —	$ 5,872,020
Net loss	$(2,308,192)	$(2,981,961)	$(6,893,691)	$ (5,433,748)
Denominator:				
Weighted average common shares outstanding, basic	8,923,170	8,825,881	8,914,487	8,782,340
Weighted average common shares outstanding, diluted	8,923,170	8,825,881	8,914,487	8,834,512
Net earnings (loss) per share:				
Loss from continuing operations, basic and diluted	$ (0.26)	$ (0.34)	$ (0.77)	$ (1.29)
Income from discontinued operations, basic	$ —	$ —	$ —	$ 0.67
Income from discontinued operations, diluted	$ —	$ —	$	$ 0.66
Net loss per share, basic and diluted	$ (0.26)	$ (0.34)	$ (0.77)	$ (0.62)

Schedule of anti-dilutive securities

	For the Three Months Ended September 30,		For the Nine Months Ended September 30,	
	2024	2023	2024	2023
Common stock options	596,000	800,000	596,000	748,000
Common stock purchase warrants	—	1,848,000	—	1,848,000
Potentially dilutive securities	596,000	2,648,000	596,000	2,596,000

XML 39 R25.htm IDEA: XBRL DOCUMENT

DISCONTINUED OPERATIONS (Tables)

9 Months Ended
Sep. 30, 2024

DISCONTINUED OPERATIONS

Schedule of income statement information and summary of cash flows for discontinued operations

	For the Three Months Ended September 30, 2023	For the Nine Months Ended September 30, 2023
Revenues:		
Service Revenue	$ —	$ 816,641
Related party service revenue	—	3,500,000
Total revenues	—	4,316,641
Operating expenses:		
Research and development	—	6,561,957
General and administrative	—	677,090
Total operating expenses	—	7,239,048
Loss from discontinued operations	$ —	$ (2,922,406)

	For the Nine Months Ended September 30, 2023
Discontinued operations:	
Net cash used in operating activities	(6,036,000)
Net cash provided by investing activities	18,664,000
Net increase (decrease) in cash and cash equivalents	$ 12,628,000

XML 40 R26.htm IDEA: XBRL DOCUMENT

ACCOUNTS PAYABLE, ACCRUED LIABILITIES AND RELATED PARTY PAYABLE (Tables)

9 Months Ended
Sep. 30, 2024

ACCOUNTS PAYABLE, ACCRUED LIABILITIES AND RELATED PARTY PAYABLE

Schedule of accounts payable, accrued liabilities and related party payable

	September 30, 2024	December 31, 2023
Accounts payable	$ 1,904,000	$ 961,000
Compensation and benefits	39,000	57,000
Professional fees	359,000	303,000
Related party payable	903,000	1,330,000
Tax fees	52,000	219,000
Other	204,000	205,000
Total accounts payable, accrued liabilities and related party payable	$ 3,461,000	$ 3,075,000

XML 41 R27.htm IDEA: XBRL DOCUMENT

STOCK BASED COMPENSATION (Tables)

9 Months Ended
Sep. 30, 2024

STOCK-BASED COMPENSATION

Schedule of the company's stock option activity

	Number of Shares	Weighted Average Exercise Price	Total Intrinsic Value	Weighted Average Remaining Contractual Life (in years)
Outstanding as of January 1, 2024	737,895	$ 25.42	$ 1,317,000	7.6
Exercised	(23,892)	2.45	—	—
Canceled/Expired	(117,670)	43.37	—	—
Outstanding as of September 30, 2024	596,333	$ 22.80	$ 291,000	7.1
Options vested and exercisable	386,062	$ 33.76	$ 109,000	6.4

Schedule of stock-based compensation expenses

	For the Three Months Ended September 30,		For the Nine Months Ended September 30,	
	2024	2023	2024	2023
Stock Compensation expenses:				
Research and development	$ 3,000	$ 106,000	$ 13,000	$ 299,000
General and administrative	50,000	69,000	182,000	416,000
Stock compensation in continuing operations	53,000	175,000	195,000	715,000
Stock compensation in discontinued operations	—	—	—	725,000
Total stock compensation expenses	$ 53,000	$ 175,000	$ 195,000	$ 1,440,000

XML 42 R28.htm IDEA: XBRL DOCUMENT

RELATED PARTY EXPENSES (Tables)

9 Months Ended
Sep. 30, 2024

RELATED PARTY EXPENSES

Schedule of related party transaction expenses

	For the Three Months Ended September 30,		For the Nine Months Ended September 30,	
	2024	2023	2024	2023
Baylor College of Medicine	$ —	$ —	$ 6,000	$ 13,000
Cell Ready	1,235,000	368,000	3,071,000	368,000
Wilson Wolf Manufacturing Corporation	—	—	—	277,000
Total Research and development	$ 1,235,000	$ 368,000	$ 3,077,000	$ 658,000

XML 43 R29.htm IDEA: XBRL DOCUMENT

NATURE OF OPERATIONS (Details) $ in Millions

	3 Months Ended					
	Jun. 26, 2023 USD ($) employee	Jan. 26, 2023 shares	Jun. 30, 2023 USD ($)	Sep. 30, 2024 shares	Dec. 31, 2023 shares	Jan. 25, 2023 shares
NATURE OF OPERATIONS						
Reverse stock split		1-for-10				
Common stock authorized (in shares) | shares		30,000,000		30,000,000	30,000,000	300,000,000
Severance and termination-related costs | $			$ 0.9			
Cell Ready Purchase Agreement						
NATURE OF OPERATIONS						
Consideration for purchased assets | $	$ 19.0					
Cell Ready Purchase Agreement | Discontinued Operations, Disposed of by Sale						
NATURE OF OPERATIONS						
Consideration for purchased assets | $	$ 19.0					
Number of former employees offered employment | employee	50					
Maximum						
NATURE OF OPERATIONS						
Common stock authorized (in shares) | shares		300,000,000				
Minimum						
NATURE OF OPERATIONS						
Common stock authorized (in shares) | shares		30,000,000				

XML 44 R30.htm IDEA: XBRL DOCUMENT

LIQUIDITY AND FINANCIAL CONDITION (Details) - USD ($)

	1 Months Ended				3 Months Ended			9 Months Ended			
	Oct. 31, 2024	Aug. 31, 2024	Jun. 30, 2024	May 31, 2023	Sep. 30, 2022	Aug. 31, 2021	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Jun. 26, 2023
LIQUIDITY AND FINANCIAL CONDITION												
Cash and cash equivalents							$ 8,999,664		$ 8,999,664		$ 15,111,450	
Proceeds from issuance of common stock, net												$

							36,902	1,014,640
Amount of notice received				$ 13,100,000				
Funds received from CPRIT grant							9,700,000	
Revenue recognized					1,926,020	$ 257,606	4,339,317	2,254,601
SBIR grant								
LIQUIDITY AND FINANCIAL CONDITION								
Other receivables					300,000		300,000	
Funds received from grant							900,000	
Grant income received		$ 2,000,000.0	$ 2,000,000.0					
Grant income receivable					600,000		600,000	
Revenue recognized					300,000		700,000	
National Institutes of Health National -Cancer Institute Grant								
LIQUIDITY AND FINANCIAL CONDITION								
Grant Assistance Term			2 years					
Grant income received			$ 2,000,000.0					
SBIR lymphoma grant								
LIQUIDITY AND FINANCIAL CONDITION								
Funds received from grant							700,000	
Revenue recognized					700,000		700,000	
Grant income								
LIQUIDITY AND FINANCIAL CONDITION								
Funds received from grant							100,000	
Revenue from CPRIT					900,000		2,400,000	
Revenue recognized					1,926,020	$ 257,606	4,339,317	$ 2,254,601
FDA grant								
LIQUIDITY AND FINANCIAL CONDITION								
Funds received from grant							1,000,000.0	
Grant income received				$ 2,000,000.0				
Grant income receivable					20,000.00		20,000.00	
Revenue recognized					$ 20,000.00		$ 500,000	
Subsequent event | SBIR grant								
LIQUIDITY AND FINANCIAL CONDITION								
Funds received from grant	$ 300,000							
Subsequent event | SBIR lymphoma grant								
LIQUIDITY AND FINANCIAL CONDITION								
Funds received from grant	300,000							
Subsequent event | FDA grant								
LIQUIDITY AND FINANCIAL CONDITION								
Funds received from grant	$ 20,000.00							
ATM Agreement								
LIQUIDITY AND FINANCIAL CONDITION								
Aggregate offering price				$ 75,000,000.0				
ATM Agreement | Sales Agents								
LIQUIDITY AND FINANCIAL CONDITION								
Commission rate				3.00%				
Number of shares issued (in shares)							8,178	
Proceeds from issuance of common stock, net							$ 40,000.00	
Cell Ready Purchase Agreement								
LIQUIDITY AND FINANCIAL CONDITION								
Consideration for purchased assets								$ 19,000,000.0

XML 45 R31.htm IDEA: XBRL DOCUMENT

SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($)	**Sep. 30, 2024**	**Dec. 31, 2023**
SIGNIFICANT ACCOUNTING POLICIES		
Cash at financial institutions	$ 4,100,000	$ 1,400,000
Government agency securities	4,900,000	13,700,000
Cash and cash equivalents	$ 8,999,664	$ 15,111,450

XML 46 R32.htm IDEA: XBRL DOCUMENT

NET LOSS PER SHARE - Computation of loss per Share (Details) - USD ($)	**3 Months Ended**		**9 Months Ended**	
	Sep. 30, 2024	**Sep. 30, 2023**	**Sep. 30, 2024**	**Sep. 30, 2023**
Numerator:				
Loss from continuing operations	$ (2,308,192)	$ (2,981,961)	$ (6,893,691)	$ (11,305,768)
Income from discontinued operations				5,872,020
Net loss	$ (2,308,192)	$ (2,981,961)	$ (6,893,691)	$ (5,433,748)
Denominator:				
Weighted average common shares outstanding, basic	8,923,170	8,825,881	8,914,487	8,782,340
Weighted average common shares outstanding, diluted	8,923,170	8,825,881	8,914,487	8,834,512
Net earnings (loss) per share:				
Loss from continuing operations, basic (in dollars per share)	$ (0.26)	$ (0.34)	$ (0.77)	$ (1.29)
Loss from continuing operations, diluted (in dollars per share)	(0.26)	(0.34)	(0.77)	(1.29)
Income from discontinued operations, basic (in dollars per share)				0.67
Income from discontinued operations, diluted (in dollars per share)				0.66
Net loss per share, basic (in dollars per share)	(0.26)	(0.34)	(0.77)	(0.62)
Net loss per share, diluted (in dollars per share)	$ (0.26)	$ (0.34)	$ (0.77)	$ (0.62)

XML 47 R33.htm IDEA: XBRL DOCUMENT

NET LOSS PER SHARE - Dilutive Securities (Details) - shares	**3 Months Ended**		**9 Months Ended**	
	Sep. 30, 2024	**Sep. 30, 2023**	**Sep. 30, 2024**	**Sep. 30, 2023**
NET LOSS PER SHARE				
Potentially dilutive securities	596,000	2,648,000	596,000	2,596,000
Employee Stock Option				
NET LOSS PER SHARE				
Potentially dilutive securities	596,000	800,000	596,000	748,000
Common stock purchase warrants				
NET LOSS PER SHARE				
Potentially dilutive securities		1,848,000		1,848,000

XML 48 R34.htm IDEA: XBRL DOCUMENT

OTHER RECEIVABLE (Details) - USD ($)	1 Months Ended Oct. 31, 2024	3 Months Ended Sep. 30, 2024	3 Months Ended Sep. 30, 2023	9 Months Ended Sep. 30, 2024	9 Months Ended Sep. 30, 2023	Dec. 31, 2023
OTHER RECEIVABLE						
Revenue recognized		$ 1,926,020	$ 257,606	$ 4,339,317	$ 2,254,601	
Other receivables		744,410		744,410		$ 1,027,815
FDA grant						
OTHER RECEIVABLE						
Revenue recognized		20,000.00		500,000		
Grant revenue		20,000.00		500,000		
Grant income receivable		20,000.00		20,000.00		
Funds received from grant				1,000,000.0		
FDA grant | Subsequent event						
OTHER RECEIVABLE						
Funds received from grant	$ 20,000.00					
SBIR grant						
OTHER RECEIVABLE						
Revenue recognized		300,000		700,000		
Grant revenue		1,000,000.0		1,400,000		
Grant income receivable		600,000		600,000		
Funds received from grant				900,000		
SBIR grant | Subsequent event						
OTHER RECEIVABLE						
Funds received from grant	300,000					
Funds received from grant	$ 600,000					
CPRIT						
OTHER RECEIVABLE						
Revenue recognized		900,000		2,400,000		
Other receivables		$ 100,000		$ 100,000		

XML 49 R35.htm IDEA: XBRL DOCUMENT

DISCONTINUED OPERATIONS - Operations (Details)	9 Months Ended Sep. 30, 2023 USD ($)
DISCONTINUED OPERATIONS	
Total revenues	$ 4,316,641
Total operating expenses	7,239,048
Loss from discontinued operations	(2,922,406)
Research and development	
DISCONTINUED OPERATIONS	
Total operating expenses	6,561,957
General and administrative	
DISCONTINUED OPERATIONS	
Total operating expenses	677,090
Service Revenue	
DISCONTINUED OPERATIONS	
Total revenues	816,641
Related party service revenue	
DISCONTINUED OPERATIONS	
Total revenues	$ 3,500,000

XML 50 R36.htm IDEA: XBRL DOCUMENT

DISCONTINUED OPERATIONS - Cash Flows (Details)	9 Months Ended Sep. 30, 2023 USD ($)
DISCONTINUED OPERATIONS	
Net cash used in operating activities	$ (6,035,961)
Net cash provided by investing activities	18,664,122
Disposed by sale	
DISCONTINUED OPERATIONS	
Net cash used in operating activities	(6,036,000)
Net cash provided by investing activities	18,664,000
Net increase (decrease) in cash and cash equivalents	$ 12,628,000

XML 51 R37.htm IDEA: XBRL DOCUMENT

DISCONTINUED OPERATIONS - Additional Information (Details) - USD ($)	1 Months Ended Jun. 26, 2023	1 Months Ended May 31, 2023	1 Months Ended Mar. 31, 2023	1 Months Ended Apr. 30, 2022	3 Months Ended Sep. 30, 2024	3 Months Ended Sep. 30, 2023	9 Months Ended Sep. 30, 2024	9 Months Ended Sep. 30, 2023
DISCONTINUED OPERATIONS								
Revenue recognized					$ 1,926,020	$ 257,606	$ 4,339,317	$ 2,254,601
Cell Ready Purchase Agreement								
DISCONTINUED OPERATIONS								
Consideration for purchased assets	$ 19,000,000.0							
Related party service revenue | Binding Services Agreement | Wilson Wolf Manufacturing Corporation								
DISCONTINUED OPERATIONS								
Cash Payment				$ 8,000,000.0				
Agreement amount on cash payment			$ 8,000,000.0					
Revenue recognized			2,500,000					
Additional revenue recognized			$ 1,000,000.0					
Additional cash payment		$ 1,000,000.0						
Disposed by sale | Cell Ready Purchase Agreement								
DISCONTINUED OPERATIONS								
Consideration for purchased assets	19,000,000.0							
Gain on disposal of discontinued operations before income taxes	8,700,000							
Tax on gain on disposal of discontinued operations	$ 63,000							

XML 52 R38.htm IDEA: XBRL DOCUMENT

ACCOUNTS PAYABLE, ACCRUED LIABILITIES AND RELATED PARTY PAYABLE (Details) - USD ($)	Sep. 30, 2024	Dec. 31, 2023
ACCOUNTS PAYABLE, ACCRUED LIABILITIES AND RELATED PARTY PAYABLE		
Accounts payable	$ 1,904,000	$ 961,000
Compensation and benefits	39,000	57,000
Professional fees	359,000	303,000
Related party payable	903,438	1,329,655

Tax fees	52,000	219,000
Other	204,000	205,000
Total accounts payable, accrued liabilities and related party payable	3,461,000	3,075,000
Related party | Cell Ready		
ACCOUNTS PAYABLE, ACCRUED LIABILITIES AND RELATED PARTY PAYABLE		
Related party payable	$ 900,000	$ 1,300,000

XML 53 R39.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS' EQUITY - Reverse Stock Split And ATM Agreement (Details) - USD ($)	9 Months Ended				
	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Jan. 26, 2023	Jan. 25, 2023
STOCKHOLDERS' EQUITY					
Common stock authorized (in shares)	30,000,000		30,000,000	30,000,000	300,000,000
Proceeds from issuance of common stock, net	$ 36,902	$ 1,014,640			
ATM Agreement					
STOCKHOLDERS' EQUITY					
Number of shares issued (in shares)	8,178	265,334			
Proceeds from issuance of common stock, net	$ 37,000	$ 1,000,000.0			

XML 54 R40.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS' EQUITY - Stock Purchase Agreement And Exercise of Stock Options (Details) - USD ($)	1 Months Ended		3 Months Ended		9 Months Ended	
	Jan. 31, 2023	Dec. 31, 2022	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
STOCKHOLDERS' EQUITY						
Aggregate proceeds from shares issued under the purchase agreement				$ 394,667	$ 36,902	$ 1,014,640
Proceeds from Issuance of Common Stock					$ 36,902	1,014,640
Issuance of common stock from exercise of stock options (in shares)					23,892	
Issuance of common stock from exercise of stock options			$ 1,701	$ 84,604	$ 58,501	$ 85,342
Stock Purchase Agreement | Lincoln Park						
STOCKHOLDERS' EQUITY						
Aggregate proceeds from shares issued under the purchase agreement		$ 25,000,000				
Time to time term to purchase shares (in months)		24 months				
Shares purchased pursuant to ATM agreement (in shares)	180,410					12,500
Commitment fee	$ 500,000					
Proceeds from Issuance of Common Stock						$ 33,000

XML 55 R41.htm IDEA: XBRL DOCUMENT

STOCK-BASED COMPENSATION - Stock option activity (Details)	9 Months Ended Sep. 30, 2024 USD ($) $ / shares shares	12 Months Ended Dec. 31, 2023 USD ($) $ / shares shares
STOCK-BASED COMPENSATION		
Number of Shares, Exercised	(23,892)	
Employee Stock Option		
STOCK-BASED COMPENSATION		
Number of Shares Outstanding, Beginning Balance	737,895	
Number of Shares, Exercised	(23,892)	
Number of Shares, Cancelled / Expired	(117,670)	
Number of Shares Outstanding, Ending Balance	596,333	737,895
Number of Shares, Options vested and exercisable	386,062	
Weighted Average Exercise Price per Share, Outstanding, Beginning Balance | $ / shares	$ 25.42	
Weighted Average Exercise Price per Share, Exercised | $ / shares	2.45	
Weighted Average Exercise Price per Share, Cancelled / Expired | $ / shares	43.37	
Weighted Average Exercise Price per Share, Outstanding, Ending Balance | $ / shares	22.80	$ 25.42
Weighted Average Exercise Price, Options vested and exercisable | $ / shares	$ 33.76	
Total Intrinsic Value Outstanding | $	$ 291,000	$ 1,317,000
Total Intrinsic Value, Options vested and exercisable | $	$ 109,000	
Weighted Average Remaining Contractual Life, Outstanding (in years)	7 years 1 month 6 days	7 years 7 months 6 days
Weighted Average Remaining Contractual Life, Options vested and exercisable (in years)	6 years 4 months 24 days	

XML 56 R42.htm IDEA: XBRL DOCUMENT

STOCK-BASED COMPENSATION - Stock-based compensation expenses (Details) - USD ($)	3 Months Ended		9 Months Ended	
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
STOCK-BASED COMPENSATION				
Stock compensation in continuing operations	$ 53,000	$ 175,000	$ 195,000	$ 715,000
Stock compensation in discontinued operations				725,000
Total stock compensation expenses	53,000	175,000	195,000	1,440,000
Research and development				
STOCK-BASED COMPENSATION				
Stock compensation in continuing operations	3,000	106,000	13,000	299,000
General and administrative				
STOCK-BASED COMPENSATION				
Stock compensation in continuing operations	$ 50,000	$ 69,000	$ 182,000	$ 416,000

XML 57 R43.htm IDEA: XBRL DOCUMENT

STOCK-BASED COMPENSATION - Additional Information (Details) $ in Millions	3 Months Ended Sep. 30, 2024 USD ($) shares	9 Months Ended Sep. 30, 2024 USD ($) shares
STOCK-BASED COMPENSATION		
Number of equity incentive awards issued (in shares) | shares	0	0
Total stock-based compensation cost related to unvested awards not yet recognized | $	$ 0.2	$ 0.2
Expected weighted average period of recognition of unrecognized compensation costs (in years)		1 year 9 months 18 days

XML 58 R44.htm IDEA: XBRL DOCUMENT

GRANT INCOME (Details) - USD ($)	1 Months Ended		3 Months Ended		9 Months Ended					
	Oct. 31, 2024	Aug. 31, 2021	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Aug. 31, 2024	Dec. 31, 2023	May 31, 2023	Sep. 30, 2022
GRANT INCOME										
Revenue recognized			$ 1,926,020	$ 257,606	$ 4,339,317	$ 2,254,601				
Funds received from CPRIT grant					9,700,000					
Grant income										
GRANT INCOME										
Revenue recognized			1,926,020	$ 257,606	4,339,317	$ 2,254,601				
Funds received from grant					100,000					

CPRIT grant									
GRANT INCOME									
Receipt of product development research award		$ 13,100,000							
Restricted cash recorded			0		0		$ 0		
Revenue recognized			900,000		2,400,000				
Grant receivable			100,000		100,000				
FDA grant									
GRANT INCOME									
Revenue recognized			20,000.00		500,000				
Grant receivable			20,000.00		20,000.00				$ 2,000,000.0
Funds received from grant					1,000,000.0				
FDA grant | Subsequent event									
GRANT INCOME									
Funds received from grant		$ 20,000.00							
SBIR grant									
GRANT INCOME									
Revenue recognized			300,000		700,000				
Grant receivable			300,000		300,000	$ 2,000,000.0		$ 2,000,000.0	
Funds received from grant					900,000				
SBIR grant | Subsequent event									
GRANT INCOME									
Funds received from grant		300,000							
SBIR lymphoma grant									
GRANT INCOME									
Revenue recognized			$ 700,000		700,000				
Funds received from grant					$ 700,000				
SBIR lymphoma grant | Subsequent event									
GRANT INCOME									
Funds received from grant		$ 300,000							

XML 59 R45.htm IDEA: XBRL DOCUMENT

RELATED PARTY EXPENSES (Details) - USD ($)	**3 Months Ended**		**9 Months Ended**		
	Sep. 30, 2024	**Sep. 30, 2023**	**Sep. 30, 2024**	**Sep. 30, 2023**	**Dec. 31, 2023**
RELATED PARTY EXPENSES					
Total Research and development	$ 1,235,000	$ 368,000	$ 3,077,000	$ 658,000	
Related party payable	903,438		903,438		$ 1,329,655
Baylor College of Medicine					
RELATED PARTY EXPENSES					
Total Research and development			6,000	13,000	
Cell Ready					
RELATED PARTY EXPENSES					
Total Research and development	1,235,000	$ 368,000	3,071,000	368,000	
Wilson Wolf Manufacturing Corporation					
RELATED PARTY EXPENSES					
Total Research and development				$ 277,000	
Cell Ready | Related party					
RELATED PARTY EXPENSES					
Related party payable	900,000		900,000		$ 1,300,000
Cell Ready Purchase Agreement					
RELATED PARTY EXPENSES					
Service and manufacturing costs	1,200,000		3,100,000		
Paid invoices	$ 500,000		$ 3,400,000		

*EXCEL 60 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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|R\.WU0? TV@P>89Y)0AP5_^9[87'7..\BC*Y(&8LYV=W0/U)=Z+@N2[!/M M\G=MNX/<-!$LW =#"4(_RK_)R[XBF@3@?0#^$&!6!5C["L#S4N68=T004:7 MG.T0EV^#FKS(ZB:+!AH_DFE<" Z_^A G1C?,32$K I'(0Y-(^.(53:.\>|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`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|K98%:FDM9Z2W8_ 7 M>O9>T;99K_LUZ6_86E_,06^E%$G#?X@^X&.,B:D22,NB"H;(UP([R|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|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}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

M7M7#1@SRA:CZT&5D"#TC!$,64DI4*_18UMP#8'3 B9Z"L L*,CMBH"#A" G5 M7:=]"*,+R"D%N5*3[>\I"#_QOI'9>0,%A4A;7HP41'V*@+KI-(2*6@0!@P*%
MU%K48T,&$/,'KEWB'H*PH]M&9E,,$"1,\4/USH5]%*/+T2D$N5*3,]\#$'[D_M4WSCJY)8)R+M&6O#4WT,:,NQ4R R]SFTH/0\A)_E$:NC&TD=CIA>ST[9R*E: M|$I-3DO/1MC.1J-VFRZ)988-F(2Q=G?
4-:?OT4[EA_YI3")V3++M->U-Q)KF M5"TB.L2<(0P"]*)8?$]D:%Y//,1./(_8:O(=&@Q[34/4T%[3$#]XUS3$6O>: MI$<68D>6)^PUBBKHMU^_*.)TM>-@'B\U51U%\/FA\/[G^.>OD/ M4$L#!!0 (+"
;EE)*AT|X04 ,,8 8 >&PO=V]R:W-H965T&ULK5EM;^(X$/XK%G>RU22UOM2KMM5779O/Z?) -$F M,6L:VO[0[&R>0 '%2,/$%DC">/, ^,O /87+OP\4O. 1>5;-"7@[F2BW.AT,9 MSR&/Y">^@
)_F7*11PIOQ6PH%P*BI!R49T-F6=XPC])B,+HHGSV*T05?]BPM MX%$0N#6LO29I#(5-> M$ '3R\$5/1\S7P\H+?Y-X45N71--Y9GS7_KF2W(YL#0BR"!6VD6$7RL80Y9I M3XCC]KIH'ZG'KA]O?
%^5Y)';L^1A#'/?J:)FE\,@@%)8!HM,_7$7S[#FI"K M_<4\D^4G>:ELO7! XJ54/%\/1@1Y6E3?T>LZ$%L#T(]Y %L/8/L#G(X!]G] M71*MD)6T;B(5C2X$?R%"6Z,W?5'&IAR-:-
)"IW&B!/Z:XC@U&C_3VYO M'"%Y-'KY^N;GZCC>3[_CU[?:_^^X0\W)'QU>0SN?OZ\'-"SLB/R0WY\.???L % M*I=.AO'Z5=?5]UC]T+RC1=]+LEMD4"R.WZ(L&OL;(]FO4ZG,#B$[&MCX19
MS#'@&1|^W.Z!8]>AM$M_=E.5*O+:O1F1>$MA?2B^%]FX#!T'5LVW>"VG 'G%N#1([\&[O>6T!.@V#C-TA*D MSD*QH:)X>1WK(EM*3!GFD=<5%O57F'_*I)W(V4Z @CI 06]F)XK'O|YTWTHP
MKSDV.7=T2Q307L@/:@X"55H,Z2IZSL ,D[;>S@+;L=Q] ME 8[FP;;R|HN3-; 9+TPGR"+%%;"(A+]#3_?-%8C5-8.E,,\1OU]K&U#V_-# MZG9 ;;0!
[6V\HZLXYLL"],\;93D)HC@6NOML9H81NMU'"%!&';.:/O&UW1MW0 MI?PZ$U3I_U=_0:F(3'%+ "/)9&E+TNC]W7M;>=ITUFM3;>G[[?UUAU*!XCK]XW'IU/ MD[*P;#?TNI:
1C#0WG9[&'L9^$Z)M?5(Z#J6O8_=)%O", RZT#>ZA;VO6SXD$ O MG=_?N#145[K?E:2TF"POX/<2%7L&A7EGP4QRA5+<7'C[7 O'$ZC8?=;1\EBC M5EB_6AEW
2:1(L\P2XNBUS%@ILO0@=M\RA,CE[:HH"YR<=SI'<]:#BFC^NI* M3", 6+ ,\Z"4#^/Q]&G[KO LWWR$NN2LVH;4=WR[O54?;AT'YR!FY2FY).4& MI#I=K9_6) ,%7Y?GSWO-K>CZNSM,;-]7Q_K=
(8*(DR6"*+JU//@975"?FU8WB MB_+0^9DKQ?/R<@Y1 D(;X.]3SM7F1K^@_M]B]!02P,$% @ L(!N62_ % M0U.["P R!X !@ !X;"IW:W)KEU.:HXBT_NW.7;VT=*FW4G1.^+DO!M^KP]!?
M'8V/F@=?]6(9Z,'IQ=M*+M1,A=^K,X=OIZV47])?*>&V-<&K^[F@Z?OW^G-;S M@C^T6OO.9T&6/%C[C;Y\RM!=C4@A5:@LD 2)/RMUJ8["!$&-OY+,H_9(VMC] MW$C_P+:#E@?
IU:4M_M1Y6+X[>GDDOY1O(R6WC^7ZSCV@E. MS&H?:)DVXWNI3?PKOR<<,AM>C@YLF*0-$]8['L1:7LD@+]XZNQ:..5D.;?6!3 M>3>4TX:<,@L.;S7VA8LOT_O?OUZ+VP_B]N[ZZ_3^T^V7V=O3
,GT_C1+4MY' M*9,#4EZ)&VO"THMKDZN\O_\4&K5J31JUWD^>%#A3U5"GE9#)ZO;K0&@/41FTTIDL3GQ 9@M=
MEK6Q)I8@6NWB$0>P(.$KE6E9Z+^U60AM!)V5]IQ68HD+>!R%-3FM+Y>*RJ)*= M"V.Q2-R+#-E\0DF9IS,"6Z;5%^ KEA= 58&E81\Q6B =2#FD4;$71[J.UM-9
MWA8Z%Z$NL5>;'(OH0#\DP$3'^O&+-UZ4R'N=%DOO+50.T$.:H!<*P/[^^FT @>:$K9WK+.DM@LJ6)@("T*(5-H*06&NEA/],0WUKMCE19@&/*Z?R03O\6ZZ' M!!E
F)E=&/VW,J@B7+]>ZFPIR.=Q49!NH0)>$!K?-"G)SZ- M--H3>5L7F=*/#@KV);PAI@NG%(?.6H>EH-(AO]+P/8I;(WZKC1*3Y\Q09P/V6J,3A7>AZ!QZ M"LQ6VM:^>
(0FOM8FHQ<.7I6Q,&T)'XC/GR_%<9-$[?,FCD15.U\#&()-[M.V ME[.;]7=7(EU$ON-&/HIQ8\K#(T/VH,):*=.SC)YO) [%C1N*W^S2B#]UX6$* M)W^]2@(3\1KVI,V#E2ZGE[E&7
3K8NIA)_$IQ9:T<>/U+2WK D/9K9#8JNL+ M/M/!FV1(1U%R%T'(L:U% H#H>:SE&XXNl&[L!SI[*JJ!IYC,2ME4OO>'>&T MK%"0OM>&?:O#VHJ3X#V'IVM')^"3+G0@$D(L?K14],U
W*OOT*;KRYO>M@_M MM@WY'FOH!A,;UDOB4[)+_57K#;NRLDO:H$NDX(H! :"!UOXZD+?BK.- : AQ MU!"!2X(.R'AVL@EPH |-UV]C,44$,:NK"LG40V8V MW8
00WI:.5V(%S\,ZD$/**SY9'9)!;F_2G]OIM7$.C\T,7*!0:YGM#;%: K) MOA\.(GV,DIE]01$SH+&Y"628ZCU8M %@V+,GPS$N,='VCABC-J 40DVO<^7:
M"OOS^-5PA(:S*/!@",MIB5$=QF)N:Y(!!=V0C::RBR6 ,U,N:8.K:8@^,9]%K?K CU"EN4SFC M>VKZ0'4079#P2ST/L6-84[U?2F)!0; [|%R&\N^O\S>%LP%QS-X5M.!:E M'OA-
,Y3='(HVT2LCA$Q2)4V=L>G#5MW$GB0C*'&TJ2E"FD,X_7@IGB*A279M M&)M9P/DH+!XJYFOE[%Y3KDQGEVWYG(R>G4Q&G$5C=+%7W:-N.V"20> 0ZG[(M;GH.;:+!
6QS#.#T0E3@5T+.D#!4R_Q?XN^E[YI2Z;&%6.T>1G1PB8X3,% #) M<[8=N# [X8H,2+X;4;'Q0#Z[&S"PFDS@2H74#A3#7,.=0)_# 8.^= M3B>V9BM-45L';Y$*.-$W9W2;&R##N/X\NKF
M%F3Z.U@]5G+ !'F!12)@,ETOGW? X@Q*..#8-;&VDDZKB\C*MZB1/VHIBYZT MJ"DY*%^4=-2+0ZL>5^VJ"0KP<*)UH4&D&;?05B+Y &[_PZIW?5++%36G:\7G3 MNK#CF]F#
[(^C4Z,>$OBM1Y7_PF< M)$ ^;E2U6D0!C%CHD,X>;+5_3C5%SC:+?0TLTW("#+;R!1:;[T[U2N_3_MCZ M4'AB*9:D)@6%["X#XC8C0G'?C*]>13S;UW.PE*8@Y$K4
MT%7$%%.64%.DZ<:>'CCD.*IW"XIV5B#)E,IT;:,E#F,Q :;// LU&;C+&1C M#5_-ZX(INZ(NX(%]=@R"GIR6]'F\]T7THA/N:?1L!N+43_0G@\L M-$[]+>N3'QCS[9:;Y-D'+HDQ21!F_
6'HU//1$],V2WOU%*LD""#L!='<KF>$ MO?$*G-NA N35Y5*:!9!'&(0[[FF:]BAX8&*6%B:VLWTO*+LU93$*7]V;W'QB M%&2[N0#]P;-Q"P@\/1; *ZOR]#*%.+#0CB7SBX%Q1"+A2ZFO
YM>W6Y MU&HNKK^KK.8R>$L13*Z^4U1S/E!)31; ITDR0L3=|+:$3LEN1=R ZR7B]+/5 M$L98EA'/:P@:BJM(>U$_+,@I:UR((^:N, ^BVP5%G^?-H^*KI8'/|KH!?$V'8 M7Z)=(5M/FM8|@4H]7R4?
(Q_$7HT0I9#BEN&:L;WI('HW M'IT-LFUQ#MU67$D3V7R;HY99ZA&ZURO-Z[;_B1-!IH!6+HQE5X,28DY$B,#N M6.XV1W&3]H7&9[KY&+_88=RO4!%P:OOXK*[17%;^A*2"""&|<[]/-#.G0PSQ1/ M)-
L7+?^9-Z-"$,J12?=OFW@Y&*>@&:J+1+14<;2=EE@R&(#UF*=)LVFWT3,U2: MP-=MR=K]-VX1%9[&T"B> *N30'>P8_XX'OT*GT:QGL5Z%ILHCFZ8X=SXIML7
M[U&E%R<4BBZ6S=3$43N12A93,_6IF[NPV0=EM:IOU5]6_U>%3BXSD:CP2C^_MHZ@_:[!%>MJC6M,U)X_090YW!RPT-1 [$*PUI$(KU9VO0Y)OOIT?-9F2/ M+?
4^!*FI50FIG4X6$V#:4J"^/[&>NT\^LB*OF"?T.EH$#[QA\:VZ?MS[33^.OD MPQ@IC?=&#N4HC^.+94;O#:[X$6_%0E0V!%ORI1VI6E*,%>=#^W&(K3 M%SI@_?'ZXM]02P,$% @
L(!N63B0GS"5! ^@H !@ !X;"]W;W)K METFZ< M%-Y7)[V>RPHLA>N:"C7MK(PMA:=7N^ZYRI+(@U.I>FF_?]@KA=3)9!36KNQD M9&JOI,8K"ZXN2V$?SE"9S3@9)-N%:[DN/"_T)]-
*K'&! K;ZLO36:U%R6:)V MTFBPN!HGT\)VO':IX,)&[3Y.^DP(%6:>$03]W.$,E6(@ MHO&MP4S:(]EQ]WF+_C'$3K$LA<,947_+W!?CY#B!'%>B5O[:;'(]]WC)<9 MY<) V$3:-$T@]YTW9>-
,#$]IXZ^;.%^A^$%Y,1M9L MP+(UH?%#"*5X$SFIN2@+;VE7DI^2C?$T7YPNX_A7U /%_)F>G-^>3'[>8)F M@U[6P)O%F/0%F- @L|&^<##7.>;?^ >(4LLKW?(Z2_<"+K#]PK#?
@;2?'NS! M&[9Q#@/>|%?CC# 'S\/PB)RX2F0X3F@&'-H[3":O7PT. ^Z=[2!ZT)_VH?]W MDOMA+BYOYT">P+-P<,%,@S4)FRDKH!ZG74&M1Y]C#IFAZFD7GYQ1,A>|O)): MZ$P*!<[3 HVD=U"
(,X0EH@9*1"4LV4D=@&U.UDA][OPS6&U]GO4924!50H= MK%&C%4H]\#Y6/O|S_:T.9!9\E@.S@FF)5F8"WKQ^=9RF_=;[](+GZ;3[_^
M.'T+)$[D[90CAF"M>XKE5$6KS[AU<88(%9;:671).IYO=9(?0:86:*&]4@6UO.B_FL M9D:7-06T4Z?]U>G'><0WE=1,@PB70I/* M\G:G+V.7(#:,$2X.![AJ&F&Q]+37RX='4-\ M:C[%/F@VI+BWW3
-6O!VY,S\-!EM"IC/(QO0O2A8W\8AJ;NES]EW^=/#QMNC MJ-N6"'A?4?HXN\W)#R@L('E0DCX02+E$"\-!5,$.D%5(#+7'JO:UQ38/O$&: M/(:S NFE4&$NX[=>^"<'#&FF71QI*@<1)E[6E&W7/=
<'"2C,!N_0=]A/(3?4 MKYP FG)5YQ@:HYF5'X>1S) [Z%LMN?3+!VC',@3)S:F0"O[\?S]1L?_3MZXP MM%5KA^#O1CW2YY6Z/CM]-9/>YSUYOYSY"VKT.MRX' MX3,0KR;M:GNQF\;[S*-
YO!52F&O2:5"X(M=^]^A] C;>M.*+-U6XW2R-I[M2 M>"RHJ&C>G@/97AE+?O/ ![75W\B)02P,$% @ L(!N62.>?2!>=@ SRP M ![M:W;W)K/[/C* M*9GSH++8V=_=?:532FVV/K[G9U?
NXWM;AT(:=>6$K]M2NOF)*NSLP]:>5O/@ M6D^F@1[L?'O?R8FZ4>&7ZLKAUTXO]=>E,EY;(YP:?]@ZWGMWW\+LF1D[1W],,L_:,V20[I062)$O_=]U-5%"0(:OR69&ZU4]+ _M^-],]L M.VP92:],:?
%/G8?IAZTW6R)78UD7X=K.OJADSTN2E]G"\[/IB%K\]I.-P26>V# M+=-@:%!]$_ ^7WY(?>@/>[*X9L)\&[+/>><2+6\|,,\N-[9V?"'T=>01G^PJ3P: MRFE#0;D)#F\UQH6/7_^_LO9I[/:?XGCBT_B\|G%|
<7IV?%7<7IY@:=GEQ?O M=P*FH8]WLB3R)(K<7R/RK3BW)DRJ^-GD*E\[5[MM$'APU;APTW2OT_AS2(O+F]_%@?OQ*.BQ;$?=BP0@Z#*D7)M(8J)4XM64E MS5Q,92XRZ:=*FO2'^]W6][]0)K
657.?M/((U7,Q:,WPUW N2B0F4-QVPGZ MZ2]O)O=>' F8KCIHY877)E.",IDXDZ?R7HG,@AA\4+FH'%[I2A:02Q-EF!B/ M)GAA\SH+K%)0V=38PD[FPE&B^H%P4GOZ+),5#K(8\'>581)#1L$519U#?
9A36EAA M(=E!//[1;P1#CG2APUP$"U^1':*R :.U+, L[DX%?R2\RDCL6!L)YYH)GK1& MP\|L" TE@8V?.UBEA.#/BN)[.LK9O<4YX'OE(!M. A3PV 0'%?'D9Y8L+L=CQ9ET M<_XH
7A;Y.+-8_ U&^C&O*EO8@6E 40XO69W@HOQ/.[X]EP< T.*)8YH47)@R M!7(>^&OWN'O8$<2E$7^K 8.]E5,35#0YR2!$60L2&%VO/5PTID.4W$*V'R'N MSSKV/D&6P8B?9%0=02B0'7E]\=
M#/>;P(HQ90#/1EGB()=YC,LU\GTC\LSXH$,=>/I:]0W)\9P(=G_WZ/3]^NR6 M_]X[>D&&^;]IK LKN;BE'VWN%41.6K>?WVX?[NZ1KR-QT6@BEA@2>'VL"V;5
MY21M_8,E[75K&$91XQ]>A:1G3,O%B$* =81>8/YM*X#,?[8_/,Q+Y,%$&&"[M913UQ O6"GZL%>><5@VP*-+%0@T(8,$"33&UK,ILY&\1D50 'T\K ?]&[&W0 MF_Q%R]I
S*8:P76*2R9#UBO\BM@:IB_9R^?P"!G,G*;3< MWXSG-D" #&] R=;F[*9(KIZ(XQR9J9G.R93G]%F"W>=/QOWHIA(Z!ZZ!&/P4 MEMZ4DB+9EQCO)QG;>)GO>>FJ]31-:GGQ5_XT50T_"NX.#-
B]A;;.L#YLPT+C MJX(F.$[_^D-9L->SM&_C8]#?W5_$_N[PY5.OWTK_7T!^SX[_'O23%OC\EUFP M"?H/U4Q0!6E9SB:MZX8+ ZXCIO$+@PG0.:/*R-U%<@/U *O77 W8C6;X^ M@PZ6$^CU4Q.
(Y/Y9&?0].=/3W*<-RW\V5Z(CGYPL!QMRI?,="^0R=8.T1[(% MI9K#FWVQ+>;PBW88VN9/3:+M[GT]J+K"]9<@62STXV2A1N6(,K$DQ97'9IAV M3<"_R2@GL(G)HJB:-
\M2Y+25NA49]E7M/BSM>,:?_7O M+P! &UL>E+65)QRWG 2K)-II[\W(M[]%]ISXE'X]YV2D5:F^>GO]F[&*G%T!])'VFBJ3^0.C3WFN1(OFA6V749 M\8!Y?
@2K**9|:1CBJ+LE2UO'R==@]C:=3YS>A3#=V$O&3;$MB'V5X,5I5#] M ::JGVMI&<|<8H>!\NY:R7PNJMKYFMS9[-JZ5U$5ZM=04X6UTN]%OZ>39 MWD(#]=*(SVKD:NE0]NVO O=2K^=
<>OO&2KA[3>VIQ4F;[?T-HH<]>W_?L(/A"@4-Y=+4645>|OI3SSBO+>&@(C3M8/L66[+!UV^2, ;S.(L8L MN)YG(/"%;I18SRE6L-HIP4E]%]P*6F&XG/M M:.V]-NQ@I1.[^?!%V[R] W$0-
$HSYD5&T:G4.C MO5?WH:G;H+SG$RLZ3C^_:4 M"',,-]+[^%C 1&]W,\DO,S7UZY7+D.B)H)&O*I.U5TU[VM3X@!C*:7\79ZE1 MH::C$NYP(R86 BBDS#*^K=N0/IEEW?K;B=*F))7A'1>]-
!=DR[S(MIB6OA\F% M8YA&0^URE!Z,]>9EA*^IC?#QW,*1@OR [5 =O7[U^>X2B$%ZF& W:-01 FUT\%"0+F3:&X M[(%NIN80T_=/.?TCOYC-8(9[(ORVY%BL:*1S1#EE5VIW:@.8$NO_-8/[55NT
MO+5C\4//=6-/.4 GV-IC^(2\3]PI:F%S"@@\.;]9!I09.Y2GKLX8DQPY MS*&VZVII'F1,7]I2TO;S46T."(%#VB2LBFM/=?RJ>5QWJMNK\T#SN$3SB#O M5#P3[F(SC02!/98>-
(>V]=C1)EZRTC'+9(R3\'/4ZO'.@ !-$9A[L&V.H/LE M1_NPOP5;RI/5.0(IU#MY\))))+<7:.R@986K5S]V_A[L7OAZ/04IL M45I5H4:SM2?
C<>X<1,=PXMR:US8F8]V>#Z+IP1/=-7=BXA[_'CG#/0W@IZK M5^%><.;L;CT%R@1MND@MEU=1TWWIWU8NZLE&7+L,;+Y#P=950=SB? MF@7L,GR:-[)?;N:U'U",;2,?1?
<2LMG8'-6/[:JF3EM:G-3=M\#*G>C+G M.:8M..!Y#YO0)"3*$$CRO83**:R1L8Q2FH9*-%;+HD&Y^D^[_K9PNM*?Z>! M=: KQK#%2%L28NNI=*G2+'27\G%A[L20-20*
>4BI0G>FK5NE6&Y9;3&'(K< M(?-? ;GX.A7&U'"*B;4[R=KS1_E4UD-T6.6T?B6UHU_K5' ?-BB>=KUI78!['$)O:2 M\I@D88$MHAY-@VOSS!VEI?*9EK;VMDS_FLYPU9W%G=XE4[#_A*_2L@8FQ/NF
M[=/VMNYQO*3:?1ZO^IXCFZG&*=080W>'KU]NQ6*F^1%LQ5=61S8$6_*?4Y0H MRM$'>#^V-C0 :(+V#O/'?P-02P,$% @ L(!N6;WY,+[&"@ 4!P !D M
!X;"]W;W)K&ULM5EM<]LV$OXK&+7326<469*= MYMTSLO)2S5T=CQU?YSY")"2AH0 %_"7KW]^S"Q"D'-EI>W=?:)'$+O:EV=E=T' MY)N==5_\2]D@[N:5\6]IQO VKTY.?+%2;.^D'=],.GBRL6\N
2[<\|1NG9.E" MZ^ID/!S^'K]5]Z_86][LYM:]1K:ESKY2K0 MC9/S-ONY5#*-5"UE6XMKM?52+G&>DK:.7YK]C%M;?CGBAJ'^PZ"<."M3:Q MO[O+<>@(O!@^(#!. F.V.VI$5KZ309Z_<78G'*V&-
OK!KK(TC-.&DG(3')YJ MR(7SF]G'R]F'V71R^5E,IM-/MY>?9Y!$5 MCA]0^%+|9DU8>?'>E*H\E# ^!<=G"<6/AO?A1A3=],Q"GPIX8#|=GC^@[S1Z? MLK[3_YW'4>'9<854-
I_\1A;]:0]UX97;JM[Y3S^,?AF^?L3P4]1Y'N[% MM)-;+ M2OB &ZC;X 4T5'6I1%@IU%]A:[H);70]M>N--'LA32DT;N]6MJKV3^W.0)NO MYUZ76CJM?%_\)MT7Y05+FWMY&;?%S-3#%CXHS+]-
WDGKE8295JH.NA"5CXN M^.F'%^/1Z+60HJ0B-]%5O8<9,J1]!?;U#Z]:2B-+F?:'"

"&4T)5&C7,\:HWB&/1C>] W"*HB,Y['S3Z#91< M.:61+L;\,&SLU_/7_D\E@191_]9AC_825N+C9'*%EOJUU@ LVHE! Z7%(EA< M?8&AV03R0WKT[$UT@V,F%PMT56C86$?
[RG5.+=:]$,4]+>>ZTD$G-:7V165] M[=A+V!2T6=*N#\D$]IA<;[P_ZB"'&@^/F:/N,+X\E)4U\+SLK*.KC7+:ED@I ML.E*W*D +"2LQ@:(##H[16WX_U8C!YMIBHF\;G M[R4,,:^]8DE:OOD&6/YX<
]\6F_>D=]L#GO+&V@IX9J3E"B"DKFO/:H8#XZ\C!2K8:1Q4H"/A#RQ!$P MW G>M&AK*ZRI^-)[6VBN#08^-Z), <]$+*9L8:4[5:*[89Z]LO: 2&#&(1ZE6/DHV6,5SH#B3
MN)/-.+;UH-.I[@-L@:9J=POR$NW3/KA@#/A7)@MOCPE,E4*:IW(8(O([M>$ MTVE7_7YKWB/QK6552[^]5, F:C6 ,@M'N:IDM:0VN0,X0P$I#DA1O MX41L'@P+2;6-!@'$<#B=4F(=:8OUHJ(4 0?
(5^V.I_S79 UJK4F6LDVW7]$ MW0O4!F4U!YH:/A--]0@:HE96*$ 476E!)?H6(X!5<;O#S4$;XIV+=&DX;; M$+-RD6=08$WROMA*;@FZA5*@:.(# CK ^EW:9&;0HDD!XNC0*6-B--U5U*#7
M.H7]=G S$$N[5Y,-.B*0+3[ZJ4U+"78K7:P80][P M83[C^0L]9IXF7CX^L,IV91 CE[?-]D^QQ_&S8'PZ'Z/A\ 6U"^2<9"7+ MV*3O&.9 T(]G@O%X>%7%F*24A4[O/(@T-
^/["EYV%7PWB'W4DL/MI5-+JN_B M0821@R\'PT9[X^0[520?1^SCZ7=]' W,_CL?1Z>#Y_]')T?/VB3PD,$)N.6Q MR]#RZ%>%0@LNXZ!> C&1"V?ZHSWH
E=I75*.B*M9&\608/@75.7&XAW8#],>6H\ =3, <\EH0%!!GYE[&,< TK"-T8.5WYB=YU_<%?PWJ*4NA% 119HO##?T@C^0 M;O7G/V&$,MO&A.QJT9:8&'<3G-FM4]'8^]OWL:+B60]N$VA<
A*U(H+@MKI0 MS8V4]+@T$T3]/D4%8/Y<8G!+9[S MXD7MF$-H$]^B,&RO@5 34"TS\!'RH:5]:.2FE ZJH43\6P4O*>V&-IBM46?: MQ'L!A&NFLCR6:U0D8>\RRZ8C$#1L8 6WE?
\A1 ;HGA<6 \036METUG&DYO:+'9I!VS"T^'S?K;U.C/O)Y_!O@HO?C'\^=5?]#}.&>S5 MGFC*3@P@WQO#NV7@DZ*<_\R3T8+]2CIDAJS0]9@'I,'5*JT6#!!A=D1A1O MX41L'@P+2;6-!@'$<#B=4F(=:8OUHJ(4 0?
EZ2'LNZKGX/&"'>IP?:!+G\'3@:(XC[%TRJL\521#LU&0_&<<*,GC4#)M(W.BVMLU3BE1V%#VL22=49."':G0E(!\#3QI! #'>70 MST>_@^?IA:.,2WR0GZ+O"3(]$$30N7!CDCI1OPUV/GH.Z5
9&T.R(:LPFNH(M^)VI1IHLU(%LM7$'&D(4[M:M^0...?,<02GI_I:'6O1F:1+'^6=_<[0(YI MIP,@H',A(W1M<;[L=S1!/M7E\[-C=?G GDI(95+WF';Z+*KG
ZE>YQZG?:E+F(WGZ%W5#ZW&I^)=^P&CK<]O2 M+ [M,8GT'H\%X0^H6^+XPQOE! 9#)Y#*8N7CK3'T^N+;6J6'7.;*WLQ^0PN? M/5[I _1VBDT&+I1E8]!0R1:N-)[^;?71BS5W6)#5?
B!^1U.RPMB0#M#1\$8W M_ ^NLP@9'UED?@.3:\G\O9=B _&!7^#H-6NG_WWNH=V7+\X;_"Z;"]3322R9 M^?XOS-%C,Q0QB;C(S0+\A<7GMM3-,#IX2TK!\302TKF(PAF92@L'\A>),GQ@
MY0UVVL2^7X,AE8<\%N&MCNFIT--X=_'2)<,"GE%F<^-M2OB &ZC;X 4T5'6I1%@IU%]A:[H);70]M>N--'LA32DT;N]6MJKV3^W.0)NO MYUZ76CJM?%_\)MT7Y05+FWMY&;?%S-3#%CXHS+]-4]+#
MP?-G/>'B]ZMX$>R&OQG-;0AVS3]7.&HH1POP?&'!;M,%;9 _(I[_!U'!+ P04_M " "P@&Y9@&M"[^@$_$ &0 'AL+W=OTS+8UMHA2I):FX M^?>=H8Y8SM%T>[R8Y&B.:X:<&=)'6VV^V V
8U\+J>QOL'&N/!P.,;:!@MN! M+D'AEY4V!7>X-.NA+0WPW L5>-YP++* M.ETTPHB@$*H>^=L$NW[VZ.#T:..M1+7X=9H^.DUI$\H&/. M/FKE-I:=[ASROOP0\72@DA;42?
*HPDLH!VP4A2R)DC?=:DR.O;_133M8Z MQO?KH.0XM"7/X#C TV_17$.P>/XLGD8O'T$X[A^.'\)^1(3?T?'IZI1-#ME= M7>R$6Y$QJ:UE)1202 >2 NR@"E=["S+Q@F#P-,)BPB
MUP108<3(#:%09I=[P*X0V$I+K(T^3GPIR3 BQGKK-AYW'05OE(+=[0LY7WN- MQ|[3:0P P]SA6>#%756 F4EPYQRX#>L32S/B)-1B'&R)?CZ*&\,V?-G;1*- M7OJQ\6WCQ15W8[>F=) ,R* >EWTE?
3_[JY;'>T^>[\S,]@*/M=/F]_O_@79O M971!1P,SHJ*MQS9KFH/5\OW%7B3A*$K#>)X<]*GS- [GT[A'G8;I?!1,YWUJ M'*.*23B;I@?LO<*S!+7I7-C&.IW2^XS3+$Y>_B!E$J:S)(R2B)VU!_67^C,) MQZ-
1.!NG!]JKO#2B-K?=?'(/^V7TP>(9-I6NE4$#.>9]//(MV*&F"\4[C M79YX'(]3V0YEEF+4Q&]W^8?F_Z1L-IK.G MV;OKX%,M[D;46Y$>UHINLWY]+-
%0TG;W^MJ$RNCZ]5#_[^]4CW3D?98?[KR7P:.M1E'$TBCR8[O&\N"GG!9F6R#3SD,MC$8;-O#2@4MI9PWO?"V*X|ZC#]G:/UWI3EPI5[_O.FKW.GY5/PIOV>NG]4=N
MU@(*#)6&%HI@8DX"9^KE:+YPN_1-QJ1T^,/UT@R]\,.2 WU<;?6X69*#[SV#O M#5!+ P04_" "P@&Y9'4_UOPL#_"A" &0 'AL+W=O9(M*YVETOM>1RVLX!*O-9A%43"]
M&]!0RV!0"M:*"9_GUFBF7]=D=DR.O;_133M8Z MQO?KH.0XM"7/X#C TV_17$.P>/XLGD8O'T$X[A^.'\)^1(3?T?'IZI1-#ME= M7>R$6Y$QJ:UE)1202 >2 NR@"E=["S+Q@F#P-,)BPB
MUP108<3(#:%09I=[P*X0V$I+K(T^3GPIR3 BQGKK-AYW'05OE(+=[0LY7WN- MQ|[3:0P P]SA6>#%756 F4EPYQRX#>L32S/B)-1B'&R)?CZ*&\,V?-G;1*- M7OJQ\6WCQ15W8[>F=) ,R* >EWTE?
3_[JY;'>T^>[\S,]@*/M=/F]_O_@79O M971!1P,SHJ*MQS9KFH/5\OW%7B3A*$K#>)X<]*GS- [GT[A'G8;I?!1,YWUJ M'*.*23B;I@?LO<*S!+7I7-C&.IW2^XS3+$Y>_B!E$J:S)(R2B)VU!_67^C,) MQZ-
1.!NG!]JKO#2B-K?=?'(/^V7TP>(9-I6NE4$#.>9]//(MV*&F"\4[C M79YX'(]3V0YEEF+4Q&]W^8?F_Z1L-IK.G MV;OKX%,M[D;46Y$>UHINLWY]+-
%0TG;W^MJ$RNCZ]5#_[^]4CW3D?98?[KR7P: M1E'$TBCR8[O&\N"GG!9F6R#3SD,MC$8;-O#2@4MI9PWO?"V*X|ZC#]G:/UWI3EPI5[_O.FKW.GY5/PIOV>NG]4=N
MU@(*#)6&%HI@8DX"9^KE:+YPN_1-QJ1T^,/UT@R]\,.2 WU<;?6X69*#[SV#O M#5!+ P04_" "P@&Y9'4_UOPL#_"A" &0 'AL+W=OTS+8UMHA2I):FX M^?>=H8Y8SM%T>[R8Y&B.:X:<&=)'6VV^V V
8U\+J>QOL'&N/!P.,;:!@MN! M+D'AEY4V!7>X-.NA+0WPW L5>-YP++* M.ETTPHB@$*H>^=L$NW[VZ.#T:..M1+7X=9H^.DUI$\H&/. M/FKE-I:=[JASROOP0\72@DA;42?
*HPDLH!VP4A2R)DC?=:

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|=;,COW1*EKQI41T=]_O/ MCQ92F\[E:WYV[2Y?VSI4VJAK)WR]6$BWN5*57;_I##K-@QL]FP=Z<'3Y>BEG MZE:%N^6UP[>C+*74"V6\MD8X-7W3&0Y>7EW0>E[P;ZW6OO59D"43:S_3EW'Y MIM,GA52EBD 2)/ZMU$A5%0F"&E^2S$X^DC:V/S? 2W[/ML&4BO1K9ZD]=AOF: MSD5'E&HJZRKL>#6.NW.LC+U\ZNA:/5D$8?V%3>#>6TH:#W&OO"Y>WX MP\?Q^_%H^/&3&(Y&?]Q]_#3^^$% <__&O\6C\[E8\N;:5+K3R3U\?!9Q'NXZ* M)/LJRCY^1/8+\;LU8>[%.U.JD! M>2?9^!.6=_)SQN^S. H\W2^0,NBE7\I"Ô>D@1;QR*]6Y_.V7P?/^JP/JGF9U M3P]O[QVVA1Z62DO[%2,K/&(32D)W?M4_6EAXM,BZ1A86J@RYDY>."WWZY M.!X,7@DI2LI1$[:B-U!#AG2NP+G^45$C:60IITYE#:.'US.@I7D*@-D&Y(EDS MD17<)^19L%)XR57%SQP2JA*(T797_42?BS:7NT=0,!91L#9P:#=(2SP[SL? M- J2\OO"_F,2Q+532^EBW'=#Q[X]?^6_"PBTB%]$#AM4L# 7'X;#:U3M+[5& M(]!B&91X6BR"Q;?/<%96@7PI(=K",KJ2XR:G4Q1N2%A:1^?*1887UJH0MU5: M3G2E@TYB2NV+ROK:L970*6@SHU.? VQ/88C*ML7ZO@1QNO-RGCKI'A_005M;(MJ5EK'7U;*]=M"5@A/UR))Q7 #=#4. ">0?,@[VR@.0QV@CSB<#@@.W5V 6'6 MMWS50|)D3U) <=*DCA>+I?.+B$QM"U+R96\YM)-N MS%F#YK9"TUXV-GTK8/!Y[17OI.7+KX#E]SMWQZ8%6AXI#?O;2?A77<[X/0O7 M'M(MTA! [Q^CL9:GIF*ZP,,5E1Y!;$XRR[MU4M,@H"EQ!P9S4'FGBHV'@,U%K M*%G,)>"#39YH"(@#P9L6K6R%-15_]=X6FG.#@<_%L.6"XZ$N-E8L'@0Q8A"O M4JY$E$QOBF='<23Q)*NQ[^A>JU(]!-@4A=VN&>2TM4OGX MCP+\$P&SQ^1DQ MME)0^48$HT=2OB:4DP4BR'N<=:! /\|%^OG!\CJ2? MX5]%>\0^E;R2]7CY%3 M@*FXT?[SOK+]=|CEV#>-=UL=YF"F"&VE1L9-,7L&]L:PQ8"45'90N8)D#[902 MBTCD/ 3X+QA<%%%3]BF M8ITW*U1.ROL$O1*U%,E'8=<&: AU3*P$@SNC2<)MB'BYRATZL"3Y<-MM8Z.3VN]YM3\SL2CG#F ?V M38&BI0IRI58I$YMHT'Q$NOAHIS9;PK2>ZV+.Z-:&%?.YX[Y/NR?4J8_[K]Z_ M'8_XX^#5TX[P>.;4C"I/\2C"R, 7O7XCO3'RK2J2 MC0.V\>2;-@YZI_^;C8.3WOG_TCIACX6U@?JD"$) 6$AJD.??4!CHCSC,X@[5&F= MDHXH/>E;MZ! |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`L1*,.S/A^PUCI6_QI.KMSEHJ7%012#B4+8&([IT&VA M<@U)29;[;%UNER1A XJR58.Q^7C #A2\1%V^3+53ML-9$*0-E MMB>FR[XF\1]BI$T&]MR?QIY/E[7H#RMM:U]MFH3NMX_%'K5^%5PH-^/?/LF5T#S^0)B?YI]7 MA_%7Q>WR^-LL3IO1W46EIMC:[YV?=82+OW?&+\$N^3?&B0W!+OCC'".1[C P]0T !D !X M;"]W;W)K&ULQ1=KRIF5*E6=.HZ,4RB8'/(*2ORSX])@"D&Q=F0E@"6&J<@=ZKJA4["LM.93 M@UN(^937*L]*6 @BZZ)@XML%Y'PSLSQKB[C)UJG2"& <^K=@:EJ#^K!8"(:>3 MDF0%E#+C)1&PFEGGWNG%2-,;@K\RV,B=/=&>W'%^KX&/R^-[^C+'9-PR?,O6:+2F159)($5JW-UPS@N.945BV%F81M($]@S=^^ M\4+W(B%06=A<$SZ?(E=E]0Y$+XB,2^]6C%3OOB6V*(YEY)4@%V5,@&'C#\N M_NV;B+K^&?G5*W8042F0VU0]*JD^W6- IO;_/!6"U:"@N$/O=4GTH2V-+A3] M\7=VUW4!@BDN3G^ZGY]T?E:"%YB\4F5EG95K@B>H,%F4'=UOY(3:OAO9WH0. M^MA)Y- F3T.MA0SN:^'8XZ6,]#T6,['$8#EN*K^K/R Y\WQX'T>"GYVF[OH.2XZGZ.L7QQ8P C#E[P)BO M03=P@;UK>E42'(E2L3+!DK#U),GBCC.R)]2WO;& [@XDHQCOR=FF\P ZB\0YF M'&'4 _=%FI,LK]5.=_VH[L@/[)%'?UF]=,T!$R4Z(B M1F/X>%9TR7K]6* (BNG=H')G&HVX:CYX]C1E&ZG=C+EXCB82X%IG*0!X:PL>E M_H_#]BG)2X?N<>RAX7O9GD2*Q_=89/U)-)[$MNNZ)')=LVYAG %F[3%7M8A3 MO('3#1,"LR%[MNI:].RH9=S'++@"S"#+\V_D0!;W3*)VV'(^8K:[(P7F[%S% M\=:Q-@\,B6=*7:KF5MYANS?->7,5?R1O'D2?F5AG&*P<5LB*-8]5)9I'1@,H M7IF+_1U7^$PPVQ3?92 T ?Y?&ULI59M;]LX M#/XK@G<86L"H7^,D;1*@:[,XZ,4\BIO.(E%/AGPT5.%2[%UI&E M)H84)XYONM&3DY98J8P5\"*(K/*$ &;J77K7=^%6M\H?&:PE[TYT9&L.?^B M%T_)U'*U0Y!!K#0#Q6$'!Y!EF@C=^-IP6IU)#>S/6_:_3>P8RYI*N.?9?RQ1 MZ=0:622!#:TRM>#[? Z")9Z#Y8IY)\R7[1M>U2%Q)Q?,&C![DK*A'^MKLPSD MOP'XQN_:D/'R@2HZFPB^)T)K(YN>F% -&IUCA3Z4I1+XER%.S1Z>EO?/\]73 M_-/C WE^>5SYTMRL:+K#.3EQ%%H1>LZ<<-X5S/Z1QC'Y",O5"K@8Y% M\CW>0>|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

TX80>*:DQNU1U"YU>AMKO9JDJG$+LF0]#@3R"E[Q_-YX'GP:4I[WR=(B> M[&H&:!P<9O?CK?%S0KGG_6'$F3NNJ!"J:BY;EM%O]HW MVE7:7_Z&MUW2$&ULM5EIEC MB=WI<=CMG=B/HDJ I@=]EE1@_OV^3*E$X<;TL;-?;*B24GF\S'PI7]^M^^SG M2@5QOZB,?].9A[!\>73DB[E:2-^S2V7P9FK=0@9|=;,COW1*EKQI41T=]_O/ MCQ92F\[E:WYV[2Y?VSI4VJAK)WR]6$BWN5*57;_I##K-@QL]FP=Z<'3Y>BEG MZE:%N^6UP[>C+*74"V6\MD8X-7W3&0Y>7EW0>E[P;ZW6OO59D"43:S_3EW'Y MIM,GA52EBD 2)/ZMU$A5%0F"&E^2S$X^DC:V/S? 2W[/ML&4BO1K9ZD]=AOF: MSD5'E&HJZRKL>#6.NW.LC+U\ZNA:/5D$8?V%3>#>6TH:#W&OO"Y>WX MP\?Q^_%H^/&3&(Y&?]Q]_#3^^$% <__&O\6C\[E8\N;:5+K3R3U\?!9Q'NXZ* M)/LJRCY^1/8+\;LU8>[%.U.JD! M>2?9^!.6=_)SQN^S. H\W2^0,NBE7\I"Ô>D@1;QR*]6Y_.V7P?/^JP/JGF9U M3P]O[QVVA1Z62DO[%2,K/&(32D)W?M4_6EAXM,BZ1A86J@RYDY>."WWZY M.!X,7@DI2LI1$[:B-U!#AG2NP+G^45$C:60IITYE#:.'US.@I7D*@-D&Y(EDS MD17<)^19L%)XR57%SQP2JA*(T797_42?BS:7NT=0,!91L#9P:#=(2SP[SL? M- J2\OO"_F,2Q+532^EBW'=#Q[X]?^6_"PBTB%]$#AM4L# 7'X;#:U3M+[5& M(]!B&91X6BR"Q;?/<%96@7PI(=K",KJ2XR:G4Q1N2%A:1^?*1887UJH0MU5: M3G2E@TYB2NV+ROK:L970*6@SHU.? VQ/88C*ML7ZO@1QNO-RGCKI'A_005M;(MJ5EK'7U;*]=M"5@A/UR))Q7 #=#4. ">0?,@[VR@.0QV@CSB<#@@.W5V 6'6 MMWS50|)D3U) <=*DCA>+I?.+B$QM"U+R96\YM)-N MS%F#YK9"TUXV-GTK8/!Y[17OI.7+KX#E]SMWQZ8%6AXI#?O;2?A77<[X/0O7 M'M(MTA! [Q^CL9:GIF*ZP,,5E1Y!;$XRR[MU4M,@H"EQ!P9S4'FGBHV'@,U%K M*%G,)>"#39YH"(@#P9L6K6R%-15_]=X6FG.#@<_%L.6"XZ$N-E8L'@0Q8A"O M4JY$E$QOBF='<23Q)*NQ[^A>JU(]!-@4A=VN&>2TM4OGX MCP+\$P&SQ^1DQ MME)0^48$HT=2OB:4DP4BR'N<=:! /\|%^OG!\CJ2? MX5]%>\0^E;R2]7CY%3 M@*FXT?[SOK+]=|CEV#>-=UL=YF"F"&VE1L9-,7L&]L:PQ8"45'90N8)D#[902 MBTCD/ 3X+QA<%%%3]BF M8ITW*U1.ROL$O1*U%,E'8=<&: AU3*P$@SNC2<)MB'BYRATZL"3Y<-MM8Z.3VN]YM3\SL2CG#F ?V M38&BI0IRI58I$YMHT'Q$NOAHIS9;PK2>ZV+.Z-:&%?.YX[Y/NR?4J8_[K]Z_ M'8_XX^#5TX[P>.;4C"I/\2C"R, 7O7XCO3'RK2J2 MC0.V\>2;-@YZI_^;C8.3WOG_TCIACX6U@?JD"$) 6$AJD.??4!CHCSC,X@[5&F= MDHXH/>E;MZ! |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`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|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

*(/!8B!+KG#V#2YDJ'8Q^4RS"LB?; 7DC!7D M%:B0Y^2^4E+1(M&T]=1HGVA1H9(2M[X:)/*CWG 4-G[?$B_L!UZK[_9|-^HY MCM/8HOZ@H9,TUC//1R3O_" |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|YR1! N9MY!RP67&3MJ2 MI84?FRQ(F%O";&OGE5D75\W7ZD'6Z$/" B!80Q.#6A,#_3=8KC703"Z5WM## MFH4KN7A -TM&B%S5M';N6MRQ*H"$N9 P#Q+F0\("(%A#+9>U6BY!9HF7D"*! MA+F0, \2YD/" B!80R17M4BN/ID49#R.Y$A36!IR?H;RJF>)$.:<[!]A2FY_ MIQNW/_3B4VW5QXH!$N9!PGQ(6 $:XC!MK8^AO7?1QBI!#?F(J84MC;4^JJG:7\#WK MHTQ S4]0F@=*\T%/I 12M*9.M VKK#<=;_!JGZ[0UZZ"^)RC-!:5YH#0?E9 MT9KZV!JB=@|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|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|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|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||QDGH9_EFLAVGAX3[F[(HW(^)KMOCT ^BT6)>[KM+ M%O/XF.V#B-\E6GH,0S_YYYKOX^?+D3%ZV;$*MKNLV#%>S _^EM_S[,OA+LFW MQ@UE$X0\2H,XTA+ ^>#FZ,BX8F18Y8BO 7]_3UYKQ:$\Q/&W8N-F0T>-9E%X^OJ%[I4'GQ_,@Y_R9;S_.)ADN\O1 M=*1M^*-_W&>K^/DCKP]H4O#6\3XM_VK/U5C3&6GK8YK%85VHAO8ICK)=]M%H MPS>2^]6ZWOQ9/577SQ3UX_P,-;>)O)RF:Z($WJZS#YI[_*X1G5BRXU&7W_-# M7]Z_6>[V+S=E9^,|=>||=:8N=_FZ.76FP@]SZ5BSY)D].U:6G17!DA.*]_M% M>O#7_'*47[Y3GCSQT>*W7PQ;_U-F+1+F(F$4"?.0, :""0UB-0UBJ>B+%7_B MT9'G-\]UO(V"?Z47D&LE8VB+5#" [A!4W_Z>%,2.V3O3Y^.G4_>XX.G%LW1:' MT>XPRS1GIN&(XSP)CDPL6S?$<0QTK((:D\:-B=*-VVS'D\(+'CSY#WN>RLQ0 M(H::4<$F)V?%L2S+>.T%4I/VT_20FFS2:3]=.%-CTH@*AMF-8:;2,_^]TK:) M'V4RHY2E0XU"PEPDC")A'A+&0#"A,YRF[YRS[[P.LD&0.!<)HTB8AX0Q$$QH MD&G3(%/G5?)&-HBT\Z%-Y^$ZZ^O]4A)VI6&36,=0/\4=HTU:6\LWVF,2AV_U:E9@SU& MTEPHC=:TTU8P=-F7'2K+4#2Q&4C;#*3?([WVGW9_?$CY]R//-XHKNKP?E+C! M_8"DN5 :A=(*(VA:&+3M#&;<7[.9D"#-BC-A=(HE.9!:0Q%$QNEC=L,==XV M[%8CR:RZE]^E6G)P*R!I%$KSH#2&HHFMT&9]ACKLN[^^62F\A|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|F Z368GDD]O.&*I?@Z;"!?@^RBJ^S]TEZ_DYO0ZU'?]^C(WG0X M[C>.^\]PS*M#D2\)W&-BD-T(E5)_#R%P>T/'&W0C^_V";T3XSJ4D"\$S$BO!*V .&\SAP8[7\%%(_:Y/A_V@.Z+4:7.A8X3X"CGZ M3\N0LABS;2*5YME*

*9^(SBKUPO^A>XJ:'"FRM=&!2MR5U#Q;;6N]OX :!,W2> MB&V;WJDQ+6/=$)LD C*K4F>G[]=([+3-[-0[6$"-1>*EI&TIH, ^I!:8B1! ^7 M@(&A"-&V!%!S#9A!RA0F_8()]4!D'51A"*I1[Z5;U58)&APL]*]1)FA;)Z@Q MOS\G](-'K46O[^B_?Z)I[_6C&8AEV75+$O%UKJK6M+G;=/8G53_;3]\^"RZ8 M6";8@J:P0%/G*, C):I.NQHH7I3=[1U7V"N7ERO\.@&A)^#S!>=]-] .FN^= M\ ]02P,$% @ L(!N63S/B1?(@ 70@ !D !X;"]W;W)K&ULM99;;]HP%,>_BI5-4RNMS04(T(5(]5J-AU)4RO9LD@.Q MFMBI:;#]]O.EI$Q-63>M+\2W_?//N?X$.T8?Q 9@$1/14[%P,FD+"]<5R09 M%%B]"=23IP/T.2122V#UV<((\EPK*8['2M2I]]2& MA^V]^K4YO#K,$@L8L?PG264V<'H.2F&%-[F\8[OO4!VHH_42E@OSBW9V::?E MH&0C)"LJ8T50$&J_^*FZ8B_#(C'(*@, L-M-S*48RQQ'&V0URO5FJZ88Y] MK!41V.D=G:(1%AJZ5UP0Z M&8/$)!>GD2O5GMK232K]H=4/WM#OHQM&92;0%4TA_=W>5:PU<+ ''@9'!>=0 MGJ.6]Q4%7M!"B_D8G7P^/:+;JB^B971;? W<132>V0NUF(9U&%Z+$"0PQ]5^$YS7[M5\#]3\NV/K-P?8FE.^]O*'>'[$(3515%(!.4K"M4WUCAA;3U#;@ M<4.V*AZI;"2LMCE,4C\(@]YK1/?@Q2^ KTU=$RAA&RKMXU^/UK7STE:,E^6V M\-Y@OB94H!Q6RM0[[ZH;XK:6V8YDI:D?2R95-3+-3-5_X'J!FE\Q)O<=O4'] MCR+^!5!+ P04_" "P@&Y98F92V^ % "&-0 &0 'AL+W=OL>9Y0(5?SS;#(Z4QZ\/)A[6K!K'G^-0K&]&,P&)&1K MNHO%'7_T6'U $\4+>%R4_\ECW58;D&!7")[48MF#)$JK7_I4GX@#@>1T"XQ: M8!PK&-6"T?>"\1N"<2T8'RN8U(+)L5TR:X%Y>&V%6"V;'11C7@M)? MP^KZE1??HH(N)SE_)+EJ+6EJH710J9;7/$J5V5 M#(7LB>(-@SKJ=175>".J3FYX*K8%L=.0A1UZIU_>D_O]>OG/?JA/(/-:31> M3N.5T0O\?9>>$HZ'_WR&_I,1OJ;:NL]=7[6)[?[Y9>9DFNEW.BZ M%OWR%LL'H^9V&I6\T6FW4T?'KBK0N!NDGG'G M148#=C&0#[&"Y0]LL/SI!]W4? NNR%Q)F(6VN8@82X2YB%A/@C64F9TQFPJ++,KVX4RV#A%E(F(V$.4B8BX1Y2)@/@K5\ M;#8^-E%/;!/I8"3,0L)1),Q!PEPDS$/"?!"LY>!IX^!I_TC,TR(*65Z]G\DW M-9+5 W)(:%$P4729>=KQ--+*Q_;SX[HW^*E&1<)L),Q!PEPDS$/"?!"L9=19 M8]39.ZEE3(4T949S\4P4/0I4HEDEG'^3JR@-HW1#5M6>8I]/R)U?H[B0]O[* MXS6YH>EN30.QRU7S:YYGO')_E]%[^W3]J(V$64B8C80Y2)B+A'E(F^"M6Z& M>7,SS%%YQQSI8"3,0L)1),Q!PEPDS$/"?!"LY6!=VW\[UOHS#UILR2U]?NN5 MKU]^JG.A- M*LVO:83HUZ\JF'&A8%TKSH#0?16M[\Z"NH?=Z5":CZ*US;JO8NG]9:P#L[[[U(<6L_2,,D^7L2QH6!M* MPDPMK_2%.]B^TM :E MV5": Z6Y4)H'I?DH6MOD^PJ;#BNQZ= :&Y1F06DVE.9 :2Z4YD%I/HK6]O*^ MUJ;_'\6V&GKX:O1&M:T_,F6A=;;H#0'2G.A-]*\U&TMF7W53>]O^SFTBA5 M7[_",M>0"3%?J^6 IR*2+W$AX5GMYX+<,VEI1J(TXDC@CZC/_7OEY-NVT M,I(@!J794)H#I;E0F@>E^2A:V\[INIG>8!I28?J9/RLV;XUW=Z>#Y]U=V1S[WN[9[:I)1.0=D'[::H71#\TTD!_.8K647M+.I'*?S:M)/MM2)X5LX(N>="*1&PO=V]R:W-H965TV*:VT#S\[23-8 M0M1*W=Z [=S]_;OSTPUV7/R0&P"%'A*6RJ&U42H[LVT9;R A\I1GD.HO:RX2 MHG17W-DR$T!6N5/";!?CKIT0FEKA(!^;BG# MXK1%*8"R6V2$/%X#HSOAI9C M/0W,Z-U&F0$['&3D#N:@;K*IT#V[4EG1!%))>8H$K(=6Y)R-'-G<\3!+1WP1B M#MDI|O)T|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|?2\C(&' &5 >+^BA# ^VI /:'X= M\?X#4$L#!!0 (+" ;EFRL4&&V@0 %(? 9 >&PO=V]R:W-H965T M)C0D[?2E M8P1X8EM4$B&=Z8>O)!N#0='!59WF1;'%]K=K[Y^UO!IL$7XA*P@I>"ORD@R-M%:7K:],DZ0H6";E":UBR:Q8(%PEEIWAID6C&R5P8%:GI6)9O%DE6&J.I&)OB MT0!M:)Z5<(H!V11%@O^Z@3G:#@W;V T\9,L5Y0/F:+!.EG &Z=-ZBMF9V5#F M60%+DJ$28+@8&F/[.K8];B!F_):!+3DX!OQ2GA%ZX2>W\Z%A\8A@#E/*$0G[M>(43F.>'B\HT?BXMG%/"<$3E#^>S:GJZ'1,\ <+I)-3A_0 M]A.L+ZC#>2G*B?@/MO5NATYMT#G7@U\;^.=ZZ-8&79&LZNZ*U 0)348#C+8 \|E_MQ@]$?H4URTA68@B9 "D8EW,0OD&<9FP8+>J)IVNN*P(^!) F64X^,L33+ ? MOOTX,"D+DSLSTSJDFRHDYYV0;'"'2KHB("SG<'ZQ#]3V[I?L([5]7V%OLMO; MW&-G=X]O'"7PYZ2\ J[] W LQY7$,U&:!S!MS!W9[5";S^:F5O"W).8A^>; MRX*/_IWW^*N]MU+A-G)W!<^]0.XRA5843T[ACX=KLDY2.#18_2<O%T)CI-TW MMF_I)$NO3EB@$Q;JA$4Z8;$F6$LD7B,23T4?C9>LW"T3'L$:HQ3".0$+C I M5@ES!C)"-G .-JPZ8$!7;-:N3":[,BF3E-+GI9+2"0MTPL(*Y@L87P>]CMR^MY_O=@?EZ*!;)-+]O.>U9|>DLV([]W[.:>:T$=YH$=Y0)GK;2>LORF92I>)Q- M4%&P!9)XJLF2J.1>FD2=L$ G+-0)BSIGI;J:U3DWU7Z3:E^9ZL/DIE5RB5BR MB-3#@Y5,-8QV*YFLK'_OTA6,TNFE.M_)"W3"0IVPR#_)L./V^L/C2LA = M)GES3.GB8I&H W:|.A1IFTUG)*%66J25%NNBM67C[&7CJ!['57YTGM)[:CU&M6S//NH(DS4 5WZ2-)*"[72([VT6'9_>=&5+V;M M? 5O25C:T1KSOD%&1X06$TLRZIXMM2:V?J!U=G%FM[4:MM$@K+=9%:PM@WW*T MU3W'KV|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|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|GC\G26'\N9@O\\O>RIGZ^R))YN@A;SOC48C/N+>+;L75UL[ON675VDZV(^6R;? M.B-?+Q9QJOTFF:>OESVSIW;'W>SIN:CNZ%]=K.*GY#XI? EU]R\I;_9TRG2V2 M93Y+ET:6/%[VKLWSR#ZM C:/^&V6O.9[7QO52WE(T]^K&V)ZV1M4SRB9)Y.B M(N+RCY?D-IG/*ZE\'G_4:&^7LPK<__I-]S8OOGPQ#W&>W*;S_\RFQ?-E[[1G M3)/'>#TO[M+7(*E?T*CR)ND|W_S?>-T^=CCN&9-U7J2+.KA\!HO9;$17QUD:6O1E8]OO2[+S;K M=!-?KJS9LBJI^R(KOSLKXXHK_^[ZIU\,\=/MSU]=XP+9//_1^)?QZ[UC M_/#W'R_Z19FE>FQ_4HLW6]'Z0#2-K^FR>,X-=SE-IHIX1Q]O?Q;OZ>//-/'] M\MW9O476VUMT8VG!GR?%%\,V_VE8 VNH>#ZW^O#K]=,NW%2]'?KP^V15A@|^ MS.ZV#[=5;^9QV?WCL@?MWSI5=]$/=Y+)+ER5/=2'?XV_ZZ^CB_=TJQ">U>H M]L:S6Q2]JBBWT4-U=/6#^3Q?Q9/DLE?^Y,V3[^7I7?WC;^9X\&_5BB8QA\1< M$O-(S^>Q@,0$B84D%D&85%##74$-=?K57?*2+-=)>5TX29^6L_\]?];<:(VN M945BSA8;;[#]PQGERCRSQ@-K<-%_V:^8P|=9HY/Q8"P_S#M|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|(MP$):]ZCFH)]+:AZJ^:@6H)I M1#5(DJ3BZMI[UOZ]GZWR\'#GK#BHO]6G[)S M":'_E!_5/%3S42U -8%](:I%E":74#,Y8.DG!^YOQ)VF9M") 51S4,U%-0_5 M? %0+4$V@6HAJ$:7)I=4,'UBCXR[!T,$#5'-0S44U#]5\5 M03:!:B&H1IK5V]==:'S1K@&H" MU4)4BRA-+HMFTL#N?]S!QU=WZ-@!JCFHYJ*:5VN? 5:Z/9@U03:!:B&H1IJ.5GYGJX?^]@#B)NWV$.ZOWBC2U>8XXH>T*-+%YLOG))XF6?6 |ON/:5J\W:@2[$X7O_H_4$L#!!0 M (+" ;ED%37MY 04 #XF 9 >&PO=V]R:W-H965T:2M/@21=&JDMH#MIG:*D=]U>NN DZ +.C)/< M2OOP.P^%N+A>[DA&CS>&;;Q>6*:;+:\NF//9#F_(BO#/NP439V9'2=*<%&5*"\3(M^L;XM:\CIPZH6_R9DF-YO]*CNO.C,.R|)/TH1O;XR)@1*RQON,+^GQ$VD[Y%6\ MF&9E_8F.3=N1:Z!X7W*:M\'B#O*T:+[QU[80)P&"HPYPV@#G: <#HG0"W#7#/ MS3!J T;G9O#:._< +|-|.O:-\6J*QU@CN8?MH@=:|&V)PB(AB2(^T,=/-?&FZ&?76>>ULW>.%K@B MNRODC6C\CQW&BONY/S_<577G^[*'WY<|TH<')!;AMBIG!4 M#TG#&:DYUYP3&X,,326A!V(,?_I!]NW?E4I! D+(&$A)"P"@DG*CCIE M1SKZ_)%RG*&EX&(6:QNC%4'\0Y[;B>95DS\W J MWK"=ZT\&S0)%,VL\'K0+A^U\;XB+M+W]QEIZ72T];2V7),.<)&B'&7\1GR_X M.2.J$C88[Z0O4\L=N9,W%=1FN_3Q/R[G")DS\H:/BNM,?<_KDDIU|KLZ^]HZ MW^&7C#(DUA<9V1!$U^B!)&DL6IF*K65=.B)!P@)(6 @)BX!@DKKC3MTQT%PS MAE06$A9 PD)(6 0$DY2==,I.@.<:+>]2A2%AP60PG/K#.6O8R':'4Q;0?4F2 M3#M)IEI)JK<\H0A.7E3EU\9>6GY(6)"R%A$1!,4M.V^A<|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|%O$'!GY3Y5-GIR+H/)<;N-,OXLNXOLU8 QM[%V6E1B-5' MP>=YTPR3<6V:%O[I[S*+U8<7?\KR?6ORKY@K\9F]SQUD?W7(#(^?9%1 M$UAK 46Q$OL&13FR"!M.*"\-ETUOP-&7R MV4G!TALZM0?]'7X|/F49K81Y:,$1V;2_LI17>=*.NH.%:$9MVE|@>MVX/0?: M6%RF;.G22=/5\VG=#&S#1FTN<-A';NO+CV ^#O,C@&%Q, 68C_/"XOQ/\QF@ M\W$8IFW@10:HSP#U<5X^9%+?6!R_3V(O_TR3)(KB&%O1R<2K8(*M6QS#Q\^& M:0,/+*

Y$ ^K.UQK.-5|CA.L!R>]A"L)GBE8C-%%]K0/SK!AY)XL|V%@<|L"Q@ MM0/Q_7&@IOP^4019Q;1A;S",) F&0"WZ:S2.D=6)X?;G!WM+HBA)_ A@?@51 MA"'P-N((I@ T8$@4U?O@WGX4KO>I-8?20$3;8T.P6BP^0"X99K>]9!:G=E;:; &EGIIJ,1,%MK66 !5)MGU84G,8J@NBZ)_+/IFG58K+6>GLYG:IJS3>E^KW;\A;NK#JY*34D MY>-4;24O:[7F7&^;J3N;74PWI6@G7[|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|=U*=;O>&Y^/OR|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end XML 61 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)? w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent) {a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 62 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 64 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.3 html1241881false330false5 falsefalseR1.htm995200090 - Document - Document and Entity InformationSheethttp://www.tapimmune.com/role/DocumentDocumentAndEntityInformationDocument and Entity InformationCover1 falsefalseR2.htm995200100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETSSheethttp://www.tapimmune.com/role/StatementCondensedConsolidatedBalanceSheetsCONDENSED CONSOLIDATED BALANCE SHEETSStatements2 falsefalseR3.htm995200105 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)Sheethttp://www.tapimmune.com/role/StatementCondensedConsolidatedBalanceSheetsParentheticalCONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)Statements3 falsefalseR4.htm995200200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONSSheethttp://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfOperationsCONDENSED CONSOLIDATED STATEMENTS OF OPERATIONSStatements4 falsefalseR5.htm995200300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITYSheethttp://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityCONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITYStatements5 falsefalseR6.htm995200400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWSSheethttp://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWSStatements6 falsefalseR7.htm995210101 - Disclosure - NATURE OF OPERATIONSSheethttp://www.tapimmune.com/role/DisclosureNatureOfOperationsNATURE OF OPERATIONSNotes7 falsefalseR8.htm995210201 - Disclosure - BASIS OF PRESENTATIONSheethttp://www.tapimmune.com/role/DisclosureBasisOfPresentationBASIS OF PRESENTATIONNotes8 falsefalseR9.htm995210301 - Disclosure - LIQUIDITY AND FINANCIAL CONDITIONSheethttp://www.tapimmune.com/role/DisclosureLiquidityAndFinancialConditionLIQUIDITY AND FINANCIAL CONDITIONNotes9 falsefalseR10.htm995210401 - Disclosure - SIGNIFICANT ACCOUNTING POLICIESSheethttp://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesSIGNIFICANT ACCOUNTING POLICIESNotes10 falsefalseR11.htm995210501 - Disclosure - NET LOSS PER SHARESheethttp://www.tapimmune.com/role/DisclosureNetLossPerShareNET LOSS PER SHARENotes11 falsefalseR12.htm995210601 - Disclosure - OTHER RECEIVABLESheethttp://www.tapimmune.com/role/DisclosureOtherReceivableOTHER RECEIVABLENotes12 falsefalseR13.htm995210701 - Disclosure - DISCONTINUED OPERATIONSSheethttp://www.tapimmune.com/role/DisclosureDiscontinuedOperationsDISCONTINUED OPERATIONSNotes13 falsefalseR14.htm995210801 - Disclosure - ACCOUNTS PAYABLE, ACCRUED LIABILITIES AND RELATED PARTY PAYABLESheethttp://www.tapimmune.com/role/DisclosureAccountsPayableAccruedLiabilitiesAndRelatedPartyPayableACCOUNTS PAYABLE, ACCRUED LIABILITIES AND RELATED PARTY PAYABLENotes14 falsefalseR15.htm995210901 - Disclosure - STOCKHOLDERS' EQUITYSheethttp://www.tapimmune.com/role/DisclosureStockholdersEquitySTOCKHOLDERS' EQUITYNotes15 falsefalseR16.htm995211001 - Disclosure - STOCK-BASED COMPENSATIONSheethttp://www.tapimmune.com/role/DisclosureStockBasedCompensationSTOCK-BASED COMPENSATIONNotes16 falsefalseR17.htm995211101 - Disclosure - GRANT INCOMESheethttp://www.tapimmune.com/role/DisclosureGrantIncomeGRANT INCOMENotes17 falsefalseR18.htm995211201 - Disclosure - LEGAL PROCEEDINGSSheethttp://www.tapimmune.com/role/DisclosureLegalProceedingsLEGAL PROCEEDINGSNotes18 falsefalseR19.htm995211301 - Disclosure - RELATED PARTY EXPENSESSheethttp://www.tapimmune.com/role/DisclosureRelatedPartyExpensesRELATED PARTY EXPENSESNotes19 falsefalseR20.htm995211401 - Disclosure - SUBSEQUENT EVENTSSheethttp://www.tapimmune.com/role/DisclosureSubsequentEventsSUBSEQUENT EVENTSNotes20 falsefalseR21.htm995410 - Disclosure - Pay vs Performance DisclosureSheethttp://xbrl.sec.gov/ecd/role/PvpDisclosurePay vs Performance DisclosureNotes21 falsefalseR22.htm995445 - Disclosure - Insider Trading ArrangementsSheethttp://xbrl.sec.gov/ecd/role/InsiderTradingArrangementsInsider Trading ArrangementsNotes22 falsefalseR23.htm99920402 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)Sheethttp://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesPoliciesSIGNIFICANT ACCOUNTING POLICIES (Policies)Policies23 falsefalseR24.htm99930503 - Disclosure - NET LOSS PER SHARE (Tables)Sheethttp://www.tapimmune.com/role/DisclosureNetLossPerShareTablesNET LOSS PER SHARE (Tables)Tableshttp://www.tapimmune.com/role/DisclosureNetLossPerShare24 falsefalseR25.htm99930703 - Disclosure - DISCONTINUED OPERATIONS (Tables)Sheethttp://www.tapimmune.com/role/DisclosureDiscontinuedOperationsTablesDISCONTINUED OPERATIONS (Tables)Tableshttp://www.tapimmune.com/role/DisclosureDiscontinuedOperations25 falsefalseR26.htm99930803 - Disclosure - ACCOUNTS PAYABLE, ACCRUED LIABILITIES AND RELATED PARTY PAYABLE (Tables)Sheethttp://www.tapimmune.com/role/DisclosureAccountsPayableAccruedLiabilitiesAndRelatedPartyPayableTablesACCOUNTS PAYABLE, ACCRUED LIABILITIES AND RELATED PARTY PAYABLE (Tables)Tableshttp://www.tapimmune.com/role/DisclosureAccountsPayableAccruedLiabilitiesAndRelatedPartyPayable26

falsefalseR27.htm99931003 - Disclosure - STOCK BASED COMPENSATION (Tables)Sheethttp://www.tapimmune.com/role/DisclosureStockBasedCompensationTablesSTOCK BASED COMPENSATION (Tables)Tables27 falsefalseR28.htm99931303 - Disclosure - RELATED PARTY EXPENSES (Tables)Sheethttp://www.tapimmune.com/role/DisclosureRelatedPartyExpensesTablesRELATED PARTY EXPENSES (Tables)Tableshttp://www.tapimmune.com/role/DisclosureRelatedPartyExpenses28 falsefalseR29.htm99940101 - Disclosure - NATURE OF OPERATIONS (Details)Sheethttp://www.tapimmune.com/role/DisclosureNatureOfOperationsDetailsNATURE OF OPERATIONS (Details)Detailshttp://www.tapimmune.com/role/DisclosureNatureOfOperations29 falsefalseR30.htm99940301 - Disclosure - LIQUIDITY AND FINANCIAL CONDITION (Details)Sheethttp://www.tapimmune.com/role/DisclosureLiquidityAndFinancialConditionDetailsLIQUIDITY AND FINANCIAL CONDITION (Details)Detailshttp://www.tapimmune.com/role/DisclosureLiquidityAndFinancialCondition30 falsefalseR31.htm99940401 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)Sheethttp://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesDetailsSIGNIFICANT ACCOUNTING POLICIES (Details)Detailshttp://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesPolicies31 falsefalseR32.htm99940501 - Disclosure - NET LOSS PER SHARE - Computation of loss per Share (Details)Sheethttp://www.tapimmune.com/role/DisclosureNetLossPerShareComputationOfLossPerShareDetailsNET LOSS PER SHARE - Computation of loss per Share (Details)Details32 falsefalseR33.htm99940502 - Disclosure - NET LOSS PER SHARE - Dilutive Securities (Details)Sheethttp://www.tapimmune.com/role/DisclosureNetLossPerShareDilutiveSecuritiesDetailsNET LOSS PER SHARE - Dilutive Securities (Details)Details33 falsefalseR34.htm99940601 - Disclosure - OTHER RECEIVABLE (Details)Sheethttp://www.tapimmune.com/role/DisclosureOtherReceivableDetailsOTHER RECEIVABLE (Details)Detailshttp://www.tapimmune.com/role/DisclosureOtherReceivable34 falsefalseR35.htm99940701 - Disclosure - DISCONTINUED OPERATIONS - Operations (Details)Sheethttp://www.tapimmune.com/role/DisclosureDiscontinuedOperationsOperationsDetailsDISCONTINUED OPERATIONS - Operations (Details)Details35 falsefalseR36.htm99940702 - Disclosure - DISCONTINUED OPERATIONS - Cash Flows (Details)Sheethttp://www.tapimmune.com/role/DisclosureDiscontinuedOperationsCashFlowsDetailsDISCONTINUED OPERATIONS - Cash Flows (Details)Details36 falsefalseR37.htm99940703 - Disclosure - DISCONTINUED OPERATIONS - Additional Information (Details)Sheethttp://www.tapimmune.com/role/DisclosureDiscontinuedOperationsAdditionalInformationDetailsDISCONTINUED OPERATIONS - Additional Information (Details)Details37 falsefalseR38.htm99940801 - Disclosure - ACCOUNTS PAYABLE, ACCRUED LIABILITIES AND RELATED PARTY PAYABLE (Details)Sheethttp://www.tapimmune.com/role/DisclosureAccountsPayableAccruedLiabilitiesAndRelatedPartyPayableDetailsACCOUNTS PAYABLE, ACCRUED LIABILITIES AND RELATED PARTY PAYABLE (Details)Detailshttp://www.tapimmune.com/role/DisclosureAccountsPayableAccruedLiabilitiesAndRelatedPartyPayableTables38 falsefalseR39.htm99940901 - Disclosure - STOCKHOLDERS' EQUITY - Reverse Stock Split And ATM Agreement (Details)Sheethttp://www.tapimmune.com/role/DisclosureStockholdersEquityReverseStockSplitAndAtmAgreementDetailsSTOCKHOLDERS' EQUITY - Reverse Stock Split And ATM Agreement (Details)Details39 falsefalseR40.htm99940902 - Disclosure - STOCKHOLDERS' EQUITY - Stock Purchase Agreement And Exercise of Stock Options (Details)Sheethttp://www.tapimmune.com/role/DisclosureStockholdersEquityStockPurchaseAgreementAndExerciseOfStockOptionsDetailsSTOCKHOLDERS' EQUITY - Stock Purchase Agreement And Exercise of Stock Options (Details)Details40 falsefalseR41.htm99941001 - Disclosure - STOCK-BASED COMPENSATION - Stock option activity (Details)Sheethttp://www.tapimmune.com/role/DisclosureStockBasedCompensationStockOptionActivityDetailsSTOCK-BASED COMPENSATION - Stock option activity (Details)Details41 falsefalseR42.htm99941002 - Disclosure - STOCK-BASED COMPENSATION - Stock-based compensation expenses (Details)Sheethttp://www.tapimmune.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpensesDetailsSTOCK-BASED COMPENSATION - Stock-based compensation expenses (Details)Details42 falsefalseR43.htm99941003 - Disclosure - STOCK-BASED COMPENSATION - Additional Information (Details)Sheethttp://www.tapimmune.com/role/DisclosureStockBasedCompensationAdditionalInformationDetailsSTOCK-BASED COMPENSATION - Additional Information (Details)Details43 falsefalseR44.htm99941101 - Disclosure - GRANT INCOME (Details)Sheethttp://www.tapimmune.com/role/DisclosureGrantIncomeDetailsGRANT INCOME (Details)Detailshttp://www.tapimmune.com/role/DisclosureGrantIncome44 falsefalseR45.htm99941301 - Disclosure - RELATED PARTY EXPENSES (Details)Sheethttp://www.tapimmune.com/role/DisclosureRelatedPartyExpensesDetailsRELATED PARTY EXPENSES (Details)Detailshttp://www.tapimmune.com/role/DisclosureRelatedPartyExpensesTables45 falsefalseAll ReportsBookAll Reports mrkr-20240930.xsdmrkr-20240930_cal.xmlmrkr-20240930_def.xmlmrkr-20240930_lab.xmlmrkr-20240930_pre.xmlmrkr-20240930x10q.htm mrkr-20240930x10q001.jpgmrkr-20240930x10q002.jpgmrkr-20240930x10q003.jpg http://fasb.org/us-gaap/2024http://xbrl.sec.gov/dei/2024http://xbrl.sec.gov/ecd/2024truetrue JSON 67 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "mrkr-20240930x10q.htm": { "nsprefix": "mrkr", "nsuri": "http://www.tapimmune.com/20240930", "dts": { "schema": { "local": ["mrkr-20240930.xsd"], "remote": ["http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/2023/calculation-1.1.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"] }, "calculationLink": { "local": ["mrkr-20240930_cal.xml"] }, "definitionLink": { "local": ["mrkr-20240930_def.xml"] }, "labelLink": { "local": ["mrkr-20240930_lab.xml"] }, "presentationLink": { "local": ["mrkr-20240930_pre.xml"] }, "inline": { "local": ["mrkr-20240930x10q.htm"] } }, "keyStandard": 159, "keyCustom": 29, "axisStandard": 13, "axisCustom": 0, "memberStandard": 14, "memberCustom": 17, "hidden": { "total": 10, "http://xbrl.sec.gov/dei/2024": 5, "http://fasb.org/us-gaap/2024": 5 }, "contextCount": 124, "entityCount": 1, "segmentCount": 33, "elementCount": 409, "unitCount": 5, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 419, "http://xbrl.sec.gov/dei/2024": 29, "http://xbrl.sec.gov/ecd/2024": 4 }, "report": { "R1": { "role": "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation", "longName": "995200090 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_p6qUqANBPkuM1y-o6OxPPg", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "mrkr-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_p6qUqANBPkuM1y-o6OxPPg", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "mrkr-20240930x10q.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.tapimmune.com/role/StatementCondensedConsolidatedBalanceSheets", "longName": "995200100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "As_Of_9_30_2024_S-gRu4_PtE-ao1jNFwcW0Q", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "Unit_Standard_USD_DU7chW01skKAkcvxiCqo5w", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "mrkr-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_S-gRu4_PtE-ao1jNFwcW0Q", "name": "us-gaap:PrepaidExpenseCurrent", "unitRef": "Unit_Standard_USD_DU7chW01skKAkcvxiCqo5w", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "mrkr-20240930x10q.htm", "unique": true } }, "R3": { "role": "http://www.tapimmune.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical", "longName": "995200105 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "As_Of_9_30_2024_S-gRu4_PtE-ao1jNFwcW0Q", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "Unit_Divide_USD_shares_0wgl5f82Lk-ADiiHl3mZOw", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "mrkr-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_S-gRu4_PtE-ao1jNFwcW0Q", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "Unit_Divide_USD_shares_0wgl5f82Lk-ADiiHl3mZOw", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "mrkr-20240930x10q.htm", "first": true, "unique": true } }, "R4": { "role": "http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations", "longName": "995200200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_8iASascTdkqxi7dbg6Y8ww", "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "unitRef": "Unit_Standard_USD_DU7chW01skKAkcvxiCqo5w", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "mrkr-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_8iASascTdkqxi7dbg6Y8ww", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "Unit_Standard_USD_DU7chW01skKAkcvxiCqo5w", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "td", "tr", "table", "div", "div",

"div", "body", "html"], "reportCount": 1, "baseRef": "mrkr-20240930x10q.htm", "unique": true } }, "R5": { "role": "http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity", "longName": "995200300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_tutvTyl4_UWDHV2QTpfH2w", "name": "us-gaap:StockholdersEquity", "unitRef": "Unit_Standard_USD_DU7chW01skKAkcvxiCqo5w", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["b", "p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "mrkr-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_tutvTyl4_UWDHV2QTpfH2w", "name": "us-gaap:StockholdersEquity", "unitRef": "Unit_Standard_USD_DU7chW01skKAkcvxiCqo5w", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["b", "p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "mrkr-20240930x10q.htm", "first": true, "unique": true } }, "R6": { "role": "http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "longName": "995200400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_p6qUqANBPkuM1y-o6OxPPg", "name": "us-gaap:ProfitLoss", "unitRef": "Unit_Standard_USD_DU7chW01skKAkcvxiCqo5w", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "mrkr-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_p6qUqANBPkuM1y-o6OxPPg", "name": "us-gaap:ProfitLoss", "unitRef": "Unit_Standard_USD_DU7chW01skKAkcvxiCqo5w", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "mrkr-20240930x10q.htm", "first": true, "unique": true } }, "R7": { "role": "http://www.tapimmune.com/role/DisclosureNatureOfOperations", "longName": "995210101 - Disclosure - NATURE OF OPERATIONS", "shortName": "NATURE OF OPERATIONS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_p6qUqANBPkuM1y-o6OxPPg", "name": "us-gaap:NatureOfOperations", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "mrkr-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_p6qUqANBPkuM1y-o6OxPPg", "name": "us-gaap:NatureOfOperations", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "mrkr-20240930x10q.htm", "first": true, "unique": true } }, "R8": { "role": "http://www.tapimmune.com/role/DisclosureBasisOfPresentation", "longName": "995210201 - Disclosure - BASIS OF PRESENTATION", "shortName": "BASIS OF PRESENTATION", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_p6qUqANBPkuM1y-o6OxPPg", "name": "us-gaap:BasisOfAccounting", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "mrkr-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_p6qUqANBPkuM1y-o6OxPPg", "name": "us-gaap:BasisOfAccounting", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "mrkr-20240930x10q.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.tapimmune.com/role/DisclosureLiquidityAndFinancialCondition", "longName": "995210301 - Disclosure - LIQUIDITY AND FINANCIAL CONDITION", "shortName": "LIQUIDITY AND FINANCIAL CONDITION", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_p6qUqANBPkuM1y-o6OxPPg", "name": "mrkr:LiquidityFinancialConditionAndGoingConcernTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "mrkr-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_p6qUqANBPkuM1y-o6OxPPg", "name": "mrkr:LiquidityFinancialConditionAndGoingConcernTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "mrkr-20240930x10q.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.tapimmune.com/role/DisclosureSignificantAccountingPolicies", "longName": "995210401 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES", "shortName": "SIGNIFICANT ACCOUNTING POLICIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_p6qUqANBPkuM1y-o6OxPPg", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "mrkr-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_p6qUqANBPkuM1y-o6OxPPg", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "mrkr-20240930x10q.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.tapimmune.com/role/DisclosureNetLossPerShare", "longName": "995210501 - Disclosure - NET LOSS PER SHARE", "shortName": "NET LOSS PER SHARE", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_p6qUqANBPkuM1y-o6OxPPg", "name": "us-gaap:MinorityInterestDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "mrkr-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_p6qUqANBPkuM1y-o6OxPPg", "name": "us-gaap:MinorityInterestDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "mrkr-20240930x10q.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.tapimmune.com/role/DisclosureOtherReceivable", "longName": "995210601 - Disclosure - OTHER RECEIVABLE", "shortName": "OTHER RECEIVABLE", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_p6qUqANBPkuM1y-o6OxPPg", "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "mrkr-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_p6qUqANBPkuM1y-o6OxPPg", "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "mrkr-20240930x10q.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.tapimmune.com/role/DisclosureDiscontinuedOperations", "longName": "995210701 - Disclosure - DISCONTINUED OPERATIONS", "shortName": "DISCONTINUED OPERATIONS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_p6qUqANBPkuM1y-o6OxPPg", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "mrkr-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_p6qUqANBPkuM1y-o6OxPPg", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "mrkr-20240930x10q.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.tapimmune.com/role/DisclosureAccountsPayableAccruedLiabilitiesAndRelatedPartyPayable", "longName": "995210801 - Disclosure - ACCOUNTS PAYABLE, ACCRUED LIABILITIES AND RELATED PARTY PAYABLE", "shortName": "ACCOUNTS PAYABLE, ACCRUED LIABILITIES AND RELATED PARTY PAYABLE", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_p6qUqANBPkuM1y-o6OxPPg", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "mrkr-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_p6qUqANBPkuM1y-o6OxPPg", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "mrkr-20240930x10q.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.tapimmune.com/role/DisclosureStockholdersEquity", "longName": "995210901 - Disclosure - STOCKHOLDERS' EQUITY", "shortName": "STOCKHOLDERS' EQUITY", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_p6qUqANBPkuM1y-o6OxPPg", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "mrkr-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_p6qUqANBPkuM1y-o6OxPPg", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "mrkr-20240930x10q.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.tapimmune.com/role/DisclosureStockBasedCompensation", "longName": "995211001 - Disclosure - STOCK-BASED COMPENSATION", "shortName": "STOCK-BASED COMPENSATION", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_p6qUqANBPkuM1y-o6OxPPg", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "mrkr-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_p6qUqANBPkuM1y-o6OxPPg", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "mrkr-20240930x10q.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.tapimmune.com/role/DisclosureGrantIncome", "longName": "995211101 - Disclosure - GRANT INCOME", "shortName": "GRANT INCOME", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_p6qUqANBPkuM1y-o6OxPPg", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef":

null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "mrkr-20240930x10q.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_p6qUqANBPkuM1y-o6OxPPg", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "mrkr-20240930x10q.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.tapimmune.com/role/DisclosureLegalProceedings", "longName": "995211201 - Disclosure - LEGAL PROCEEDINGS", "shortName": "LEGAL PROCEEDINGS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_p6qUqANBPkuM1y-o6OxPPg", "name": "us-gaap:LegalMattersAndContingenciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "mrkr-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_p6qUqANBPkuM1y-o6OxPPg", "name": "us-gaap:LegalMattersAndContingenciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "mrkr-20240930x10q.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.tapimmune.com/role/DisclosureRelatedPartyExpenses", "longName": "995211301 - Disclosure - RELATED PARTY EXPENSES", "shortName": "RELATED PARTY EXPENSES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_p6qUqANBPkuM1y-o6OxPPg", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "mrkr-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_p6qUqANBPkuM1y-o6OxPPg", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "mrkr-20240930x10q.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.tapimmune.com/role/DisclosureSubsequentEvents", "longName": "995211401 - Disclosure - SUBSEQUENT EVENTS", "shortName": "SUBSEQUENT EVENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_p6qUqANBPkuM1y-o6OxPPg", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "mrkr-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_p6qUqANBPkuM1y-o6OxPPg", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "mrkr-20240930x10q.htm", "first": true, "unique": true } }, "R21": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_8iASascTdkqxi7dbg6Y8ww", "name": "us-gaap:NetIncomeLoss", "unitRef": "Unit_Standard_USD_DU7chW01skKAkcvxiCqo5w", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["b", "p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "mrkr-20240930x10q.htm", "first": true }, "uniqueAnchor": null }, "R22": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_8iASascTdkqxi7dbg6Y8ww", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "mrkr-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_8iASascTdkqxi7dbg6Y8ww", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "mrkr-20240930x10q.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesPolicies", "longName": "99920402 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)", "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "23", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_p6qUqANBPkuM1y-o6OxPPg", "name": "us-gaap:ConsolidationPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "mrkr-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_p6qUqANBPkuM1y-o6OxPPg", "name": "us-gaap:ConsolidationPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "mrkr-20240930x10q.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.tapimmune.com/role/DisclosureNetLossPerShareTables", "longName": "99930503 - Disclosure - NET LOSS PER SHARE (Tables)", "shortName": "NET LOSS PER SHARE (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "24", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_p6qUqANBPkuM1y-o6OxPPg", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:MinorityInterestDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "mrkr-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_p6qUqANBPkuM1y-o6OxPPg", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:MinorityInterestDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "mrkr-20240930x10q.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.tapimmune.com/role/DisclosureDiscontinuedOperationsTables", "longName": "99930703 - Disclosure - DISCONTINUED OPERATIONS (Tables)", "shortName": "DISCONTINUED OPERATIONS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_p6qUqANBPkuM1y-o6OxPPg", "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "mrkr-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_p6qUqANBPkuM1y-o6OxPPg", "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "mrkr-20240930x10q.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.tapimmune.com/role/DisclosureAccountsPayableAccruedLiabilitiesAndRelatedPartyPayableTables", "longName": "99930803 - Disclosure - ACCOUNTS PAYABLE, ACCRUED LIABILITIES AND RELATED PARTY PAYABLE (Tables)", "shortName": "ACCOUNTS PAYABLE, ACCRUED LIABILITIES AND RELATED PARTY PAYABLE (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_p6qUqANBPkuM1y-o6OxPPg", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "mrkr-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_p6qUqANBPkuM1y-o6OxPPg", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "mrkr-20240930x10q.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.tapimmune.com/role/DisclosureStockBasedCompensationTables", "longName": "99931003 - Disclosure - STOCK BASED COMPENSATION (Tables)", "shortName": "STOCK BASED COMPENSATION (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_p6qUqANBPkuM1y-o6OxPPg", "name": "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "mrkr-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_p6qUqANBPkuM1y-o6OxPPg", "name": "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "mrkr-20240930x10q.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.tapimmune.com/role/DisclosureRelatedPartyExpensesTables", "longName": "99931303 - Disclosure - RELATED PARTY EXPENSES (Tables)", "shortName": "RELATED PARTY EXPENSES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_p6qUqANBPkuM1y-o6OxPPg", "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "mrkr-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_p6qUqANBPkuM1y-o6OxPPg", "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "mrkr-20240930x10q.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.tapimmune.com/role/DisclosureNatureOfOperationsDetails", "longName": "99940101 -

Disclosure - NATURE OF OPERATIONS (Details)", "shortName": "NATURE OF OPERATIONS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "29", "firstAnchor": { "contextRef": "Duration_1_26_2023_To_1_26_2023_oq4tKd8XTE-uIYhD8U3bBQ", "name": "us-gaap:StockholdersEquityReverseStockSplit", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "mrkr-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_26_2023_To_1_26_2023_oq4tKd8XTE-uIYhD8U3bBQ", "name": "us-gaap:StockholdersEquityReverseStockSplit", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "mrkr-20240930x10q.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.tapimmune.com/role/DisclosureLiquidityAndFinancialConditionDetails", "longName": "99940301 - Disclosure - LIQUIDITY AND FINANCIAL CONDITION (Details)", "shortName": "LIQUIDITY AND FINANCIAL CONDITION (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "30", "firstAnchor": { "contextRef": "As_Of_9_30_2024_S-gRu4_PtE-ao1jNFwcW0Q", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "Unit_Standard_USD_DU7chW01skKAkcvxiCqo5w", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "mrkr-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_8_1_2021_To_8_31_2021_HXzqb9AI8EWxB_GHKY3y9g", "name": "us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned", "unitRef": "Unit_Standard_USD_DU7chW01skKAkcvxiCqo5w", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "mrkr-20240930x10q.htm", "unique": true } }, "R31": { "role": "http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesDetails", "longName": "99940401 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)", "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "As_Of_9_30_2024_S-gRu4_PtE-ao1jNFwcW0Q", "name": "mrkr:CashAtFinancialInstitutions", "unitRef": "Unit_Standard_USD_DU7chW01skKAkcvxiCqo5w", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "mrkr-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_S-gRu4_PtE-ao1jNFwcW0Q", "name": "mrkr:CashAtFinancialInstitutions", "unitRef": "Unit_Standard_USD_DU7chW01skKAkcvxiCqo5w", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "mrkr-20240930x10q.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.tapimmune.com/role/DisclosureNetLossPerShareComputationOfLossPerShareDetails", "longName": "99940501 - Disclosure - NET LOSS PER SHARE - Computation of loss per Share (Details)", "shortName": "NET LOSS PER SHARE - Computation of loss per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_8iASascTdkqxi7dbg6Y8ww", "name": "us-gaap:IncomeLossFromContinuingOperations", "unitRef": "Unit_Standard_USD_DU7chW01skKAkcvxiCqo5w", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "mrkr-20240930x10q.htm", "first": true }, "uniqueAnchor": null }, "R33": { "role": "http://www.tapimmune.com/role/DisclosureNetLossPerShareDilutiveSecuritiesDetails", "longName": "99940502 - Disclosure - NET LOSS PER SHARE - Dilutive Securities (Details)", "shortName": "NET LOSS PER SHARE - Dilutive Securities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_8iASascTdkqxi7dbg6Y8ww", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Unit_Standard_shares_HGz2sEx03E-8NqJ8jkE_6g", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "td", "tr", "table", "mrkr:NetLossPerShareTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "mrkr-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_8iASascTdkqxi7dbg6Y8ww", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Unit_Standard_shares_HGz2sEx03E-8NqJ8jkE_6g", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "td", "tr", "table", "mrkr:NetLossPerShareTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "mrkr-20240930x10q.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.tapimmune.com/role/DisclosureOtherReceivableDetails", "longName": "99940601 - Disclosure - OTHER RECEIVABLE (Details)", "shortName": "OTHER RECEIVABLE (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_8iASascTdkqxi7dbg6Y8ww", "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "unitRef": "Unit_Standard_USD_DU7chW01skKAkcvxiCqo5w", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "mrkr-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_srt_ProductOrServiceAxis_mrkr_FdaGrantMember_JS6Q6fsN00W5GzgKrIFc2g", "name": "mrkr:RevenueFromOrphanProductsGrantProgram", "unitRef": "Unit_Standard_USD_DU7chW01skKAkcvxiCqo5w", "xsiNil": "false", "lang": null, "decimals": "-4", "ancestors": ["p", "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "mrkr-20240930x10q.htm", "unique": true } }, "R35": { "role": "http://www.tapimmune.com/role/DisclosureDiscontinuedOperationsOperationsDetails", "longName": "99940701 - Disclosure - DISCONTINUED OPERATIONS - Operations (Details)", "shortName": "DISCONTINUED OPERATIONS - Operations (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_KIjWWbz6wUObHw0P-L3nnQ", "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue", "unitRef": "Unit_Standard_USD_DU7chW01skKAkcvxiCqo5w", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "mrkr-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_KIjWWbz6wUObHw0P-L3nnQ", "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue", "unitRef": "Unit_Standard_USD_DU7chW01skKAkcvxiCqo5w", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "mrkr-20240930x10q.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.tapimmune.com/role/DisclosureDiscontinuedOperationsCashFlowsDetails", "longName": "99940702 - Disclosure - DISCONTINUED OPERATIONS - Cash Flows (Details)", "shortName": "DISCONTINUED OPERATIONS - Cash Flows (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_KIjWWbz6wUObHw0P-L3nnQ", "name": "us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations", "unitRef": "Unit_Standard_USD_DU7chW01skKAkcvxiCqo5w", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "mrkr-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_us-gaap_DisposalGroupClassificationAxis_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_islUPw7w4kavtCHTJvebRg", "name": "us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations", "unitRef": "Unit_Standard_USD_DU7chW01skKAkcvxiCqo5w", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "td", "tr", "table", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "mrkr-20240930x10q.htm", "unique": true } }, "R37": { "role": "http://www.tapimmune.com/role/DisclosureDiscontinuedOperationsAdditionalInformationDetails", "longName": "99940703 - Disclosure - DISCONTINUED OPERATIONS - Additional Information (Details)", "shortName": "DISCONTINUED OPERATIONS - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_8iASascTdkqxi7dbg6Y8ww", "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "unitRef": "Unit_Standard_USD_DU7chW01skKAkcvxiCqo5w", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "mrkr-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_4_1_2022_To_4_30_2022_srt_ProductOrServiceAxis_mrkr_RelatedPartyServiceMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_WilsonWolfManufacturingCorporationMember_us-gaap_TypeOfArrangementAxis_mrkr_BindingServicesAgreementMember_ywqFsFOAuU-msspnmXgzug", "name": "mrkr:CashPayment", "unitRef": "Unit_Standard_USD_DU7chW01skKAkcvxiCqo5w", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "mrkr-20240930x10q.htm", "unique": true } }, "R38": { "role": "http://www.tapimmune.com/role/DisclosureAccountsPayableAccruedLiabilitiesAndRelatedPartyPayableDetails", "longName": "99940801 - Disclosure - ACCOUNTS PAYABLE, ACCRUED LIABILITIES AND RELATED PARTY PAYABLE (Details)", "shortName": "ACCOUNTS PAYABLE, ACCRUED LIABILITIES AND RELATED PARTY PAYABLE (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "As_Of_9_30_2024_S-gRu4_PtE-ao1jNFwcW0Q", "name": "us-gaap:AccountsPayableCurrent", "unitRef": "Unit_Standard_USD_DU7chW01skKAkcvxiCqo5w", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "mrkr-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_S-gRu4_PtE-ao1jNFwcW0Q", "name": "us-gaap:AccountsPayableCurrent", "unitRef": "Unit_Standard_USD_DU7chW01skKAkcvxiCqo5w", "xsiNil": "false", "lang": null, "decimals": "0",

```
"ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrkr-20240930x10q.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.tapimmune.com/role/DisclosureStockholdersEquityReverseStockSplitAndAtmAgreementDetails", "longName": "99940901 - Disclosure - STOCKHOLDERS' EQUITY - Reverse Stock Split And ATM Agreement (Details)", "shortName": "STOCKHOLDERS' EQUITY - Reverse Stock Split And ATM Agreement (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "As_Of_9_30_2024_S-gRu4_PtE-ao1jNFwcW0Q", "name": "us-gaap:CommonStockSharesAuthorized", "unitRef": "Unit_Standard_shares_HGz2sEx03E-8NqJ8jkE_6g", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrkr-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_us-gaap_SubsidiarySaleOfStockAxis_mrkr_AtmAgreementMember_IfwWO47Nuk2kgLuMb88DOQ", "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "unitRef": "Unit_Standard_shares_HGz2sEx03E-8NqJ8jkE_6g", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrkr-20240930x10q.htm", "unique": true } }, "R40": { "role": "http://www.tapimmune.com/role/DisclosureStockholdersEquityStockPurchaseAgreementAndExerciseOfStockOptionsDetails", "longName": "99940902 - Disclosure - STOCKHOLDERS' EQUITY - Stock Purchase Agreement And Exercise of Stock Options (Details)", "shortName": "STOCKHOLDERS' EQUITY - Stock Purchase Agreement And Exercise of Stock Options (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_9_30_2023_7hNVwOlwGUqzvW_EIx2k5w", "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues", "unitRef": "Unit_Standard_USD_DU7chW01skKAkcvxiCqo5w", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrkr-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_12_1_2022_To_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_LincolnParkMember_us-gaap_SubsidiarySaleOfStockAxis_mrkr_StockPurchaseAgreementMember_TmWG-EVMw0OWEiZ5Pa-IQQ", "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues", "unitRef": "Unit_Standard_USD_DU7chW01skKAkcvxiCqo5w", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrkr-20240930x10q.htm", "unique": true } }, "R41": { "role": "http://www.tapimmune.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails", "longName": "99941001 - Disclosure - STOCK-BASED COMPENSATION - Stock option activity (Details)", "shortName": "STOCK-BASED COMPENSATION - Stock option activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_p6qUqANBPkuM1y-o6OxPPg", "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised", "unitRef": "Unit_Standard_shares_HGz2sEx03E-8NqJ8jkE_6g", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrkr-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_EmployeeStockOptionMember_2XeOhDjOdU2Zanigd5FQPg", "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised", "unitRef": "Unit_Standard_shares_HGz2sEx03E-8NqJ8jkE_6g", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrkr-20240930x10q.htm", "unique": true } }, "R42": { "role": "http://www.tapimmune.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpensesDetails", "longName": "99941002 - Disclosure - STOCK-BASED COMPENSATION - Stock-based compensation expenses (Details)", "shortName": "STOCK-BASED COMPENSATION - Stock-based compensation expenses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_8iASascTdkqxi7dbg6Y8ww", "name": "mrkr:StockCompensationInContinuingOperations", "unitRef": "Unit_Standard_USD_DU7chW01skKAkcvxiCqo5w", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "mrkr:StockBasedCompensationExpensesTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrkr-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_8iASascTdkqxi7dbg6Y8ww", "name": "mrkr:StockCompensationInContinuingOperations", "unitRef": "Unit_Standard_USD_DU7chW01skKAkcvxiCqo5w", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "mrkr:StockBasedCompensationExpensesTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrkr-20240930x10q.htm", "first": true, "unique": true } }, "R43": { "role": "http://www.tapimmune.com/role/DisclosureStockBasedCompensationAdditionalInformationDetails", "longName": "99941003 - Disclosure - STOCK-BASED COMPENSATION - Additional Information (Details)", "shortName": "STOCK-BASED COMPENSATION - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_8iASascTdkqxi7dbg6Y8ww", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod", "unitRef": "Unit_Standard_shares_HGz2sEx03E-8NqJ8jkE_6g", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrkr-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_8iASascTdkqxi7dbg6Y8ww", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod", "unitRef": "Unit_Standard_shares_HGz2sEx03E-8NqJ8jkE_6g", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrkr-20240930x10q.htm", "first": true, "unique": true } }, "R44": { "role": "http://www.tapimmune.com/role/DisclosureGrantIncomeDetails", "longName": "99941101 - Disclosure - GRANT INCOME (Details)", "shortName": "GRANT INCOME (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_8iASascTdkqxi7dbg6Y8ww", "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "unitRef": "Unit_Standard_USD_DU7chW01skKAkcvxiCqo5w", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrkr-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_8_1_2021_To_8_31_2021_srt_ProductOrServiceAxis_mrkr_CpritGrantMember_UpTB3OyY00-35kM0Z6kezA", "name": "mrkr:ReceiptOfProductDevelopmentResearchAward", "unitRef": "Unit_Standard_USD_DU7chW01skKAkcvxiCqo5w", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrkr-20240930x10q.htm", "unique": true } }, "R45": { "role": "http://www.tapimmune.com/role/DisclosureRelatedPartyExpensesDetails", "longName": "99941301 - Disclosure - RELATED PARTY EXPENSES (Details)", "shortName": "RELATED PARTY EXPENSES (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_8iASascTdkqxi7dbg6Y8ww", "name": "us-gaap:OperatingCostsAndExpenses", "unitRef": "Unit_Standard_USD_DU7chW01skKAkcvxiCqo5w", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrkr-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_8iASascTdkqxi7dbg6Y8ww", "name": "us-gaap:OperatingCostsAndExpenses", "unitRef": "Unit_Standard_USD_DU7chW01skKAkcvxiCqo5w", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrkr-20240930x10q.htm", "first": true, "unique": true } } }, "tag": { "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "SIGNIFICANT ACCOUNTING POLICIES" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "crdr": "credit", "presentation": [ "http://www.tapimmune.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accounts Payable and Accrued Liabilities, Current", "terseLabel": "Accounts payable and accrued liabilities", "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits." } } }, "auth_ref": [ "r54", "r55" ] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "presentation": [ "http://www.tapimmune.com/role/DisclosureAccountsPayableAccruedLiabilitiesAndRelatedPartyPayable" ], "lang": { "en-us": { "role": { "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]", "terseLabel": "ACCOUNTS PAYABLE, ACCRUED LIABILITIES AND RELATED PARTY PAYABLE", "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period." } } }, "auth_ref": [ "r53", "r55", "r58", "r601" ] }, "mrkr_AccountsPayableAndAccruedLiabilitiesIncludingRelatedPartyPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tapimmune.com/20240930", "localname": "AccountsPayableAndAccruedLiabilitiesIncludingRelatedPartyPayableCurrent", "crdr": "credit", "presentation": [ "http://www.tapimmune.com/role/DisclosureAccountsPayableAccruedLiabilitiesAndRelatedPartyPayableDetails" ], "lang": { "en-us": { "role": {
```

"documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Accounts Payable and Accrued Liabilities Including Related party payable, Current", "totalLabel": "Total accounts payable, accrued liabilities and related party payable" } } }, "auth_ref": [] }, "mrkr_AccountsPayableAndAccruedLiabilitiesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.tapimmune.com/20240930", "localname": "AccountsPayableAndAccruedLiabilitiesLineItems", "presentation": ["http://www.tapimmune.com/role/DisclosureAccountsPayableAccruedLiabilitiesAndRelatedPartyPayableDetails"], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Accounts Payable And Accrued Liabilities [Line Items]", "verboseLabel": "ACCOUNTS PAYABLE, ACCRUED LIABILITIES AND RELATED PARTY PAYABLE" } } }, "auth_ref": [] }, "mrkr_AccountsPayableAndAccruedLiabilitiesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.tapimmune.com/20240930", "localname": "AccountsPayableAndAccruedLiabilitiesTable", "presentation": ["http://www.tapimmune.com/role/DisclosureAccountsPayableAccruedLiabilitiesAndRelatedPartyPayableDetails"], "lang": { "en-us": { "role": { "documentation": "This table lists the accounts payable and accrued liabilities. The line items identify information about the accounts payable and accrued liabilities.", "label": "Accounts Payable And Accrued Liabilities [Table]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "presentation": ["http://www.tapimmune.com/role/DisclosureAccountsPayableAccruedLiabilitiesAndRelatedPartyPayableDetails"], "lang": { "en-us": { "role": { "label": "Accounts Payable, Current", "verboseLabel": "Accounts payable", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r53", "r468"] }, "us-gaap_AccruedProfessionalFeesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedProfessionalFeesCurrent", "crdr": "credit", "presentation": ["http://www.tapimmune.com/role/DisclosureAccountsPayableAccruedLiabilitiesAndRelatedPartyPayableDetails"], "lang": { "en-us": { "role": { "label": "Accrued Professional Fees, Current", "verboseLabel": "Professional fees", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r55"] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure [Text Block]", "terseLabel": "Additional 402(v) Disclosure" } } }, "auth_ref": ["r521"] }, "mrkr_AdditionalCashPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tapimmune.com/20240930", "localname": "AdditionalCashPayment", "crdr": "credit", "presentation": ["http://www.tapimmune.com/role/DisclosureDiscontinuedOperationsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "The amount of additional cash payment.", "label": "Additional cash payment", "terseLabel": "Additional cash payment" } } }, "auth_ref": [] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapital", "crdr": "credit", "presentation": ["http://www.tapimmune.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": ["r63", "r468", "r655"] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": ["http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in Capital", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": ["r371", "r581", "r582", "r583", "r584", "r603", "r656"] }, "mrkr_AdditionalRevenueRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tapimmune.com/20240930", "localname": "AdditionalRevenueRecognized", "crdr": "credit", "presentation": ["http://www.tapimmune.com/role/DisclosureDiscontinuedOperationsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "The amount of additional revenue recognized.", "label": "Additional Revenue Recognized", "terseLabel": "Additional revenue recognized" } } }, "auth_ref": [] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation Amount", "terseLabel": "Adjustment to Compensation, Amount" } } }, "auth_ref": ["r534"] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation [Axis]", "terseLabel": "Adjustment to Compensation:" } } }, "auth_ref": ["r534"] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]", "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote" } } }, "auth_ref": ["r534"] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeoCompFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment To PEO Compensation, Footnote [Text Block]", "terseLabel": "Adjustment To PEO Compensation, Footnote" } } }, "auth_ref": ["r534"] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": ["http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Reconciliation of net loss to net cash used in operating activities:" } } }, "auth_ref": [] }, "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table" } } }, "auth_ref": ["r567"] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount", "terseLabel": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": ["r493", "r503", "r513", "r545"] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]", "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined" } } }, "auth_ref": ["r496", "r506", "r516", "r548"] }, "ecd_AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtPnsnAdjsSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Pension Adjustments Service Cost [Member]", "terseLabel": "Aggregate Pension Adjustments Service Cost" } } }, "auth_ref": ["r568"] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "All Adjustments to Compensation [Member]", "terseLabel": "All Adjustments to Compensation" } } }, "auth_ref": ["r534"] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "All Executive Categories [Member]", "terseLabel": "All Executive Categories" } } }, "auth_ref": ["r541"] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "All Individuals [Member]", "terseLabel": "All Individuals" } } }, "auth_ref": ["r497", "r507", "r517", "r541", "r549", "r553", "r561"] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllTradingArrangementsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "All Trading Arrangements [Member]", "terseLabel": "All Trading Arrangements" } } }, "auth_ref": ["r559"] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": ["http://www.tapimmune.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpensesDetails"], "lang": { "en-us": { "role": { "label": "Allocated Share-based Compensation Expense", "verboseLabel": "Total stock compensation expenses", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": ["r257", "r262"] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": ["http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": ["http://www.tapimmune.com/role/DisclosureNetLossPerShareDilutiveSecuritiesDetails"], "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Potentially dilutive securities", "documentation": "Securities

(including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": ["r159"] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": ["http://www.tapimmune.com/role/DisclosureNetLossPerShareDilutiveSecuritiesDetails"], "lang": { "en-us": { "role": { "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": ["r16"] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": ["http://www.tapimmune.com/role/DisclosureNetLossPerShareDilutiveSecuritiesDetails"], "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "NET LOSS PER SHARE", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": ["http://www.tapimmune.com/role/DisclosureNetLossPerShareDilutiveSecuritiesDetails"], "lang": { "en-us": { "role": { "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": ["r16"] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": ["http://www.tapimmune.com/role/DisclosureDiscontinuedOperationsAdditionalInformationDetails", "http://www.tapimmune.com/role/DisclosureLiquidityAndFinancialConditionDetails", "http://www.tapimmune.com/role/DisclosureNatureOfOperationsDetails", "http://www.tapimmune.com/role/DisclosureRelatedPartyExpensesDetails"], "lang": { "en-us": { "role": { "label": "Arrangements and Non-arrangement Transactions [Domain]", "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": ["r276"] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "presentation": ["http://www.tapimmune.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Assets", "totalLabel": "Total assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": ["r93", "r100", "r114", "r132", "r161", "r164", "r169", "r170", "r175", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r278", "r282", "r298", "r331", "r395", "r454", "r455", "r468", "r484", "r596", "r597", "r609"] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": ["http://www.tapimmune.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "presentation": ["http://www.tapimmune.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Assets, Current", "totalLabel": "Total current assets", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": ["r111", "r120", "r132", "r175", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r278", "r282", "r298", "r468", "r596", "r597", "r609"] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": ["http://www.tapimmune.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "verboseLabel": "Current assets:" } } }, "auth_ref": [] }, "mrkr_AtmAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tapimmune.com/20240930", "localname": "AtmAgreementMember", "presentation": ["http://www.tapimmune.com/role/DisclosureStockholdersEquityReverseStockSplitAndAtmAgreementDetails"], "lang": { "en-us": { "role": { "documentation": "The member stands for ATM agreement.", "label": "ATM Agreement [Member]", "terseLabel": "ATM Agreement" } } }, "auth_ref": [] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExrcPrice", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Exercise Price", "terseLabel": "Exercise Price" } } }, "auth_ref": ["r556"] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Grant Date Fair Value", "terseLabel": "Fair Value as of Grant Date" } } }, "auth_ref": ["r557"] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]", "terseLabel": "Award Timing Disclosures" } } }, "auth_ref": ["r552"] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing, How MNPI Considered [Text Block]", "terseLabel": "Award Timing, How MNPI Considered" } } }, "auth_ref": ["r552"] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing Method [Text Block]", "terseLabel": "Award Timing Method" } } }, "auth_ref": ["r552"] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Considered [Flag]", "terseLabel": "Award Timing MNPI Considered" } } }, "auth_ref": ["r552"] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Disclosure [Text Block]", "terseLabel": "Award Timing MNPI Disclosure" } } }, "auth_ref": ["r552"] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmndFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing Predetermined [Flag]", "terseLabel": "Award Timing Predetermined" } } }, "auth_ref": ["r552"] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "terseLabel": "Award Type", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": ["r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256"] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlygSecuritiesAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Underlying Securities Amount", "terseLabel": "Underlying Securities" } } }, "auth_ref": ["r555"] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r554"] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTable", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table]", "terseLabel": "Awards Close in Time to MNPI Disclosures" } } }, "auth_ref": ["r553"] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]", "terseLabel": "Awards Close in Time to MNPI Disclosures, Table" } } }, "auth_ref": ["r553"] }, "us-gaap_BasisOfAccounting": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfAccounting", "presentation": ["http://www.tapimmune.com/role/DisclosureBasisOfPresentation"], "lang": { "en-us": { "role": { "label": "Basis of Accounting [Text Block]", "verboseLabel": "BASIS OF PRESENTATION", "documentation": "The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": ["r76"] }, "mrkr_BasisOfPresentationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.tapimmune.com/20240930", "localname": "BasisOfPresentationAbstract", "lang": { "en-us": { "role": { "documentation": "n/a", "label": "BASIS OF PRESENTATION" } } }, "auth_ref": [] }, "mrkr_BindingServicesAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tapimmune.com/20240930", "localname": "BindingServicesAgreementMember", "presentation": ["http://www.tapimmune.com/role/DisclosureDiscontinuedOperationsAdditionalInformationDetails", "http://www.tapimmune.com/role/DisclosureLiquidityAndFinancialConditionDetails"], "lang": { "en-us": { "role": { "documentation": "This member stands for binding services agreement.", "label": "Binding Services Agreement [Member]", "terseLabel": "Binding Services Agreement" } } }, "auth_ref": [] }, "mrkr_CancerPreventionAndResearchInstituteOfTexasMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tapimmune.com/20240930", "localname": "CancerPreventionAndResearchInstituteOfTexasMember", "presentation": ["http://www.tapimmune.com/role/DisclosureOtherReceivableDetails"], "lang": { "en-us": { "role": { "documentation": "The information pertaining to cancer Prevention And Research Institute Of Texas.", "label": "Cancer Prevention And Research Institute Of Texas [Member]", "terseLabel": "CPRIT" } } }, "auth_ref": [] }, "mrkr_CantorFitzgeraldCo.AndRbcCapitalMarketsLlcMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tapimmune.com/20240930", "localname": "CantorFitzgeraldCo.AndRbcCapitalMarketsLlcMember", "presentation": ["http://www.tapimmune.com/role/DisclosureLiquidityAndFinancialConditionDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to Cantor Fitzgerald & Co and RBC Capital Markets, LLC.", "label": "Cantor Fitzgerald Co. And Rbc Capital Markets Llc [Member]", "terseLabel": "Sales Agents" } } }, "auth_ref": [] }, "us-

gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis", "presentation": ["http://www.tapimmune.com/role/DisclosureOtherReceivableDetails"], "lang": { "en-us": { "role": { "label": "Project [Axis]", "documentation": "Information by project." } } }, "auth_ref": ["r326", "r327", "r618"] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "presentation": ["http://www.tapimmune.com/role/DisclosureLiquidityAndFinancialConditionDetails", "http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesDetails", "http://www.tapimmune.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents", "verboseLabel": "Cash and cash equivalents", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": ["r14", "r113", "r445"] }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsPolicyTextBlock", "presentation": ["http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "verboseLabel": "Cash, Cash Equivalents and Credit Risk", "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value." } } }, "auth_ref": ["r15"] }, "mrkr_CashAtFinancialInstitutions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tapimmune.com/20240930", "localname": "CashAtFinancialInstitutions", "crdr": "debit", "presentation": ["http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "documentation": "The amount of cash held at financial institutions.", "label": "Cash at Financial Institutions", "terseLabel": "Cash at financial institutions" } } }, "auth_ref": [] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": ["http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "Cash and cash equivalents at end of the period", "periodStartLabel": "Cash and cash equivalents at beginning of the period", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r14", "r73", "r129"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "crdr": "debit", "presentation": ["http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect", "totalLabel": "Net (decrease) increase in cash and cash equivalents", "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r0", "r73"] }, "mrkr_CashPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tapimmune.com/20240930", "localname": "CashPayment", "crdr": "credit", "presentation": ["http://www.tapimmune.com/role/DisclosureDiscontinuedOperationsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "The amount of cash payment.", "label": "Cash Payment" } } }, "auth_ref": [] }, "us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations", "crdr": "debit", "presentation": ["http://www.tapimmune.com/role/DisclosureDiscontinuedOperationsCashFlowsDetails", "http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Cash Provided by (Used in) Investing Activities, Discontinued Operations", "terseLabel": "Net cash provided by investing activities - discontinued operations", "verboseLabel": "Net cash provided by investing activities", "documentation": "Amount of cash inflow (outflow) of investing activities of discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": ["r48", "r73"] }, "us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations", "crdr": "debit", "presentation": ["http://www.tapimmune.com/role/DisclosureDiscontinuedOperationsCashFlowsDetails", "http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Cash Provided by (Used in) Operating Activities, Discontinued Operations", "terseLabel": "Net cash used in operating activities - discontinued operations", "verboseLabel": "Net cash used in operating activities", "documentation": "Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": ["r48", "r73"] }, "mrkr_CellReadyAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tapimmune.com/20240930", "localname": "CellReadyAgreementMember", "presentation": ["http://www.tapimmune.com/role/DisclosureDiscontinuedOperationsAdditionalInformationDetails", "http://www.tapimmune.com/role/DisclosureLiquidityAndFinancialConditionDetails", "http://www.tapimmune.com/role/DisclosureNatureOfOperationsDetails", "http://www.tapimmune.com/role/DisclosureRelatedPartyExpensesDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to Cell Ready Agreement.", "label": "Cell Ready Agreement [Member]", "terseLabel": "Cell Ready Purchase Agreement" } } }, "auth_ref": [] }, "mrkr_CellReadyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tapimmune.com/20240930", "localname": "CellReadyMember", "presentation": ["http://www.tapimmune.com/role/DisclosureAccountsPayableAccruedLiabilitiesAndRelatedPartyPayableDetails", "http://www.tapimmune.com/role/DisclosureRelatedPartyExpensesDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to Cell Ready.", "label": "Cell Ready [Member]", "terseLabel": "Cell Ready" } } }, "auth_ref": [] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Changed Peer Group, Footnote [Text Block]", "terseLabel": "Changed Peer Group, Footnote" } } }, "auth_ref": ["r532"] }, "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]", "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year" } } }, "auth_ref": ["r529"] }, "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]", "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested" } } }, "auth_ref": ["r527"] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": ["http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockLineItems", "presentation": ["http://www.tapimmune.com/role/DisclosureStockholdersEquityReverseStockSplitAndAtmAgreementDetails"], "lang": { "en-us": { "role": { "label": "Class of Stock [Line Items]", "terseLabel": "STOCKHOLDERS' EQUITY", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r115", "r116", "r117", "r163", "r199", "r200", "r201", "r203", "r206", "r211", "r213", "r362", "r363", "r364", "r365", "r457", "r571", "r579"] }, "mrkr_ClinicalTrialAgreementWithBaylorCollegeOfMedicineMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tapimmune.com/20240930", "localname": "ClinicalTrialAgreementWithBaylorCollegeOfMedicineMember", "presentation": ["http://www.tapimmune.com/role/DisclosureRelatedPartyExpensesDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Clinical Trial Agreement with Baylor College of Medicine.", "label": "Clinical Trial Agreement with Baylor College of Medicine [Member]", "terseLabel": "Baylor College of Medicine" } } }, "auth_ref": [] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": [

"http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Company Selected Measure Amount", "terseLabel": "Company Selected Measure Amount" } } }, "auth_ref": ["r533"] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Company Selected Measure Name", "terseLabel": "Company Selected Measure Name" } } }, "auth_ref": ["r533"] }, "mrkr_CommitmentFee": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tapimmune.com/20240930", "localname": "CommitmentFee", "crdr": "credit", "presentation": [
"http://www.tapimmune.com/role/DisclosureStockholdersEquityStockPurchaseAgreementAndExerciseOfStockOptionsDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the amount of commitment fees.", "label": "Commitment Fee", "terseLabel": "Commitment fee" } } }, "auth_ref": [] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": ["http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "terseLabel": "Common Stock", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": ["r474", "r475", "r476", "r478", "r479", "r480", "r481", "r581", "r582", "r584", "r603", "r654", "r656"] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [
"http://www.tapimmune.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Common Stock, Par or Stated Value Per Share", "verboseLabel": "Common stock par value (in $ per share)", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": ["r62"] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": [
"http://www.tapimmune.com/role/DisclosureNatureOfOperationsDetails",
"http://www.tapimmune.com/role/DisclosureStockholdersEquityReverseStockSplitAndAtmAgreementDetails",
"http://www.tapimmune.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock authorized (in shares)", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r62", "r382"] }, "mrkr_CommonStockSharesCommissionRateCalculationOnGrossSalesPricePerSharePercent": { "xbrltype": "percentItemType", "nsuri": "http://www.tapimmune.com/20240930", "localname": "CommonStockSharesCommissionRateCalculationOnGrossSalesPricePerSharePercent", "presentation": ["http://www.tapimmune.com/role/DisclosureLiquidityAndFinancialConditionDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the percent of calculation of compensation rate by using gross sales price per share sold.", "label": "Common Stock, Shares, Commission Rate Calculation on Gross Sales Price per Share, Percent", "terseLabel": "Commission rate" } } }, "auth_ref": [] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": ["http://www.tapimmune.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": ["r62"] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": [
"http://www.tapimmune.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Common Stock, Shares, Outstanding", "verboseLabel": "Common stock outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": ["r6", "r62", "r382", "r401", "r656", "r657"] }, "us-gaap_CommonStockSharesSubscriptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesSubscriptions", "crdr": "credit", "presentation": [
"http://www.tapimmune.com/role/DisclosureLiquidityAndFinancialConditionDetails"], "lang": { "en-us": { "role": { "label": "Common Stock, Value, Subscriptions", "terseLabel": "Aggregate offering price", "documentation": "Monetary value of common stock allocated to investors to buy shares of a new issue of common stock before they are offered to the public. When stock is sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the shares to the investor until it receives the entire proceeds." } } }, "auth_ref": ["r21", "r62"] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "presentation": ["http://www.tapimmune.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Common Stock, Value, Issued", "terseLabel": "Common stock, $0.001 par value, 30 million shares authorized, 8.9 million shares issued and outstanding as of September 30, 2024 and December 31, 2023 (see Note 9)", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": ["r62", "r334", "r468"] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Company Selected Measure" } } }, "auth_ref": ["r538"] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Net Income [Text Block]", "terseLabel": "Compensation Actually Paid vs. Net Income" } } }, "auth_ref": ["r537"] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Other Measure" } } }, "auth_ref": ["r539"] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]", "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return" } } }, "auth_ref": ["r536"] }, "us-gaap_ConsolidationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConsolidationPolicyTextBlock", "presentation": [
"http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Consolidation, Policy [Policy Text Block]", "verboseLabel": "Principles of Consolidation", "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary." } } }, "auth_ref": ["r30", "r450"] }, "mrkr_ControlledEquityOfferingSalesAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tapimmune.com/20240930", "localname": "ControlledEquityOfferingSalesAgreementMember", "presentation": [
"http://www.tapimmune.com/role/DisclosureLiquidityAndFinancialConditionDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to controlled equity offering sales agreement.", "label": "Controlled Equity Offering Sales Agreement [Member]", "terseLabel": "ATM Agreement" } } }, "auth_ref": [] }, "us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization", "crdr": "debit", "presentation": [
"http://www.tapimmune.com/role/DisclosureRelatedPartyExpensesDetails"], "lang": { "en-us": { "role": { "label": "Cost of Goods and Service, Excluding Depreciation, Depletion, and Amortization", "terseLabel": "Service and manufacturing costs", "documentation": "Cost of product sold and service rendered, excluding depreciation, depletion, and amortization." } } }, "auth_ref": ["r572", "r573"] }, "us-gaap_CostsAndExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostsAndExpensesAbstract", "presentation": ["http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Costs and Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "auth_ref": [] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "CounterpartyNameAxis", "presentation": ["http://www.tapimmune.com/role/DisclosureAccountsPayableAccruedLiabilitiesAndRelatedPartyPayableDetails",
"http://www.tapimmune.com/role/DisclosureLiquidityAndFinancialConditionDetails",
"http://www.tapimmune.com/role/DisclosureRelatedPartyExpensesDetails"], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]" } } }, "auth_ref": ["r135", "r136", "r197", "r201", "r316", "r323", "r330", "r447", "r449"] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Document and Entity Information", "documentation": "Cover page." } } }, "auth_ref": [] }, "mrkr_CpritGrantMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tapimmune.com/20240930", "localname": "CpritGrantMember", "presentation": [
"http://www.tapimmune.com/role/DisclosureGrantIncomeDetails"], "lang": { "en-us": { "role": { "documentation": "Award of money not required to be repaid for CPRIT grant.", "label": "CPRIT Grant [Member]", "terseLabel": "CPRIT grant" } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [
"http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-

gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": ["http://www.tapimmune.com/role/DisclosureStockBasedCompensation"], "lang": { "en-us": { "role": { "label": "Disclosure of Compensation Related Costs, Share-based Payments [Text Block]", "terseLabel": "STOCK-BASED COMPENSATION", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": ["r229", "r230", "r258", "r259", "r261", "r460"] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "label": "STOCK-BASED COMPENSATION" } } }, "auth_ref": [] }, "us-gaap_DisclosureTextBlockSupplementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureTextBlockSupplementAbstract", "lang": { "en-us": { "role": { "label": "LEGAL PROCEEDINGS" } } }, "auth_ref": [] }, "us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax", "crdr": "credit", "presentation": ["http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Discontinued Operation, Gain (Loss) from Disposal of Discontinued Operation, before Income Tax", "terseLabel": "Gain on disposal of discontinued operations before income taxes", "documentation": "Amount before tax of gain (loss) not previously recognized resulting from the disposal of a discontinued operation." } } }, "auth_ref": ["r37", "r39", "r41"] }, "us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax", "crdr": "credit", "presentation": ["http://www.tapimmune.com/role/DisclosureDiscontinuedOperationsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax", "terseLabel": "Gain on disposal of discontinued operations before income taxes", "documentation": "Amount after tax of gain (loss) not previously recognized resulting from the disposal of a discontinued operation." } } }, "auth_ref": ["r37", "r39", "r41", "r50"] }, "mrkr_DiscontinuedOperationIncomeLossFromDiscontinuedOperationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.tapimmune.com/20240930", "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationAbstract", "presentation": ["http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Discontinued Operation, Income (Loss) from Discontinued Operation [Abstract]", "terseLabel": "Discontinued operations:" } } }, "auth_ref": [] }, "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax", "crdr": "credit", "presentation": ["http://www.tapimmune.com/role/DisclosureDiscontinuedOperationsDetails", "http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Discontinued Operation, Income (Loss) from Discontinued Operation During Phase-out Period, Net of Tax", "totalLabel": "Loss from discontinued operations", "verboseLabel": "Loss from discontinued operations, net of tax", "documentation": "Amount after tax of income (loss) from operations classified as a discontinued operation. Excludes gain (loss) on disposal and provision for gain (loss) until disposal." } } }, "auth_ref": ["r37", "r38", "r50"] }, "us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation", "crdr": "debit", "presentation": ["http://www.tapimmune.com/role/DisclosureDiscontinuedOperationsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Discontinued Operation, Tax Effect of Gain (Loss) from Disposal of Discontinued Operation", "terseLabel": "Tax on gain on disposal of discontinued operations", "documentation": "Amount of tax expense (benefit) on gain (loss) not previously recognized resulting from the disposal of a discontinued operation." } } }, "auth_ref": ["r39", "r41", "r50", "r602"] }, "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract", "lang": { "en-us": { "role": { "label": "DISCONTINUED OPERATIONS" } } }, "auth_ref": [] }, "us-gaap_DiscontinuedOperationsDisposedOfBySaleMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DiscontinuedOperationsDisposedOfBySaleMember", "presentation": ["http://www.tapimmune.com/role/DisclosureDiscontinuedOperationsAdditionalInformationDetails", "http://www.tapimmune.com/role/DisclosureDiscontinuedOperationsCashFlowsDetails", "http://www.tapimmune.com/role/DisclosureNatureOfOperationsDetails"], "lang": { "en-us": { "role": { "label": "Discontinued Operations, Disposed of by Sale [Member]", "terseLabel": "Disposed by sale", "verboseLabel": "Discontinued Operations, Disposed of by Sale", "documentation": "Component or group of components representing strategic shift that has or will have major effect on operation and financial result, disposed of by sale." } } }, "auth_ref": ["r2"] }, "us-gaap_DiscontinuedOperationsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DiscontinuedOperationsPolicyTextBlock", "presentation": ["http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Discontinued Operations, Policy [Policy Text Block]", "terseLabel": "Discontinued Operations", "documentation": "Disclosure of accounting policy for discontinued operations. Includes, but is not limited to, method of interest allocation to a discontinued operation." } } }, "auth_ref": ["r5", "r13"] }, "us-gaap_DisposalGroupClassificationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupClassificationAxis", "presentation": ["http://www.tapimmune.com/role/DisclosureDiscontinuedOperationsAdditionalInformationDetails", "http://www.tapimmune.com/role/DisclosureDiscontinuedOperationsCashFlowsDetails", "http://www.tapimmune.com/role/DisclosureNatureOfOperationsDetails"], "lang": { "en-us": { "role": { "label": "Disposal Group Classification [Axis]", "documentation": "Information by disposal group classification." } } }, "auth_ref": ["r109"] }, "us-gaap_DisposalGroupClassificationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupClassificationDomain", "presentation": ["http://www.tapimmune.com/role/DisclosureDiscontinuedOperationsAdditionalInformationDetails", "http://www.tapimmune.com/role/DisclosureDiscontinuedOperationsCashFlowsDetails", "http://www.tapimmune.com/role/DisclosureNatureOfOperationsDetails"], "lang": { "en-us": { "role": { "label": "Disposal Group Classification [Domain]", "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations." } } }, "auth_ref": [] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationConsideration", "crdr": "debit", "presentation": ["http://www.tapimmune.com/role/DisclosureDiscontinuedOperationsAdditionalInformationDetails", "http://www.tapimmune.com/role/DisclosureLiquidityAndFinancialConditionDetails", "http://www.tapimmune.com/role/DisclosureNatureOfOperationsDetails"], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Consideration", "terseLabel": "Consideration for purchased assets", "verboseLabel": "Consideration for purchased assets", "documentation": "Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation." } } }, "auth_ref": [] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingExpense", "crdr": "debit", "presentation": ["http://www.tapimmune.com/role/DisclosureDiscontinuedOperationsDetails"], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Operating Expense", "terseLabel": "Total operating expenses", "documentation": "Amount of operating expense attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": ["r47"] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationRevenue", "crdr": "credit", "presentation": ["http://www.tapimmune.com/role/DisclosureDiscontinuedOperationsDetails"], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Revenue", "terseLabel": "Total revenues", "documentation": "Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": ["r47", "r110"] }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "presentation": ["http://www.tapimmune.com/role/DisclosureDiscontinuedOperations"], "lang": { "en-us": { "role": { "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]", "terseLabel": "DISCONTINUED OPERATIONS", "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component." } } }, "auth_ref": ["r35", "r78"] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": ["http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": ["http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate",

"presentation": ["http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": ["http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": ["r488"] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": ["http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": ["r520"] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": ["http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]", "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year" } } }, "auth_ref": ["r531"] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "presentation": ["http://www.tapimmune.com/role/DisclosureNetLossPerShareComputationOfLossPerShareDetails", "http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Net earnings (loss) per share:", "verboseLabel": "Net (loss) earnings per share:" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": ["http://www.tapimmune.com/role/DisclosureNetLossPerShareComputationOfLossPerShareDetails", "http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic", "terseLabel": "Net loss per share, basic (in dollars per share)", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": ["r126", "r142", "r143", "r144", "r145", "r146", "r147", "r151", "r153", "r156", "r157", "r158", "r160", "r272", "r275", "r292", "r293", "r328", "r343", "r451"] }, "us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasicOtherDisclosuresAbstract", "presentation": ["http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic, Other Disclosure [Abstract]", "terseLabel": "Weighted average number of common shares outstanding:" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": ["http://www.tapimmune.com/role/DisclosureNetLossPerShareComputationOfLossPerShareDetails", "http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Diluted", "terseLabel": "Net loss per share, diluted (in dollars per share)", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": ["r126", "r142", "r143", "r144", "r145", "r146", "r147", "r153", "r156", "r157", "r158", "r160", "r272", "r275", "r292", "r293", "r328", "r343", "r451"] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "presentation": ["http://www.tapimmune.com/role/DisclosureAccountsPayableAccruedLiabilitiesAndRelatedPartyPayableDetails"], "lang": { "en-us": { "role": { "label": "Employee-related Liabilities, Current", "verboseLabel": "Compensation and benefits", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r55"] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "crdr": "debit", "presentation": ["http://www.tapimmune.com/role/DisclosureStockBasedCompensationAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "terseLabel": "Total stock-based compensation cost related to unvested awards not yet recognized", "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement." } } }, "auth_ref": ["r260"] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": ["http://www.tapimmune.com/role/DisclosureStockBasedCompensationAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Expected weighted average period of recognition of unrecognized compensation costs (in years)", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r260"] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": ["http://www.tapimmune.com/role/DisclosureNetLossPerShareDilutiveSecuritiesDetails", "http://www.tapimmune.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Employee Stock Option [Member]", "terseLabel": "Employee Stock Option", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": ["http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": ["http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": ["http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": ["http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": ["http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": ["r486"] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": ["http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": ["http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": ["http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": ["r486"] },

"dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": ["http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": ["http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": ["r486"] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": ["http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": ["http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": ["r570"] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": ["http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": ["r486"] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": ["http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "terseLabel": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": ["r486"] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": ["http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": ["r486"] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": ["http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": ["r486"] }, "ecd_EqtyAwrdsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Footnote [Text Block]", "terseLabel": "Equity Awards Adjustments, Footnote" } } }, "auth_ref": ["r525"] }, "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]", "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table" } } }, "auth_ref": ["r566"] }, "ecd_EqtyAwrdsAdjsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments [Member]", "terseLabel": "Equity Awards Adjustments" } } }, "auth_ref": ["r566"] }, "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table" } } }, "auth_ref": ["r566"] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": ["http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": ["r6", "r108", "r123", "r124", "r125", "r137", "r138", "r139", "r141", "r146", "r148", "r150", "r162", "r176", "r177", "r180", "r214", "r266", "r267", "r269", "r270", "r271", "r273", "r274", "r275", "r284", "r285", "r286", "r287", "r288", "r289", "r291", "r299", "r300", "r301", "r302", "r303", "r304", "r307", "r308", "r309", "r342", "r355", "r356", "r357", "r371", "r425"] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Valuation Assumption Difference, Footnote [Text Block]", "terseLabel": "Equity Valuation Assumption Difference, Footnote" } } }, "auth_ref": ["r535"] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Erroneous Compensation Analysis [Text Block]", "terseLabel": "Erroneous Compensation Analysis" } } }, "auth_ref": ["r493", "r503", "r513", "r545"] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Erroneously Awarded Compensation Recovery [Table]", "terseLabel": "Erroneously Awarded Compensation Recovery" } } }, "auth_ref": ["r490", "r500", "r510", "r542"] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ExecutiveCategoryAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Executive Category [Axis]", "terseLabel": "Executive Category:" } } }, "auth_ref": ["r541"] }, "mrkr_FdaGrantMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tapimmune.com/20240930", "localname": "FdaGrantMember", "presentation": ["http://www.tapimmune.com/role/DisclosureGrantIncomeDetails", "http://www.tapimmune.com/role/DisclosureLiquidityAndFinancialConditionDetails", "http://www.tapimmune.com/role/DisclosureOtherReceivableDetails"], "lang": { "en-us": { "role": { "documentation": "Award of money not required to be repaid for FDA grant.", "label": "FDA Grant [Member]", "terseLabel": "FDA grant" } } }, "auth_ref": [] }, "mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.tapimmune.com/20240930", "localname": "FinancialConditionGoingConcernAndManagementPlansLineItems", "presentation": ["http://www.tapimmune.com/role/DisclosureLiquidityAndFinancialConditionDetails"], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS [Line Items]", "terseLabel": "LIQUIDITY AND FINANCIAL CONDITION" } } }, "auth_ref": [] }, "mrkr_FinancialConditionGoingConcernAndManagementPlansTable": { "xbrltype": "stringItemType", "nsuri": "http://www.tapimmune.com/20240930", "localname": "FinancialConditionGoingConcernAndManagementPlansTable", "presentation": ["http://www.tapimmune.com/role/DisclosureLiquidityAndFinancialConditionDetails"], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Financial Condition Going Concern And Management Plans [Table]" } } }, "auth_ref": [] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": ["r497", "r507", "r517", "r549"] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Expense of Enforcement, Amount", "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": ["r497", "r507", "r517", "r549"] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Violation of Home Country Law, Amount", "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": ["r497", "r507", "r517", "r549"] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Explanation of Impracticability [Text Block]", "terseLabel": "Forgone Recovery, Explanation of Impracticability" } } }, "auth_ref": ["r497", "r507", "r517", "r549"] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r497", "r507", "r517", "r549"] }, "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember", "presentation": [

"http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]", "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year" } } }, "auth_ref": ["r530"] }, "mrkr_FundReceivedFromGrant": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tapimmune.com/20240930", "localname": "FundReceivedFromGrant", "crdr": "debit", "presentation": ["http://www.tapimmune.com/role/DisclosureOtherReceivableDetails"], "lang": { "en-us": { "role": { "documentation": "Fund received from grant", "label": "Fund Received From Grant", "terseLabel": "Funds received from grant" } } }, "auth_ref": [] }, "mrkr_FundsReceivedFromCpritGrant": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tapimmune.com/20240930", "localname": "FundsReceivedFromCpritGrant", "crdr": "debit", "presentation": ["http://www.tapimmune.com/role/DisclosureGrantIncomeDetails", "http://www.tapimmune.com/role/DisclosureLiquidityAndFinancialConditionDetails"], "lang": { "en-us": { "role": { "documentation": "Funds received from grant.", "label": "Funds Received From CPRIT Grant", "terseLabel": "Funds received from CPRIT grant" } } }, "auth_ref": [] }, "mrkr_FundsReceivedFromGrant": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tapimmune.com/20240930", "localname": "FundsReceivedFromGrant", "crdr": "debit", "presentation": ["http://www.tapimmune.com/role/DisclosureGrantIncomeDetails", "http://www.tapimmune.com/role/DisclosureLiquidityAndFinancialConditionDetails", "http://www.tapimmune.com/role/DisclosureOtherReceivableDetails"], "lang": { "en-us": { "role": { "documentation": "Funds received from grant", "label": "Funds Received From Grant", "terseLabel": "Funds received from grant" } } }, "auth_ref": [] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "presentation": ["http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "General and Administrative Expense", "terseLabel": "General and administrative", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": ["r72", "r405"] }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpenseMember", "presentation": ["http://www.tapimmune.com/role/DisclosureDiscontinuedOperationsOperationsDetails", "http://www.tapimmune.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpensesDetails"], "lang": { "en-us": { "role": { "label": "General and Administrative [Member]", "terseLabel": "General and administrative", "documentation": "Primary financial statement caption encompassing general and administrative expense." } } }, "auth_ref": ["r72"] }, "mrkr_GrantAssistanceTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.tapimmune.com/20240930", "localname": "GrantAssistanceTerm", "presentation": ["http://www.tapimmune.com/role/DisclosureLiquidityAndFinancialConditionDetails"], "lang": { "en-us": { "role": { "documentation": "Duration of grant assistance transaction, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Grant Assistance Term", "terseLabel": "Grant Assistance Term" } } }, "auth_ref": [] }, "mrkr_GrantIncomeLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.tapimmune.com/20240930", "localname": "GrantIncomeLineItems", "presentation": ["http://www.tapimmune.com/role/DisclosureGrantIncomeDetails"], "lang": { "en-us": { "role": { "documentation": "Line items represents grant income.", "label": "Grant Income [Line Items]", "terseLabel": "GRANT INCOME" } } }, "auth_ref": [] }, "mrkr_GrantIncomeTable": { "xbrltype": "stringItemType", "nsuri": "http://www.tapimmune.com/20240930", "localname": "GrantIncomeTable", "presentation": ["http://www.tapimmune.com/role/DisclosureGrantIncomeDetails"], "lang": { "en-us": { "role": { "documentation": "This table lists the grant income.", "label": "Grant Income [Table]" } } }, "auth_ref": [] }, "us-gaap_GrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GrantMember", "presentation": ["http://www.tapimmune.com/role/DisclosureGrantIncomeDetails", "http://www.tapimmune.com/role/DisclosureLiquidityAndFinancialConditionDetails", "http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Grant [Member]", "terseLabel": "Grant income", "documentation": "Award of money not required to be repaid." } } }, "auth_ref": ["r600"] }, "mrkr_GrantReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tapimmune.com/20240930", "localname": "GrantReceived", "crdr": "credit", "presentation": ["http://www.tapimmune.com/role/DisclosureLiquidityAndFinancialConditionDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of grant income transfer product and service to customer for which consideration has been received or is receivable.", "label": "Grant Received", "terseLabel": "Grant income received" } } }, "auth_ref": [] }, "us-gaap_GrantsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GrantsReceivable", "crdr": "debit", "presentation": ["http://www.tapimmune.com/role/DisclosureGrantIncomeDetails"], "lang": { "en-us": { "role": { "label": "Grants Receivable", "terseLabel": "Grant receivable", "documentation": "Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants." } } }, "auth_ref": ["r575"] }, "us-gaap_IncomeLossFromContinuingOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperations", "crdr": "credit", "presentation": ["http://www.tapimmune.com/role/DisclosureNetLossPerShareComputationOfLossPerShareDetails", "http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent", "terseLabel": "Loss from continuing operations", "totalLabel": "Loss from continuing operations", "documentation": "Amount after tax of income (loss) from continuing operations attributable to the parent." } } }, "auth_ref": ["r29", "r69", "r75", "r142", "r143", "r144", "r145", "r146", "r155", "r158", "r275"] }, "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "presentation": ["http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net loss from continuing operations", "documentation": "Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest." } } }, "auth_ref": ["r90", "r99", "r132", "r140", "r146", "r175", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r272", "r275", "r293", "r298", "r338", "r453", "r586", "r587", "r588", "r589", "r590", "r596"] }, "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsPerBasicShare", "presentation": ["http://www.tapimmune.com/role/DisclosureNetLossPerShareComputationOfLossPerShareDetails", "http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Income (Loss) from Continuing Operations, Per Basic Share", "terseLabel": "Loss from continuing operations, basic (in dollars per share)", "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": ["r69", "r95", "r126", "r140", "r142", "r143", "r144", "r145", "r146", "r153", "r156", "r157", "r272", "r275", "r293", "r328", "r623"] }, "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsPerDilutedShare", "presentation": ["http://www.tapimmune.com/role/DisclosureNetLossPerShareComputationOfLossPerShareDetails", "http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Income (Loss) from Continuing Operations, Per Diluted Share", "terseLabel": "Loss from continuing operations, diluted (in dollars per share)", "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": ["r69", "r126", "r140", "r142", "r143", "r144", "r145", "r146", "r153", "r156", "r157", "r158", "r275", "r293", "r328", "r623"] }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromDiscontinuedOperationsNetOfTax", "crdr": "credit", "presentation": ["http://www.tapimmune.com/role/DisclosureNetLossPerShareComputationOfLossPerShareDetails", "http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Income from discontinued operations", "totalLabel": "Income from discontinued operations", "verboseLabel": "Less: gain from discontinued operations, net of tax", "documentation": "Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal." } } }, "auth_ref": ["r37", "r38", "r39", "r40", "r41", "r50", "r110", "r268", "r339"] }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare", "presentation": ["http://www.tapimmune.com/role/DisclosureNetLossPerShareComputationOfLossPerShareDetails", "http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share", "terseLabel": "Income from discontinued operations, basic (in dollars per share)", "documentation": "Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation." } } }, "auth_ref": ["r70", "r126", "r154", "r156", "r157", "r620", "r623"] }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare", "presentation": ["http://www.tapimmune.com/role/DisclosureNetLossPerShareComputationOfLossPerShareDetails",

"http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share", "terseLabel": "Income from discontinued operations, diluted (in dollars per share)", "documentation": "Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation." } } }, "auth_ref": ["r91", "r154", "r156", "r157"] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "CONSOLIDATED STATEMENTS OF OPERATIONS" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems", "presentation": ["http://www.tapimmune.com/role/DisclosureDiscontinuedOperationsAdditionalInformationDetails", "http://www.tapimmune.com/role/DisclosureDiscontinuedOperationsCashFlowsDetails", "http://www.tapimmune.com/role/DisclosureDiscontinuedOperationsOperationsDetails"], "lang": { "en-us": { "role": { "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]", "terseLabel": "DISCONTINUED OPERATIONS", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable", "presentation": ["http://www.tapimmune.com/role/DisclosureDiscontinuedOperationsAdditionalInformationDetails", "http://www.tapimmune.com/role/DisclosureDiscontinuedOperationsCashFlowsDetails", "http://www.tapimmune.com/role/DisclosureDiscontinuedOperationsOperationsDetails"], "lang": { "en-us": { "role": { "label": "Disposal Groups, Including Discontinued Operations [Table]", "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component." } } }, "auth_ref": ["r5", "r10", "r12", "r36", "r42", "r43", "r44", "r45", "r46", "r49", "r51", "r52", "r79"] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationAxis", "presentation": ["http://www.tapimmune.com/role/DisclosureDiscontinuedOperationsOperationsDetails", "http://www.tapimmune.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpensesDetails"], "lang": { "en-us": { "role": { "label": "Income Statement Location [Axis]", "documentation": "Information by location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": ["r181", "r182", "r183", "r295", "r296", "r297", "r352", "r354", "r410", "r442", "r463", "r625"] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain", "presentation": ["http://www.tapimmune.com/role/DisclosureDiscontinuedOperationsOperationsDetails", "http://www.tapimmune.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpensesDetails"], "lang": { "en-us": { "role": { "label": "Income Statement Location [Domain]", "documentation": "Location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": ["r182", "r183", "r295", "r296", "r297", "r352", "r354", "r410", "r442", "r463", "r625"] }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "crdr": "debit", "presentation": ["http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "verboseLabel": "Accounts payable and accrued expenses", "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid." } } }, "auth_ref": ["r3"] }, "us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccruedInterestReceivableNet", "crdr": "credit", "presentation": ["http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Accrued Interest Receivable, Net", "negatedLabel": "Other receivables", "documentation": "The increase (decrease) during the reporting period in the amount due from borrowers for interest payments." } } }, "auth_ref": ["r3"] }, "us-gaap_IncreaseDecreaseInDeferredRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInDeferredRevenue", "crdr": "debit", "presentation": ["http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Deferred Revenue", "terseLabel": "Deferred revenue", "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable." } } }, "auth_ref": ["r443"] }, "us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInDueToRelatedPartiesCurrent", "crdr": "debit", "presentation": ["http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Due to Related Parties, Current", "terseLabel": "Related party payable", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence." } } }, "auth_ref": ["r3"] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": ["http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInPrepaidExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPrepaidExpense", "crdr": "credit", "presentation": ["http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Prepaid Expense", "negatedLabel": "Prepaid expenses and deposits", "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods." } } }, "auth_ref": ["r3"] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Individual [Axis]", "terseLabel": "Individual:" } } }, "auth_ref": ["r497", "r507", "r517", "r541", "r549", "r553", "r561"] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]", "terseLabel": "Insider Trading Arrangements:" } } }, "auth_ref": ["r559"] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]", "terseLabel": "Insider Trading Policies and Procedures:" } } }, "auth_ref": ["r489", "r565"] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Adopted [Flag]", "terseLabel": "Insider Trading Policies and Procedures Adopted" } } }, "auth_ref": ["r489", "r565"] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]", "terseLabel": "Insider Trading Policies and Procedures Not Adopted" } } }, "auth_ref": ["r489", "r565"] }, "us-gaap_InvestmentIncomeInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentIncomeInterest", "crdr": "credit", "presentation": ["http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Investment Income, Interest", "verboseLabel": "Interest income", "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities." } } }, "auth_ref": ["r161", "r167", "r170", "r454", "r577"] }, "mrkr_InvoicesReceivedForServicesAndManufacturingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tapimmune.com/20240930", "localname": "InvoicesReceivedForServicesAndManufacturingCosts", "crdr": "debit", "presentation": ["http://www.tapimmune.com/role/DisclosureRelatedPartyExpensesDetails"], "lang": { "en-us": { "role": { "documentation": "Invoices for the cost of product sold and service rendered, excluding depreciation, depletion, and amortization.", "label": "Invoices Received for Services and Manufacturing Costs", "terseLabel": "Paid invoices" } } }, "auth_ref": [] }, "mrkr_IssuanceOfCommonStockSharesAsCommitmentFeeForFutureFinancing": { "xbrltype": "sharesItemType", "nsuri": "http://www.tapimmune.com/20240930", "localname": "IssuanceOfCommonStockSharesAsCommitmentFeeForFutureFinancing", "presentation": ["http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "documentation": "It represents number of common stock issued as commitment fee for future financing.", "label": "Issuance Of Common Stock, Shares, As Commitment Fee For Future Financing", "verboseLabel": "Issuance of common stock as commitment fee for future financing (in shares)" } } }, "auth_ref": [] }, "mrkr_IssuanceOfCommonStockValueAsCommitmentFeeForFutureFinancing": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tapimmune.com/20240930", "localname": "IssuanceOfCommonStockValueAsCommitmentFeeForFutureFinancing", "crdr":

"credit", "presentation": ["http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "documentation": "It represents value of common stock as commitment fee for future financing.", "label": "Issuance Of Common Stock , Value, As Commitment Fee For Future Financing", "verboseLabel": "Issuance of common stock as commitment fee for future financing" } } }, "auth_ref": [] }, "us-gaap_LegalMattersAndContingenciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LegalMattersAndContingenciesTextBlock", "presentation": ["http://www.tapimmune.com/role/DisclosureLegalProceedings"], "lang": { "en-us": { "role": { "label": "Legal Matters and Contingencies [Text Block]", "verboseLabel": "LEGAL PROCEEDINGS", "documentation": "The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies." } } }, "auth_ref": ["r80"] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "presentation": ["http://www.tapimmune.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Liabilities", "totalLabel": "Total liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": ["r11", "r54", "r55", "r56", "r57", "r58", "r59", "r60", "r132", "r175", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r279", "r282", "r283", "r298", "r381", "r452", "r484", "r596", "r609", "r610"] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "presentation": ["http://www.tapimmune.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders' equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": ["r67", "r94", "r336", "r468", "r580", "r592", "r605"] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": ["http://www.tapimmune.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "presentation": ["http://www.tapimmune.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Liabilities, Current", "totalLabel": "Total current liabilities", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": ["r56", "r112", "r132", "r175", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r279", "r282", "r283", "r298", "r468", "r596", "r609", "r610"] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": ["http://www.tapimmune.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "auth_ref": [] }, "mrkr_LincolnParkMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tapimmune.com/20240930", "localname": "LincolnParkMember", "presentation": ["http://www.tapimmune.com/role/DisclosureLiquidityAndFinancialConditionDetails", "http://www.tapimmune.com/role/DisclosureStockholdersEquityStockPurchaseAgreementAndExerciseOfStockOptionsDetails"], "lang": { "en-us": { "role": { "documentation": "The information pertaining to Lincoln Park.", "label": "Lincoln Park [Member]", "terseLabel": "Lincoln Park" } } }, "auth_ref": [] }, "mrkr_LiquidityFinancialConditionAndGoingConcernAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.tapimmune.com/20240930", "localname": "LiquidityFinancialConditionAndGoingConcernAbstract", "lang": { "en-us": { "role": { "documentation": "n/a", "label": "LIQUIDITY AND FINANCIAL CONDITION" } } }, "auth_ref": [] }, "mrkr_LiquidityFinancialConditionAndGoingConcernTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.tapimmune.com/20240930", "localname": "LiquidityFinancialConditionAndGoingConcernTextBlock", "presentation": ["http://www.tapimmune.com/role/DisclosureLiquidityAndFinancialCondition"], "lang": { "en-us": { "role": { "documentation": "Liquidity Financial Condition And Going Concern Text Block", "label": "Liquidity Financial Condition And Going Concern [Text Block]", "terseLabel": "LIQUIDITY AND FINANCIAL CONDITION" } } }, "auth_ref": [] }, "us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "presentation": ["http://www.tapimmune.com/role/DisclosureOtherReceivable"], "lang": { "en-us": { "role": { "label": "Loans, Notes, Trade and Other Receivables Disclosure [Text Block]", "terseLabel": "OTHER RECEIVABLE", "documentation": "The entire disclosure for claims held for amounts due to entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses." } } }, "auth_ref": ["r306", "r591"] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": ["http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": ["http://www.tapimmune.com/role/DisclosureNatureOfOperationsDetails", "http://www.tapimmune.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "auth_ref": ["r184", "r185", "r186", "r187", "r228", "r263", "r294", "r324", "r351", "r353", "r360", "r373", "r374", "r433", "r434", "r435", "r436", "r437", "r440", "r441", "r456", "r457", "r459", "r464", "r465", "r466", "r467", "r470", "r598", "r611", "r612", "r613", "r614", "r615", "r616"] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Measure [Axis]", "terseLabel": "Measure:" } } }, "auth_ref": ["r533"] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Measure Name", "terseLabel": "Name" } } }, "auth_ref": ["r533"] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": ["http://www.tapimmune.com/role/DisclosureNatureOfOperationsDetails", "http://www.tapimmune.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "auth_ref": ["r184", "r185", "r186", "r187", "r228", "r263", "r294", "r324", "r351", "r353", "r360", "r373", "r374", "r433", "r434", "r435", "r436", "r437", "r440", "r441", "r456", "r457", "r459", "r464", "r465", "r466", "r470", "r598", "r611", "r612", "r613", "r614", "r615", "r616"] }, "us-gaap_MinorityInterestDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MinorityInterestDisclosureTextBlock", "presentation": ["http://www.tapimmune.com/role/DisclosureNetLossPerShare"], "lang": { "en-us": { "role": { "label": "Noncontrolling Interest Disclosure [Text Block]", "terseLabel": "NET LOSS PER SHARE", "documentation": "The entire disclosure for noncontrolling interest in consolidated subsidiaries, which could include the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock." } } }, "auth_ref": ["r89"] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "MNPI Disclosure Timed for Compensation Value [Flag]", "terseLabel": "MNPI Disclosure Timed for Compensation Value" } } }, "auth_ref": ["r552"] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement [Text Block]", "terseLabel": "Material Terms of Trading Arrangement" } } }, "auth_ref": ["r560"] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Named Executive Officers, Footnote [Text Block]", "terseLabel": "Named Executive Officers, Footnote" } } }, "auth_ref": ["r534"] }, "mrkr_NationalInstitutesOfHealthNationalCancerInstituteGrantMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tapimmune.com/20240930", "localname": "NationalInstitutesOfHealthNationalCancerInstituteGrantMember", "presentation": ["http://www.tapimmune.com/role/DisclosureLiquidityAndFinancialConditionDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to \ngrants from National Institutes of Health-National Cancer Institute.", "label": "National Institutes of Health National Cancer Institute Grant [Member]", "terseLabel": "National Institutes of Health National -Cancer Institute Grant" } } }, "auth_ref": [] }, "mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchForLymphomaGrantMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tapimmune.com/20240930", "localname": "NationalInstitutesOfHealthSmallBusinessInnovationResearchForLymphomaGrantMember", "presentation": ["http://www.tapimmune.com/role/DisclosureGrantIncomeDetails", "http://www.tapimmune.com/role/DisclosureLiquidityAndFinancialConditionDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to grant from National Institutes of Health and Business Innovation research for Lymphoma.", "label": "National Institutes of Health Small Business Innovation Research For Lymphoma Grant [Member]", "terseLabel": "SBIR lymphoma grant" } } }, "auth_ref": [] }, "mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tapimmune.com/20240930", "localname": "NationalInstitutesOfHealthSmallBusinessInnovationResearchMember", "presentation": ["http://www.tapimmune.com/role/DisclosureGrantIncomeDetails", "http://www.tapimmune.com/role/DisclosureLiquidityAndFinancialConditionDetails", "http://www.tapimmune.com/role/DisclosureOtherReceivableDetails"], "lang": { "en-us": { "role": { "documentation": "This member represents information pertaining to National Institutes of Health Small Business Innovation Research.", "label": "National Institutes of Health Small Business Innovation Research [Member]", "verboseLabel": "SBIR grant" } } }, "auth_ref": [] }, "us-gaap_NatureOfOperations": { "xbrltype":

"textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NatureOfOperations", "presentation": ["http://www.tapimmune.com/role/DisclosureNatureOfOperations"], "lang": { "en-us": { "role": { "label": "Nature of Operations [Text Block]", "verboseLabel": "NATURE OF OPERATIONS", "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward." } } }, "auth_ref": ["r101", "r106"] }, "us-gaap_NetCashProvidedByUsedInDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInDiscontinuedOperations", "crdr": "debit", "presentation": ["http://www.tapimmune.com/role/DisclosureDiscontinuedOperationsCashFlowsDetails"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Discontinued Operations", "totalLabel": "Net increase (decrease) in cash and cash equivalents", "documentation": "Increase (decrease) in cash associated with the entity's discontinued operations." } } }, "auth_ref": ["r73"] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "presentation": ["http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": ["r128"] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": ["http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash Flows from Financing Activities:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "presentation": ["http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash provided by investing activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": ["r128"] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": ["http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "verboseLabel": "Cash Flows from Investing Activities:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "presentation": ["http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": ["r73", "r74", "r75"] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": ["http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash Flows from Operating Activities:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "presentation": ["http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations", "totalLabel": "Net cash used in operating activities - continuing operations", "documentation": "Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": ["r73", "r74", "r75"] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "presentation": ["http://www.tapimmune.com/role/DisclosureNetLossPerShareComputationOfLossPerShareDetails", "http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations", "http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "totalLabel": "Net loss", "verboseLabel": "Net loss", "label": "Net Income (Loss)", "terseLabel": "Net Income (Loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": ["r71", "r75", "r96", "r110", "r121", "r122", "r125", "r132", "r140", "r142", "r143", "r144", "r145", "r146", "r149", "r150", "r155", "r175", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r272", "r275", "r293", "r298", "r341", "r403", "r423", "r424", "r482", "r596"] }, "us-gaap_NetIncomeLossAttributableToParentDilutedAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAttributableToParentDilutedAbstract", "presentation": ["http://www.tapimmune.com/role/DisclosureNetLossPerShareComputationOfLossPerShareDetails"], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Attributable to Parent, Diluted [Abstract]", "verboseLabel": "Numerator:" } } }, "auth_ref": [] }, "mrkr_NetLossPerShareTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.tapimmune.com/20240930", "localname": "NetLossPerShareTableTextBlock", "presentation": ["http://www.tapimmune.com/role/DisclosureNetLossPerShareTables"], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of net loss per share.", "label": "Net Loss Per Share [Table Text Block]", "terseLabel": "Schedule of anti-dilutive securities" } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-GAAP Measure Description [Text Block]", "terseLabel": "Non-GAAP Measure Description" } } }, "auth_ref": ["r533"] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonNeosMember", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Non-NEOs [Member]", "terseLabel": "Non-NEOs" } } }, "auth_ref": ["r497", "r507", "r517", "r541", "r549"] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Compensation Actually Paid Amount", "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": ["r524"] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Total Compensation Amount", "terseLabel": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": ["r523"] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-PEO NEO [Member]", "terseLabel": "Non-PEO NEO" } } }, "auth_ref": ["r541"] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": ["r560"] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": ["r560"] }, "us-gaap_NoncontrollingInterestAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncontrollingInterestAbstract", "lang": { "en-us": { "role": { "label": "NET LOSS PER SHARE" } } }, "auth_ref": [] }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": ["http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense) [Abstract]", "verboseLabel": "Other income (expenses):" } } }, "auth_ref": [] }, "mrkr_OffersEmploymentToNumberOfEmployees": { "xbrltype": "integerItemType", "nsuri": "http://www.tapimmune.com/20240930", "localname": "OffersEmploymentToNumberOfEmployees", "presentation": ["http://www.tapimmune.com/role/DisclosureNatureOfOperationsDetails"], "lang": { "en-us": { "role": { "documentation": "The number of employees extended for employment.", "label": "Offers Employment to Number of Employees", "terseLabel": "Number of former employees offered employment" } } }, "auth_ref": [] }, "us-gaap_OperatingCostsAndExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingCostsAndExpenses", "crdr": "debit", "presentation": ["http://www.tapimmune.com/role/DisclosureRelatedPartyExpensesDetails"], "lang": { "en-us": { "role": { "label": "Related Party Transaction, Expenses from Transactions with Related Party", "terseLabel": "Total Research and development", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense." } } }, "auth_ref": [] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpenses", "crdr": "debit", "presentation": ["http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Operating

Expenses", "totalLabel": "Total operating expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "presentation": ["http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Operating Income (Loss)", "totalLabel": "Loss from operations", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": ["r99", "r453", "r586", "r587", "r588", "r589", "r590"] }, "us-gaap_OptionIndexedToIssuersEquityTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OptionIndexedToIssuersEquityTypeAxis", "presentation": ["http://www.tapimmune.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Option Indexed to Issuer's Equity, Type [Axis]", "documentation": "Information by type of freestanding contracts issued by an entity that are indexed to, and potentially settled in, an entity's own stock." } } }, "auth_ref": ["r20", "r31", "r32", "r92"] }, "us-gaap_OptionIndexedToIssuersEquityTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OptionIndexedToIssuersEquityTypeDomain", "presentation": ["http://www.tapimmune.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Option Indexed to Issuer's Equity, Type [Domain]", "documentation": "Description of the type of freestanding contract issued by a Company that is indexed to, and potentially settled in, a Company's own stock. Specifically, the pertinent rights and privileges of the securities outstanding." } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "NATURE OF OPERATIONS" } } }, "auth_ref": [] }, "mrkr_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.tapimmune.com/20240930", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems", "presentation": ["http://www.tapimmune.com/role/DisclosureNatureOfOperationsDetails"], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Organization, Consolidation and Presentation of Financial Statements [Line Items]", "terseLabel": "NATURE OF OPERATIONS" } } }, "auth_ref": [] }, "mrkr_OrganizationConsolidationAndPresentationOfFinancialStatementsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.tapimmune.com/20240930", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsTable", "presentation": ["http://www.tapimmune.com/role/DisclosureNatureOfOperationsDetails"], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about organization, consolidation and presentation of financial statements.", "label": "Organization, Consolidation and Presentation of Financial Statements" } } }, "auth_ref": [] }, "mrkr_OrphanProductsGrantProgram": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tapimmune.com/20240930", "localname": "OrphanProductsGrantProgram", "crdr": "debit", "presentation": ["http://www.tapimmune.com/role/DisclosureLiquidityAndFinancialConditionDetails", "http://www.tapimmune.com/role/DisclosureOtherReceivableDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of receivable from Orphan Products Grant program.", "label": "Orphan Products Grant Program", "terseLabel": "Grant income receivable" } } }, "auth_ref": [] }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "presentation": ["http://www.tapimmune.com/role/DisclosureAccountsPayableAccruedLiabilitiesAndRelatedPartyPayableDetails"], "lang": { "en-us": { "role": { "label": "Other Accrued Liabilities, Current", "verboseLabel": "Other", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r55"] }, "us-gaap_OtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesCurrent", "crdr": "credit", "presentation": ["http://www.tapimmune.com/role/DisclosureAccountsPayableAccruedLiabilitiesAndRelatedPartyPayableDetails", "http://www.tapimmune.com/role/DisclosureRelatedPartyExpensesDetails", "http://www.tapimmune.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Due to Related Parties, Current", "terseLabel": "Related party payable", "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r55", "r468"] }, "us-gaap_OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration", "presentation": ["http://www.tapimmune.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Other Liability, Current, Related Party, Type [Extensible Enumeration]", "documentation": "Indicates status and type of related party for liability classified as other and current." } } }, "auth_ref": ["r608"] }, "us-gaap_OtherOperatingIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherOperatingIncome", "crdr": "credit", "presentation": ["http://www.tapimmune.com/role/DisclosureDiscontinuedOperationsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Other Operating Income", "terseLabel": "Agreement amount on cash payment", "documentation": "The total amount of other operating income, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operation." } } }, "auth_ref": ["r68"] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Other Performance Measure, Amount", "terseLabel": "Other Performance Measure, Amount" } } }, "auth_ref": ["r533"] }, "us-gaap_OtherReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherReceivables", "crdr": "debit", "presentation": ["http://www.tapimmune.com/role/DisclosureLiquidityAndFinancialConditionDetails"], "lang": { "en-us": { "role": { "label": "Other Receivables", "terseLabel": "Other receivables", "documentation": "Amount due from parties in nontrade transactions, classified as other." } } }, "auth_ref": ["r118", "r390", "r455", "r622"] }, "us-gaap_OtherReceivablesNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherReceivablesNetCurrent", "crdr": "debit", "presentation": ["http://www.tapimmune.com/role/DisclosureOtherReceivableDetails", "http://www.tapimmune.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Other Receivables, Net, Current", "terseLabel": "Other receivables", "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer." } } }, "auth_ref": [] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount", "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": ["r495", "r505", "r515", "r547"] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Outstanding Recovery Compensation Amount", "terseLabel": "Compensation Amount" } } }, "auth_ref": ["r498", "r508", "r518", "r550"] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Outstanding Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r498", "r508", "r518", "r550"] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": ["r522"] }, "us-gaap_PayablesAndAccrualsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PayablesAndAccrualsAbstract", "lang": { "en-us": { "role": { "label": "ACCOUNTS PAYABLE, ACCRUED LIABILITIES AND RELATED PARTY PAYABLE" } } }, "auth_ref": [] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Peer Group Issuers, Footnote [Text Block]", "terseLabel": "Peer Group Issuers, Footnote" } } }, "auth_ref": ["r532"] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Peer Group Total Shareholder Return Amount", "terseLabel": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": ["r532"] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO Actually Paid Compensation Amount", "terseLabel": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": ["r524"] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO [Member]", "terseLabel": "PEO" } } }, "auth_ref": ["r541"] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO Name", "terseLabel": "PEO Name" } } }, "auth_ref": ["r534"] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO Total Compensation Amount", "terseLabel": "PEO Total Compensation Amount" } } }, "auth_ref": ["r523"] }, "ecd_PnsnAdjsPrrSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsPrrSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pension Adjustments Prior Service Cost [Member]", "terseLabel": "Pension Adjustments Prior Service Cost" } } }, "auth_ref": ["r525"] }, "ecd_PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pension

Adjustments Service Cost [Member]", "terseLabel": "Pension Adjustments Service Cost" } } }, "auth_ref": ["r569"] }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pension Benefits Adjustments, Footnote [Text Block]", "terseLabel": "Pension Benefits Adjustments, Footnote" } } }, "auth_ref": ["r524"] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": ["http://www.tapimmune.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock par value (in $ per share)", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": ["r61", "r199"] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesAuthorized", "presentation": ["http://www.tapimmune.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock authorized (in shares)", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r61", "r382"] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesIssued", "presentation": ["http://www.tapimmune.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock issued", "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt." } } }, "auth_ref": ["r61", "r199"] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesOutstanding", "presentation": ["http://www.tapimmune.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": ["r61", "r382", "r401", "r656", "r657"] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockValue", "crdr": "credit", "presentation": ["http://www.tapimmune.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred stock, $0.001 par value, 5 million shares authorized, 0 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": ["r61", "r333", "r468"] }, "us-gaap_PrepaidExpenseCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseCurrent", "crdr": "debit", "presentation": ["http://www.tapimmune.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Prepaid Expense, Current", "terseLabel": "Prepaid expenses and deposits", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r119", "r178", "r179", "r446"] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "presentation": ["http://www.tapimmune.com/role/DisclosureLiquidityAndFinancialConditionDetails", "http://www.tapimmune.com/role/DisclosureStockholdersEquityReverseStockSplitAndAtmAgreementDetails", "http://www.tapimmune.com/role/DisclosureStockholdersEquityStockPurchaseAgreementAndExerciseOfStockOptionsDetails", "http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Proceeds from Issuance of Common Stock", "verboseLabel": "Proceeds from issuance of common stock, net", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": ["r1"] }, "us-gaap_ProceedsFromStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromStockOptionsExercised", "crdr": "debit", "presentation": ["http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Proceeds from Stock Options Exercised", "verboseLabel": "Proceeds from stock options exercise", "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement." } } }, "auth_ref": ["r1", "r9"] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductOrServiceAxis", "presentation": ["http://www.tapimmune.com/role/DisclosureDiscontinuedOperationsAdditionalInformationDetails", "http://www.tapimmune.com/role/DisclosureDiscontinuedOperationsOperationsDetails", "http://www.tapimmune.com/role/DisclosureGrantIncomeDetails", "http://www.tapimmune.com/role/DisclosureLiquidityAndFinancialConditionDetails", "http://www.tapimmune.com/role/DisclosureOtherReceivableDetails", "http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "auth_ref": ["r171", "r325", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r444", "r458", "r469", "r470", "r471", "r472", "r473", "r594", "r595", "r599", "r624", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653"] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductsAndServicesDomain", "presentation": ["http://www.tapimmune.com/role/DisclosureDiscontinuedOperationsAdditionalInformationDetails", "http://www.tapimmune.com/role/DisclosureDiscontinuedOperationsOperationsDetails", "http://www.tapimmune.com/role/DisclosureGrantIncomeDetails", "http://www.tapimmune.com/role/DisclosureLiquidityAndFinancialConditionDetails", "http://www.tapimmune.com/role/DisclosureOtherReceivableDetails", "http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]" } } }, "auth_ref": ["r171", "r325", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r444", "r458", "r469", "r470", "r471", "r472", "r473", "r594", "r595", "r599", "r624", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653"] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProfitLoss", "crdr": "credit", "presentation": ["http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "totalLabel": "Net loss", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": ["r110", "r121", "r122", "r127", "r132", "r140", "r146", "r149", "r150", "r175", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r272", "r275", "r277", "r280", "r281", "r293", "r298", "r329", "r340", "r370", "r403", "r423", "r424", "r461", "r462", "r483", "r576", "r596"] }, "us-gaap_ProjectMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProjectMember", "presentation": ["http://www.tapimmune.com/role/DisclosureOtherReceivableDetails"], "lang": { "en-us": { "role": { "label": "Project [Domain]", "documentation": "Planned program of work." } } }, "auth_ref": ["r326", "r327", "r618"] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Table]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": ["r522"] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pay vs Performance [Table Text Block]", "terseLabel": "Pay vs Performance Disclosure, Table" } } }, "auth_ref": ["r522"] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": ["http://www.tapimmune.com/role/DisclosureNatureOfOperationsDetails", "http://www.tapimmune.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "auth_ref": ["r184", "r185", "r186", "r187", "r226", "r228", "r253", "r254", "r255", "r263", "r294", "r321", "r322", "r324", "r351", "r353", "r360", "r373", "r374", "r433", "r434", "r435", "r436", "r437", "r440", "r441", "r456", "r457", "r459", "r464", "r465", "r466", "r467", "r470", "r476", "r593", "r598", "r604", "r612", "r613", "r614", "r615", "r616"] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": ["http://www.tapimmune.com/role/DisclosureNatureOfOperationsDetails", "http://www.tapimmune.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]" } } }, "auth_ref": ["r184", "r185", "r186", "r187", "r226", "r228", "r253", "r254", "r255", "r263", "r294", "r321", "r322", "r324", "r351", "r353", "r360", "r373", "r374", "r433", "r434", "r435", "r436", "r437", "r440", "r441", "r456", "r457", "r459", "r464", "r465", "r466", "r467", "r470", "r476", "r593", "r598", "r604", "r612", "r613", "r614", "r615", "r616"] }, "mrkr_ReceiptOfProductDevelopmentResearchAward": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tapimmune.com/20240930", "localname": "ReceiptOfProductDevelopmentResearchAward", "crdr": "debit", "presentation": ["http://www.tapimmune.com/role/DisclosureGrantIncomeDetails"], "lang": { "en-us": { "role": { "documentation": "Receipt of product development research award", "label": "Receipt Of Product Development Research Award", "terseLabel": "Receipt of product development research award" } } }, "auth_ref": [] }, "us-gaap_ReceivablesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-

gaap/2024", "localname": "ReceivablesAbstract", "lang": { "en-us": { "role": { "label": "OTHER RECEIVABLE" } } }, "auth_ref": [] }, "us-gaap_ReceivablesWithImputedInterestLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReceivablesWithImputedInterestLineItems", "presentation": ["http://www.tapimmune.com/role/DisclosureOtherReceivableDetails"], "lang": { "en-us": { "role": { "label": "Receivables with Imputed Interest [Line Items]", "terseLabel": "OTHER RECEIVABLE", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r606", "r607"] },
"mrkr_RecentlyIssuedAccountingStandardsNotYetAdoptedPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.tapimmune.com/20240930", "localname": "RecentlyIssuedAccountingStandardsNotYetAdoptedPolicyTextBlock", "presentation": ["http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for recently issued accounting standards not yet adopted.", "label": "Recently Issued Accounting Standards Not yet Adopted [Policy Text Block]", "terseLabel": "Recently Issued Accounting Standards Not Yet Adopted" } } }, "auth_ref": [] },
"ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]", "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure" } } }, "auth_ref": ["r490", "r500", "r510", "r542"] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyDomain", "presentation": ["http://www.tapimmune.com/role/DisclosureAccountsPayableAccruedLiabilitiesAndRelatedPartyPayableDetails",
"http://www.tapimmune.com/role/DisclosureDiscontinuedOperationsAdditionalInformationDetails",
"http://www.tapimmune.com/role/DisclosureLiquidityAndFinancialConditionDetails",
"http://www.tapimmune.com/role/DisclosureRelatedPartyExpensesDetails",
"http://www.tapimmune.com/role/DisclosureStockholdersEquityStockPurchaseAgreementAndExerciseOfStockOptionsDetails"], "lang": { "en-us": { "role": { "label": "Related Party [Domain]", "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": ["r174", "r227", "r313", "r314", "r332", "r337", "r376", "r377", "r378", "r379", "r380", "r400", "r402", "r432"] }, "us-gaap_RelatedPartyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyMember", "presentation": ["http://www.tapimmune.com/role/DisclosureAccountsPayableAccruedLiabilitiesAndRelatedPartyPayableDetails",
"http://www.tapimmune.com/role/DisclosureDiscontinuedOperationsAdditionalInformationDetails",
"http://www.tapimmune.com/role/DisclosureRelatedPartyExpensesDetails"], "lang": { "en-us": { "role": { "label": "Related Party [Member]", "terseLabel": "Related party", "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family." } } }, "auth_ref": ["r133", "r134", "r313", "r314", "r315", "r316", "r332", "r337", "r376", "r377", "r378", "r379", "r380", "r400", "r402", "r432"] }, "mrkr_RelatedPartyServiceMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tapimmune.com/20240930", "localname": "RelatedPartyServiceMember", "presentation": [
"http://www.tapimmune.com/role/DisclosureDiscontinuedOperationsAdditionalInformationDetails",
"http://www.tapimmune.com/role/DisclosureDiscontinuedOperationsOperationsDetails"], "lang": { "en-us": { "role": { "documentation": "This member stands for related party service.", "label": "Related Party Service [Member]", "terseLabel": "Related party service revenue" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionLineItems", "presentation": ["http://www.tapimmune.com/role/DisclosureRelatedPartyExpensesDetails"], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Line Items]", "terseLabel": "RELATED PARTY EXPENSES", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r174", "r406", "r407", "r410"] }, "us-gaap_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "label": "RELATED PARTY EXPENSES" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": [
"http://www.tapimmune.com/role/DisclosureAccountsPayableAccruedLiabilitiesAndRelatedPartyPayableDetails",
"http://www.tapimmune.com/role/DisclosureDiscontinuedOperationsAdditionalInformationDetails",
"http://www.tapimmune.com/role/DisclosureLiquidityAndFinancialConditionDetails",
"http://www.tapimmune.com/role/DisclosureRelatedPartyExpensesDetails",
"http://www.tapimmune.com/role/DisclosureStockholdersEquityStockPurchaseAgreementAndExerciseOfStockOptionsDetails"], "lang": { "en-us": { "role": { "label": "Related Party [Axis]", "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": ["r174", "r227", "r313", "r314", "r332", "r337", "r376", "r377", "r378", "r379", "r380", "r400", "r402", "r432", "r608"] }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": [
"http://www.tapimmune.com/role/DisclosureRelatedPartyExpenses"], "lang": { "en-us": { "role": { "label": "Related Party Transactions Disclosure [Text Block]", "verboseLabel": "RELATED PARTY EXPENSES", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": ["r310", "r311", "r312", "r314", "r317", "r367", "r368", "r369", "r408", "r409", "r410", "r429", "r431"] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": [
"http://www.tapimmune.com/role/DisclosureAccountsPayableAccruedLiabilitiesAndRelatedPartyPayableDetails",
"http://www.tapimmune.com/role/DisclosureLiquidityAndFinancialConditionDetails",
"http://www.tapimmune.com/role/DisclosureRelatedPartyExpensesDetails"], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]" } } }, "auth_ref": ["r135", "r136", "r197", "r201", "r316", "r323", "r330", "r448", "r449"] }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned", "crdr": "credit", "presentation": ["http://www.tapimmune.com/role/DisclosureLiquidityAndFinancialConditionDetails"], "lang": { "en-us": { "role": { "label": "Research and Development Arrangement, Contract to Perform for Others, Compensation Earned", "terseLabel": "Amount of notice received", "documentation": "The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others." } } }, "auth_ref": ["r265"] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "presentation": ["http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Research and Development Expense", "terseLabel": "Research and development", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": ["r264", "r442", "r454", "r617"] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": [
"http://www.tapimmune.com/role/DisclosureDiscontinuedOperationsOperationsDetails",
"http://www.tapimmune.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpensesDetails"], "lang": { "en-us": { "role": { "label": "Research and Development [Member]", "terseLabel": "Research and development", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Restatement Determination Date [Axis]", "terseLabel": "Restatement Determination Date:" } } }, "auth_ref": ["r491", "r501", "r511", "r543"] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Restatement Determination Date", "terseLabel": "Restatement Determination Date" } } }, "auth_ref": ["r492", "r502", "r512", "r544"] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Restatement Does Not Require Recovery [Text Block]", "terseLabel": "Restatement does not require Recovery" } } }, "auth_ref": ["r499", "r509", "r519", "r551"] }, "us-gaap_RestrictedCash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCash", "crdr": "debit", "presentation": ["http://www.tapimmune.com/role/DisclosureGrantIncomeDetails"], "lang": { "en-us": { "role": { "label": "Restricted Cash", "terseLabel": "Restricted cash recorded", "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": ["r574", "r578", "r619", "r621"] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "presentation": [
"http://www.tapimmune.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Retained Earnings

(Accumulated Deficit)", "terseLabel": "Accumulated deficit", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r64", "r85", "r335", "r358", "r359", "r366", "r383", "r468"] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": ["http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r108", "r137", "r138", "r139", "r141", "r146", "r148", "r150", "r176", "r177", "r180", "r266", "r267", "r269", "r270", "r271", "r273", "r274", "r275", "r284", "r286", "r287", "r289", "r291", "r307", "r308", "r355", "r357", "r371", "r656"] }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerAbstract", "lang": { "en-us": { "role": { "label": "GRANT INCOME" } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerIncludingAssessedTax", "crdr": "credit", "presentation": ["http://www.tapimmune.com/role/DisclosureDiscontinuedOperationsAdditionalInformationDetails", "http://www.tapimmune.com/role/DisclosureGrantIncomeDetails", "http://www.tapimmune.com/role/DisclosureLiquidityAndFinancialConditionDetails", "http://www.tapimmune.com/role/DisclosureOtherReceivableDetails", "http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer, Including Assessed Tax", "terseLabel": "Revenue recognized", "verboseLabel": "Total revenues", "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise." } } }, "auth_ref": ["r97", "r98", "r161", "r165", "r166", "r168", "r170", "r171", "r172", "r173", "r223", "r224", "r325"] }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerTextBlock", "presentation": ["http://www.tapimmune.com/role/DisclosureGrantIncome"], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Text Block]", "terseLabel": "GRANT INCOME", "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts." } } }, "auth_ref": ["r107", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r225"] }, "mrkr_RevenueFromGrantRelatedToCprit": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tapimmune.com/20240930", "localname": "RevenueFromGrantRelatedToCprit", "crdr": "credit", "presentation": ["http://www.tapimmune.com/role/DisclosureLiquidityAndFinancialConditionDetails"], "lang": { "en-us": { "role": { "documentation": "Revenue from grant related to CPRIT.", "label": "Revenue From Grant Related to CPRIT", "terseLabel": "Revenue from CPRIT" } } }, "auth_ref": [] }, "mrkr_RevenueFromOrphanProductsGrantProgram": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tapimmune.com/20240930", "localname": "RevenueFromOrphanProductsGrantProgram", "crdr": "credit", "presentation": ["http://www.tapimmune.com/role/DisclosureOtherReceivableDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized for grant from Orphan Products Grant program.", "label": "Revenue From Orphan Products Grant Program", "terseLabel": "Grant revenue" } } }, "auth_ref": [] }, "us-gaap_RevenuesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenuesAbstract", "presentation": ["http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Revenues [Abstract]", "terseLabel": "Revenues:" } } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": ["r560"] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmntdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": ["r560"] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": ["http://www.tapimmune.com/role/DisclosureStockholdersEquityReverseStockSplitAndAtmAgreementDetails", "http://www.tapimmune.com/role/DisclosureStockholdersEquityStockPurchaseAgreementAndExerciseOfStockOptionsDetails"], "lang": { "en-us": { "role": { "label": "Sale of Stock [Domain]", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "presentation": ["http://www.tapimmune.com/role/DisclosureAccountsPayableAccruedLiabilitiesAndRelatedPartyPayableTables"], "lang": { "en-us": { "role": { "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]", "verboseLabel": "Schedule of accounts payable, accrued liabilities and related party payable", "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": ["http://www.tapimmune.com/role/DisclosureNetLossPerShareDilutiveSecuritiesDetails"], "lang": { "en-us": { "role": { "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS." } } }, "auth_ref": ["r16"] }, "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "presentation": ["http://www.tapimmune.com/role/DisclosureDiscontinuedOperationsTables"], "lang": { "en-us": { "role": { "label": "Disposal Groups, Including Discontinued Operations [Table Text Block]", "terseLabel": "Schedule of income statement information and summary of cash flows for discontinued operations", "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component." } } }, "auth_ref": ["r5", "r10", "r12", "r36", "r42", "r43", "r44", "r45", "r46", "r49", "r51", "r52", "r79"] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": ["http://www.tapimmune.com/role/DisclosureNetLossPerShareTables"], "lang": { "en-us": { "role": { "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "verboseLabel": "Schedule of computation of net loss per share", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": ["r585"] }, "us-gaap_ScheduleOfReceivablesWithImputedInterestTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfReceivablesWithImputedInterestTable", "presentation": ["http://www.tapimmune.com/role/DisclosureOtherReceivableDetails"], "lang": { "en-us": { "role": { "label": "Schedule of Receivables with Imputed Interest [Table]", "documentation": "Disclosure of information about receivable with discount or premium resulting from determination of present value in cash or noncash transaction. Includes, but is not limited to, description of receivable, amortization period and method, effective interest rate, and face amount." } } }, "auth_ref": ["r606", "r607"] }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "presentation": ["http://www.tapimmune.com/role/DisclosureRelatedPartyExpensesDetails"], "lang": { "en-us": { "role": { "label": "Schedule of Related Party Transactions, by Related Party [Table]", "documentation": "Disclosure of information about related party transaction." } } }, "auth_ref": ["r33", "r34", "r406", "r407", "r410"] }, "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock", "presentation": ["http://www.tapimmune.com/role/DisclosureRelatedPartyExpensesTables"], "lang": { "en-us": { "role": { "label": "Schedule of Related Party Transactions [Table Text Block]", "terseLabel": "Schedule of related party transaction expenses", "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock", "presentation": ["http://www.tapimmune.com/role/DisclosureStockBasedCompensationTables"], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement, Activity [Table Text Block]", "terseLabel": "Schedule of the company's stock option activity", "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value." } } }, "auth_ref": ["r7", "r8", "r87"] }, "us-gaap_ScheduleOfStockByClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfStockByClassTable", "presentation": [

"http://www.tapimmune.com/role/DisclosureStockholdersEquityReverseStockSplitAndAtmAgreementDetails"], "lang": { "en-us": { "role": { "label": "Schedule of Stock by Class [Table]", "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks." } } }, "auth_ref": ["r21", "r22", "r23", "r24", "r25", "r26", "r81", "r83", "r84", "r85", "r115", "r116", "r117", "r163", "r199", "r200", "r201", "r203", "r206", "r211", "r213", "r362", "r363", "r364", "r365", "r457", "r571", "r579"] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": ["http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": ["r485"] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": ["http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": ["r487"] }, "us-gaap_ServiceMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ServiceMember", "presentation": ["http://www.tapimmune.com/role/DisclosureDiscontinuedOperationsOperationsDetails"], "lang": { "en-us": { "role": { "label": "Service [Member]", "terseLabel": "Service Revenue", "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service." } } }, "auth_ref": ["r458"] }, "us-gaap_SeveranceCosts1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SeveranceCosts1", "crdr": "debit", "presentation": ["http://www.tapimmune.com/role/DisclosureNatureOfOperationsDetails"], "lang": { "en-us": { "role": { "label": "Severance Costs", "terseLabel": "Severance and termination-related costs", "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation." } } }, "auth_ref": ["r4"] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "presentation": ["http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": ["r3"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": ["http://www.tapimmune.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number", "verboseLabel": "Number of Shares, Options vested and exercisable", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": ["r236"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "presentation": ["http://www.tapimmune.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "verboseLabel": "Weighted Average Exercise Price, Options vested and exercisable", "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } }, "auth_ref": ["r236"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": ["http://www.tapimmune.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period", "negatedLabel": "Number of Shares, Cancelled / Expired", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } }, "auth_ref": ["r240"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": ["http://www.tapimmune.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel": "Total Intrinsic Value Outstanding", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": ["r27"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": ["http://www.tapimmune.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Number of Shares Outstanding, Ending Balance", "periodStartLabel": "Number of Shares Outstanding, Beginning Balance", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": ["r234", "r235"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": ["http://www.tapimmune.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Weighted Average Exercise Price per Share, Outstanding, Ending Balance", "periodStartLabel": "Weighted Average Exercise Price per Share, Outstanding, Beginning Balance", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": ["r234", "r235"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod", "presentation": ["http://www.tapimmune.com/role/DisclosureStockBasedCompensationAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period", "terseLabel": "Number of equity incentive awards issued (in shares)", "documentation": "Number of shares issued under share-based payment arrangement." } } }, "auth_ref": ["r27"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "All Award Types", "terseLabel": "All Award Types", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": ["r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": ["http://www.tapimmune.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "verboseLabel": "Weighted Average Exercise Price per Share, Exercised", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": ["r239"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": ["http://www.tapimmune.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "verboseLabel": "Weighted Average Exercise Price per Share, Cancelled / Expired", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } } }, "auth_ref": ["r240"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "crdr": "debit", "presentation": ["http://www.tapimmune.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value", "verboseLabel": "Total Intrinsic Value, Options vested and exercisable", "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable." } } }, "auth_ref": ["r27"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":

"SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": ["http://www.tapimmune.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted Average Remaining Contractual Life, Outstanding (in years)", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r88"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingC { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContr "presentation": ["http://www.tapimmune.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted Average Remaining Contractual Life, Options vested and exercisable (in years)", "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": ["r251"] }, "us-gaap_SharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesIssued", "presentation": ["http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Shares, Issued", "periodEndLabel": "Ending Balance, Shares", "periodStartLabel": "Beginning Balance, Shares", "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury." } } }, "auth_ref": ["r6"] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": ["http://www.tapimmune.com/role/DisclosureSignificantAccountingPolicies"], "lang": { "en-us": { "role": { "label": "Significant Accounting Policies [Text Block]", "terseLabel": "SIGNIFICANT ACCOUNTING POLICIES", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": ["r76", "r130"] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": ["http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": ["r6", "r62", "r65", "r66", "r108", "r123", "r124", "r125", "r137", "r138", "r139", "r141", "r146", "r148", "r150", "r162", "r176", "r177", "r180", "r214", "r266", "r267", "r269", "r270", "r271", "r273", "r274", "r275", "r284", "r285", "r286", "r287", "r288", "r289", "r291", "r299", "r300", "r301", "r302", "r303", "r304", "r307", "r308", "r309", "r342", "r355", "r356", "r357", "r371", "r425"] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": ["http://www.tapimmune.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical", "http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations", "http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Statements", "verboseLabel": "Statement", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r137", "r138", "r139", "r162", "r308", "r325", "r361", "r372", "r375", "r376", "r377", "r378", "r379", "r380", "r382", "r385", "r386", "r387", "r388", "r389", "r391", "r392", "r393", "r394", "r396", "r397", "r398", "r399", "r400", "r402", "r404", "r405", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r425", "r477"] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "CONDENSED CONSOLIDATED BALANCE SHEETS" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": ["http://www.tapimmune.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical", "http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations", "http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": ["r137", "r138", "r139", "r162", "r174", "r308", "r325", "r361", "r372", "r375", "r376", "r377", "r378", "r379", "r380", "r382", "r385", "r386", "r387", "r388", "r389", "r391", "r392", "r393", "r394", "r396", "r397", "r398", "r399", "r400", "r402", "r404", "r405", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r425", "r477"] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Stock Price or TSR Estimation Method [Text Block]", "terseLabel": "Stock Price or TSR Estimation Method" } } }, "auth_ref": ["r494", "r504", "r514", "r546"] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockAppreciationRightsSARSMember", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Stock Appreciation Rights (SARs) [Member]", "terseLabel": "Stock Appreciation Rights (SARs)", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "mrkr_StockBasedCompensationExpensesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.tapimmune.com/20240930", "localname": "StockBasedCompensationExpensesTableTextBlock", "presentation": ["http://www.tapimmune.com/role/DisclosureStockBasedCompensationTables"], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of stock based compensation expenses recorded.", "label": "Stock based Compensation Expenses [Table Text Block]", "terseLabel": "Schedule of stock-based compensation expenses" } } }, "auth_ref": [] }, "mrkr_StockBasedCompensationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.tapimmune.com/20240930", "localname": "StockBasedCompensationLineItems", "presentation": ["http://www.tapimmune.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpensesDetails", "http://www.tapimmune.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"], "lang": { "en-us": { "role": { "documentation": "Line items represent stock-based compensation.", "label": "Stock-Based Compensation [Line Items]", "terseLabel": "STOCK-BASED COMPENSATION" } } }, "auth_ref": [] }, "mrkr_StockBasedCompensationTable": { "xbrltype": "stringItemType", "nsuri": "http://www.tapimmune.com/20240930", "localname": "StockBasedCompensationTable", "presentation": ["http://www.tapimmune.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpensesDetails", "http://www.tapimmune.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"], "lang": { "en-us": { "role": { "documentation": "This table lists the stock-based compensation.", "label": "Stock-Based Compensation [Table]" } } }, "auth_ref": [] }, "mrkr_StockCompensationInContinuingOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tapimmune.com/20240930", "localname": "StockCompensationInContinuingOperations", "crdr": "debit", "presentation": ["http://www.tapimmune.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpensesDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of expense for Stock compensation in continuing operations.", "label": "Stock Compensation In Continuing Operations", "terseLabel": "Stock compensation in continuing operations" } } }, "auth_ref": [] }, "mrkr_StockCompensationInDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tapimmune.com/20240930", "localname": "StockCompensationInDiscontinuedOperations", "crdr": "debit", "presentation": ["http://www.tapimmune.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpensesDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of expense for Stock compensation in discontinued operations.", "label": "Stock Compensation In Discontinued Operations", "verboseLabel": "Stock compensation in discontinued operations" } } }, "auth_ref": [] }, "mrkr_StockIssuedDuringPeriodSharesFractionalSharesAdjustmentDueToReverseSplit": { "xbrltype": "sharesItemType", "nsuri": "http://www.tapimmune.com/20240930", "localname": "StockIssuedDuringPeriodSharesFractionalSharesAdjustmentDueToReverseSplit", "presentation": ["http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "documentation": "Reduction in the number of shares during the period as a result of a fractional shares adjustment due to reverse split.", "label": "Stock Issued During Period, Shares, Fractional Shares Adjustment Due to Reverse Split", "terseLabel": "Fractional shares adjustment due to reverse split" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": ["http://www.tapimmune.com/role/DisclosureLiquidityAndFinancialConditionDetails", "http://www.tapimmune.com/role/DisclosureStockholdersEquityReverseStockSplitAndAtmAgreementDetails", "http://www.tapimmune.com/role/DisclosureStockholdersEquityStockPurchaseAgreementAndExerciseOfStockOptionsDetails", "http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Shares purchased pursuant to ATM agreement (in shares)", "verboseLabel": "Number of shares issued (in shares)", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": ["r6", "r61", "r62", "r85", "r362", "r425", "r438"] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [

"http://www.tapimmune.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails",
"http://www.tapimmune.com/role/DisclosureStockholdersEquityStockPurchaseAgreementAndExerciseOfStockOptionsDetails",
"http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label":
"Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "negatedTerseLabel": "Number of Shares,
Exercised", "terseLabel": "Issuance of common stock from exercise of stock options (in shares)", "verboseLabel": "Issuance of common stock from
exercise of stock options (in shares)", "documentation": "Number of share options (or share units) exercised during the current period." } } },
"auth_ref": ["r6", "r61", "r62", "r85", "r239"] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": [
"http://www.tapimmune.com/role/DisclosureStockholdersEquityStockPurchaseAgreementAndExerciseOfStockOptionsDetails",
"http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Stock
Issued During Period, Value, New Issues", "terseLabel": "Shares purchased pursuant to ATM agreement", "verboseLabel": "Aggregate proceeds
from shares issued under the purchase agreement", "documentation": "Equity impact of the value of new stock issued during the period. Includes
shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": ["r6", "r61", "r62", "r85", "r371", "r425", "r438", "r483"
] }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "crdr": "credit", "presentation": [
"http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label":
"Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture", "terseLabel": "Stock-based compensation", "documentation": "Value,
after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)." } } }, "auth_ref": [
"r28", "r61", "r62", "r85"] }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "crdr": "credit", "presentation": [
"http://www.tapimmune.com/role/DisclosureStockholdersEquityStockPurchaseAgreementAndExerciseOfStockOptionsDetails",
"http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Stock
Issued During Period, Value, Stock Options Exercised", "verboseLabel": "Issuance of common stock from exercise of stock options",
"documentation": "Value of stock issued as a result of the exercise of stock options." } } }, "auth_ref": ["r6", "r62", "r65", "r66", "r85"] },
"mrkr_StockPurchaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tapimmune.com/20240930", "localname":
"StockPurchaseAgreementMember", "presentation": [
"http://www.tapimmune.com/role/DisclosureStockholdersEquityStockPurchaseAgreementAndExerciseOfStockOptionsDetails"], "lang": { "en-us": {
"role": { "documentation": "This Member represents stock purchase agreement", "label": "Stock Purchase Agreement [Member]", "terseLabel":
"Stock Purchase Agreement" } } }, "auth_ref": [] }, "mrkr_StockPurchaseAgreementTimeToTimeTermToPurchaseShares": { "xbrltype":
"durationItemType", "nsuri": "http://www.tapimmune.com/20240930", "localname":
"StockPurchaseAgreementTimeToTimeTermToPurchaseShares", "presentation": [
"http://www.tapimmune.com/role/DisclosureStockholdersEquityStockPurchaseAgreementAndExerciseOfStockOptionsDetails"], "lang": { "en-us": {
"role": { "documentation": "The time to time term to purchase shares in stock purchase agreement, in PnYnMnDTnHnMnS' format, for example,
'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Stock Purchase Agreement, Time to Time Term to
Purchase Shares", "terseLabel": "Time to time term to purchase shares (in months)" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquity": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "presentation": [
"http://www.tapimmune.com/role/StatementCondensedConsolidatedBalanceSheets",
"http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label":
"Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending Balance", "periodStartLabel": "Beginning Balance", "totalLabel": "Total
stockholders' equity", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to
noncontrolling interest." } } }, "auth_ref": ["r62", "r65", "r66", "r77", "r384", "r401", "r426", "r427", "r468", "r484", "r580", "r592", "r605", "r656"]
}, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"StockholdersEquityAbstract", "presentation": ["http://www.tapimmune.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-
us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders' equity:" } } }, "auth_ref": [] }, "us-
gaap_StockholdersEquityNoteAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"StockholdersEquityNoteAbstract", "lang": { "en-us": { "role": { "label": "STOCKHOLDERS' EQUITY" } } }, "auth_ref": [] }, "us-
gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"StockholdersEquityNoteDisclosureTextBlock", "presentation": ["http://www.tapimmune.com/role/DisclosureStockholdersEquity"], "lang": { "en-
us": { "role": { "label": "Stockholders' Equity Note Disclosure [Text Block]", "verboseLabel": "STOCKHOLDERS' EQUITY", "documentation": "The
entire disclosure for equity." } } }, "auth_ref": ["r82", "r131", "r198", "r200", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210",
"r212", "r214", "r290", "r428", "r430", "r439"] }, "us-gaap_StockholdersEquityReverseStockSplit": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityReverseStockSplit", "presentation": [
"http://www.tapimmune.com/role/DisclosureNatureOfOperationsDetails"], "lang": { "en-us": { "role": { "label": "Stockholders' Equity, Reverse
Stock Split", "terseLabel": "Reverse stock split", "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive
effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements." } } }, "auth_ref": ["r86"]
}, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"SubsequentEventMember", "presentation": ["http://www.tapimmune.com/role/DisclosureGrantIncomeDetails",
"http://www.tapimmune.com/role/DisclosureLiquidityAndFinancialConditionDetails",
"http://www.tapimmune.com/role/DisclosureOtherReceivableDetails"], "lang": { "en-us": { "role": { "label": "Subsequent Event [Member]",
"terseLabel": "Subsequent event", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are
issued or available to be issued." } } }, "auth_ref": ["r305", "r319"] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeAxis", "presentation": [
"http://www.tapimmune.com/role/DisclosureGrantIncomeDetails",
"http://www.tapimmune.com/role/DisclosureLiquidityAndFinancialConditionDetails",
"http://www.tapimmune.com/role/DisclosureOtherReceivableDetails"], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Axis]",
"documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be
issued." } } }, "auth_ref": ["r305", "r319"] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "SubsequentEventTypeDomain", "presentation": ["http://www.tapimmune.com/role/DisclosureGrantIncomeDetails",
"http://www.tapimmune.com/role/DisclosureLiquidityAndFinancialConditionDetails",
"http://www.tapimmune.com/role/DisclosureOtherReceivableDetails"], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Domain]",
"documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } },
"auth_ref": ["r305", "r319"] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "SUBSEQUENT EVENTS" } } }, "auth_ref": [] }, "us-
gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"SubsequentEventsTextBlock", "presentation": ["http://www.tapimmune.com/role/DisclosureSubsequentEvents"], "lang": { "en-us": { "role": {
"label": "Subsequent Events [Text Block]", "terseLabel": "SUBSEQUENT EVENTS", "documentation": "The entire disclosure for significant events
or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial
statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation,
catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of
business." } } }, "auth_ref": ["r318", "r320"] }, "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable", "presentation": [
"http://www.tapimmune.com/role/DisclosureStockholdersEquityStockPurchaseAgreementAndExerciseOfStockOptionsDetails"], "lang": { "en-us": {
"role": { "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]", "documentation": "Disclosure of
information about sale of stock made by subsidiary or equity method investee to investor outside consolidated group by type of sale. Includes, but
is not limited to, stock issued in business combination in exchange for share of acquired entity." } } }, "auth_ref": [] }, "us-
gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"SubsidiarySaleOfStockAxis", "presentation": [
"http://www.tapimmune.com/role/DisclosureStockholdersEquityReverseStockSplitAndAtmAgreementDetails",
"http://www.tapimmune.com/role/DisclosureStockholdersEquityStockPurchaseAgreementAndExerciseOfStockOptionsDetails"], "lang": { "en-us": {
"role": { "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "us-
gaap_SubsidiarySaleOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"SubsidiarySaleOfStockLineItems", "presentation": [
"http://www.tapimmune.com/role/DisclosureStockholdersEquityStockPurchaseAgreementAndExerciseOfStockOptionsDetails"], "lang": { "en-us": {
"role": { "label": "Subsidiary, Sale of Stock [Line Items]", "terseLabel": "STOCKHOLDERS' EQUITY", "documentation": "Line items represent
financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one
or many axes to the table." } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": {
"en-us": { "role": { "label": "Tabular List [Table Text Block]", "terseLabel": "Tabular List, Table" } } }, "auth_ref": ["r540"] },

```
"mrkr_TaxFeesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tapimmune.com/20240930", "localname": "TaxFeesPayable", "crdr": "credit", "presentation": [ "http://www.tapimmune.com/role/DisclosureAccountsPayableAccruedLiabilitiesAndRelatedPartyPayableDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of tax fees payable.", "label": "Tax Fees Payable", "terseLabel": "Tax fees" } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Amount", "terseLabel": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r532" ] },
"ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Vs Peer Group [Text Block]", "terseLabel": "Total Shareholder Return Vs Peer Group" } } }, "auth_ref": [ "r539" ] },
"ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement [Axis]", "terseLabel": "Trading Arrangement:" } } }, "auth_ref": [ "r559" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangements, by Individual [Table]", "terseLabel": "Trading Arrangements, by Individual" } } }, "auth_ref": [ "r561" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] },
"ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Adoption Date", "terseLabel": "Adoption Date" } } }, "auth_ref": [ "r562" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Duration", "terseLabel": "Arrangement Duration" } } }, "auth_ref": [ "r563" ] },
"ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrExpirationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Expiration Date", "terseLabel": "Expiration Date" } } }, "auth_ref": [ "r563" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r561" ] },
"ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Title", "terseLabel": "Title" } } }, "auth_ref": [ "r561" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Securities Aggregate Available Amount", "terseLabel": "Aggregate Available" } } }, "auth_ref": [ "r564" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Termination Date", "terseLabel": "Termination Date" } } }, "auth_ref": [ "r562" ] }, "us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TypeOfArrangementAxis", "presentation": [ "http://www.tapimmune.com/role/DisclosureDiscontinuedOperationsAdditionalInformationDetails", "http://www.tapimmune.com/role/DisclosureLiquidityAndFinancialConditionDetails", "http://www.tapimmune.com/role/DisclosureNatureOfOperationsDetails", "http://www.tapimmune.com/role/DisclosureRelatedPartyExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Type of Arrangement and Non-arrangement Transactions [Axis]", "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r276" ] }, "us-gaap_USGovernmentAgenciesSecuritiesAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "USGovernmentAgenciesSecuritiesAtCarryingValue", "crdr": "debit", "presentation": [ "http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "US Government Agencies Securities, at Carrying Value", "terseLabel": "Government agency securities", "documentation": "Debt securities issued by a United States government agency such as Government National Mortgage Association (Ginnie Mae), Federal Home Loan Mortgage Corporation (Freddie Mac), and Federal National Mortgage Association (Fannie Mae), which are short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months." } } }, "auth_ref": [] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Underlying Security Market Price Change, Percent", "terseLabel": "Underlying Security Market Price Change" } } }, "auth_ref": [ "r558" ] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates", "presentation": [ "http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r17", "r18", "r19", "r102", "r103", "r104", "r105" ] }, "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]", "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year" } } }, "auth_ref": [ "r528" ] }, "us-gaap_WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantMember", "presentation": [ "http://www.tapimmune.com/role/DisclosureNetLossPerShareDilutiveSecuritiesDetails" ], "lang": { "en-us": { "role": { "label": "Warrant [Member]", "terseLabel": "Common stock purchase warrants", "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount." } } }, "auth_ref": [ "r474", "r475", "r478", "r479", "r480", "r481" ] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [ "http://www.tapimmune.com/role/DisclosureNetLossPerShareComputationOfLossPerShareDetails", "http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted average number of common shares outstanding, diluted (in shares)", "verboseLabel": "Weighted average common shares outstanding, diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r152", "r158" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "presentation": [ "http://www.tapimmune.com/role/DisclosureNetLossPerShareComputationOfLossPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]", "verboseLabel": "Denominator:" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://www.tapimmune.com/role/DisclosureNetLossPerShareComputationOfLossPerShareDetails", "http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted average number of common shares outstanding, basic (in shares)", "verboseLabel": "Weighted average common shares outstanding, basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r151", "r158" ] },
"mrkr_WilsonWolfManufacturingCorporationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tapimmune.com/20240930", "localname": "WilsonWolfManufacturingCorporationMember", "presentation": [ "http://www.tapimmune.com/role/DisclosureDiscontinuedOperationsAdditionalInformationDetails", "http://www.tapimmune.com/role/DisclosureRelatedPartyExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Clinical Trial Agreement with Wilson Wolf Manufacturing Corporation.", "label": "Wilson Wolf Manufacturing Corporation [Member]", "terseLabel": "Wilson Wolf Manufacturing Corporation" } } }, "auth_ref": [] },
"ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]", "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested" } } }, "auth_ref": [ "r526" ] } } }
}, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r1": {
```

"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-1B" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "205", "SubTopic": "20", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-3" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "205", "SubTopic": "20", "Section": "S99", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480781/205-20-S99-3" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "480", "SubTopic": "10", "Section": "55", "Paragraph": "63", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481620/480-10-55-63" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-18" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "40", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-4" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "40", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205-20/tableOfContent" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-11" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-3" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-3A" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-3B" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-4" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-3A" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-4A" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-4B" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5A" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic":

"20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5D" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/360/tableOfContent" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3A" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450/tableOfContent" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/505/tableOfContent" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SAB Topic 4.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-4" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/810/tableOfContent" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 5.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479836/810-10-S99-5" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-3" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r100": { "role": "http://fasb.org/us-

gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, r101": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r102": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r103": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r104": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11" }, "r105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12" }, "r106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/275/tableOfContent" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org/606/tableOfContent" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",

"Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99",

"Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-15" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-9" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher":

"FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477349/740-270-45-3" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section":

"65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/850/tableOfContent" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/855/tableOfContent" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-10(c)(7)(ii)(B)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479664/932-10-S99-1" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477385/932-360-S50-1" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r341": { "role":

"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946",

"SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(5)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r429": { "role":

"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r443": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r444": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r445": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r446": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r447": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16" }, "r448": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21" }, "r449": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22" }, "r450": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r451": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r452": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r453": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r454": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r455": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r456": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r457": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r458": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r459": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r460": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r461": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J" }, "r462": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K" }, "r463": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "102", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102" }, "r464": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r465": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r466": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r467": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r468": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r469": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2" }, "r470": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r471": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r472": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E" }, "r473": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18" }, "r474": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r475": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r476": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r477": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946",

"SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r478": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r479": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r480": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r481": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r482": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r483": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11" }, "r484": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r485": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r486": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r487": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r488": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r489": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r490": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r491": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r492": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r493": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r494": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r495": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r496": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r497": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r498": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r499": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r500": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r501": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r502": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r503": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r504": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r505": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r506": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r507": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r508": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r509": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r510": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r511": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r512": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r513": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r514": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r515": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r516": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r517": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r518": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r519": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r520": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r521": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r522": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r523": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r524": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r525": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "ii" }, "r526": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "i" }, "r527": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "ii" }, "r528": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iii" }, "r529": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iv" }, "r530": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "v" }, "r531": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "vi" }, "r532": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r533": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r534": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r535": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r536": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r537": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r538": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r539": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r540": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r541": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r542": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r543": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection":

"w", "Paragraph": "1", "Subparagraph": "i" }, "r544": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r545": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r546": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r547": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r548": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r549": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r550": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r551": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r552": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r553": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r554": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r555": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r556": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r557": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r558": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r559": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r560": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r561": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r562": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r563": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r564": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r565": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r566": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Number": "229", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1" }, "r567": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "y", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "A", "Number": "229" }, "r568": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Number": "229" }, "r569": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "i", "Number": "229" }, "r570": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r571": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3" }, "r572": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(a))", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r573": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(d))", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r574": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r575": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r576": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r577": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r578": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r579": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r580": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r581": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r582": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r583": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r584": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r585": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r586": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r587": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r588": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r589": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r590": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r591": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/310-10/tableOfContent" }, "r592": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r593": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r594": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r595": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r596": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r597": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))",

"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r598": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r599": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r600": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r601": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "720", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1" }, "r602": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r603": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r604": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r605": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r606": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r607": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r608": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r609": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r610": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r611": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r612": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r613": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r614": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r615": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r616": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r617": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1" }, "r618": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-1B" }, "r619": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r620": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r621": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r622": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r623": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r624": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B" }, "r625": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r626": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r627": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r628": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C" }, "r629": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D" }, "r630": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4G", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G" }, "r631": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r632": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r633": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r634": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r635": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r636": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r637": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r638": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r639": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r640": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r641": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r642": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r643": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r644": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944",

*"SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r645": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r646": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r647": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r648": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r649": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r650": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r651": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r652": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r653": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r654": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r655": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r656": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r657": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" } } } ZIP 68 0001410578-24-001978-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001410578-24-001978-xbrl.zip M4$L#!!0 (+" ;EG*?>,YOP\ 'V; 1 ;7)KU1$@R V9GYFE+V)T:VQ6 MDC/()?OIKR3;XCVS9)MEU[OR2@-7=4NO7:K5:LOCQI\>=;3Q@RHCKO#OKGG?. M#.R8KD6VPPPV38L2Q97PC? &LL MW?T>.<8]II38MG%+B;7!AM'MG/]PWCF_?F.T6N^EC%O$@,=U#"GLXKP;%O0# M<:YS8W2[[>Y5^Z)S<65$]M&U-M)2/S+IAYA:OD,$1W6 ^ M03Q,]LC$[\ZVG.]OVNUOW[Z=<[0GNYWGX'/3W4E!G>M+T0N70WP&OD MV?S=V6\>LF759P9TEL-NH(Z8L&^7YR[=@)1.M_WE?KR0U8? $._HK+52U3VYA M_.-XWK"6L36%284E.W,%<9[= ,@[D.0P2]+&F0W%;% N>BU;GLG79C=DN4=KN6]!VR:%G-D5& M=4 6&=+*P1QK/WXTM^I>%"4Q4L0Y)2N/XY@K])R4,Q0.(P/X0U$<'D;TWK-% M',:18^)H!Y(<\T_2!\.WA5?98UL4QOO'M#*ZQ[22A"WFK3*)1:'/\/X[PY"3 M$G(8OQC(EKTGG'?)#D,)K(-CVI/-^Q69ELP<,0K)>$\%#*INOI/O361;#, MX-2">E$4U,42_MT/)\N%,;TSIK/AO+<<< 4$#;Q3> 6&F[3*/8BU*?<2V=[;[MC?5!MPL?X^KL.4!W.E<2Y*/PHBCW>XN/QMUX^GEA?"\0,"[^WL!=;30?X"H[MF(^,VK%\56TL'U%NP%6/9?')=3AQ/*CLX%R/GP:8(V*SY!@NRI8+ [/55Y^= M;G+X#D8+0'0YFGP".(_.&$].XHWO@PJ:05L*U\.(*P5KBDN/ZD5Q5(5T0XIO M4-6AVC/EJI7-T!."A2]\I8#4F* 5L:%!F/4<:XYMX6AGB/*G@"X# [1.EZ:S@ MA_38[O7[TT_"-\]Z7WNWX^$_Q).Y,(GQJ'<[&H^6H^'"Z$T&QGPXEOY\UILO MOX;DC8%D&$B0UPS_ VY#&,7\:03K,KJ3"@3@%Z'4SL:=:QETA=G4R$?D6(8O MT(A(;-"]N-2%80=T6\P)*%=ZW1OG+K (?E-E$6Q\'ZNG&9H5P^@%=\U?MZYM M8T!0=GXI9A*4U-R+FW^A'O9!323$Z[$"0:L# ^?]#("5@9?QO2^S&:T9 MH$T0A[_1A%-&$)5-J(N/NNGX:-);?IH/XUFH)NC1834FX.PL<'<0S=P1!R9 M@FSA+65K,G KQJ3#\#*-X7@$WG _E#&L7>C"DVP< MLH9H @)4?XU"G,T,ICP3%B49>!;BT<%YE89S,?HP&=V-^KW),ER^C"8?C!E, MC'VQ6&G U'E2S,D)4UJ)=$?4!LCY,'O,"F1V5NH1CYL>H=/E1X!L/NP/1S\W MB:#J^=^>Y8\-P[5 M-C91WB;DDYE'S2UB^-"3(AW\B*E)& [22=-]WN+WV>3J+28UFV=8C&\I80LB M1B+,)FR$B.A\P] =C0E5RV0%L.R9$$:!!>292AE^C4ET.QE.I*7(=H5FX7JE- M/#UNY;?O&M0*;=]H=FGTR!3:=6O *+3;HMEFT8-18(.E@:+,MDJQK1,],,7? MAFCP>=8#\L]T.EZ/\.?B6\LH>B6AW[S0H]?P9VK!I0R:<-BJ4$M.&5V!!J MM,FIG*R>'@I- /J_I_HQE+MX@>T9=$V-QB5'ZT&JR7 N$(O$P'GZ A>ML/NT/ MAP-8##7!1(F<;I%DJAZ5PFG4!IJ,B<1;,?R:!]H.'\3++ZDI)%FNA425._AT MNX#Y? AN:_BS>/.E0:-"CJ=2KJ=8SN?ZHG.EV/G5G=@.A3=;$\6R/^I7E=1$ M^7A==MZDIV@5QW*;MY.JI"'4..72ZN J<6*SP>Q%4A-J4$\3ID/]AS3J)[^Y MWUA'Z5A3#7T.I097"#M3N&;MWO]?P"7^B&-@<[PVY)6*-^+FPW=GC.SV(BGH M/]O*RSW%%:BM*+37T#5\|>='9((\3GW^DFLD[T35!R*0- 1,24E=^0A"7'#A M8H"WP|:?&>WGT@IP**M5 KH:*@5&4E:IN%W54"<;K'?:3UV3?GL MR)8PV33K.50;V%M."[(O/,VJ6$DN[SX5'ZK5>KSCNE"M(:GX4* [6O/MC554K M6<2WPSVU+?&HU;UH79;L\=0-U@7K#QE$Q6\J*YZ\3+A(Y3:E,2[1@FNA>O=M MM78H[TTN9/ *3OF=%6Y(UBW5N0:HO"2|C<&_'<24L\>,6\=/:(2\W[A:&XZW M1A>K/Z3WZQ:7/E?W +&[DROX'N!5UA[/W)7[DMS:0^;.G MB"%^*%@TXG@GY@[0SULQ3K@GQ'R@KK=_=R;ON;XA0')F.,2V MA=!W9QR6J!!UR#(()HAK+7WI'@VV ;-43:YV'2N]X%T>]_&EGB5X?"7]AC%. MB:/1:F?QFRV44]-;X9'4P=128/]?RC](9)7K: E=0]PE=!_Q#=E]!:<<"V_M%U03T3&7JF8:]6W$H*V?$15[]%,Z)YLM#]]%%!%F1*\"M-7LU2([\7L)KO-R M]IK;=C^(+JII2)UT0)9_]>B.6+,$]'2= T>=!>\PO8SLCW<8^()X?+75[#X MU8$[3QSA#\X@.YN(]B=)B5H |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|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|_ 8\PLM48)1V4;Z63";#(<8HF49:19$ZR6FV++)%KJV_* M*0H<-F-+=N[)C4QFG^*()DW"81" <&AC0Q'$$BU/.1%(PC8VB 'D,.>-&(A# MDOZ9()0#E"0KJ^"L#HDZ\SHR26^3,_Q7"Y%$;2(0OU:72T@J$)E5K^Y76><0.PN3=+T1?08N(YKH=W"\H# E5D%EQZK M^7 ZJ#O@,+4V^.,2BR.P;* [QEF^0TBO10./)NU)IL ;-N2,X;P0R"V1ZUNT: M71*:9BM\N'&?72>R6,<"(4S"% Z,+BJ^NN&:1H9(;NS:W2[AV]=3DY!S=8|*

MRJM:ZYL/8D'"IIS(3@SF4&12]AVG(!?HN(R^T9_|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||:L5IL^L\YR2,O"BXH#Y^'[H46^R#& [A0P]^K597CR\XL=" MZBN+(&>'XA9#+@YADHV_<8,M#"SO$X+1EF+OKEQNN%&R%?<%4XEV9O& .8ND MV]7APZ%ET[<>Y84$%3%K^.@C]TEN[L./E:1D7X&5(J&U21< ^\T3?+YP@!OK M&OYP4#'\QR]C6N)VZ#@(+WX@2#YP7$/5#4I*)=>D;7T\"HDJ!U,%_']^ 'T7(?<=,KF M(0/%L)P:Q#B*;AG6RRKXGNI"2O>O__^[>7EU>7W@_-#H0;|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|^EKKNRVA7(_DN;;KDMDJHM^GGGXM7>P2-CFO94 MD.NVM%OE2.B[!9/C\26K.CDZ^^5I"TD=A.[OF3>[XE]SQYU@IZ M'G#B\Q)=DK$>$C=* (..R5VIO@-NIL1M?B> .)';MTBH6Z4.,$C*J:F' O;BF M4JDB\138XM^-.Z; 5D5ZQ A&Y*F0K87"W=3:\#*FV&!FQ/ ;[POX!/:?.@6V M$;))E?Z]:A0QXSX]K-!6?]J52._V&5CR!'5AK2P?@]ZZX>]/Y"TW9P3?8%V: M/]II!00+_0KP<<^S!59,N0_=B5RJ^G>P:B='&0XG* M#? &@S0C:MW8RXM)IFJR$<7D!O!GGG0KEJY"($?W E["4RD'UH"C3:5F"41A MA!E: X]4Q'L@QCF[\:S>97\16#:5#OHW=JQ(26O&3H5T8X0L-'PL0#,LGKJ> M\B35X8[OSO5MZ/EX&':!-1Z0 8:,KR+[#1H#|=Z/-P\(,I$=SE#B=N"<-ME@ M_9L?5F"OE=,FFT!=XB ^C-0/Q#U="F#UGR9%>E7@.8N #FS)U(IF_A!Z(91 M"(+9ZC.PO'"]V%B>=QT%K@^"8.+[\)E"IB^\|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|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|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|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

MUMO5H8^;H3!R|C/>;FE;\'!EG>F6DS@I\DEPPO8U[Z)PI1$$V!:L((U";"P_M':Z-]S"A'&7'N%",C*W<,3I4YA',%%B8D,@Q)Q$KEDC.61C+VTK[!?
%HV#Z@ MALNK=.V0;+N.8.4*YA-&D8_NLIU]9@7FK[8K7A,DC8?*>@0$J?>Z8#YHR R$FL*<$!&K20KH=TW@C80UZ#&4[MSCQ1W MZC9&!8="/J1*
MM7?T.L08+?P(H^^_-G+N:MOL1KSEKBS'GGD3Z^B0?8/H!$HX&K;QUW!9.#LM M'PK7%=01K'P"F,)%%#!R/!2#-G/XV3V;]';*&|+FMI3-*
7LSQ'D>6XV%[:@4> M\2;A>+L]'4XL^7R+=\[6$>V:I2;"-E)YWO/V6C\+KNDVH%W]E)"C0 D.I#]' M!<5H+I>>?DRZ!_;SO-H<)HPTF'1N*
;S9BGFK3G?!-7];(V3JR@JAGWF[PH^-Y';-7>V+0 6/\X" L245" MO+Y1?Y(BF@;;K2:!ER7*TVYWFL9I@_YNN'UZN2/<0S%H-.^?!NZ[@G= MVL4@V,9:SE-*
I+T4V JX\"NA4CWMB<.A7!E!?=5081#EM(__*-(W\XU_W](7. M\;-S6:5Q^1U,O2KE@*I3X0MX6E1.7AOE<<+(H;V((V(K/ 6Q*E'H_6K21USR*
MX/WUM\"UJ2G=2Z2AX%B1!:^L=E:EF MG5WR9+[4<64%RX#18[.ZDQ4.V%MY F%*
(3X9M>OMZ+O[?"'&0%45O8@"9:0S$]PT&O'0_^&CD0(K,+*2#E440C\E:TS8#YZ6,9[0;-NPP5SSZ$C;KG!.F5<&C-0\L5>_ M]ZV9,C";K-GU5HT?*
D'7]W/>5FVC'N]UF@7!G3((8ZD/|\G"XV:[2\0\O5]'Z\F9$! M?172K0+?/FTCLB/%P9.S%57""X;!5,XZOI+]NK(Q\-2QEE+UU" #RN|\Q'|[MKIB/*6"WFS@!*
(:^N%HN@=*"QX-11S>*&+UP-!*V0%N5]U4G?-?8-U_$-@>5%I MG7'Y")BZ6,%-?HW.?0U/[Z](5-4V!LM,M7%W[#@L<#'3E>8)>R<(8N*
8DI%2]=PP';+KA:F>,&6FM&B._(YHX\3W&T"],M)^L)68:6DBB/XZ*,&* MOA"T*,$[0BEFE*!&!+=)'V%$1@'> ^H]>5V=8MDW|SS)A-![$G-I,]#ME.9*
M/A^Q%]9&)Q7#8;O$.CZ+*?/RL7"=6RW%ZEEC ICW>HE!FXYC.F-U>62/#Q$_ MC&/0AB*;$!.]WA,6;XE?G.'S^:FX!@U$3[I-MJX#!R#.<21"0A!<"J92-*
@VVJ0LX* M;V%>#H)KCF)2VP> "4@CG0WU,\9WF?Y5?&O4P'@%P=P/:TVL,'(@1G;-7:F9 M9<,&8&@EQ+8W-0X4O:9@NVF@+FUO&OFC0'C6+[8ZWS-*
B;0O?\XOLQ4ZE)LTC M,P^V)4ISGK?+VDEPK52>=%6=SF-(S39&\G7'62&)]&WW N O6SLQY\DB^K61 M+-',>\)A1#>[G->91P)Y\HE .!7#89MQ'9_%*
(LKRL7"-MI9B557- ,>62H^9 M.&Q#YMDAJQR0P;^N=ZZ:!=EHI6E7 MU^E<4)R='G,*$,T0@L74&J31CW(* NQMYEHA-%V/UL)<&S+ MN+]#\%O ?-*
HWWW_W#?-K])- W3IAC ';*?U%!DN'""86NF#"](9:)48=I1: M9GVH[6]/=+UG)'6A#11V-.PY,X\178BL)\MQJ>]\VX7O*%M18$@A#SU;6T:H*
M9!$]'VJJ(@"@^#)';&;17]"J,VU- EI'5GC"T/$4K]AH8B2R6.W'99$>H8+KW M/N2;#X^[P ,WH.Z46W->D9.'&'UO_%.$.(7YF-U(D I2W%E8:Y?[4T-IBV$*
M;X0\KF/1E8Z96X<^6(Z7D]G1#RUWN2L=>H-W?H"YF!LN0:VP#'#U;2_5VH5' M'<7 UAP-C.I>;BA)EXL-HXM:MVC2 R,N6:I,72:*
)F(F2K(NVSD)"OQG(L'X MK(=X43/%$A(+35@3IS<$ =L#]LA#G':NG@_7=REQH3$57>YV+I+1V:VFE1^P M>/@R/;T@OS>]9^.*
[+C]1[NY\]F&^NA^1]AWM-LQ>OTPA2)U4]BB&.0[#']C M79H@!_2$W]IZO24HX*M4#Y 687@UK++:=5.2U.5,TE@$P5\O3!3"]6 M,*
[4"CRQM8=+%N*;HKF(X;%NJXS-O5J*Q<,.M6HI553,!G#7@-GVWLC-6]17B MA-W7+HLETZ[;ETD("G5#/H@(Q\5EKK/K?.F'K5'?*
Q'B1DP'I5J=58<=1M>)] M'%$UA?BB7%NS**L1N!?CWKJ.O+0[.&CQFA$)5SLY>-';9>J-N7W)-%TR%K9K MJN2P*B'.!L)U)I7DZDN%CWCD B(-*
KH?'Y"0[,SUXX<9E0YD_63]*6CX0>@_T5(=XM)4,*[6R[6\'\@IW'/?49UA.)PQ\Q\D[T$1.Z M<]G&#_'QIWMS+_$9.1E."!US.A>,S.7NZOW!J@BJ*0S8GD1)*
(GE/T@@ 7$^B MQD9K@XG1H45J./$CUSF4)C<'AL32P(_DMQ7E3V3W56%C6%9U$@+D;_-)(8D7 MC)M#&:3/K9.*A-<5@1BFS*
MQ60IHL]A(WW7)JHW_?WD1.>:7:/L7-C^MI$$)EV;B)KU9 M3O[QXW@^.[U?OT+3GS[--I^-F@!G?>(?CKY'_AF6O'$M.V<@*E_%<:FJETT8*
M@(I7DJV<\&% 4095]ZO839*@109+7\>N&PM;9RLY+"0ORP;"U=%J=HR(LLQMI.CN$JC%0Z&;:W5/!9?L2P;"=<^:^A55=$$+$K/DHW:*
M8T=SA<]_#M:Q2 M*E4UC0,;(0ZN"QLZLFZ64|^NLB.M/$U9SAC=6&3^%H_B%M'5A#UQMT- M?G0\KY[!GA*#)+#GC,4]3)E$?K;<$U[@+^P;*
<8)0;BYPG|)$ L6$H<1$P%ZH M$?G*[HEMBCF:M$5RW!B9H:(W/+[P =VT0:N+ 'J2 S\2.Q+R:9-@F_X5GBPO MHJWQQIN/R'H,,"YYS;JOL\-*
^Q#!^)&P^DK ('0-_B[$=WT..3PP=KB1!NDF!#"3\Y,7,P3E*$?U=>,HDR((I*K5+0MI7 M JBYZ$DF69%.T56*!=#B+2A*,PU,E[M<0IFM!..0?N*PA_WN,+*
[S@[M3= KP MG>.1"=<%;!K P72+NN24/O[4 A;P=Y]T<*9\7S9" 3X2MMC9]1-%FJ_F8B[7*
M"MF_.1EHAS':^0':,4K0+B&EWU>BC,HLQHV6.U0XVDHC]G&(,B(0H0(1,A"G M Z6$].R0X7!#9$%]Z4-3T^_+HDE]E8 M' X-QI?W)CR!,|_V% -*
SYKT+3LV;MPS,.|WKLN^61]8M9/],@ZT3BH^'%.# M=/BM)2.;^RT%,KCTA@0K'>:$^9 8,TI1P]KC=R@BH?=AV5(XG@NV\.U&)'42 !KFJ2S-*
>RFN(9ER]P(63OB4>D.?X<=NF.%Y+,[%1=%&2_NVQQ@?5G7 M2M]Z1R^:LL+L.']A_^^/?XBJ"$;9,W4A&3]+C(Z.(S&&RC(E"C*I>EP58\KQK*
MJG>&6UI,K'!_Y_I?ZOH_UDR!N2XTX5?0M^)]/.0P4H+J%ETJ;J>+]2065?2K MF(S7/Z*[^?*7M:%G9RG?]\!_\G:>?0O7?DMH;&.7A<='1O2?[HE= M(UOY*
4_W1U'@/)PBZ\%E0=R""-GW(D*G2X?-/&)+..PF]*U[T5NS+$R]@%W_ME%WZL\2_2OY'V?C%GR3Y100RZPP9;/O5L;-7J%4P037(77,K_()BO1[EOFW*
MDF#YO_9O8!H1??HZA/BQ3#--<9*1B3']1I."XFQ&9BW/AZ=E(=H8+M8KN4 M;[%SCWX|<-UKI]RJ=\Q)B>))T)@L=!52TJ\'MO<#*?*
&$#H<7X9#URDN\+)$P M_7M+I7SB@DT\+9&K97;SV.S4?Z G^_*G]T,IH>_P%+[JO)T&)E2=I\|4J:'C M=O!'ZCHVG@$FE-QB_M^<"XL;H-7$.8T*
P#;BYK*XV/1)SH9K[H\M-B<,13H M=8+L:[IJ9=% VG70;"C0HT@F>^K^PHO%.PQQQ)_])2O_ UG^C2WDUZ)8!?AH M.7;LHZ4E>#5M:'ZAG.]J;U"*
<,R0?(*!.C'SJ1]=3S!6F:.%D98$/S&TUD5!MJU$(:DB]I MQ(_^T(A1C%R%]\G\4@.OZ&+B8:$E4KEF).*%4LEV=K <#VW>(>)?[5IK;MW*
MDD]27,\;FD,1<%X3?10G#UEE2\" MT;4&"ML/Z)&96NU[&42X'D037SW6Q(_*"]B,5-X"D%YMO0-Z Z?V3%)8MTX8 MDXSM6E?6%B9L3Z9%8H7'%ML*
A.O']+#5ZM)*$Q>6IZ-K)U;[IJ-1T%0QT7M M:D"#=!H2LI%P'A50!N=$9'CIR)FDJ/LKUI>(2 S(Z?*]=IE@C!3I20]B]3:S M"4S8?D>+Q.]VF=(*
X7HC/6QUL,TLLSWXV\S^1)=&0|><^)Q4: /;:@*4&^Q(MLO6B"=Z#-Y>%6L0(USZ/4.BH$;_/-9;&V M(8+K!11XZ'$#!"FCTI5(KC(JV1NQ9C,J5*
CT_Z>_GYPGRZ5=PNXQV>8YVPC; M](NQ9Q<_R(WDKS-0/U@7DWHKP=+?#PFQ,[T3 =EAF?I/+4[_^ M*(#K.*
W)H4U>9<3=;XZ.$%V\6%Q!]<=E=P:HD\|)DUE$Q80Y0%Q M)HQX\X']3G1%>&WG[F"%4G8\OE#0GX?]0,3.]!{*/C>>PF5X6P*
M>O'RR^#1\IP_6*')Q/="WW5L]@\BG17Y=9+7!I>[>'=DN>D;577GK+I@P_;Z M6B68]_Y: ,-=!??RIQR-C3>?[J?TX;/E:GH_WLR6"S,/GUGT+=[EKO[2=]E*
MV!8BYJV0:[L:!5=W*VA55D0&DBX(&5#TZP8_1^B&J-QOQDK2.V!5C\T)7F&^ ML4(G7.[R+D2P3DD,AVE8LGRFSQ]7C*
7^HK$,Y:IZZ+VS>GTPN$M>;L;K&7N_ MIK4+FR*4&!;8(M MI9*N@\U! %\>6S TE%73 (OSV4^?9K>SS67!O*
ACOY*+@K6G,%Z,N5]SI&P,"4Z4(D4I5D30(H87Q8A1MMX# M=1/F1--U+"2L_34GH0X\:>LM2A8(KGS7V4H\@5DU :83E>>U\!RE<#3<;8P$*
MS;K:NYY]6,SN9I/Q8H/&D\GRTV(S6WQ [^5\-IE-C>2)U\ZCY^R5%UXR+ M0H3&DV'K=#,9%-XLE)H)5]*
<;TJ^L]QF;_%8^061N'>M;#O#LO_R9Z[H+KW63 M8-N[',^%LZ3*&7#M6Y)NY8.7Z0;-E^LU6DWOT?K'|?W4A I_=#P_(&%HPAYM M>N'ZX2G*
=>N7W$S8RMR ^[Q&2TR#J]9-B%?6[8+I9]L9;C,+UN]R &$C6?O MA=7MK^GD^GLY_'-W(@FSGW+"Q=^*
M1.+"P++I*S+L];DM6P>908/L41:GDO4E# M$'#]B"HCRN\=S=:3)&]YJ+7(X|^);5>42D5^'-8 %;SY:Y'9A3ZU@ M@C8P/9PI6UQ, .*
(4C%!*@ZAYZPC4ZFU>@'!<5OS:9)@\-VFY=6MW]0S8CD:" MVT(S'/%PN.Y!AFA5Q8U/!=9H-?Y,() 1/2>XIUH\GXUO9O/99C9=LI/O^^E\ MO"&?K\;WF_)*
<(.GWY7/JLHOQ>K08!M&2RF5'*HW\077H-HRI&QLDB\8@UI; MCOEX>)Z)=>G:^ZY-9$KOXD9GFE&H67UK)\'V.W(\%VH8*F? 1]J2="N?U6^6*
MDW_\N)S?3N_7K]#TIT^SS6&[\/5Y3*\0Q\4R MR'VNA!(7<7J4"!!OD/'&>LP>L1>R7?0]=BW:=<(/HW"]MP),R;9)C"#35Z$U M4-A^0X_,+E/)ZA#A>AA-?*
+4RLC$ M^D),K5IJ2K96#O(%&%L-8RV2S,E2SCNIIQ2@F 3$:|@A1L4;9O.HHI-:/1>VV3>20'D873$1KL$W(U^Y M5G+Z83Q'J_OE9#J]G2T^&"D8F.-*
'R_UH1=3LQYX]8143C]B3N9 I.Q>VDC>2 M0*%@6&8B7"5O1KZRDE,L*$;#CCP+B"#D=7L2! 1KCW>K*RN(SIO (GO8+2_G MK-NRU4Z#;>.R?!?
CUNHY<"U;FG+E.+5PYC[I)\U&F+E0+&)5_L2R&81AJKGD MJ66#Z<-3_B[.Z9+,)4.&\MB '5WV*A0PSF%]>@CQ[R<2LT^?) XF*X;#-OLZ M/@N5"8*Q<*
VZEF+EE/JGF_7TIT_3Q09-?R;_"T)':PML*L8/2TNK"VA$@X>C MIQK/?E+(B(,VGP3LD%D(5EEXT8%UYCG7&6;-%-BV*<-OX6FGBO%P+52*:N4G M<_+*
1[S;U!G]&O_7? C8*?.KP/&VSI'>ZV:G^SE4)LSW4XB7NVD8.0<2]8J> M(KD:!-M$RWG*&V5Q!%PS%-"IJGL$'%6Z%&#?ME>[5G;,KZG7%6FJ].(U2KF%*
M4G(N;'-L)('+5Q%K)\(UWF;D*R^FR?MS)<^[@EM8>Y/(J;N/7$8!MIT(W3OA M9<[J@RU$Y'R![%S8O]"1!.J;A_S&%S0COTWE:&D/*
F#+O%%IZ'O2@38]\B+W M/ M#@B+K3[N.B*^Q IOV2?J,H['M'VE&N=+,M0"$:?OZ9)4^^- *&O"G'_3P MIJ?XW,IZ0A^YZ]CY*
0IB"I'#2,R/"A,BD>='Z(PC9'$ZW_;Z1H19&2;8$4>? M[ZR=$D!OJ3'YQ#08]\U#DMOG3&Y&#B*V>VR?7+I5M0+ZNG.XPD%RH\'9LH9? M[HD0MZ&-*
&J/*92AP73WFJ14..)0 P4W'&S+D(*)08R7945BS(B@YC>)1HAA M9SNE&#_ZE5$ 8.\(061;_W ||96;_M,C;HBLE2%[U1V%E!1]L>4"1W,".N&Q MTI-*
(38#I+.1Y36,_RM' 8SLYVE55E8 [N5: [$(,=ZVE_<9BW?),H",*/O-B M/;FLZD"J6Z;S/LDB =(;F[H^YPFC$&]/ 6LU9#8P:M1HD'SM'S)\2)V:^#&*
M(F+9XO4>DTC3L\3#7&QE#" 3[%T9_35!- MN^0A2SOOZQU&"$VR<$K(!SL_./" E$;MX>EPL((SBU7I^6@GD4/RVNKS*'7!S>$/PI"VXTF&DTLTK*
6ZM#8O.2D1W MY/A']!,F-S+A^G;?K'\9:T^2;V#"."^+]JN'P_0NLGRF M^^Z*LYX>$;"H,N*1^2HQ@80<"HHL M&4?" HV:(9NG/M;%)LJ$PI*
8R(QUSC:@[E]98)7U.\MS/=Y&SL3G1ON<1H" M@^GL],BH?%_3!-(0=C1*_"@;T'53030. @*,Y1Q&*,$++ZO3KYQR&Q<:]-&5 MQ/+.KT*^OB#_R-*
,R,?:N(Z+I,_VS)E^B,A^F^U"61$W@5#YYD%%4#2MZ3QFY MSE_'5 C'5-"J,3^P^ZX$ZU4TZYP0"B%7@L^TRS0@DIR7%,7=J8Z8C=%$G1\: M1F?28&*
ZUK9R*8_(Y& ,(19KR(D.NZGHG0(N!#,@GF(N.,J0MO$K@MAK&3Q: MGO,',(I!!V":'9"7;8;S0(0*C+(@M F*
M5T);70@M)01EE)B(DS8$]G*72P2,GQU1OP#16)@N2HK#?%A3.A!N[%)-KO(V MD$!EQ]T97*:_"]|[8^4^*X8K%+7*X5!K]!H/5B?
8=>^Q99_'CP%F&$M5 MOVXL3 67XC -)D4#@8>(M62K7\2+0S=>SI"/_(XXB(@>TF+/R$>4 L1(0"D- M_49TG?)@Q;*A)1E;:.W&M,'1VSI9'Z>*0LWX6*
M3$?5D.N+EAA54^"NM+*$ZRE01T4.!F/0"K[YZMY<7NF\P6IWD7-)_>:3!JGA M%Z1WI./JT:(.+2^Y0\'I)9_L;LYKR\65VZR&(.#K?F-*
YU'<^*I\/VB*:>L$Y\WTW$R9;BX'(@D%^/-I_LI6MZAY6IZS\K/S;R800NN M]KYK$Z'15JC1F;Y(2@3(OE@?74?XP(O43)AKB*
+WA:*E^FEPP^PFQ+>J!"O@628S)0B]2"!A%=>]!J6\-I_/JFZAP%UAHX=_T.F:=$,'&Q' MT%9.PJ14*
UAP749KCO2DL.K;B/"8),5O:K]N1E@%:*RCQS$^K;%IT(NOBH)Z MW,T/1")M]O.['5U.#D?79Q>B-O[B1'<4RQW_#%\]G=)@&DSGV93O;)M=/P?Z*
M'KH!!^I] S#R&%2ZE<()7(2?(^S1#3%5:)R2T/.&M U&P234*IC.KX;]P M_2L.@1NWB0A5WM8E\! #:&;SUAZ/-(%%T!\]0*
M$85V\9;UV;>R7"Y=G'CGPU'Q0 ;RTAWM+'CQ19807OFAP[=LA0'L?OY%YHA9 MYC+;DS607D)@WSV==;VT J1AW'O=XG-_$R95%.TB.%%,6)$*
M,*,,-6*X]3=B(M@B(A\7V_R'8V$2?1O"Y3(N/-QU9U MS0*O>..-X--^UQL&3LY7R@[4S 'L^.6Y37U<]'+AWDR2^5>-(7I? 7\WB?9H? M.%84QFA-*
>:N.N8_!HP0^"']DC&=M"9XPB'+)'?*O+++%#_D$<[LDC(F"-$A;6 M 9?YO)BBF<5CM!\/NEYF]RW^*ZE0E"RG!I!>BD01/":W#'W+9PD*
M66"JZ\SZ]!#BWT\$_?2)'L425!67@,6C8?I/22X+QY/E0^$M_;($*VMF"A"$S\I+O57C!Z>MXDN\PL&#TEA- :I 9PU>UKW@M?)6KFCLH+15*
M?, ^V=.!@M%37>G^IH49OOW;.(WXR5%XE:I-Z<\Y_4Q']- (VT*;RR)OMO*S MX=JR @_JF\5|+V%SX5*>L"H]#3"QS M+W8?*
[4$"=C::Y)6ZII;P@#LR7=SI*"<)L@,!L2=,"$89Q:1$E],.&-$HH1IE M9*.$[GZ]IVGQMI56I_ZYXI8F".&M;V;WZ)'L:S36W8EY2KZ9T'L?0?K]\XI?*
MQ95+P1ND'Y>7E(03KP@#4-9[ABE_TG9D,AHC]NM?]^DW[+:L %E03$C^-;[@KN<* &O/&;D MRS8.;B(=S3N(.[MN@:@: =B_EW.3W9JV!^1=!*
<0JW_SZ8@6LS>_!]_ 9>7Y$ M/-GO)R?@+44?6#-1R^$M5^YNQUS1>KY;K)=ERH5I9](!2[H]0./[W/.JQLQM M@$'V*VUEI-RX83Z0CLOM^?K_39;*
[\+#&?J:[V6*\F,S&3Z?T"C1>WZ.-X,?XP_3A=;-'J/EZL#;=2-JC6LY\^S8BV3'7X\?' #^292)KP'$,G*W&9S:N&* ?.&%(M=Z8$[\1RMR>7-*
WSW@1^&++K+"M*Q H'; KY[Y:XL#(/J!4Z3$OO2(IY%>Z M0 ,/ CM@5--UP",'2_>_VXP*]D__<,1>&.?V]T^G!%-\3R2C18A.6Z7PVR6*
M@D$A)1.%OMMSWV PBUZ81BRDQT MWP$EU5A^5]-Q'>L ,T]WF+GB>Y-1!%=R3"8GKV.KWS4=CD&;IPFI%2Y"S'K*
M+)B#;"00ZXBM0,A6FZ39R;-#3BNV[XBNL21?Z0Y2-!*FQ4APE^6R2HJ=+YA*XB (NK73H(R%C]N?KZ580/T\<>_8M M?L*N?*
Z0:/0X(/8]QYQ@O"JQMM/%)[$$SDG=^P)P=C5[2:'9J!1ZV!7#Y 2S5R]* <0>RY'$82S;K'1+$S3DX6V[9D M&T!.F9'P!Y9LQP?:1HIND#T_HINUQ#?*
JBZ&8YQZ3#0]M_+C%&QP)'<2/^1LRS=3BZ>$1&O?_\EX_OO[M]E;|PH_PZ,).'0'1H_DSL3< MR&S:9?U 3&M/? %['V'OD*80[9U#OM-\70A8UX*
D0%%%&K_<9LIUG3N\2;' MP(GD-WJ%X8#]E02?XBU?-A:X_Y*A7/ONH>?#_U?23-0QR'O>C"PYL=#M Q\.T3*
MB4IH[!'W.V(=N<;>&MQ[T5H@<:IZ1Z2@8Z82[?:2!X MT28UOK:?EV\Z^HI7-',3__+Z=U++X+BWO!57I) A(_\@ZE:ZH:H<#=C!U'.9 MO;XI'
K<]4@0WMX/91Z"+VT<*4JPQC731XZWYS1+O^[GDM_TU-'-Y_6G_PGW#@L<.[1TR(PN$:;T_$M9*_QM'$ M"H*SXSVR^G?!46!3&# J62N)Y_7&P&*
>WBNQH;J97Q:HPP=2O"A#.&(VDV" MDU_',':+NW:]8ZPEG_$^?^:U%EN'V M#|*
<37TZ7.WK.3Z02)E7(96^H=X8$ML/11J:%+OE:,8)R7@TE),7[CXPH.BDABQ8"\:L'+5X(:VW[+64Z%US$[P \;'O7+<>\I>N" M#=?&M7.HG*#69=%S0S?*
&P4ET,=V@^7*]1JOI/5K_.+Z?FG!S"QS-6"YZ[HS!>.(Y:QR' AC8CD-5+GG'T10&7,>AS(FJ420(M48P1<90T&N%*
(40XK(._1NZ!NL>PSM'I9BEL(A;3Q#CH2 M8O?D8_2%XS!R$M=R;>7EM=VLVRELV,:K58(:8ST.&*ZST,N>X?3["'%ZAIAY*
MUR3)E1]A0HCENF>42A1*F4&NP=(O3K2?47%@>^81V>(PD]LBD(,!VUDI2:2\ M!D_" %SGH\:&CA/\'#*

*[>03O&B!*4)L_F)|;1B2S7^0/;$S^,PN7NDW<,_"=L MKP*?OBASX5>(ZR"?_<$!N2O_\3;J")GU TFV,;7H70+C9CUHX%K MR%TRJ[P2MFM(7HI:*
*[#7ZV0O$C2BI 8*IA.YGD;JTTA #^+HLJ/VUNN(B? MN=ORERDS@A"A*'MP+7NQ MW\Q5]D+K.P,T:THB.Q&F'3?GO:Q=P&"*
[EC3C04<#$W[%/,!;_]&C.U[6)2GW MM"^@EB;]"*?0:0!8JY-^)/ A;B?!<.GM BG=Z'^ ??[EVOP/L?]AANCY#OT)^T]83 M:KB;OKX%H%S"'J-$'.
<(I5A1'BW\)H\M%SS[]&5AQV78V#;:"E'A5/X_ "X M^EY.IO(I>MPFUF@]8#N.W^/N9BLKB,Y5]E$[&*:AR/&8RS8(1@*/Y^OI M5C]&*
*<<+XT7;$;D"%+)>0M"4\4HQ)7^:^$P==\9ST(&2@D5%OTA.GA9^Q19) M=^@_ITCH"8^X/JAZ!DROU(#;BK X/QSNTBY#M*KZQO?34^ H@6ZPHD;*
:^65 MJKHY@]1B\66JR@F#TV1-UZ@]=-G@%:KR5]>FS_0!M>]-E-Q.V)K=@/OZUPX+ MT^]>1/BU<,.P!X#FUK0.]BR%BW[%S8 M]MU(
GD+EYH(U\;;D:]\XLBQ,%4OXC%KY_US:Q7P (A.T@HSVMJT?JE +;? M,?!K]'N\,H=?5V="":+KV!B,4DXL8O;&'32A&.9+1PQFT'-+,#9?Z#>G7N9VM*
*M)\O%9K;X-+U%R]7T?KR9+1=K$VZ^((%] <0G"0+Y*P&"[73599/WG(-UK@B#YBM K\)\?& M]LWY4TBO?)3'=)9-H4!V^,H2>2B*;8\ +A>18V--*
*NVPV6M:"3ZZLWI-42+' M^UJTD>K$=5#KK'(=_OO&\;8!I@W*7MN8__4U^8P_*T?WINP/_/O)>;)<;*A_ M6;Z(HN;@JF0@;)*
<@YJUX+'4Y"JYQ5]"JIZK'\$E39]RQ2AY]Y8&_.&[H>[_X M[NZCY9UVUC8Z!20DF/C!T><>1%PMV& N3/-2DD!;2R@[$7AI86,VU#7X2!B@ MRT-
*%WX8)&>]L272Z">AKEN/'/-J"79EF=.**+&H0"W^D=MOE6)OXI/BW6 1 M(RQ!&$JL7 =@'XANT^=*EEZRXUON2@>2.&NYVUC/XOVB'N*
*P77$W,KS(O&B M##>BTLQ?BWQ,:=:%4I(\-$2L-TW;^#MAHH;N/,C7A"I3&1H(F6"(Q*S$1^Y!H;I=\ WN&64MFDZ:*5]>%C:|\A!]]T_ M4!]//.O-*
*@9F(%I;1'@?I&1?W$@(7(Q@*TX1D^,LOP67CX*ZDE=0J-V:C0',' MM!RLD=6L$_ZR=%;B1+R"$]&W!&45="'ARGW:*ZS,GU0/AVE?LGRF2U;%6.!+ MF*
*SE>I8T*ZLRO>XRU^|:UR73N6+:I'-8"YFX8'9>S9M*!],]>&Z>QW5(M"0G!M&D4K?S?;@.R M+9\[UH/CLN>BREJY-9X,V:DTE4'F<&1G0G="C?*
EHU>PFHJ"0ZX01^9MZJA@] M56_V%;O1QRD@PU(2WB+JUUQZ<<:A]TJ08]/V]+MSX3C;>O!/43.X_3K"WH2=
M8$(Q*O:@0(P,Y;"UZ!@GRK]AEP12EEU>!R88 MA%"/C)6:(!0Q8IA[3M9I9CCCP^0;'9TQU6]X,1=<:U8" -B*'$,FB4:@QAW$G6$NX
*M<Y6UI@5O\L]&2N/B9682$$#Q&80%'B+,Q5H#1B5:D M$V=F\XNQ=#-_] ,>TQ3BD##T"09:,LI*YVS68RCN]!""$WT_C7R*
*,N_VMO03#A[\]MU=OV*93):?%ILU6HT_T]=1 M1HA\$,^7XWO-Y^3X4;>+B|*:'(*@NOL M4^U@F-Y;CL?"*
<^&E(^$>)=70]!N\1RB&W+,)]\5FO,TT87_3P]'USQC'EQ1R M;JG:%&7FP;9*:<[S!EH[":ZMRI.NJL\)AC=)"^(<#M,FW#WW$_] [^+&,1R)
*M1QZP1T(U,U?JXBAC%?@'(8L$7R'ZVRZ=A)L&Y;C^6*YK9@!UY0EZ6ZQ+K% M.@)2402FC;ACO@O*
[K!2!;8@G[&QGBFE<0!1ME.X&@'3V"JX25,.Q:^!YQ0$ MQ.HY0(VL9Z9(2837[YY<-VN$&0HOBLIG;S.!50OT+638/], M9CQ?
*%58*9\!=H"7I;E=L69+O,KU]\%WOX<,:7^??&. RF259M P3;H+^34Z MLI" "SSPT,VEJE&M3P<6JI# 96L%P9D>N3Y9[HDL]%:8?/,0-S4-65-3F]!" MO_$?*
*7.%M*D$V&!_I1<4_^:\4C64/U$V:G&?&IQ1E; 7KM!POXULY] M>][2;)^S0Z[O/>+@ZU%\ND* S!5>9-A>4^#TV:,O>V>I)Y_^@,>I^D" M>.8*
<:VP\D'8ZADPE\X&W!:>BQ0/AQL'RQ"MO&[%L.E" MQ#3MF\,OM&'3$\/H6,[5G!>6RG?%6^D58T'KK]UG!:T5S08L.[6DJRLN59>*
M:\V]AY;C:V$=R)^;P/)":UO[*)K41.#:*\U[08UK9P'69WG:-2FV^N-HH@U[M=$CO88H+A$M'P=3&&JZR'2'5;3+KUZ_=HQ'F([(25#WOG?0S2;G)
MKAJ;JQ'NFC43RQV+#6,/.]Y$DDT%J8;D>(POXZ5#H2[=%63JURPP?8*V7(U M-_RP3C=E& : MH6*0_7!&I=.2\?JOZ#&*_(C[G1$N%XS7B85B;-*
:1JB5PT&'JQ+D=[JXBZ' ME5VC"4D(3[7W&"/-(OA>_.A.&>?VF4 '$=4;X1=,%K8NY]^=!--5->.Y-BD[M@.V)-WME^'+Q=;X%]%KSO7L%1H%#AOG@#
*<^^U\<'#9^,F"]MX@(Y;U8+1R8 MUMM:,C4!2#60008FDBRUR3-&SH$5AO#_$BST'VFP$C)$] *N*(JA)2)HY7WV M/GJW&^]'\A]B3_R&[XBE+?*
*&S=3C20_E7J_>?__+Q_7>WK_+1$:V*X;>#L8WH M*PFLVB:NFR$0Z$/M!]^+]K3>"TB,_$:B6&.$-O$OQ_Z[MB7^Y="'!'#R7PZEJ1993X-*
*;U9SC3I:XU=7/S#P8DHBW>X]++#Y0# OKF4EZQ_ M2_Y;X-ZTG%9-O5HMR953-*RXON>&+5IYS*#1BP]&.K5TQ&_ < U"8A[<[5HCZI6O!C D*,9"*
M5SJ.YU489T1):$!P&:RVJ1-#9<6-].1A&X"X\D9NYG"-0%,%CK09J-?FM$_. MT"! M;5Z=2;:0-=2-![1=L>]\L:7HGM#_[91H>%$CBAV)I@;%Q.&&&4C%--*
&_LBH M&R%.7Q:DN5,P]! >:HZ[+8%ZB!P@\.5)[MSQ@58C62-CM"Q1G:(?K17)#]"W8>]X2M,?FQK$<1C7/_:7[7,; M_@H=I56]4+]<_]Q4
*!"\=F%KG%"-8K(3GXX1(_PEY&8Z_6%]Y$>?%.$_RNCE MYW) "GH8N9]0+C[)-G==K+>ZB1CXLMO);])H]=5*P8 7X6[DT.5:'#;<0N4S*
M4$8691U[+%@_4X,%(_D&9C*K3]PEJ3\3JT-S,E[X^]#XNVA=(1K2\(+7"%5) M@%@E2D\J7NPZT?=/U6"E>'D'(82=_+8![Y"Z/T5.CI">;'K@68!0$C<%8Y;
*M!NK@?PL-=)[X8G*AL0P)5_]=\'&OBUD*#ZDOL?T2AKY?.(3 M.5C;Z&2YM#'"MQW]FF]4O&SOW>+7T>G6%_;T^8BW$:U633\2YZU$ MOT!7NP"M!+*
*[L=4?_;ZES.=)'W:E//,H78YW(B0N^6N7A*2+'ZKA5)@+@@K_Q1:6 M]?.]UEKRH7R@RIIRS7\3'%AUEF2MT;T?!M2D#RVBJAP$"CR![$P@50*
M\/LS#V6H4(:+4"/(WH0@I06=NKU;)XR18KNQXO-.'I;KJY9!E?.KGSD\IU?# M1Q\.T,Z1 ,D%=B2:81]:Q&ZS(QAL1A:0^F.B#C%T&%]OEI\)3KMN"J%YZ
*M,DR?J2:#_-Y>;B;0HQX .5R M$-[/@+5XM+OJ1"7 =N?=")1+;5B90C@>J=NV&R7V+N13.S=E"7V.%V*ZK= M4:NISJO .A%NUB4%\R?*
D'&)E)$]ZPLBB2$/D<'1C%G(*#!R;#0]"W_C/$: M\T_,%I<+<>'S]^]L)[^0>?W\]Q,_C!9^]!E'IWCK/WK.'UCD.+O$!]N)=B[I MO$/M#!EI ,*
[\T0BE5B5^E9)!/(W3&$% MQI%X(1;=4F$&V+7BTZ93(NS8$7NQG(.4HA?EB/F"=N<'\4=TG.B,OG9 AI/\]>=DB<+V(A)T<;W\@:A'-
*/(*M]#EVT1B8GK.2H_1PYG(\#,8(;FM M7G&.6,&$ZX3QFU^/% O=)A(T_1ZD:.>/ 40$5OL!^ID&9T+GB:O&@?8.U1Q5K:DSF&\.=YD6;TF*
M656W"3D4%#Y%X!!K*WZF"RNKW-#SZAWR-_]>+%!L\5D^7&JST.0S05VCM%R MMPI\^[2-;O$3=OTCU=%[HB?*
$'/=LG2ECL\%T'JYVH03"]7S5,^L5H< 3?Q:!371L3<(C",Y)&[(ZE+8''4GJ! M;>80AT5#(3/YIY)<7L4PV/8DXBMO49=CX-J4D-)6\7B(,HA&[*H;MJ@]E7/5*
M3S'?=H_MDXN7NWM^GKNR@NB\(92%UI85&=^<"]]4E)TJ+-BVV4I"A2(\%4!P MK;P=.\HG?S%6&N_%T!$#C_*81[2NKOBU_C0Y&>)L+7<3.}8[?
*@PP.WK\Q8GV M-];9]8.)[IKXD8CG([:=+=F[5V33E4'!-!T=\LER\VIP@&^5VW*E'LVE23O' MV_G!@1^_'G$0Q7>2(Q\EQ"%&'4K)0U\(?8@3B&(*J2$F-*
*/9\'&!(A*K2,7G$ M8$A48F&8V8F7KE.BXXP&TV"ZX;9\%_?OU7/@QB72F*N[4$'88>ZHH#_>I_/Q M9GJ+5N/IS6=]NEA/UR:..;YS2?MUA%$8-*
*_J@5Z($HJD:#]M\;SG-VZUP M,%R#K2=9NZ6.DNN#(:*R+NP=^#)>F&K$EKL3"Z_G3D\(:(^97,K[M#[YO4T;C^L?I\]8]T/LAA:*V#8[D&? M[/) ^I#U4N*
Y'(V_*>PA:CDS"848$L\"8#.J98D)0GI(12FD9L?%Y1PL[[2CK;0"*CI63JPOUS/SGGR"*$[^8EI'>.FO'_,HV;>NFP/I@ # MIN-I)9$TK=,4 /!\CC([JKJ?*
*(&0EF;2^1N[E.04!1=WC\NC*TDP)Z- WKG M ;_0# M !4 !M4-G%L_/XAT%4G6W1U#L_ M_WQ^]?GBI.*]=_53_^*GR[O>]$M<\ MLV\HH+&D:UA_H?*
\\PS?VH)"6^].K M:_S\8>-YNY\^?_[QX\>G'Y>?;&<-'S\[__SO+^.%M@%;]:-AN9YJ:>!##Y;_ MR0V^'-N:Z@4:2CS^^NR8<067G_?OPI9 ?
WV,BWU$7WT\O_AX>?[IU=4_1$U$ M/U.\)"Z.?C4(Y1.RA.4S]4\-5/WML. M_/S!-;8[$U45?+=QP.KG#UOG#^49$N3_/D0$B?]5+'UH>8;W-K)6 MMK,-
*U/BAA^K_.A^EFN*I.V.[]2WP2;.WGU&)SW25!;)1:>US1>$6'B0I:LC MMG1@02[##ZYM&CHB[[UJ(F4O-@!X+K6,3'5**>I,=6"Y#? ,337KD/OH!;(H M8?*
*^K.UU-=\ )Z,@+>%SE,@J_\&SMCXUMZG <&?[IP_Y9@Q+R7B*C,@;JNWDT M[1]U$'"%1=W.B/QBN9MJN[X")ZL'_EB([N1(1PL"IB %5.G. "Y7+."Z1:Q$A*
*MSMB ?4*O0*.D8^&8VGH9J(4$9)R8HJ%"'DPEA;XIF@#)<+*A/2!\#WMAVW1EP$&IQ?2):^R((ZJ[TF / M)8A8Y:'-9JZ4:%[5%86D!E PR%-*
(QDGP.'@\&P+@APEIU L'?V#3I._J"84 MVE6\@>HX;W"9)MJ^L>+$Z9GTXH[AWJ[E(2-.AFF5%>X XP9>: G6KHT2G;
*M_,TK8MDN,8%>0.P1J:8,"D<)B[P)\,C@XQ_H$@,8I<0>U"I/@QUV&|24'"*R>BI:"LU6X+PS"=7"J;-JA@?D_[MN"P|*+NNJR1GZP?WA/1TRS[\ [(0@0NP1)*
*[0"-Y^7\!1QCI+SR:M*Y@ T-<@ M,7=HP,X96"K*7@-*
]#M/%8$IWCB,L_0\K=1+E$:RC!5!NK6$A10*GJ>N!DA4SAA*.V/46:O^CW;\2[B4$E8^O7LHDX8.) ^YE&QS@%.)6#K?5J'!,XSU=!'UD#= M&9YZ?*
*%:XH'3GL&>1L_5V2HY20%M 'ZJ.A2Z%5#3-W_K!,N@$A_L M'#%*BLQKCTL81W+OI:6;'7:. Y0B8C,NMGU-F#N7+KDQEM:<9?_ZK%L;8KGR*
MU> M$!^F/ MTNP&>H1VF#U0QR_TR,^%_O,Z_&):Q];=8[:=^ET[_A&:E$2@6HP4[[$50 MJJ]D). MQC*0C%:[[':CP=P+@M&\"-*
NDRI;4!9<2PUMC&)QPIG?.%=ZYP%. M]=.(+4>.&+C2X^I-B-P#Z=U=M6':W8Y]$!&M6A?@DG! M \M?A^4FD1_'#W64%U1BMGYHR)-*
YY+H^$Q?"!SK- X*(K=_-R),7G\6)\JE. MLZ%(SM9O7B1VJSPDD$X8DN$H)E^E U+Y44 M=H)B[H IW5WXBV<-5;-:201]\92!.E]BITA
.5FHFAPK9S1H>G=S_ZL[74UW M4>0_2S:F"]IL3(LE_.?+<+)<]:/O>EL.%>6(UA UCU-=#_>%NP%PVQC8DNU M:.<2\OKZ3DCO+= S[69E)$#;-*
*KYFCJW[F@,5D 9$ G[<:G M%DK@YEC4QB#N)6RE^V!O5>/XV!FQK(,2D]%RM*V>H$C,$J/]'K:G,WPW)* M2 @2I:;SAK)(K-;[Q+EMC[7,;#**Q%Y.6*
*M7^(&XRQ4<$D;P?RWA\L8;RD-BP? MZC"[@9HA1M&#W:5(*W"&98X5)GUVA4GU)]S<+?> *#LBIZ!V(S&RCNF#]>^'E6=X M/2KL5C9D"@S<*
O/,4D5:HS?"[FAKDI25]=.M;+A0U$)?5ZJ,+)RI[M0HE*KU MG]TXCUM\PJ7 H84KWAG(F02LY>2/-&-+WDH=0V-=&:,L1;9J,/$@#+>
*MC&+I6Y!MA#>K'@S31V<.JO(J6<\I.JM0_M.=#;/;+H;Z.LVUJGKHEB.-43?, MEHVIQM/F':VUXWET7R#SCI4;=#O*F7I0-JVCVW[_YJ+-;*&7D5@,[C?*
("Q]HUF/CHE-ATE3GX3AIWF.J0C4G5"9$E676%=,L=@-'^6(^!.? MZ2(7V 5N_2&ZXVOEB(3(+IQ%)C![VO]\Q4=]RDVE1"S;10+0"XK=Z6AI]AV)
M\"LU&R.+57/VG<93L7"['E,BV,D(YD%/)1JG.=PNB,J'C74\,6FVBA.$X[/F MMAGE(J$X=6WA^"(VAV)&QTF"!@7IT"?@1_ +WK93/)M2WM59_^9,[ETD?
*0]WP'1S:29_9ZJU;6>,;4HH.; ==9L;2PLBFYBX$8CROHZ MS*,J&N 4_R!-VC_26![\-@TD=(>OP-$,%S_U9:VG]?SB*SFG^S1PO.I+PJNP*
MZW$@%J&BKC.+571.%W3(/>D.NUL468*B(;8HI48 N"K'?1M,P.*I8]]=F?B6T(M)$LC+%R//Q& \MO77[M :T&N4BH&-Z]7MY<>$6&T@Y4=_-*
*HVC]8KH2[*A=!.U 6O_0>Q]-OTEX)EXC9 MW.NE.%PVICC4$[4AIECOQ@0L_NWKQ#PD;5/[*O ,>W%\(S" T3L%1&8BZS*)*BNE MYN B"1/([*\IFME.0*
*/N5L>KT@A=]/O7Y]TD>&/*JR'.0X!'@'K[M@<+/+IY5C8&\3/0*:CU2PNH30= 41] ^&]"2]%9F (+1U^!; RK\97-V@<5H &@!%2N:?S\<&UY.=D(09GP'-*
C;DMHHN8;KZ]%\HCE/'GAWIXZ;J4R_@K$/AQV M1W2U]%E"N=-5-&E3S<-)>(Q/AU.=#4__L20XGN9G"LHRRG#%,C6-IQ.Y%L]" M[;T?
74#G3E=)!3%T_XML][]7%L.@=|-L/EP,)\O -34_S&9D7)DPO158LEF M>V#4E"B$$'|!8J9\M M#TJR8C!VMLML9QN/?
*OTZ>A@MO_>4R4/O<311)H.1,@Z2]XR:[WA[4;-R0N&? M;!0B:5L:<'#]L4P%/'*IT;]W"2&Z-[/^^;+5R-)[RT.W3Y/&2_I:]YV;Z/$+ M8VT9*T-*
3+>]@WF9P/(EW<4'?X]V^$7HZ?)Z'$T4";+GC(83+],EJ/)4V\V M'8\&HZ&T\^RL&C &@%2PX5/,)!!Q5H#M85GZ?*
C$ZJ0/)Y66KZX!RKK'PZ5,O3@ZVP/GBY_M@5UW/AP,1[\I]V-I^^]!7MQ0FUNBV9XZME7+G=@>'#<<54?GY8ZP2QJ46E3020UZG
MG3D^TITYSQUI%.Z3#+Q%Y1@,T6W6$$4K>[A,4+ZC2<9_HV_FR"J-1\K]:#Q: MPK5^X/;#\=!VN29,E]^CXO+:K*
*BW;CQN7C5Q!DG8LF&_-1G.FGMSLE:Y/% MW% @F,J9QU':-OH.\)F[@)T5-@S.B-U*D M3-7*&E^)T+7V/ME:BH5(E5IEL2!\>'&T'.&NF#:.(9XQ4#X?*
*5$]Q""XQ V39*V!11,H0/5LFO:W?VA]P0PU"!+)V?%,#V.5Q.WG;U]X3^[X$\?UC-\21ZTHNCI>1%^ M7^\7PU^_#N%L86SC5PQQ33A=J)-(4,O#*H$6.S*
*M&SW>C:1]DEZ#HZS;/MY$%YT3AED)&FZ^?'(M$1A:K9=A*DO&@UW#58/H<5 MYFP>BFZU//.-Y7@#^D$S"T^U=-7144#L=^*
*I.FP]7'L2R5"]PG8QI"9Y&[E[MHL%#/Q'@7@*7)_/KN*XD=?'B>,"\8&4[/VS?Q_N M5G*P2\I4ZV*B"=N>/QMB-?*
*$W61./.1XBO9T79NUF15/LDAO6UMYI.70KV@.:#!.H=FKE,5V.1YNX2YR2W>_(0FIUL=93Q_(W1IK!4)HLUX1\1SU$?=07"5URR MY]N2.(*N>*
*7\GQ:+^@VP+.6\X2/"FI8_PN)MV0=@2ZS(U!^T*7TXT]-T9;N_D!>*IA4AN&*]H4Y[V_1S5+:Q>Z MDNP<,WFHU)1E,FE'#B,0*[C);H+_.O05> ?O_1*

M737]W$<6I;Z3190Z\3@@'2QZ)P&"I/;K2HT('\!VV?@X& .?Y4%Z&(((J2' 9D9-=%9P8PL\PLYPI.#$7@ A?D@I>$H6EC0[N)11"]>C(4*& M&8*|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|#VQ2B0[0]TS#KXLG M^P5:P,"%MP86TLX":#XT%4A/5'%53'6TDQS\1!4=R]^V"+RV,:2\B'7%V]]6#A=T>G&CU@K?*/PN8P/EGE(82'!1=,|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|>8I-:|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|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|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|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||137=H.8;H :]"BE 21M(PCF[<1UOGP#@XD[G MU<5S74?QK;=MBCO*\%E24;_W>W^]B|0I2E|9$7=)]*M&H9Q*C>2981%$1I' M'LBP)UP[30CN/LK5.\0*R,IA2KPF*!B,43NRJ1Z432J23?7]]|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

[S!85U90LW017M2=0 M^(H\A3_K/@BI1%=Y*EE]9WC/#E?M*<^A?L|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|^K&+:ZCIXT<'||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|-$?[M7'8N\"L."ZV156H.LX/95/.';9GV1&M**+%S+I+MM5Z1 M\[?-'$)/*^?$UD@<<>1(W/,G^+U7/[JJ[EIFU]*'5='TAZ"T'\!-UG)L*VKH M\;8CHYIR %51P_:LQ7(^S;MYCO%YV'!=VS1ZHY4?2VMQTD,&SZ>FQ_+NO!;K M9:Z?[&1'>!,<6/M[OX\|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|:Q*3E7=$= M\7V+/,:RMUD;P!@D01NO9]0$A2CS <6]U^GK1/+99DZ99SNP&[@_;.-P$^ M!M_V;D"YQD.!=OR)\N#/A)=4,HE[@[*0?FKWIW]Z(#0._T?OG2@4/@4 :,-C2M!Z*N6][6ER=1P(;/@BC@3@LFXIM.=Z6,*Z6=WSAKCFFV*ZA36:N,C4FF,8A MGFQ(V%)&E@+Q):BU-(!P/H73@!ETBJ >F?%$K@XS>_-HH)?:GYM:7GKJH7=0 MU#V(#V0?:BEA2AM"<:HVP"I(":96C3J&<9>RL'V\6 9HYE<;D$KK)BGHFS]:!=;)3[V 89M>UZ^JZ*VI(F95#F[P"H&X3'(ZEI$R)9B>U%:'D>NG^GE67J15UW@]O%7VY.:N'>&FNP?O<\HBWP3YAJAL,>T)Y55<@(! =6_ W+9,!,?O#5ZMZ9;||W=:I]!GI#QK#'S&&?9K]UYCON>8/O3C,]U4))B)F*)Q^O-|U3<&6|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

MS_3W9+U.%"!1@.^@ /$,/<^Z+XFNBJ$2]$JR..? M*L< -=]+EG0PD@0ZX;F0+2[#H[."A:VB)#F^(F\;L,2333S99 ^ V(YVC ^P]$]PNX @;;HOA'V%2&%]:!(S5K'R]X6VVYH:%>;@I)D/G?8= M5@0X F1$W]D|\?WWIZG^I7AHA,-#3,XC0>M@=U29D'D!'ZBCA&7U/DZ=?77GX*[N"2 MVR3IED38\0#7'QF/G\L#.PD)AV/U+@?S68V=HN-4FN9+JPS."&BX02]PO2CD M.I5Z*>I.<"+!B00G+MKO.@HHG'O;(,>NK?.P//)K+,,LZ_T0**@ *) 4<9U^ M<1^ 'Y&>0[;O+Y>/'I_C=VF@YMI=!EZ13NK)I:85S$<".= M;=Y1(P&E/LE;BIE<)^]?]/_W|84.Z#^Z$+%Q9:P*6OF.)4L]FINWC7F@_V=U M@I)0(D?D_#QNX:/,2!,HDR),B7*]&./-6YYEJ2-+1UXE>YF36UP,B,@4Q*Z M)*LO+G7U1;)%12+JB:@G.T\\/X^V[BA#Q7&4H._ !%Y#_WXY6Y%39ZJLA+D* M=RPZBBL@\ZE.#M-818.9G*H6==RXYSZ LG*Y-[](3C16HT4?E!Z;>3;:01B[C>V/+ XHQ4!P(1ZZA0!#"4CE%6E]%PZOX-03JL150[4S1ETD^,D&K::C6T>&Q2%.U_$&O)D_A5+[Z PFX?]=:;:5=HD8)PK^ M$Q7<=.,$&=G^?Y=@EG\N(2CMEYP=?LK;V-07_$8,842XG:QE&$%E=<" (GZL+; MLQ<%?U7 4&YLL=2|UC=4+Y/UR-&%9G'>2P09G3N-J2%RK'AWYQ7L10;7U/G/ M2.%LT>RH% (;>TO.E]G#"\0J&FQ/$%MB1L8","Q(T*RV&=OR(\0[H4PMKC$TG3:(J=:>4AD8=]ND:E<;,3E7+T>%Z>- M6HFP[UF_Z%:FU+3/4,ZKJ'H)K'XM3S7RF^BRQ;4 /'1-OS1Q3)4W8Y/>/6O7 MK6F:-2I2JL66E9K2[E/Y(G('F)Z^H4^2LWD"(<_E;ES(&AZ=OH'^ M M%_)]/8WWH4^C>>M'#A:TJV0"AT8P],+!_U_3O7KL)SK5";]I5W 6'9% ,: M$RPL25_36+*H)%'T1-'COGKD"$U7BTI3S',3.>)WN8ZG+Z?|_6(4:#H5:'HZ M.8GW^9V#09T!040=!.NJ#)Z$)-%6/5%/,MD)1ON[GWIQX4[0H_+6@>Z6S&RD MN0<0|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| M7'K&".*/;/I;A,9. ,+_:G/9YP7VI<70[0#@@H4SV0#3@98IR*[XQ;H6/KMY M%%@'RQ$#AL&Z:@9=,I6W:>"+NA<*"XP"*_H0.Z^EY?'BKI3MB4JT$]@BZ8^@ M!/2_$!8^^> <3P=J1SYT@/WIA=.F9ZC>R)H:V3ABF"%JF1%(@E*H)2""FF$ M0 6*0&B2Q"4B19%7$2M/P\8]?^(5*U%EFF6V";6+;).ILWR[E&U=1_FX4BU[M$W(GZD[6]^786HO-@2\MKE+*,6TVUV]X*/MX%/JBJ:D MALE#<,$ +7!O .?.U,/7'RV.A659GFT_PL:E/TA71">]G_ -[[8\1,"Q9NN7<;E!PJU/C""2P$!!'"CQP M%%&#Q2%X[ZVHS\6EN^YD.KV%L+<4W'K!"?MJC,EJ'NGUI IGF7?8NA-,%_ #_7O4*)&^+| M7'K&".*/;/I;A,9. ,+_:G/9YP7VI<70[0#@@H4SV0#3@98IR*[XQ;H6/KMY M%%@'RQ$#AL&Z:@9=,I6W:>"+NA<*"XP"*_H0.Z^EY?'BKI3MB4JT$]@BZ8^@ M!/2_$!8^^> <3P=J1SYT@/WIA=.F9ZC>R)H:V3ABF"%JF1%(@E*H)2""FF$ M0 6*0&B2Q"4B19%7$2M/P\8]?^(5*U%EFF6V";6+;).ILWR[E&U=1_FX4BU[M$W(GZD[6]^786HO-@2\MKE+*,6TVUV]X*/MX%/JBJ:D MALE#<,$ +7!O .?.U,/7'RV.A659GFT_PL:E/TA71">]G_ - [

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|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`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|!'GCR?C&FCLCBO3O5B1 (VK5661@?MBKD9,\SWY(TV M&(P9('X2Q"51;)XDN$.R^C|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

M#^;::0Q;@;027+'$X;)+E$6FOVY(^!%VR72S9#'=018HGL^(@3QL>$.,!T,/ MGE]96#ICC2I+D^;T5=K%:63N (9RE M"=7S#5XWU[-Z,X15-YG%UPX4,O:'36GNDT2HI@5)K]LEZHE4K9:.@!!II^"ELB MFV+.-!3%QTELRO):-'0/@I'1_V#R;'T]H;DSE>>N]FO_YO$1"8R$G8$ M$5E MJU_43%EW[.?ZI?1)T]TPD.5|- B])S]Q/86R?8 ?EN4'H.]4B_ID;KZZ/EV M^$Q]:@?[PWO_;P2XQGYM#;P@I-.KMM5.)WBBZ,I#UY[ZWG-%-TZN6.P=P:2/ MC/|/^JI/UYJ 6Q6:K0JE"H-:=1M;A?X\66$+;E5LM@H"X,UL%03 V]DJ"(!? MO%7OS*1Y54>/$UW8=]#EHH=!W(CRV>Q F_*/"A.$_4>R>A E'|)Q_6E26E.+\0%7TW53;^"K1&;KJWJ]0]WK*T[MFYXKQ6Z+[%"==4L M&S):DN>KQ6)IC#HI$/A)_/A-)UF.2-(<=J$ZSU"@H4#?ET!?M'G%VP1:;ZV(MA4"42F9WS!>9+$ENV)E'YW7MX;BN:EY-;|NK(YH09\AX=M573%3N$KDYT2H45@60519I M0BR#OU H]"X],%N=9T= <"GR1^.!MMQ=VW+7@L[O9?E=U)7S% C3#T+\!P;# M$5,?T+AN.^ #WO,<8^A':6AMNVI;8.Z./9V&0PK@NEES3W;^$KU-J>5G#4HT MQ$6KM2&*U;P$\FRA6PA""822>]&IO@)*9$RAV(91U4T-+?-98F)Y.84/H80& M/023!$HE&?I;>]1.AK,TM9#.2BA?T:X AY2U5^4|.WJO@(7'Y3",JR].A1TSRIRS(_75K]W? -$PA@7*")21"\G(C?M%HFI2/WY'A4"1H;PM M)3F;:Y8;G;30A($FS)V9,%_N%;ZH,R3]#Y4"%$L$ MT=QD|@TNA8"Z7D1H>'!4DCCI_872#Z4?2G_L_!=OEGYN,)APGH*3J.RB Z,: ME"?C3".<%_WC-X.129;CSG[W$V^5<'05S 9&;U@4:H9&%_I] M)>@M(@FG?_QFT22&T=]K-&&GPM2|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|V-%*X_1#YOF<*X40>FRMQ9JLPA&%ZK MW&#,)ABR.F3U,Q<-C+/BMRO6^^!3F,_4B<1PG3 >CKDO01B),[EB9T'$R-<9 M4\K=1W==V,(:"EF,*7LO>E1^;2XR$R^D MH)&K8J-PYI%C@$W2-)G$\%,9CC?N%]BE'[U9,X(&$;SLAI?=,#$RDH=.2_AV(55CQNPB=YS2Y$U M+-E2+GE+<0.$BX\1&3/*?+>[7MA-" M49_U(^:;$%0AB7FHW,30W-XUQ9S!36J70G(BJWA)TDD,O6*C5B\ES++6/&]@M;+N-(!\ W=!$L7()$U^KXHF1Q6:2'M)V//H MQB>AK31',=SSE5.+,SUB9^C$R!,94\K!&^4XZ5H1]M:VT"'LD$,]@L5EG-TL M"DT/%==ZIJ:ED&%6TD<2'A7%I=@DA9[JG0(1"")0?"@'$2A.VN!;$:BIE*C! M8,((HDP,FYA5#7 [U0 (!,J<4$GB9%7N6W=DG8A9T1^N@V#,"KR'OXA_.SZK MOSXP7B-7^.'&]^3U>@XC@@J^PDJHKPWZ_)K'\[T@D' *Z&@I30,&U1'FIM-.,B)?MFIJSM";C-0!0;!UK')?DV/-H4R_QRPWXVM ' ME>O?ZJX*|U\)8U>7&91GB30QT&0J>J.M?&.9$MKR8.84C#'X?C$&-UVC!6 I M^$_X(1-S?4<0_$T%7S!6^K3#QZ-K(?4L]7G%=N%E3+UP:.$;\:R-=*:LJ<) MNJXIIQN@=^8%=[P)"%,N"!16;L]6"#J2\%WI8 S#D@Q[LIHGQ!R(.7>).?>E MP7TYY#Q'&B:UZLDKHC(76P4'10M:8Y:C(Z0)M4 *=$-/.OAA@9B[\:EM?S7] MDA*T0+W$4 O_SHH:0N@);ZPEYA'=H=$,C69H-)|%Z@57 =DCF.G8:HUJE&NVD/-'Q)(GQ_F>'4@X [0SC(K4 M,Y(Z%9,"$0,B!D2,\R$&+A5J[@ =.AW)U%;^$%T5%WD|>QU+|\ ABC K#1:I> M1]MBMQP0#81AYVLQ0@S@:P/&')[$&)CS=BSG[26U3 L_?Z:0P>2W.$2;$"$4 MJ;8_G&IQ1>+_^;H DNL2XUK_.=#UT)&39^4ZIZ R#8VJ68#I8M>QUP^@LL2 MYFQ2_8F_,DOY24?B3'(E4KR$1_64V23'<2 =&<:T092!*!-?E"&D/NY6AXI1 M2XF+"9?O55=IW,-B@S)S;FX2X_;"1-=]K30JY>0FA34 R@#MCTF2#)%DN<.R M[<^TO[\]T&?^2YCYN>!OOWFP-4#^P1NQX.R354(B:\ZSN1I/?B5Z_\OPPC]0 MPF];FI:0%<6>A9-:S>>97OAKWLVT!U=+>1%V5=#^5,!BX4+<;?O(FM*!A_O M8NOD:?@KX0_\"?)YU/_K\=S_W,P(8H]M9U?M^]/GT:+&6TKAT4$TTI"AH\DF(NOA[_Z2IX&|=G>+9-F?.+GW:_QZ.,'^/WO? MV9RXLB;|_?T5JKE[M\ZI!5[])Y)G=4R5 !).3L?V%$@H@(R10(/WZMY]N28CH M,,:&'E7MGNN!1NI^^LD1P$ E;M+I?U/;/P$8!Y"<"]MH %ZNV(MJLF+_)+_R M/L(2R_O.L%1@MS]-61-L=2'#LW>>BB_%-F8_6>8FB8XQ1?]T3\7$;^*7OZ43 MVD9L>TW_*U!C$R3CQ[J-W&ERTT$$:K^"&.Q^]..?+D@7L*AA]"1)8'%Q5_AD M3H%_Z_T4R6R#!.BBFJK#D73Y=11XEO8PLD21V@6[<3|CV++]2C$X_W<$W 2L8@IHAQ46:8089-B(.X ME)(& I-D!JP8DV+TD$[*2?8'NR_1TD;Z(^UYTIVI+X'FE$>]F6@NV8Q(^C1NDL) 7XS5@Y^\RZ 2QC?E RLAQFZ(6V MZ:I1H!I-1+/=,D+MCQ(#^QNK">8$X6IW MC _DQUD0%L1JJR+-Q%*H/*(,2X%4T; -F>N:*# ^ KAWXUE9+C"'F!SU!2##2P2M![>1>(^MC-%OU5U"2W" MV'D# *,"IV=2ORQJZFBVZBX6+,M 6P0;1T"(.I(1X/#W78[S0!/%IU4009%] M4[8LCG4"$ 0T<@J# ,&2-1E2CF5*7J&76OZQ]:BLH[N595.6(N3E^\|%!ME8 ML"D3B?>1CM#DY!;1U2_'JCBFX,I)(AMACFRC+P :$Q4VB3\GST5[,67+@LNR MQP8R^-SE&#[HG][[X7F2#$EYZ&7(.MQN!<-DINV]#M;,3$-R1)D:FH8@8<1 MQ#O%6XVZ!RYV.N=VZ"6@@59Q"[&DD&/=7DA2 +|Q60R++#Z*>\O\K$=_=T0 M:0-X.$LSZ9MWI,WW9-5-QQ3'D"K-C4P9F\|44K7'5 Y0J2T+TOJ#K;G](S5T MZM;198I-8D$8BV!,]NX)2%Z3 ?8XSF3*"]5P+&V-;D='9H|(7Y@(TUVWUM[1 M(E2UFJ/^\OB0_[E'6]3,,:$+A@VH)%!'8+7#Q_S?'UF)6!AQ5M2$-<5X1QFN M,1H-97LIR_K.R>#S[1-OJ]IY0]T:8YWJJYJ%CH(9XI0H"6Z8;9^5# W!Q#$X M246T8ALF84?HE^A>%K@6T2(_Y!O8L @!CB>C)B='/B4O!,KNN@@,\$$]FD& M0(2?=0X*$4K&B6[@M"[O7UK!J;^/'KN[O7^I?X-',8G^<##89D&^71;GKQ_ M?GMI(&:L.PJZ?<>$-Z"_P H!QHSHLX10Q3;T"-655V@WP;NL[?RLX/]L*Y#^ M4M'>$&??WY>_G+/!0'1K<3!FQW##]0I5(82/Q5$2F'MJ1?BGZ)WG0:$BAZ" M#1+$7VW51EP07S(H=;)E>_)O'S8UP4(+J X@@HA>LT5I@&83LTV:ZCBS&2*F M'L MY:.HBY*[]W 2TG\A-<*5CQJA_,_'B

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|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|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|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

*M'%.MD)5@VO$*F<7/I*M7M[5-;K[?>C\%-<=@$B&D*3IN22?O+BC_-O%19 F! MT;WF 2ZVK!]N8MD.^K O049+WW$$][^<0'_YSQ9B;>!GQ"> (W1>R1R],[^&: MN*JA)MSI62O1O^LHAC,T].L;F30:*#._L2-SBL=43\K%I M/(TC4]LC]2R?:\PDO=>97MUDVLNNR |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|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

M6UU)Z8U[.I9E2.RVA'=EQ[M>1H>U,ZLLIM#J+@_;,,@7::0S2 *2RL2"73 / MNPF:R%"'PZ/;43%3: 3(@@\(H#(!KK?,;^&KH$I48;#LA1TXCKE<0QP;&YLMR.ND$0R#8TH2)C>(>+&#:%Y4 +4+>)O%Z:+M8-R;3KZ]:#=[!V] V(I/=?FW M#*K3&D1]T"ID3TM
'6KB.4&\K=&L$JX/RP#RI3P4C9@78&I1]0=@:6$BC::H MQ%4C/4AZZ'+!>5#?73A%:5S%!H!'H,B!"F^QQ#C4R*E7>*+8QH2L;"_FN[:4 MQ394O 6ZB0.R\H1VQ2-MYC.F X)N3MC5XU PVQ3$X0B(BYX0F]^NE.!V0'/ M1'K$[%PT0[&9D/4.!R$]*2Q5S-O@?L1A;V8FC\7-%!'G@!/W8(?AGPFU SS$
M;6>;'LY2G176IH$EQ*P[M@]9G#]]-\L:H*ZN+O^D$Z&[4N_#=^-K "$PL^AH M]X&Z>' 2$Z@L4(&)MDL*@37OH;?G7H"K2UFN:?
KRG5I*G_22E4)56& M>)4U M3"]8C8 :5OG6+#F&38K)B6A@.!0W6>+53GYBR3.MW%MH%^S6%LH#F \DB,E% MXKQW7A;-
F&.IA"ZK\F55L@/RNR.TY7@R M!?K EQO 3)A4]$R;'=/T&>:,11 MP;P4Z5XSE;+W/9NAKXD6LMO-4648!5Q5PL5BM--%97356[:'+NQ.(LN8M !V
M\&YOV\;VMBUQ#I()@UD2/8 5M/K [@<*V(N4C7N)F!Y=40]XD[D<<(1X6HFS'GQUF/XY'*1LTF..Z2*CI1W083C!]JIJ&N/9+H7B?$\Z-
M4KJI;O#3/9HIJJ^6@Q=U#.KO]4Q6[Y6@>#-#=Z2PI$C/5EZ9YM28R&::H3;+ MW42KR:0!1=%"_K\R9P*U-= AD$%6/%O6_L AXFG8S\
YT:HB+K>43#_9(O[MT@"\-P0H7QDS6YUY4)GC@SEZ3DAO#9#NQ)!N58''$@?H;_$02C?6)E+("[5@
MZH2+>!M)"1ZVT6\,YHD(^3S",G%,8^6YL):Z;!ICPGTO93-54)0-+\& LDC] M-B"FM7H3][V5R5OHU]1?VK:I]!W?O1%Z"W/P'OX//T#N?D+T$-
AQIT4.55#[M]FD8@&UK?Q.['NU1RBHJ/=XR%FFQ"[RA/ ^"I^.\HL(M/^5Y(?PT&7[C1,W^OV]%0-21(GWS5B@KU@3H[U+1T0((]?$FRH]MO9IJT#XK
MT$?0N_JS1]MNFY^($$Y'79(\DH>VP/Q@-.&#ZJ.7?LT8E6*BRQBS1+?%5M3) MC?]N^2IF>7DW<-ULQX&C[?BY69R7R1D:BW&=_U211B-
I*T:\%18^]CM[PV:@ MMQ45S&GSPGG4 -D@)3>.A$DDQMSR5WC=".XB(%@0]V4!YI*^%X!WO9*NEAC& MK B8 E/L"#U$ZGFW+%_8;)U31\O?C?
NL0.!K/G7&XUBZ!Y7-JU]6QS]$FLYE M)J:B<2E?%1-VJP@9*H8),:<$PR2 .8"W;N0!#ZQ(C,')$NN-0)\!C#EPK7P M!5\;4Q(5Q5=
^1!M$PUYG53%5T+D<3 M5B[Y(.5B;3"A6)[U^R!T'0;ZM=W!CPAE&3@^R?,Y+F1ZY7;/3QBJZ+MZPP_YB"T3PJQ8&O&5Q>>&>6,([,29Y
M,)V'N)D&;*NKL"S+9-3<>XJLJB4F8<$2-4Q.@3-W"]/*9 S+L-E V3&9G.P_ MN;+8+7:!ECS-=60N_+5.&S[C:TBIP&
<:^$P#G^FG^TP%>!873MEG^HMYBG5E M0O!@OO@>M&%BT70X%OMT&V8;&/Q[$/R Y0M]588JK,$HUE'@/&NAA'4Z!L
MZ]TU_=8EO$^TPN"Q,":H$?@5-0+;#++K2Z$2' P<)JU,YQI^##_1+,0R-JO+ M,EAZ9:RO? %K4+-9/>L'KS1YMT7Q35A[D%8J8RGP# GI-3O
#E:MS"VO@;FW M]!+CW%1L^(I5?O.RGEC"K,GNB^859N73[C0[L1,MW_P3&*2Q-TEN! MFXS|O?\/SKOS*LO%#VKZT;N4F)IL(>;HTI)=ACL:#085)
(,*DK^OKG9Q^[!* MK 4,.|*K51H&'9"T8;T !GMYL:)3%X!N?1Q*@(Q4:/5:(SB%BDF6!'.8A=) M0$I2]%"3!N92;+>O%;W'12S*0.E52"I,%).
[6OD9N%*=H8JFT:XD.L-4. \L M4<7$ F,'&S_Y3I^M?@#<@17*'1#3105@&P4#]NW]Y)_PUEO1V6RY[]T#$XXP MKH:)4DVDA9??: SUX>I%<
MIGGVR\VZUBM"W.6 #5Q9G27*1 K;I=?(S2V]SDX/*\;)7E.WK#W%RI7BRJVU M6W0+*/2.FJ<^T(.!-;KUU9@:N%,:'%!I8VKF"L70"_R]!$C6CJ:8/QD#S.;
MBRK C%:[&@._OO"]9OU\]42^X*BWFS['.P6 2K1^ [>'K&#MYTX. -'+R!@_=DZTP=P9"@,I16OPVA#$5>MREP M\0D804R(4JRB]S]I1U(F5SV!NBW-
7I"H*%\X<28JFG_;]$Z&?=KG]Y M*7Q7ZOV]M>1.X>X-ZX6ME(J=]=1'L^$^O4)X)"QL5M:-AB.K![]1(/G"5R&9 M#\>WWQ%;/?#-NU-
1=K/L[$'JRQ[A#%%?$?O&C-XWEDQEXGD:/1U<-@CS40!F MTW(3;$\L(CL+W&'C*ZC;;5;C>/6G<5?%@]_=Z\4
MKX+_/FIGO2N],@A^F\4U<_UJGK4-.X6=%*O]Q="/YM10W9EZ0XCKGEW2>EFX M['4%6 L1P;&W:),Y,BC_=#,4K#W;HC=\6;
("WK1=V]Q[EM0G%ZYWF1948?XO M:M=Y#CH1*-97F7:]H'B!\O6W9K!2P3;]#[Z#-(?%)$W M0 FS^PO9#2AD7/+T0]/UY\;N1PS!=
M6WC%*ZF7%:N$X?HE6#,< NSAV)31RB N8;#WN9ZF,Y(:0PK#[U4OV GM_&#BP@&HEUUG-6
M@LY70WPGE.2]G"SE>!VPPXHH]+90INIKSN(Q7%!9W85LKM1+71[!Y!*6Y?)? M16!Z$M")Z(]ETO CJ)XCA0Q B@*14>]>#9WLZ(VN8X4>
[MH0L0TUK89!VXE' M5_7;-B;(2/2U^+K5#!40VR+1N+*AB%B1D$YS@[32*[V-MAA#)XSG _?Y5E:7-%R8MBDO7*ZXI@M0VDB#LF9/M9'9
M2EEPC2TVO_)_(B B%[L+?+5!W61B*!2/,,'P!LP$[@[6O.I4MS5#'9@2]5[2 M';UP1,=KV+2&!3U-5[=WH?']JO-P9C97"7-E.'NTO/;OO^062F,[7U?17:$6
M+>0)D@(#T^Y4*[\DEES#+%YT,7K6P9:OPS M(X.)3V\R^N/_WM>KZ#_S9#+K :4K(A;:H)0 &6#6=5)]"DM-YZH@<:C)%$GN
M0:)U#%+VI(>W]G4@\ZU=7/B\^3=@,Z&+->+JI,?,9=ZS==\!2ZS:RW:3QX^A
M#H,#3$K)#W.2U\CY(C%Z:=#KV6BAYQV6]T5=2X\BLIN$74!K8;=UKC4!5>^8 MI?T 6SS,=:VI+3IA&$[SX V=A
#O0QCM_QZA'R/\/]AE@^Z(]H\'55UC2CC+ ML_G_[7W9 L%+37]B4B]\N@=3];0*S*2KY2>Y,IR2'BM+T M#!OA*#=/YNXI3A 5M59SKB/.;XHMD?>X5-
;Q.I#8MVC@!XL(7KE/6E$FTI;> M>DJY>NGUDT+(0S@U_,4 /'E]PE@;+Z5UY!*$1OR:*<8.[OPGC/O&^_X'/> M?W9,YI$"
,,@BTS)0U[4[$4Q^3A+WBH'8QD$*;4D#G)U R=2[1DTI+6D :TE MB3E,10$9IA5MI<[E!R_@-!G#94N"IZE]88DYH^RUV6BF=C%E(#,+(VW2.??A
MG7$2"TGSD5L>\./E;^<76 =)4\-D^0P%_"9J8%E:(26;1EQ_KE=M8404G%W6#X+;\I-P8-HD\IY M%&^,C* MM:S'X&2*_/B;&:O%^[ON!Z#/"TR/$N-
$;76B%'5\.WN<3#;;.IFLD\DZF:R3R9FFS:IM:<[QV3MC ML']0$3LZ.[TXGILM^QB%][K9Z.5#6D^NZ*IG=U7L1*1S.7/?R4YWDHT28;;4 MK-
%"U&>EUGH:U*^EQR2X?NYW&A*!X[#B] PB>%1=^ ORCEK>T$=ME&6]?6Y1 M_2G62$;PYF>BC!7R5YZ:I*3)CF@]=*,LN7%%U0*R2.#]BB(!
B;Z;4_::W8_M#:"[F%WBMH BN)@Z(:H&*HGM1TV@9=-)K&&$IR64 MH(_6&PD/.$)T;HC0"DRLG$[4&'0U;]J*&]/4N*DF;@:-MD9--5$#(]VG<5-5
MW)@MC9MJX@9$FL9-17&C95]5<:-E6E5Q S+-T+BD)FZT3*LN;K0M4%W<&(U^ M1^/F27%#$YZ+T\0?
%>$L%1#]+0#QI+'$T]&PD+G8$BQVX.&7O[S]O'H@B,Q6 MPWQ:&/5G:VHD[LW\I<.Q90+G&Q8O-I3-"701KK3;W226,;*&BC2AM53VE4R:
()==K6[(<\0$/5 M+578Z$JK0_[VD]%MOFTU:^*#MKBTQ:4MKOVSN/J:$,(Z@2#8?_'?'0D$;5L] M@VVU"1$HK&H;J=(VTO/QSL-
66(T4([HXV#,0VR'L>3GVR;\]&H?&MA'1ZQ9[U/>'2R M.S;O5A(*\^A]9)5X!7?XD(.F=E"472XDEC@Z1=F](\5507SODJ;E=QA*11= M.B@T26N2WGD
4I/T2T)XZ;3_'A'G^&0$+Z'L'!T>!3O@]A MQHHRL/0PR@L.; 27USMS(*JST7FQQ5J%^48%4LAO:A9RJNN%:YA1&YA='!^X M1_FSZC)"JU+T\92,4*V=
]H(3S$Y?\X'F@PST;IH M=H6HZ%D,A$I#H,(ND^8BS47K4D$5@D"E':X*I$6L>6[914DBT=[:F5O8&W5
MFAQE[8_3\XMW6]I6^N9+\M3*WO=NW:X*]=L<1IM5=6FW HV&.U;$FG@U\>XG M]%>[OHDI66'A*'2Q*0YK6K7,.!][GLF-/
MICJ[W84DZW>>Q)@K&^>ZQ%\7?#_(IC-:FATT.QQ>V\NF+'#4$06,QX?& B]' M\FV,ZM9@IUBN0@KG5&A@'><"%9@;=^+)A@-
X05<$'ESA\.7)O8U1W M^CH7L^^YF*SJRH8?73_!UIA\ =8+2LDL@*=*'3,M$!%.D P]7AGMMY:P7N^(
M=#9KIRD7.LLDZ&K8K"D=:S55U^BNV*Z:4<)]L-TFQ<]59+OR@;=AY?B!<.6@ M;VJNU%Q9#66X23-/M?AN/HZR/0]V>VT153EP_EM'0LK_W!4=59_-
=B6_6[L3 MW%7-Q*TCG)^+NR>W]DUL 5)WM;Q'APIWO0R2-H:Y/'0K[L+/)VX,0+7?+@': MA3@&=?>+O#_+F%OW7YPXLI\(&9C&KP7 M-
HD8]QWNLL^B_ETR/6:M:8V33;-+8//K1]\(AHQFTQ8V;#,UP'5A(UR@++N<].DS%RW5NBP&(>"X"ZM&6SPASN%C7EW]+71:A@.
MMN*Y@9]!Y\SR:0#G-X(_QD<(H.DCSWU8>9S$]/HK_L.*V!%2N]E!>_;MXOR* M/AMOC^&M+$IFLR",Z;$VK #%$'/]&PZ/&%/L!1_R^:K>;AH-]N[AB!;_"
<8^ MP-IAKYN-0;HOO B^,-.OX(V2M.8)Q(JBP'8!. Z[=>.)@ ;NB8U#RX\;K$1: MR+8/.S:7DD.*P0_O3N&_5LS3P=+R0!!*HB@1!KX;-
T5=KHH#-8A]POA!'"4; MO)Q:GL=^2T :\BB";_S@1B QY7S%YI>_G5^D7+Z"(')G0!#HMZ(+H ,V@ROA MSPBN\+S@%DDBBN%)0,GU8%2WK1#I [3%
[$Y@:7(W"Z8|GMQY8O*1-<;;MZ>G M)6346D(S2ZD$(:-DQ9;O!:3Z0?KP6Y"JN37<\ZZR2/(*EF$-@QL0/6 H*J#;
M+KQQ8L&WUACVC>I'A=T)96[(1]X/2L8%6E0T@S2")#1Q1S$]+<(_<9^"4.I? MKRX5K55#)0.AD'X(IC-AK3PW.WY[@"CN LNY?L9<1$U^X-
<_!LIXN^NGTM^[MF\XF $%V].7CIV-V.PD$2D/N6;,(MIFQ)>S*K9^],P;.G@"L0]>FKX 2""BS M&%C\Z.STXIA=,9O#KB3;-
MA5$7X!*2G@MUZ>WP389!-OCX6)!5/W$C^2,PB M&">5)YNPNB"D-XY[H_Z%?Q19V1Z &;VEB;2(U%]$8I"^4K/Y\Y,X0&"6QCQ4 MI&BV<[5Y@A1-
8W[M_Y5??.:^U>W "\(3Y=GF=C41OH!)_MR8UX<@@K_7K1&\ M^,3R;JV[2.ZRWV^8:4'72>H=(QQ8! _.!+/N(T%@ Y=3Z4<\!3']/=8^/XA-Q
ME_J*O&'U71"Y2+HGA'3@+7QVX:F$E3BB8G9A& TL6[_"GW)71;K2?'DTK1$8K M%P>R&%#BZ)=7/UU|/5OMH_E!" Q?\-'D5R!ET8M%3CB#7Y%K4W_-
>C:?;;E[M2?>J6QUD8)(U=9! N"6?;QQ.O9_YB%CJ!EAPJ1,LJ27[LDAE"^0C?@31:!_A M%>R_00C@G<=SA%6@3R,7[Y O%%^M>/QN:6V7WGYVC.
/[="ADJ8[_XKF^*.;3 M, 1AO;73?\O!('S=SMEJ-FJ64"B+UZU&)_TA]^S(_J4"RW #9Z5A5[JY<0F7 MN2/0Y:#B;/#%QO JM),
(6@Z8#'"%!:,FT3X;6<9#$R(AH/4IMC>072!P6,IM7P MCO5 /,V3[5:F3:U(_GD[=)OGE$?\:!LJD*#R>VWD0 %$+Y@>2'L6NO 4%_WV M.
[=84)17^4]I&;J('WQFS*21!H 2)!LVA/UX>T.^$(9B[EOT% A,. :ZIYU M!PQZ,G)_<&<99'+:1!E>@KF*Q5KRLC[^]B;_PZ/V.)U5,DNY"4T,6IB7$F,*=&!3(-
_4W)B MFIXT/6U&3T:>GI;)*))@-;AZ%/$8S Y-6IJT51 60:UYTFKE26L'*M,.$KA+ MA>8N8>*O(@][@U$.YQWF9ZC'ML--I[M%QVZHBQK@2^T@ZQ%
[5,J>COPH\0K1!JUUM:D]!"MO1N;D32&SZEH) +')L32 M-6U0:M)\#&EZ?"QM$?"91^ SBS*-$1>T&25%*J,K]\L(W3YU2-L[E[-,I48SND(I',Y JD|
(WEN&A.9=@7272ATWN[NMQ=XE>WP!#71OBSGQ2FD5Q 5O ;WF)"3%Z:U?]O9Y^+O? MM7&6<<;70M8B
M>LZ;.FF\/W^I[$]8HM%]=7JJ"NA6=2GL9R6;J2O9="6;KF0[\$]VK;35]BJ8 MRHA#-Q(UPU1?#:A3>N?]?4;/,U?"2864E,H\MY$N!XZPD#HKL1M\46&21
M0Q8U9!RJA2D!+1WRS08H#1K&VI-ES[:QB.@%04U]33B$>FEUA#_7"^.M1*[\]Y&MSSV-F\KBIKGVI#^-FQ)OTVP,UHZU
MT\C10DWC9JE0TWQ35=PT-7(JBQRST=+60$5Q8S2,M<;CI:7U36=QHOGERW&P])?Z^(&>I@.AO 8@G];R?.-=Z+Q 6 MTBA:0L4.//SREU>=5P\UX]N-
ISWSK+\!@-:-E?P0A&(D:3SAX@.FE<2GSY1L M$9\IP;2C 9SW^39ED|TS\&Y[&YU]I(T>;?0\G=%3XM%8CS6*TL(2P3&M9DU;/MKRT9:/MGSVT?+9
M!R!H^TC;1\^EW5>;^<,5EI#Y4$O(.!J#_3:%L*IV9^>NE$\8&[EX.\&[4>Y! MP#O >VM?C-[G%PCM![M&S88QV&O".*,YK3L]BND@U/Z^G20&0
MC>#R>H>^3W6V>M^1[GEB6'40=[O6:@W$,>Y[DS&H+BM4BSZ>DA4]MM5=L()9 M,SN=W;+"LQ>(5(85R NJ#GT\&2M()ZN#=DH-_!8Y^:P
MT#XP#PW?/Q]@&N@JB"U/G1\P-H*O:\+I][OME:O].V7Y*V5O>]=NUXE2B:4-*RL2KJR\5B6DU3V MOG?M\;P\^GW969ZR]
[UC1^/ED6\U0O4[=@DT&O=,"AU&?F:NR.QBQ9E:.MC\ M(AITGB$KV=QC'ZMU3=UUN6E]>$\0U9ESQBA5^L-=IQ^U%F3ZG?A/'U69,_X MH--
OZ9S'_C76[0O@"D[W=*8[YE9N5!QCH(?. --#OW9*JSWUV(LE;--'9< M_.'"^:%:]/$\#DUU]KL+?NC6FD_CW92-=]U*\SQ^376VNR2ZOQ$+')FUOJCG
M.CZT&/_+Z:+9&-GMWL%A^7![9X*%2BP=AM9=-,^3KZD0"'9AZ!E&K3/HZ82. M;J/1;32/Y*16K3_HZXR0[J/1?30/<;9:3>-)G*T*GO7 6]6"]N0 3L
ML#IC-M2:1]W;;NV8C%]V[J;L?1].@\P#Y[ST=YZ:KT)_I :9C833]V^SK+L M099E?1M\/.&AG+O,CE0'YEB?6Z/;8@ZC+>9MF4WT%<1VA;(F98/BL-
M@2B)\ MG>30;2\OD>XK&Y(^Z$87C>P="];D]S%;,M<,&-T#\RMK=7?> MR?EBN:%:U*$[8![#:TG]>4J&^NZ_^6E]!\:+2Q3L#L=1M,);K[RT;W(69J
MLN(K&VYT_02;8IZ@#JN"6R\0\4*>JDI],BT0!4Z0##U>&76W-L/W>E>IO V;
M:,J%S]D]FKHK$QM=VO\04>6W:R@1&AIC%=]PMJ>\91!LBONVP,@[8C[#*/6 M:NZ4_?8C*U46^VW4B[-O[+1=B>"=NUMM$4?N*.%&!54R;/
M)L,W[.^I%B4]4(2W!KNSG/:1<'XN[IYQ!4BMB$>A)]/ MW!B>8+]= MH+<=9JR>O^BS/'=9@?Q&Q,@_ABSBS_3IT$RYPD1.\]GG#FNSYG M4WC7)&+
<=[C#+ODLYM,A#UFK66-FTVS3%#_XT*K!$Z(9MW&.GW=7$^$?$ID M>;";(&0 %NY%!H8L2)V2P,G,2.F0W/+ M\ROZ;+P]AK>R*)G-@C"FQ]JP
I15S/5O.#QB3)$8?,CG]WJ[:338NP?C6< F M&/L :+K)]-AQM=D7S_Q$%"5A")#>UEZ_1>'WVC : MW13O-
E)%*!"-9NH@_27W\,@"BH!UN(&S4K9*H^V-X]ZH?^$?!2_; U9"MWDB MMYH&#G"7*ES<_/E)/&%P/6(>*AB;[5P9IH"QV9I?^W_E%Y_Y\74[\(+P1(4X
MC2MX(56+B1HL4G(1[^\^NGJZ]EJ[O:#$(1Z@:OE M5Z!),9R!TNX,?D7)G+*W]6PLOEPPT;WJ5@>%-.F3.F@9W)+/-XZLW\]\1"QU MS,_,5-
Q,4DOV99'*%LA'_ CJSS["*]A_@Q3 .X_G"*M GT8N\"5?*+Y:\?CG MIK6S8X:&-X%=L)(4=,"-"DL1+)H$RM)J#)$;$H44I-3B>
MU5R2%G17J\!Y:BL*N*6T"'*0A_AIX6?Q9*HY>CMW"!PI/,!TS$P*80%@7 M0.JST(6GN.C?QW'H#A,*'RL/(S5E!2N(WY22%?D$H#^R>T_4A[>/VF71V,A]
M@XJ.P(KJ'O6'3#&G%$S>2 M/P+?**91,F43=B^-CK8WU+,C-M^Q@]U*M=D7S_Q$%"5A")#>UEZ_1>'WVC : MW13O-
E)%*!"-9NH@_27W\,@"BH!UN(&S4K9*H^V-X]ZH?^$?!2_; U9"MWDB MMYH&#G"7*ES<_/E)/&%P/6(>*AB;[5P9IH"QV9I?^W_E%Y_Y\74[\(+P1(4X
MC2MX(56+B1HL4G(1[^\^NGJZ]EJ[O:#$(1Z@:OE M5Z!),9R!TNX,?D7)G+*W]6PLOEPPT;WJ5@>%-.F3.F@9W)+/-XZLW\]\1"QU MS,_,5-
Q,4DOV99'*%LA'_ CJSS["*]A_@Q3 .X_G"*M GT8N\"5?*+Y:\?CG MIK6S8X:&-X%=L)(4=,"-"DL1+)H$RM)J#)$;$H44I-3B>
MU5R2%G17J\!Y:BL*N*6T"'*0A_AIX6?Q9*HY>CMW"!PI/,!TS$P*80%@7 M0.JST(6GN.C?QW'H#A,*'RL/(S5E!2N(WY22%?D$H#^R>T_4A[>/VF71V,A]
M@XJ.P(KJ'O6'3#&G%$S>2_M/P+?**91,F43=B^-CK8WU+,C-M^Q@]U*M=D7S_Q$%"5A")#>UEZ_1>'WVC : MW13O-
E)%*!"-9NH@_27W\,@"BH!UN(&S4K9*H^V-X]ZH?^$?!2_; U9"MWDB MMYH&#G"7*ES<_/E)/&%P/6(>*AB;[5P9IH"QV9I?^W_E%Y_Y\74[\(+P1(4X
MC2MX(56+B1HL4G(1[^\^NGJZ]EJ[O:#$(1Z@:OE M5Z!),9R!TNX,?D7)G+*W]6PLOEPPT;WJ5@>%-.F3.F@9W)+/-XZLW\]\1"QU MS,_,5-
Q,4DOV99'*%LA'_ CJSS["*]A_@Q3 .X_G"*M GT8N\"5?*+Y:\?CG MIK6S8X:&-X%=L)(4=,"-"DL1+)H$RM)J#)$;$H44I-3B>
MU5R2%G17J\!Y:BL*N*6T"'*0A_AIX6?Q9*HY>CMW"!PI/,!TS$P*80%@7 M0.JST(6GN.C?QW'H#A,*'RL/(S5E!2N(WY22%?D$H#^R>T_4A[>/VF71V,A]
M@XJ.P(KJ'O6'3#&G%$S>2 4F?HP%QPR[EC M1X";*$A"FSO'F=<%ZTA&EAT+,]4.HE@(:/!=;?3DEC%U+=63"PD.38R:&?*
MMY3H0*;!ORDYP;6CB,>@(31A:<):05A@(&6$931:><*:@("SP;.,ZRK@DM$6 M$*27."(F&]C?ZT,R1M"0@ M$K$E>K,6:IKX-J:^9ISZM*C5-
/9JFFCF?"/UA M&LZDJ*BQFHJ6!Y_0Z!'>,S=7%W!PP+3)7G-!58Q<^%U[35KZ;L3C=[;O3U);.YS*A.(P#8(L5!) M&YN:-+OFB*F.=<#F26_NIQV4T:Y3CR
MZ4BWA[Z NW7O+(U2&:H0SD"5F83D)'KK5[UUE6(^\+-I9<1<&,5) MN"B&!FJ#)R6V6(E<]/C^8):@X@D@"%Z2+XQML+\X5=W:[@S;IXAD;X&W@(-R

MQ=>!-),X2-JA2B:DV#I$)8%P5W%&VX$\("F?6#"_%FFPJ!"B;%X (J$H[WTKG MY'OIHHY4Q=?M*H_@B@U4@(U)20B6G] Z > MR_'U.1[-6">>A$$RGK!9,O2HP!S]=??&HC:T$4=6CM3Z*8XD]708YTCRU@K% M2]C;8()\Q4/;C40W"0]&-;E4P6?3(!2M-GZ<6P'5V%O11*2IN!-EI?]9"UU6 M)4+]39:=0@VM1%GXOPHLSUCP^1L%VP(A@%*.M7*K6>!V[-42$,1[8D"]-"OM M6&*M4*3/1=<&YO,R\L*^A8BZ;>9E%JT#H8LOH |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||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|*\D,$?N=+I4JY* M#.HK5C8&."QQ'224'\T\?/CIYT^/HG(CM[,"5.XA[:99I.U\CN@>VDZ?OA/* MWIJ6X"&?I^D/BD?7($FV)R/95^L:0B/?=A 7&"=BGL M_B.W/%"AEU,+].]O203P!A/M'-YT(Z@QE>%'2.1F\^WE;^<7]-%X>[R*LO/J M#M&X%8$#08/Y!688."RY0XC0*'" -^O!J&ZC1H<;0VMV)VR R=T,\!=/[CP9 M=1WC[8]BC+ST)C#BSE?S0VN>'7J;L@,^MTQ^:%6;'1#>UA |OM0$1-S:& H@ M-](:AUS_F'^@@RLETU'H.DK21 @BI4[<42S5N42!H,? ZUZM+1=)E6E[_DP"6 ME^)LT>Y:PO-X% '\8M;1?V5@#;N!LZD@($UFO,VN.@,8PN/2B_.LC@ / T^| M,$ZFZ.Y,I[AX'H%]30X7K!R]+U@P.A_X*!0R@$0@<'C\%;.Q Z?\$W 4@#/& M=X]A7%@"7(].5M%D@WN%2]N$3?U W.Y.GG] [@%'2!9E-.)72F42O'_CUCX$S M_N[ZJ1WDW4UG$X @,_KR\=,Q.%F!8%:4?#-.)65R'5V]^MD[8\#L"< Z!$+! MKX#'"2BS&*CJZ.STXEC1BI3[CY3MJTW[E$Y6BOH-):MZ4%Z]IQIO6Y%.V-VY M5*\T*UC "X#KQ[!:M85A&XY-RB/E-6QBKH7Y-<#Z YC9+E=W94LEP#^]\F) MHK,.NRV>KDRIW%[FO=8HR A6&)'ZLHN-=K[F@U[W#D @WF:(\'N#97G\-+A$ MD2A\|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|>RNHNU>6R0)6R MPE'29&;P26)'0I/S5CS/M8@:1,\|:HJ\FYSP6!+X3P4F98^PLX;#>@#@@ @C M,Q,)70)!YK=2WG*%#%XNF45V2@*74" (,_%'U@VPL,P5)%&1WX=I_LT1.8D[MYEA3H5RZF>K@5D%> ?SRY.Z@)@(%3%RU!#4-7S%.'P53($L0M*XPHFE)_WINPB< MRUCA12CA\E!".I-P+ M+756#A;I5N&Y(-!$VUDV:@:G$HFDCWROJCTMODGQ:BJID3^XDJT%\?F$#<2Y MTI2M9|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|-2VTI'DN4!DK78,07C:[PQK5%CUZ &3", ML@J)(KX2=2UR5GDD,G<1<56055/GYS-A'V(2>\1:U.2_,.R,/^1&T/+LHYT ME-;N9V&U;#Z@&\FJ;*0I$G 4,$@SB&E6,AT%M9C(*8W"K@H11;&\?"(1S_Y M*VELA@.EE^.N2T)L;E:I[9QG9'7+N8]Y(MM!.AU5A\+#:-N)%2+V M>"[/+'4RHO,IOY!;65M(-N87@U$@>&2+R!S0[]# MR0O&$&LH/)4L^4%U^LO6+X?3J4P835!Q$ 7B9ZG@L&4:I_U())17!3 Q"2R MKYK6G#HDRR_.+U]$M5$BH"^1Y;2C"06+;Q' N>Z'=?C;'Z%WACE-+! (X!;|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||3$B=Y*#"4K!@8HK*ST1"A%VXT?? G/YJ@8("01<$B')O'0^GV"*M+SE[- M0L##.W:1 +,;YK!N*B/J_0\QA */TQ!Z-.1R[E>N(E'&RF(JD,VZ(M)KE)D& MUIL+&!"J3Q)IQ^+#7K_I7'=LAU^W^ZWV]; Y<*Y;CF&V>CVG;8V:"T3:EE51 M$2SI&Z;2'(3^=;O3,EN#BE'G8"OB;&]/G H6A)\,&CNFO'6[RDMG<-AGGG5W MXOI4@S;TP(\19.M2]/(D9'T&\8RL#Q-;X^$\I%U+" C-, ZA+S/G&4<\Y9% M(IX'XO?S^F A")*

*]V='(G'SJQ\PN>I0NF@1ZB\P/#SVXA'R2$0$T6Y#Q M BZR.EH0P'YNZM+]>Y:CDN@)6,$^R@5[J-(^%+*0I)40F#3 Q:>'IH[<4CDG MY@;)-8C')&D\23PK"R*/L((/:TN2X=2--X5-X&X!B0OHY;%<+H3!+4VFB2?^\!$-6 GVB.5.'LS3:Q;S$=UH\#=0 M-T[1@G>)8J71R+5E)6OV>^;"IK]'^1@):,L'"JK3MH!6U<&.K)\20J?C/Y% M!J' 4F+NYQ+&>|1R:S0)5+7?.CO@S.WY,S?#C5"?R8K:H[&!:0JD:3FHPG9JKIGRAU,9R M=V5,!SX==:JB?#7:B#4$4S-!J8#QK)!*_U*5%%"%"SRV&)-ER+(P*=96AGSDJ4 RZ5^54)=!FTCK:3>%22NBE;(=GD|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|>N79H5M4AXU<'*&ZMDBL1@';7-XLE[E 4*9>WEG6EAOXLJW([*I3 MUH2+F34^^)DSEC]<, MQ"2'OLPA_D^A/*5=\/RRI;E][$@\#|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|__T2F2/=4)1E/G2/;,1M,YDCWEM(:. MMN\7I[5DIX<^;F6O.$W[.=JA?RDND4:OEF,:N?MH7&CL:M;5R-6L^[*Q>T"L M>X#>0TL?V[%_+L%39TE4BJ/='+2:/_#D#:>$X51X:G@P8F<3EX_8^Q_<3F+W MAK.O(_B5A^Q;$D:)):96720>9T;+JAOM(^N8!2$S.H[Z8\3B"6>7<'_HQBXL M\OT/>V+Y8\Y.[1A_-@:M5HU9$;/$\"O=#O+B)+M&KC;*7A)V->L>,'(UZQXR M=JO'NO\|:_])D^YA.U,:O8$7N^;.1JUCUD[!X0ZQZ@]] R&\;?HZ3X M,KJ]1POQ7)_7U4:;P*BP&[IUR29? _8I3CI*99H=]\S&>/6%C5KPAQNBS/QN7 MC;,&,UJ=)N5>G&"&H[UFN:LNN4T/'32[:1K'"H>6SZ/ZUQ\>OU,9'+/9-'76*

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{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

*M*YRVS[=.J-:)@.MF;_"^Q/=9B7T>[X/W8N04\RR.Z3/2V.>NWSK$-0U\,ND$ MZJQ4[#BOU#WEK'?[ABE)R%=HJ@.9(%"K(!I$,YP(6*(C O:_@_YMC"_[W$#H M[SZ[6 D+AB>?5Q$!3+>QZA?#4"(8$8$)!C^^S_,5O78H/;/0PF8\V.PX+$5 M0< 8$XO+(@((-*F?!5/B(N]7 N:PO=*
(,9<==&8E^FX*6E74USGLEQKU.CAU M'19VB@GIS>HE<&.-EX@ A5[2 7YSN4)],%[16\<@AJUD[;9H^'7CGBOA;KW, MR)B5WM6/KLQZ-PE0#*\|+*;"<
;1>4)-!+Q)"KV50+,>XL%K2*:A< M/8&@%ICBQ*N4H#A/Y8@ /!F8H A6"91<&DE=II=\W<&Q_Q@9T!*V5H&&A Q9 MZ39PC-5='I#O#.NT\!FPIAO
2':"HX!GJ*TNQ, M28YQ5I&7_A0O4^Q=.@>$^46!94MI9Q_J$+9((F#%(GRV=79Q"O'C/($)>YNI M.Z0YG4LVE&R 1FVIK]\R%Y4Q+90[JFUDH>*]+)>?
T4$.(&B M@N&O522A: N;8R"7?)GG^8< G^@Z(N"FV5-S\>7H:;;R4V2T9
M"VU[9P$\5395/(0J@M,X&'.0_P[\FR0QA@J*707^ZS"4&@?"4NCNZY>AI7BXH-)U[5%K\LFE.0(V0LAZP/GEH]H*A&(H!#SN)(M],)>"[,6^WF+@\?;5?
IA5*LWG#NI>B=S8,&FT\$38OGQ,KLB3AX&-9D>.GZD MR6QKN#9Q3@1$JJ40 5%IH=='Y'"%$)8<@?>&Y1/H[F,^3R49N*'OTI?ZL6QT MZ=
[^TR/Y3:U^R6)1(97QNSU8X\6:89++>8#A76F=ZI*VIRR9B2"G)E/TKL[M> .,+DWTO3+>(+]25]2X_V M5?M?5[A*]UNNZ;YYI2=2D&QW/V['.D\F
4)A@KV!:>W11+]HO<@/@;OP<$;Y MSGO/Z>IN?+IC(MS>#OB/%7T/NG.JD_=_K#+?H1A3*G@]'XOY&]F,H2\PP @U7OQ+S)/QH\SL'J6^R+0J[4)K
M&XY;PE?;KEL[P/FU]FPG]A50 ^_P#W$/0TVFZ@TH^SBCCKC%]F[D[9FFCWPS MD&"[U7HPI_I6<9G#R@3.GR*N2OW?4=4+@SI6X6-MA-
MK:CBWOMO(F=HF920 MT,MJ3):AUE-^DHR;:H(-F(7&YXZP&7Z]G0[=;(\[E0EL*6PIP0X[% FNA&R< MG^0G5+V9]0(]#\HBZP21&?]VN M:K-5^+P
]U)]QS>,\I\!Z0EH"0:F>4_] O%VXN*?T] 1,Q.H1$0XGS:[CXCC M.2AM%_I^A7J(\I"?\]LUCM=V4K#6RY]2P^^O(.'+\(@!*FSL/M0P;ZLGNL@E MG!O#G@
_D8$*R9^_=O[YJ'*#VR'ABO])/5T'UACPTRY?HX;V-H0R$?#QHC[\ MSPGB7UU4],_P13KED\)7H=3WT'>I];Y M&",F"):'0H-N:,U(E:
4B2RZXF!W98S,G*HKZ%_%;?-!WR"EH:SC1=EJ!Z9H M[[/%9K"T >QAX$_ZF4=M=\,0K0_\|>5*$F1KS1N(%P91EO*-R^W^5L;R4<56 MSA/F?
[+2R\28.ST^,^X((6N,=.F;]%FS3DY[=3^;;2N\T6@RI4D$=R>AH?<_M1%00 4UV@\KCH7/NK0\-0B[D7K] MMV5E]LWOY
M6,CYU'+/M,J9^X)GEKI/\2Z$FXFMO?$'CBI2[H"H_L@&"3<;JARK63'4)8L"ZF ?[9!NO3/89-G^A% M3?S;-R!3,ZS=%U.
M%9NI#^*0=^+::C42KYI0N+YJ&N2N))2]JO*X_3+4+_-_GV^JG M\%$$]28; ,]\^,QIO,7%\9?(M^&JB/')R)# +8^8/>@S]
[^N'%L37+QW0H$1D^1FP?/%_*WCXTS'-$WG.T3TF MN,G!?RY.MCMX"7-$ &W'S2U/%P[+E5G;0F7*2'Y+"D!:(IG)@9GP%R&G^G#E M\0KV9_>[^-
Z(.*:@LFK #4,=,/):(:P;I5LRKHU) M4MH::629S*^[>_ 8DA-ZD6['P;XU(>!4VX]I]8K SXPY"\3=U+(2.OVJP
M4@W@^G!;-4BX*E1,6U@XU=:45<2$K[UVIKXD^5Q>+VWBQZT+NXK0=A:0/@)% MXF\Z1&LU=(F%)+LOM*>'P X-L"8".DDYA=XZY(@Y0M3<68
&'8$W"4RC>T3 MJ_#>(MXLVE,!%!18!UJQ<1=T#,#[B)71K3?+B MLME&8X)X'2X_%K(OK?[*.E!X]*=0=$O;8;:7ZZ]SZ\$SNJ7>)<]?_FG9[><7
M\TIY+V3$NE WN X;?<^/36OF*ORY2#Y^,AJ1W&R6;*-)3679=Y_Z-V!7*C;EFSRV%=6;',B;9B%'+,G!\S,SYG84@ E7@^"*C;2\T? M\[K*[\VW5'], &
<,ELZ:^6^V$ $9N8FE*R171^#%([X/,K;S)J)" "4'DGK_ MR>ZQX1-0ZCH]#5(=RW+M]I3<,.3)N&PT+'+9P9+2PXVN8IAK=?8QBTP$7T"E
M!Q=A!,PHIO(04OCK\0DR74VX9DSBFI[%;A'BC1F[H)8*C&,\;I>.*[YD]C/7 M2[:/V4;(HF?27.RTI>KOK9P<+2L.?0"^_ C](_BKP^
(UF8/=@WCQZS]TIVD1W[7/9,LDW!?A^D M7<_A,WJH%.5XCF7C38EW4N%!N%)0%,;S3!^ E+[T'LRVHV'+SG"Q>KX=(N#Q<.<]<$),T=$.>Q9J$?
UWZ&2:#X#Z!BUP4JY Q18P2>!,-9ZJHLJQ=1U='1(X\R^'?]/93G)_&8:1 MS_&K+K2^R%,1M,E1?%]!^[K]]A*NWN/KQTXYYW
MI[W2O=ZM6[WT*P0EV_Z=ESU\0BZ'^#B^O#/DM./30=_M4EAXMV5X1%5[X]NZZ./L29Z"H']J[Z_'C"]=]3Y_KYGP9O)[[.7Q$C6)?)U#!
M,O'QY!&#&BE:@Q/?>_C&/S2Z-E^0S'*W#9V9 ,J_<9+:2,T.-.FRD(?!2R $ M#:CAD)&1:W#%;DLQ:6&O&EM<:,LBZ&B%E%U # E>(\#S2!"&%HIM
M(0TN!3*AD._D@#S6OS9 ->109)O*&K@QW:YY?U;9[@_I,U?,&YDB?1,'H M8[U,&!4 ?,%Z%=S5YY9&2V]';IE; M\V]/(N
'I!*+ZO40W(G[:!-1!4)5AXF3XET4Y=O['H4LNLKRP/S2U0 5D([3 M/YRI.51U2 3H_P.4XO&RV# 4.'+AYE2='DAC]EIN&AOD4VX=&+W;:#FZ/A?I M8-Z
>NH Z*I-N@^_BF4 1D%1]_&0YJDVI=F^U>IL9R.'_*%DYA41N'%]7]YI.?Q,*-WA&N=[RHSK)P9ZD+*H2V M;16D+DDQ>R?*Y]
[^'U4[B_\H0W)!__\6.Z3:D1[D"HJ"]06TIMOG,4 M\RB\HRM<_0.S>$\;;@'OX1=]VC+F)VJ%XXT6]Q OLK#+NCG[:=.;"_A$/7PL
M5'C_*>$NUA'E<<6Z5#=75^_-YA,E#PG5+?EDV"9-9_0&BY&B_& MV+V?>#^,V?;4OB1:.'+'CPA@Q)HN&X]+Z%8J:,NZ\A6RN]-3=%&:+N*E2OH]
MSIFK$9CK0!(0KUU$.LSAI+!/H1.0Q8O:*>U;P_"'LL0*VN^WQ7D)C2#%>"[9 M;) PJ2>)5Y.!_HPG;?SZRC_MS\/Z@@@HX-DB LBO_:7=OAPF%2U-
1!_&) M9VG;UW[C__V<-AA(N"!')) 22+UOC$BX+++?C;A'02.IXDBQ01\FDD^43YQ MAV<^8YGP_+]>A/1 C;[+K]=\IR(G'%6GU:8-^Y/ K1?? ./I+^C @/-
%-=!WQ>9=2B& MHX?;D1['O:#L-V>*QO4$"BSM_F+7^4"4[6GG;$)C@7/C:.G#SQW%#?O1UL]7 M-.-[--;?-
@60(W159AVGT!:6!C[2W^TC;WYXG]3ZY8D^>4(1.K5_TG5$%"Q, M"'^I^L&TT:D'RBX+3.R0KL<<-T;B:=!B9'5A#\),5?6) +#NUDESFDIMM#8O
ML[$(&^/Q6@M3%V@VI'L!V/&S+@1TQ25+=4OYM\6<^_-G16A'.,$L(*QI-/B" M'S,04[?'Y>P_6YWFG2%YVNR=$>2ZWD2__WO^?:6>6XZO?
HI)^'#+O.@]3>& M92YE"CX'N"Y$;<8..V;W/&3QLK-E1X2?B@:M0VU;=.BW465S|R[N];PTB!F6 M :>+?<.OPV_P&.E'T-
F/<]QRIJS4;85YHF>]W70@773K(PYJ# MWPMYC'Z<3=E60.21/,$5<$G=]VEFNRRG G@:7]
[CT5W=W53[^DW99PN9F!@G[#"J,UWT*=\]FQZX_VF2+Q_%6!>D=ZXKZQ MMUG-=&;,H[R<7-9>7&PI2PD+\HN^F5(#A(\'_Y[=;HE,J[8=A&LD;<:KXA]
[M"#[\H"V-+\][^PD^ 2<%#9*2VYO!G:3LJU<7 M>%1L*"T4,A8(&=M4#6\;K ^R[$0OBA^RVY+);9_?S-U/[8$R7O\IN_C.BRO<3)Q;5DJAD->@&?!?
8KI3445OJ1ZH=#(3QI5%/S1QYBSB4B%)RC ME"FBQU=T^R2SK<3<'NT6 %L)M!DUL6,-X2^PJ4M1.PK+-/5<]>W*UE."D_:1 MO'U-
[1$1W0^TWX.&#]V$DO,ML[6QRCC#/Y;XK+5\%S2]GJ6N^791;P)!?)0< M(!C_^B7[DTMD?/[P\5&2PS.0PA!OC86W)SJGK:C1H7F#$|^+S_45#/I#3WX>
M9V_I&6%<.<>L%S6O-C=3D)L-K7YDE+'B!-- 72$[5++*V5!F:^,"KDQGY^?S]/&B=,.?399?PN!XICV MA=(O#+A7H2:G!%-^R1J*..U=?F/FOY
)BO=N\>A"S,9J[(MU7/M:A]RI;ZX: M'[>:1,2&)GTB$WS9P/V4[)4F%WQ\D71 |=TR#948YL82/$NN[*),:O-9Q>?0
MJQ=E;0KEKBWIF=3O=R3K+53FSOH+>>6&3@)^KW#P9Y?N6$<0 =L1^XBG[4UM M[9BPB_G5WDB+:N'6Z)7DP<$7=F=">6L(T]#9_GW-
V.U0P>+VG3,ONC)!YQ$M M[H'IS]4NQ^8M]6QV=6:- 0X=.*$H/E!Z-=60CU(O3?L\P.B9]G6[R$T*: M#*Q?[G?Z+G;+W60.+!?SI%?+U%!F5R[\>1[&5?
BI1=GB%FUX]4.H=Z&9L^= M$N2\Z?2^F!B]7 M=$4)ZEA7+7KT6?]OZ,_IW^GOM0*XH!K^3P9\8=O-/SK:SONX)?N$ZJU^PJ64 ML[:7;NE4JUDV$?
Z)8;_-LH S;I%+H /]XU'< 0)O$A+UU@!OEY<.W2O]2P0D M,X0-]X[N%:UC$P\K19:%(SY\,_KX@'BX=[ ]7FR3,1Y_MR1D+SP=))%?503
M)P+&E)'0O>\D2S^%]MP)M2("/@=4$P&+:21+5QP;[*@=A94L?"%,5^$K]I5! MT]::>%SB,L%IU0DO0]V'.!<.WKLX Q-
$$K$OF&*A1_K'B_\0*;SLHF0AL0XW M=E%E=6:&!FY)"!+"!O:))F#6@+W6_3B!6M[%/*I#8-?]U(\13PL2>YFS8 MGW\>R72
M&BJ]:OG99J$X*8%"M/Z,QN'>OWE?Y!X&53CY..8N%[TM^"6PKLK1 M*Z$W+SZUF=A[.54&@GO/(V!]AZ[>/;):)KLQ$3)\P+:G9%FX1 OLCMM%58A]
M01") F52=J@1;0R++;,:*/ZWE MUAGXP> -V1XKH>Q!F(&3Z$F@14@^8V"Y__3SR$7#A??A4WSFS-3LE"9U MF#6U:3!G65%HZAN!-?
SGD[D>Y94;WXBRON=5J.P89XZY^?!2<.W+T>.CWK>MC+5 @_M(QG[<6),AQ1VHJL;@KBR(>_?< "L?=30R#MN2N%Y[4/N6VK%NT*^_ED+P(M/ M'IE-
= MBX>;;;SE27OE6NC@K8>99]K!D M?M7O[P)[16>6^L4V7JD!HGU*,JQU9<*VZ M@(1*SIG5U[B=WU['I76CD: ZC;A9>G.L1Q_'P'T+8YW;+-
"6M!T4)"*^^!P M>-H_4PY9>P&3K=I>]MC@0VQ1Z7KCN.;&S@-V2@K.$E&))(H6".4L6W!5XGRG MHET,MGV$L1ZEO)U9Z)-N-
GCMM4K.Q#I6>?]\JS\6?19Z&QVD\J16;-E4"IXG M9/AJ9O09X*@O/.N?QTP0)G/W!ED0TR)5S2&W%MWR%H/.8(5X\8N"-I!/M;5+
M!_>^ZH=9M$IPMOKE9S85+.9W1Q1__X[SDRN!HD"S/B9C^LE!L,".]() >S:% M@C+B;3# Q#TU0>QH9\>MJ3Q>%X%3(TZ00U/$]UVJ?')K;OKF@:6D?
UPF?S MG^S;-J-(H,:PN!E,'^@]:RXN60TG3(1)I35['0S6B3J];N3][N/"O5L&NU* MY(\['I,@ HX,X?WF!/0%5B[%TXWV/_]\^'5,!.4TQ&?GP^3;
M&YRJ$Q,)HA7G3#NJKW*Y!.\]WX8XAT, MTV8KA4CL&:|0W-B2OU+!5^/$^R9%_RE?B-D'0]N!J;(3L/<=(L *0@2,O@\; M+9X/%FBWQ]T/7-
3#:,/.PP../N7R=GX4X;Z>__-RI:5*XXE!-RR5,T2#*VHU@ M.8925']NN=0N_R$KOKF^38O++4\PIY"<1C!U;SAHE8T UI.Q\B("]GZ]RS]Y
M@@P30$1O5.V_[?4H53T,S%M94,N^2)CPX,T:<0@):*+K;]*1-XM>ST)OBT48I9FJ#FU<<)TW,IMNX<|=UZ3*W")UI&]4:;;46"'F0;&]C2V'!J
M*FVW6M)VH]02GP?=&!F4/12.8KG=KW59IO&@$Y[G7);.\F$J2R:??;JT2N0* M+O\LKZ(LU&O?_6OE@BMR0:*]91(N9O4X#ZU]R7:JX^AN/SF?+|!0>
(")8VBI M#Y.*[;YHDR^]SA.0BT.(\;T;46"CQOHDNAZ4BW14&>B!R(F Z=ESR>,*J1] MX7"\WSXTIDU9X&UE8#\18#CV\RI.
[&#E#KB%_VMSYTY3CAG_10')*ZH3A]4O M8KP*:$0U'RSW&P+&GD== M[..W3M9/W(F %&H,$4#H;$"MO@YN),;0\%(=L6NO$X;5?-3>E+NW9P
M+6I9TH^S[7!',R^L/#%;,]O"FWW$EK1"(.BD7(W4D_"]'O%<4,.VS7*T= B, MI2RX&9H(M;6VC,YL&S;;=%ZQ^#;D]@UP.?5;)1-]J"\/[!O'^53C>]0HQIP7
M+.L$;$Z2,@JC /!^'=XG8W+B\F3\XP8O!R_YZ3J;?KU9/GJ^C&\L6O5 M7 ?KL++]VR-|KW'(32S|>=S(_I'7|;,.+IUIPDY=1NYIZT]<|1"Z)*)>/'A(
MO7ZZ:E=.^=N/+W/|M+_)=T7,&0HZ5P]4HV!!&3O4:*V]^G@9_9JFYGK$Q/6D M^07+W](.?7?0DZ\|_^R#5.\!R!5,\B,19(0IU,FDE0W25S!\M'S>?-:ZT]O+
M[Y1=S:=;YHH/R/3?';/W!+[M80T,O[<@,46_Q2IC_7OVWJ#XA+* 2C="*/#) MV^;EU^ ;QK]0:_.W0X8,0&#=<)?\3P]GT<^YIA);QCT:-3VLYG8=3N,Z>/=K
MMFSY:T,HIWS_5+M?RN"8-DF^EQK!=>9@^CPY+N9H+PK*E6]\=1VS]_['$XCD M:Y6BT*,L6##:H%N5OE?)ILXLT6X(MBBW^K6Q2>9U<_[*
M2V!]S"6OUIAAHXICO_=9[@JKP>WTL%68 M^-RQAL$.ZS)'!W)E;*?:AZHUK2E>:;$3H"9DI]+A>+.>(.IDH:RX)^ $> ^W0 MS+O@@=>Q7
8ZEUR77O6V6)WVSI#@D$*^;XJU#JS&R;'36_K>[\[43$^><;:WF/*B5;OO].E.P:FB+,.\ M1!+>86OBWB+G)H]\F/BVY[Q.E7#[C(!FM07[+>2V-
WQ14!D@@#41L6SW"," M9DY-:Y.]^(QT4(4'7^1+A:E_J.3?!TNY9$7"2]P7 O-N:4]F/7A]\I,M*)9< M^_<].DY!U1K1/P84H=]UV"AT^\DL_WS$=/*+!;?AE=
(J^L=#N'IUX1^FS&_7 MF#)6!RQQOS,8P)RFYBWQ=R<2A2\ZMM>F6\'IRJ @N1:70_27U/.2.AC$=L_$ MC]V18_K$K54-OB+?ZU>'^U!F[]S,'A
MK>FGBT\JBG4#/OS;G(:6T>L1S\]T.5@[&DD+?,BBJ K('58 M_5]&DD*?,KN5(AQYD7?MV#^2!W6=L.OLH1HB[!V]3Y1 'DU:2_:&QF7)Y6>Y5_DI/]
((?)0RQU!C?96J:K*" M[[OT)26GJU)=Y;7X ,Q[HII0/(FAUGQBS<02*P?BU6:9T0.-4AB#< VG\,: M=QEY@Q,OV"&&N=C]6XQAG4_:-Y-
/U"9E]OLCTA7:#K E%;K3PDQ#%3?7ZO M!H4+N'BPM^^6J<$J;DRF# :/63\2DE1^3-+>6+FQTN;0<5EFN7/1T:F M/1(6!.H;@]RO3;K5?!?Q CD!=[EWQ
M"; R@\$R1P0,;#7[N#'2!19SY9%.*0QM\33]!<5NRWY.:A)97_#:FYF?DDS6 MG$3 3T@_"/4T\.E,>X6YGA"+TN#UP2#1H":3>]6ZH4/U3Y_M=\+!F DFK(:'
M5R=O)T7C=]&WW%SED(P6)<\#=_>+A%!]SULD@#9D)7U!2I)Z> M_KTC5:3XKX:'>RQX[W$52;2X@7]VP:3[GEAAC-YT/*.5U$/US!T*Q*F7)''?3Z)8']
!3G]R"M7IU/COW2#X\CT MRTOK[W'%W1\^*1">VGA*.&_C9^4ODU,VMB55]W'Z$' +A,I#%_F =!]KZ^1 MNC\3W3@ZZ;2T?DG]YEI7W;=62 A7ML7?
P[EGE\\.%!&P_$I<(ZOITIR!TE#6 M-TQI.OO3HR3NK@KY7SZI:VPE&5-FFZ6]X5>%@ \8SQ$X M_F2YPXKG=7U[AQI/*UHI^$PE>X=%OO?
T"CI>2F^#N>E6#>\.??N$?!.G]2-5)UI^#N<@SZRO$O M1KFB?6X.AKC;W=%95X8JX>GR]#)70[6C^TUZ6Y)23F\+WY8;&8]UG8Z3#-&%
M0'YOE1FE/6:[A9,PXZP\JF\/"&B9@.M'31 !]-L%XRK,Q5:S@Y0_:7K$DN27 M!K U(3DKX>R39^NS'>J8@&@_)OI1F+H7?#,>%2):X!-DEU)>0]Y[%M,5P-
4C MOQY[]VJ*DEU')2?=)K>Y])=OCHJ4 N_,=@-#.[CXY)1DUT=2ZA=.MZ *B%&? M59E;]PVVV)R&:1O=Q"&J^5FF+986%?)_R?]6SN&1W,-A&*O?.
<]1>F"K-_<#9\]3Y._U"=' LF\XOXZ](/7[2X@%]..+71]K4@ MMT:!LWZ1M)-Z"&QVT"?(B[^]S5Y+ MG)3UAG>'.]GIQR=]]-
C74%DH/9ZY;+9RXH]_H^FA:P5 [%E_SI%"L?CU#T; MI[?UOON.$6NYQ8O9O_S8=1^EC]A9\&B0Z7P!W1[A@K;F6QX;O =?ED70;PV6
M_LF[Z4$G7^]O:J,$,?1O>.'XPL5_A>L^(%UQ:EOFZ<0C4]W6\ZTNUW5OP'/1 M>M#W6:@85\755@N14P]>?= M?I/KIM5K>F*GI^?
F*S9$\I>C)T=$=W2MK2HE-"53[MCF,[MSDKQFWFF]6FP ML3/G^=3(:Y=GYR\5DJ%.EF#KWW5PUC>M]*_(43&O/*5ELOZHB4!F)7OX@5U*
M>;G+M$(3E1.(7Z9DW5@=^L_O4:@8]>V4%WC3*(YL)P3!4XHJ[+=P=U4=5WVW MZUHL(1X(X]URD;L\=$7CIZ';4PL-'E:B?UJ=@V]6])?T'+@$IU4-
__8":Y94 MC68TO?>7?9Z)3CKXQJA9>@07Q B_]>,E MB=\P0[$#8/'W-^5:UUVX^U$!AM$]7@QY&1T\'4T+);\.:4Q&\[AW^1OO9ZN MN"
[L3#'=Q,0([38C@1G[G.N&GQN,GS_EAUY)),LK6L\MX/TT^WY/K;4.A3O= M(2)^%?TEM6D?PG8^[XY/:%QLB//:L/P^ORQ_XSM,R=MZ++C"?
9H(N.'8WHH M?\;KE4(=]8*"G$H&BO^8^1.!$,C<1XJ7RMJ+&=_?T*)"CM;EUA!DG(^1Q_,& MM@D.]4@'C73T"*I&2*\G],LIA<\MD6 GP'1
;SYWX*A9C+*>V;9G8.B/KU8N MR"MAU1;FWMRON%\0!,4P+'2DT#C,%&<=E M)=.>5<9H:$CW\,N .9-71>(QFZTYP@K*,&?UON+E2W6$F]4*
[K^19NV$#,YH M8]>BY>_C]IOS4ZD!2#?)#?OY^&FE?6U2G@49=*5>N6CM!CDT-S7EF]6DI5_L
MEKAD:0/762H4E/GXORM)"M8'("#PGYM&)SY>VX%&UM7]H[.$#V'P#?-%2.&. M7_YM!?EPY%$A*4G[<39 2.$'"3N\:\MHUR(?H^)8-><(CY0^K?
7#F_$.[3, M8V+["U5]0PJ(@*3A<"WAWV!8F.WC*OWPDN1X[&=Q-D/PHZ >=/1ZVO5XW6_; MS$_]A'+(;"/0DC,3:(]WOKQ5$ N,?
D7QAGS9VG"0BJN@^C=N8;4BLURSGX46 M8W)$0"2T]B0Z#,U+_]RC8C'>;*?2*6%:N-FHRDM@2>>*$@L9?V>UZT0.7Y"_

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|*BUT2PQ|W/A7;JN1!3IP M:U/7.JJ'Y2\1 =&6JOGO?'-9=:?Q"NQX N5T94&B\1W9VSX7GQQB.*5#2[GI M^4O(OK1[BMB #'[Z2=(%PHTP'|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|>=N>$?VL)(@+*,XF VJSS M!"O$ D)PC^<,TCT K*&*)DU\@!])@-6' G!((B 0F1ICEDH$L"$>;JX0 ;\|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|/^:N[=[J1)?];>PBCVUNFTF4UTX-R+]HN)*H:VK7] MZ$$QO>=)?IE5T8=A@-P.3&"W!FG&XT!TKHEP^HRM' T$R>\#,3"EN M,_3A*M>L' [A)-$CQ)S"J$5]3=V) [D,A!T09>YA;2_#Q3DENHUHJDY)C[YQ M/.%B878'5G>6;&DY.[]I[BGXH1,)+1+K<3'_N'6I#C=6_@=DA,%__|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|FB__0[,62CI3=&+QT M4V%0|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|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|K4XG6\F/X+27UA5T1:UB!^<$=SL^WB)CYV= M!E4.HG3I\]7J(:$X#!4H?\,6ZT0 TLJ=!PZ^8!ZVTHTC6DE8Q8^8;TU]*=&A(B M'.ME9&"0IL^,.>7V11;[I(" D J<>@^2KA7[*@YG%>_96@*_+ TU YA2;7O] MWZ' K>H&9S;UXG:=EUA%4\UC'AIF1LO/H3@=-#K*UT-E/I\,I)=+\;M;LXUC MCSH^^W[E I*D1%#9:S:7) Z2;"EXC'F|*C82[T>]E9>W56I6I\V4QZ.^@,8| M^$B2)F)8!Y]Q9U165T\)#]$09J)9187^I3<;,#@T8UKX/^UA DLC*?9=LP7= M;!Y$2>"_Q]JVA^7. <6UT=Y27O*.%*7!K7LF.[*OXX2R-[C)/ UU0;9OG+I'Q MU/N)HF5&S82@MX"93=7;L=/*GX,4.;RZ(SU^RL8ZK;<\[?DR")2#|*UA^M*3D]L:L!DC"1';Q0M MP\A 2_&*M2S2@L7N(=KE['@D^@XG^[_LH MMC#4UAU]3^468BF4-7ACYF UBU#U&0\VSH=76/@XGV;7+&+A:BL7>SG%F,2^ MXMQ=GXW.0E =|K43'G)!GED@QKFJ-JS_R5OY)R_5+!+_EK5"SS.GG&KGK\VP M.MOHC_32"O:$K^#3$5@1O.N1LJ]PD-VOG.@B>1X)%D&O@;LG.W4^(6$A+=)Y M"_(H ?2'C3%K:7 ;29)G7$UV,%5KA:V&EEF["F6-K; MA>+ ?,N$HR2X087I4;.UB;Z_!#1+RXM?Z= 8^ :&WQ M#K.M56NBTK4I_Y"[B\? 0X'.;KI@E_LNO^Q*1GGG7FI!@G3'KKUM- K3[MZS%UJ;\@"1P+P"5CF;\6(S5RV!(&:.CT-%A,_=5PN"[01EF|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|LVKOH HWC2A5984KF>?GK(S##L# MV:8VQO:F#;_NAK+8;.%B9MBR)"=)-[#@EC$% [IT_26U_(GJ*E04^AD?WJ/*H M; 6T'4V2]>0A_=2O%18(*0G?]+/MJDS#522BP.$F^T)YUP=E@)>3GE;4?R4Y M-P\C&47,\0=Q4C_%X[-52E<#/TX(L- >S+*6=NK@.FN&,3#Y*)+5R[0O[L6@ MHZR!@E(L%,W.T*"R0]/,807J0/Q^[@/6&-D44I:8K_26/K$9M*>_(0M2;UKT M0>4LF>/&PK>[[G?-6>>JOR% <>E8FRD4!5Z94)NAZXRSA'.]_54A>N#%R5_AIHZTJ8R34&3(7*'W\=.L%.=O0]) M8@) 5,D E08AH@-I?2DP'6,@=[.&7Z,HGGM[N^UHMX;)? |^(JW.3*7 5MK M;OUG%9NKDF4I0)&0]1$D9KXO%/-PM*Z7^IWTB^F-N+G832]?/59G(,W('^/ MSV"ZCIPVS[O(82E?XIES(T421*=D;_HY$ HM,MJG%I=ZEB\24RDZ' MZI-I39?I&6_>I@ABY09VR$A3_/+8]W9_#[L 6HAP)SB7X.!*]O=C4:S7-R6/ M[] &Y)!&.#D<,,\%GO"GK//[NX+')'0=/9: ("Z:^66_MD]YB$Q;+ZEKP\35(MU#D (YHS_U5'K2GZF9,H(3ZK/.0P]V,N]^1&TPP;IA@/J1>UOC"B)3,9I'Y!*

M/K,YPO3)DU6LB&25[2;^):E']''K9R:+6U3>_OW@)K#5[?'M3 !@LA((A46 M-(U"Q*),3'/B$Y/MYYPF*$Y8<]>^XC5QJ_2]UDQ[E>!RIX@^Z WHPDZX7Q3 M_2@YIC"=/'YVY(\:B\R*!=:;_-@?=\G]?L^;FNO0DL,]K5T]]/I#AD&JB;,D M2QDNP)E\"%A[[$OMF&*VY$)L#?4)7WRF!;^'2!)C7Y@7; 5R28)-UB#^$>C+M7"2J4SO([JWK5FJJ/T*#5\GF M-#O#WY:,T7O?4(IQCBC&CO3.05WUX/IC=RESFX:W%8#>AIYH*F_3X\I@UWU& M@GP? G'>45CHWF436F@G+OI%RN::>9[KZ50:5!8:P'A[296VTLJ)W$8N2Y)I M4|\5-D7PMGFNG0F>4%"L2Z/53]60I?> SUW0^:5K4/WYDH_4_*$AU/%"P+]Y M8=JO*-/-;;_MU+|>^?MN\<#VVJOQ@;5!.^_HTFERZ0]-OY3=_B9ZA/JOS8[O M5^VP@/Z8FH>$6F->$%NB#;WCGTNWP|CQ|20]4L3A8? TE'GG&CJBL66WJ(O1$ MC+CN>NPAV@O#B3*N"G%>NIFUW Y3%A[2?&5>T:=1D?'<1 Z09KLXYD3[2[P M%6EE|*K1JV"O'_[./Y5>,W4P^F0')$\1$*H,=VZS-COV^]3,=EDEHP7IR;2U MD3J>T4[P);53D[;>]:F>C88E,O?F=S'6)FH0;O[95PSI03!KA[F+'K^3GQBW M;K'L\/(IKMKF6;BF -:&W-^7HNL_8 B^ %H95C5=D]0?QHXVJ/5^_%0A]4V M\UE_R.HR/|%B1W\Y# Y)UXG:N\HJMWE20Z!VF^JXS977L+#G&;SW[M!JI6VC_CO!HE%D=5]4EG\Q/V;@:@"*_4S^.Z\%B M&,@+VFM<4*[T/+H'P*J68SC_ %|>M566V_E,A[B|0$8+O|+%IZM?HHMD]+4T MV#!LFD@&M5:<7V9G33I7:D]I+]9O0W?ZXB#FYE,2?&4584[Y\]M"QEO*#.YQ M0]8$+O15=>? Z;V:9&9QE=^P@-YRE(*38E,1KU"V58_'Q/<#:3NC<@35Y/#'N MV,\WW!?\D"<*OZ?6R<#$1WD[+XLG9FA,M3#PI2Y;CE>HM\RM&^+4H%O$H M51&Z?FK"V6FVRL^,@=XK^_X"Y>:]E&*N FGY[?9BWI&B:<),2)M/;E^)M;S+ M/L<6J]=M5EP=%F5M$AI3^[KV&X$+]MKVPS 7*.:%>3]^=`'9((U=6D5CD:I' M(8V@K[>B]J>GE&B&O"$>C,6?#J"+F4V(/1R_G=Y.ZLDD:W54Y\S!.*GI8D[# M[Z8_L^CEQ+[%SV.MI<)I5&(W4)+#L_UWA@V_QWFZC3,KJ@0WYY9-# !]C5$V MS$GS0:Y/>YQNQ(ZLLU%,$?6,'-=R:C8;H][@1D)X<5PI!:)H,VEM;1F0V_KA M? 4%$C+1+A^+!A4.K8]X#GIWNKN91O^$+|FJJV;NZ::*ITQ|;5/=DF_@?UGU. M*[^X\WT7]D"N7:J5V1+"Q;IKN:9X$>Y%J@6;))GFZ_2*[I*YI0|M<+^_2A3WFQURZ.B3'S:.^=FK]E&E5<1/E?F0;PYC'_X_%:=X7:"1JENM%0E OQ@UDW*Y!\328NI78,&OT!>1 MJ4II^WMYUX3KBPY1'G^@PITLE*:]VNRK3V\A1#W*JB.#;K&UR6&<5OF6 MF<@(31%T2Z=TS=(L4J-GYX=$>ZL8KTT&-+"-4$4GF^<><$0D-NS6>TT%AP;? M1@O=S@NUR!A9!.6F56P!%]X2)WP:^8OJ:L/4MC9)! 3F_I)5A9[F=(V[2[>OVVV\,,5W/L MW<;FP#5O_/5(QL&QC^? BOM96F_0854>38QB*F&BPK XF.=6;,0;T)DD4,>L7 MVV=-X@^E4|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|WEPLL& MKK?H?MO=7OD|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|H@!M(Y1^?M?)(0N/Z3ZP: ,_%*NS56E%-]P"3V,GKE!N;:ZGA7-.^ M EM7,TRPL?D>IA#LS8V8'?4@&ZQ2_6LD|W'Y]Q9-["..:$Q@%1%COR&JX3"QA MGG]187-^P;R40V^9%Y&F,^'F$PSNC2:?5?RFR_H+!*O@+ MG[RUC/K!KRP)@G:9GR|UNDRW+/70Q@9#IK4@ODH-XV7EN1RCWFZ;"Z;B7]1$ M 1Q_7LIHB="OI35I5'L6U]\0^ERP^65;_H4_@-$OZ!+32+LCU/KP\@64^!ZP MAP]^,*/3[23ET-4=IHN^D\KY[/^KV!#B?\6&<*7NZ"4U\P?;%VSN!"_?K4+G MQJBW8[D_RKX$N=T#\I"M%B,7@JOMU:?I <]LY>_23!]Z;5;JG6C"_?-?0@H# MO'6 UV>|WLB-XEW:X<*80E.D^<"KV@@HD]NL8QD@GJ ,\&*K.8MQ<(_2@W*- M2HP7M+8VT0N,-W:^..,M EM7,TRPL?D>IA#LS8V8'?4@&ZQ2_6LD|W'Y]Q9-[".:$Q@%1%COR&JX3"QA MGG]187-^P;R40V^9%Y&F,^'F$PSNC2:?5?RFR_H+!*O@+ MG[RUC/K!KRP)@G:9GR|UNDRW+/70Q@9#IK4@ODH-XV7EN1RCWFZ;"Z;B7]1$ M 1Q_7LIHB="OI35I5'L6U]\0^ERP^65;_H4_@-$OZ!+32+LCU/KP\@64^!ZP MAP]^,*/3[23ET-4=IHN^D\KY[/^KV!#B?\6&<*7NZ"4U\P?;%VSN!"_?K4+G MQJBW8[D_RKX$N=T#\I"M%B,7@JOMU:?I <]LY>_23!]Z;5;JG6C"_?-?0@H# MO'6 UV>|WLB-XEW:X<*80E.D^<"KV@@HD]NL8QD@GJ ,\&*K.8MQ<(_2@W*- M2HP7M+8VT0N,-W:^..,M EM7,TRPL?D>IA#LS8V8'?4@&ZQ2_6LD|W'Y]Q9-["..:$Q@%1%COR&JX3"QA MGG]187-^P;R40V^9%Y&F,^'F$PSNC2:?5?RFR_H+!*O@+ MG[RUC/K!KRP)@G:9GR|UNDRW+/70Q@9#IK4@ODH-XV7EN1RCWFZ;"Z;B7]1$ M 1Q_7LIHB="OI35I5'L6U]\0^ERP^65;_H4_@-$OZ!+32+LCU/KP\@64^!ZP MAP]^,*/3[23ET-4=IHN^D\KY[/^KV!#B?\6&<*7NZ"4U\P?;%VSN!"_?K4+G MQJBW8[D_RKX$N=T#\I"M%B,7@JOMU:?I <]LY>_23!]Z;5;JG6C"_?-?0@H# MO'6 UV>|WLB-XEW:X<*80E.D^<"KV@@HD]NL8QD@GJ ,\&*K.8MQ<(_2@W*- M2HP7M+8VT0N,-W:^..,M EM7,TRPL?D>IA#LS8V8'?4@&ZQ2_6LD|W'Y]Q9-[".

*MGU&M&6XD]1RE"HOVNF[7UYSC/#K<_NX"I7(%FY2%WC-/V_HPP!R7KU]3YO+65N8Z4_(C^X_LN4%&>.MWIUZ03[&A7=>!8)1+U]55'[<".Z9 ML[I;K*WFH+OL-+6='PAW&ZY&'LB)P[-W3XM1)WOZO76PMR"9Z)T6_ FC3 8MM00%WJ?2 K)@PXV$'H:Z>.T(\YY#K'4YC#::GP5>8$^9BW MST!O+#O17L.9)10Y)O[GF66*Y2IB[;;"=9AW]J9 M@?'./OQC7+)(,+VB:.TN;EW#/),[> ^CL\GE4.*7;\P$V8G3D*56_,%9V:FN^ M,#F#C]IO$$4&2A*!\(P'-I-1%NT.K]>=:04=C<>RJ/2 M((^N]F9[=RAE_Z(;*]P(HMZU]M!1;*>DR/PW_YZ1?"I2:/I\)N#Y+>"7$G,2 MZ 2+]^24;?O=;R2"5G6:GC"? @3ETI:$BOG4/!"95#@030@V30D4YU]A/ MW,RP-N_H?W%<87W$&<3(R $AV="><G?'X=8Q):[9A+,CU&\@J6Q+'HJ=LS1B< M3ICKA1<2+!ZI/4GXXPH@%:]MPR[HP^5U=+(_;38MO'AE+(-ZOQY"_,?I_^>R3 M;DA")K9887:FPX^5[A#./2=$\H(<25NO@P%]X=#;WQYFVNM5#^S%$N'W[#: MN8(3D6L&H%ZNWFR=*BIN8GZVC5JR#_X+V()C;U?:NV:/@]>'MMO6'((.%>5Y%5>^G,558IHG7=-,S=%KI$CC M5V62R,6.? OIR:]O8$SAXP/%HEU]QNBU"B0YD9SO">ZAT&/0[GCUKVAV4ES6."YC?#NV0_"VYXJ5"IWCP..M"-V)'":[LRR2@'R_7Q/ 2]+ M^4*$O1 O5>$_M<*QMBK@0\5?IK9M,Z"Z*2TD>:IIM*9N)38!]. JW^\"/<)W MX5\D?K.3-K>U#ML.ZL0-O@4\NY8;\TP8V%3+N4E#6/7I=;K29+XX!;6<3/,= MO.:DUGY,1:K;B&BB@95N|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|WY^#O$HF_^8'')W:1^(GQ1*%-X;SY%C ET\8S)'BX]O!+5? U>1U[1IX#DW20D,R%.A)FNR:G*Y[&'RH^ M;KZPQ'%D9K6\X6#]ZC)(?.UTR>-G_NL'DS6_ A^3XUU?6#^QT16K7>$EX4 M9R!]BWN)4; (ZL6^CN5S/4VMC_IR<6!LRR+*X,ZU^2>(6"QUA?0,#/NG!,$5P M&0S<[[:/9[;<&2=__&-8N>#CZZX7:3D:ZD7)(2$% .B=$D.MG34Q@AK%\4W M"R05X ,$7X!0',Q.?HQ&>|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|?XM6=V:5G\&STTLCXF&7IKET:O*X M'!_CIH$Y]/7F)*@C^7E7M*A@?[I-R9^T$P,E]@ZYY<-WULY6U-W/.O26P[NK M*/-JKQKN6+W9%3F<.6 B2DK<5Z4OF$B*FDIG+'>|&!/JG-9[47\++FJX"J7!DKMOD>(#VBBKON&2IGUY>?Q[+F>]RPDCOG"-$1/4G7Y MQ\GER>CNNYEU4\+?;*SR]\T>G$T0FB\;0]61416SQK+TQ5>_1'|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|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|:^V;8O4M'IJ(H6H>@'T5U7TP)M+U?%1FBW'"POK0;RC6IM? 1.QVRW)%1[H M%S@,M,EU"4^&([UW5@*?LEW]RANGIV4E'M2#UL6$MZ49H!-P$ N<+[MM#P" MY.6R#TZE/#3&G:W?+(8L!TM'V] <@"B'+NS0\0Q!_0=&|!%UM@STWW6&Y."OR MB-.A":^2K4'3O7W-TU4R)CU+QW$F/770_]^#^1MN?6XZ!LLR5$ Q:0!CMB/QNG*H M@AO*:U*K%U9B.Z\]DBM?]NE "*7\5)$\$?4!-Q\>0WI_%/@D"0[^U'Q\[M3A1]+DG(L/=$;TM$%.O"3:1[.VR_E9;^/"Y=U&>MZM>M.$U78;=+$;,9F(<$ M\C_,,*X*A@1C4S_HF$SITL9^V>M$:&6E?BN+TS"T\E_W)[ALVQB+28VGG#2" M.P,[!#TQ]>A1;J6! /.DL$'3P<=)XR+B9MT:D;H-Y<)SX: [I89\P'2WTU#B# M+\F6=%6?3W3#MU+LT@>PW])T92.>:VXFX(P+H9. MG_<>?]QEGCKV1A).1(^YP7,\8T9?@NA']TX-*9"]ZGLC,_FF:RG1R7('XC_:*

*M.+G.*MLK?%%UE)T9LV^NVXY !OJ6[I]0GQK"*BV((‘NG7;.-L3.1]P>[5?X#[: MJ#($'X=ZI!Q6E0?FAK95;BQ^B^]2LU44.C(JT#,2Z^-4%.FJ M+ (4/[S4VK:,:#_D4N,2>=!460P8;$4>2M5Q";,G@:7:93.DS6M^Y.A7]JLW7BJ8"]W+|9MM3B2[6^/?] &PWK6 BE@4TJLRZN MMOF%,F>,8H/Z1P[*E_SKZU>S\#*2:^^#U'7CW4J35 :LQI:;JRD7NQW=Q>M] M0O&Z@O63UV+-1A3%UO&:Z:I]X##& %Y,7P1>/6L]6>[.C/Z H<_F4H6+D(C4 MLW@N^H8<+U71RJR$#IM4?<^+PR.G>S"_2=BC3XFUK#II52=Q7)CP#?CI-LD: M!W0D(7!>V$CWC199,40:6<.[? $YEDU_UCN@CF#W/62*HI3:\F='Q;4^6V63C M8JWO1%_UAX^H#US9-"747$]6+=/4(2J#%_7-=^"B4\I36PC[G?]3L8_/%8PE MC <-)YQC1_')D[[VP2B[&2#-ZC4.S5EH&0YOP=-[D.(V!*W" 192*?YK+=$7 MOMM/EZP1015]P<@^4IQ+2W458T^>C]_#9!T7A8@L6R+(I9"|9KOC$^)>5IY) MDI3!HXLF[J(0[WZ9II\ST^V?C6VYU;7-!E%XJ9-8< L11*4B/Z>UE+"O MLGI/1S8;PX5KM.[OAP<8GNQK:7*]?PJ^=F2$4[3Q6?%E:[/#73APQ%BA-_U4 M;3IEQ6\|J Z%;RP.N_RL.V&Z?U7_? ?%5=?U6'S*OJFHOOL%+EM60\.DX\9G M<$2WKC;E<1(‘-KG"*'8<"B>"5 -U>8; MBYG9W N:+_+/? H#@^@!|^[\3L<" M3:9^F0V.6XV^BGQP4T((-VTV#B0\8]%3(^+'DAR[M"F*AS0_)#!M_OP3?S&T\])])(52/#F446+O [*JJIL0A@>-^W.Z8Y5G)4 +[MNK? I<)23:1[2E:)**;DBX-]AW>YV|"EKK9#]]Z>DW"I$BZRYL/)O0&WP+'^ M>S%*##]S.25YLR)%/_X0SHH$_=| <5^#MQ;9V.P*'21@5QZ6ZSBN%#WOEN=+/ M^?28(F*((‘YQZG>RFS8#P: MLX"I6%+;OASCYU=ECFI-F]-D]]DC:5:BZV[M\H)H*#=.Q:B%P)=@^7T?:O:%<(G18M+'_HO2G[%IQ<>H$_9+T1.HDR[F;!.!E23*S*?P5,#VL8M0R^78M$? 0]WD.?"HGX$>3NP1HS[7RM/FT,$8C9>$(F MZ3_UZ)CK,R8B,]$4D9N?6]'QMB)I:93/T%%FNAIZ^6U5EJDR^:QRA-"CF-U!&AU:XY2#Z>FA*2T5O0FR:3OO,V>/E_-$YW7#%EH, M9O"*4?/>/^)"R5_,02]Y?J2^X+E4/4[?LW-4?W9_^:*H2\?Q3#@2H$8X@X/-MJDJW^J'"D!.UDD*?JR==)K2"S5')2Y];9$)O,EX?;_ S-/C\')'HG\F/UB'G3 MFN6NWXQ'UMZ@6?$]O$/>+6]- 5YI=(C(K:SJ;3R!0'7AB(!;N8X]'%-K7EYP MONT;,BNAR4-/=U17#^I&,@*L649'1L\|F&+M(7.Z;"5TBNHNEK1X-ZJ@MM@ MY>L3N(R;T3X3S75I22_%ZA+K3LLY72K;;4AW7_0KD).&A.TC-'#] <^T8^]8T M5FT,=RI=@K?+[)3KWH2VTB4VS=B1KBM ER80OWWKJV/A%9UL_8:1[N3)R,3M MP)P4B#:2H|=N? DW8ORIJ:F8::CHR98+OR|$;B\'!V;*_BC= MC$?D_-A\6LLOXZGQ_LY0|)&=]96-J8_07M>/V$A<^=< E2AT!KD@SGG$"E,N M,/R,K+|Q%4%1#*L=KN+3#J2(;+V7.2K+C40R 9^1RNO<5B+%0[E;: M2%>W\Z;0^.IF]2HSDYX51:"QGCH3Z)'_YLW1^R_Z?-UI.X=^SKW2.G$6@W;E M_JU#XI:]:J.@&[S)+<&VC6-%%\R42Y$*Y3)SH5S^O1'M M[3'-TC1HU^FMAIF2MG MGZ]<-L,\@/,.HE;G$ID5'&VX3F!JL]D*HOJW%&43]613QB$*:.HY@O?MEQ[MERVBK.S(.=ZIW/WHZ?;3_;$#)>L/73HB!7!)K#?4Q+%XT.IAH/K!NDM9*JI2 M_>!!_;>3]IZF^KHGTZETN8[/M^(M;O%G4;+K7[][4XIM]_N!['$Y<>!"OC\W) M 5\]^N"8D*I6R_-*@GEO9>M-;ZZUVY<\]XX@T5?!@>XM!-'A)T.O2<4CC/KL6#9I-VWI<_B2F^G/+\H92&:)1CA9F*;TBGH.?ZKUV^7Q: M(O.%V]V1@RXC(VHKU<-BVQ?U]6N$O*+O%W.5M6;.7FU>W1Y(M2XQ=H(+ MES=6-5R[6$XA:/0CD([^7-/9"J@-F.I"+G0YYGX ?UDGLB^%[\1ZUVOAX\;4 M\6B=#[\YCG5V,VC"&&,? S[P8'F[74]=Z6VACW2F2+;4QG[N:\BU;G;8D9*GFXE1FE[BK#$T%M3,PQ]?$!;234.\6*\8]%(M/ M^.V1RBB7UQ#W<_FP0C[XQV3&"NTG/^A(P204_Z7ENRA,_VO6I0 MF.8=9+44=\L8"ULE:]^NO/=C[.,RU]ZJ\9,=D=G5KAS!WF2)KG5+9ZB!OP)^ M4'OBB?EE"-?]!4H)P^WZS6[H9EWR=,K0\>5(8422ZFQ6I#"HZ) C!IZ3I;AE M'78SAE=3@.H>8OH9-[IVTU!T<7O=R0C-H_]; V=ZHEGHK4F;D5 G M8XW8B[VO:I)63#C4''U$$(?ZW 0R[G]_K+A+AY_'N%=XWH>G QL7>>-)W)@C MGG23D8SGC#;8SV> ?#H6/.IRDEC3%89*/&)$=>/NQ P+UJ1=Y&,H? CN1J.F, M0EO=+JN#6YD.W3]_C U/>XUA$UWN>)GF+, Y'$,.[AQ0GUY\N3F MS -D/5+^JCE:MJ;7+O;ZUVNC\1W,EC.M'!:+'ZN?.QDFC*NW)G0HE0L-O_R" M>-T@+HL(4>,*N(>SF%<(T)SMH0I4NVAV_^WQI)8OEWIV[&+5G6\ MXRS$U+JM(KO:M;K(&;S=|&U(*U8?F-6R5^PJ];3<_VT(4.1V;CJYF.SKT-3Q3 MN97K5,'V#*FLW'E]\DEUVL47^U]4KTSU?)-[_L$^D??U>>JOS0^?SKH%?F7> M3=[HL,XT66=H+)FAY3[=:Z-2$;3KQ@>$-@P8+_K9QJ84$T%5WF%$4*4:Y\0Z M?:&5.G=:@0GIX'PRM++T\'GID1&[6Y$Q2.?@/,H$%/DZKRK6E9J?G/J3_./+"TG%@]V%0=PII=1_EI?N2+ M*U1YN#^74?7N#NR%:8Z-\+(D['&62--"@C=KUW1'YD'I),M%&^Q#S.9$NJ85 MKI/SDR&H0!7-A5Z3H;R%[_8*G7O%8,B+*4X7)7#E MJUT:Y?;3VO8-SW;_T58KIB9:GY O:N>P\J\EGJDHS[TLPW%EKM"2P0*5D5T?/@%MHG:$.DO%!MUI*U@Q((,MU26+J,54\N(@LQ6?(MU0M5.B=_V%]$;C;.?QW9;5.(^>;\Y/F$L:=![”N_1_[:_O=1FM.C>I6U9@%' M/31K\RJ>4R$=“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|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| M;V&MEHR.9Q)@?=OX)$!>O7K 3=AL-L<+(N@#]R_KB_^R?CZ!2KJ_BA^\P^) MYN#WC86$:T00\ (*/R>,)1%"G+4%CDL(#4Q5_#45#0MM:@JPV/BOQ3A&_UAL M71W](74\@Z#-L\MS/)% !/7-_":Y4SU "C:;H_3ZKY-749@=50W"*S,K/+L|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|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‘>O;FU[Q+L(EM8Z MY,D)QQP,?]/A,VZ_>G-[LK? U9\AX*00,:M M7+_F\T+3A;G%XO33*DM*=-+7 MY@W>JF?WRS(^<%QN-R*S""<=[:J\0-Y79[6Q$)BST MB5;3[8L!N.7@GX2+S_,.5A2RKU5H_3]-.4% <>/#W'VM1W(5P_EA.,M)X_XQ1 MI/73^5BU[7.-?I&@(U/=4#4I3!-\%IFL.XC\.C_:UE::YG\I#3]BJC0O-6!! M$<)][S6^S>83R'@Y2N1$## (2MWCQ#N>Z_XF_3RF#Y#(R1/?:I.:UN]DW/O!Q MVYUWODE%\AV[3\9T9O>TXPN"07.NQ^6&L<<%3O6 JO%NT=2)"EM6-O;|;*Q;HFC/3_M\;W/>3 2W+SIO\ 3)@,%WX \2A_8S'\SU?4 *FP433(Y6]UGQ*Z@]!S!DP<5E[-?]L;0& BJB%7:T_OLR MS,?TZ@X5'-V?B: A_P_^4T26C(8=@G5?RHA IY[1> '"E4+H%(H*0_I5MEOC.,4F@M MG0%*X*%G^2@(%K.#(Z!#UFSS7TY @09XC2!90'#\!C#)X0H:_!]BQ3I)P3OZ7N"P/P^+7 MUZ(@@3,8X'U]* <1V($"5OC?IA!2O!=X950X];+$TX@*1BN- MS$7SYFX3R5M IP3>%Q4E',[\,N@2^+-|*YH($O?0Q=, `GI\>PR.R>8KF3@ MV&;PZD&Q>J:E(M]8=TY_E[B#^D/BA1,07@>0>/L?$@F41!!6F>#W)_(-@!3_ M9O0'TD"J[W=DSE 11$K 90!!Y@'&TP(B@78H(X,)O%P:#I"%_R* [*LB,0:;/C4UX8PC"(">A0"F#2=0;F.!\MT6U(!/S'IY9*#H2C+' M4M11T#8."(Z'4C-_$ 86)SW 9?]3; +AXCI6"[SN(?G;*4I+N(@(LMBUV@)4 MU2 4V**F@Y!:^2; MKG@64I6<-VK/GJOE'!N-[!E=EHYR5X%26B\-1%=Z&7IMHBSS+5G#W/""#]/! MT(Y'WIZP&]"N31.S\RZ'R^LOUN 0G9L)@U4206VT!K/3:7!Q8]+?%@HB/;+W3M;R$/F__*1E94283Q(?K2!=G:;?G*% SZ2 MJ#+:PQ4'N72S>S$A),ZOYE;Z/>%==S$/J4G!^Q:WQ^/4FP[4(K-00'\|EQDD M /N^6 RX0 L6PX/YCF($K[@- ZX41+77&U*Y%(%5 %>$!@.=[@6@1X=],IT+ M ,,V:;&\L&^+Q:!?,/*,%Q\|[|0M)1 6HT;+B&=>=B1YE%$H M8[2(P,O(M\8=LOX+HECZYA0&'N*M)]PBK#" MGK]]M;L$"S_**)86I]F-0G"O]_^,H&D39-E/LYLNP[ZOE\!^K>/" MS8Z0//+E:,;!\RZG=.,=!#)YW)#]P1M<&A%T]ZGB M]T7ZN2^T:A$L.P'"%^48OS@+I_AN*?A=LO(+H##O-:1**.TK;S\!3N6#SY#>% ML"H\1]RROYW"1\EM,O"-<0L$=0G%%O"1NR0:WS=2)+ISES"0P42.[^/H^R5O MD'Y3%*N1@2OU1/R&2B:=G_D=!2O%Z1[M_D*-4HGN7*4,$$%,&O@^I=']?8+J; MDE@MGAU5B!6.9;AHUAS8JLG]>-A7Q/X$D-34=)MG_,E\$OBGWP@* M(U*(P@R"F8B@E5]GXD6C9Q9X\$V *"!;6#Q'[:Y9 0Y R!C]%#[-"Q)9)FC M(<"]9OSEB7: 6T&3@=9"EY=+4(-<=GC">&_$7QO=;3_&\$BT6Z8W7;T>;PC MSBQO_?[Z:3'HY'(V(Q%$LW;.[&+(63988^SPVJ.C=B%Z TI3CRO%]R3Z?@8N M4F%:!V**5_A]M M7DCV6RD[-HGB0K-\7%J 7I2>S022L97ISG2A2;WE9Y9:W)L4114BH!IL%,7 MJ'W<;/:R7:J)#F^!#[N745_)14=&9+YG2I M=0] (@7MYV38Z@V&M27JX03=78Q[^I/504B4EK)!19<3A"4..X69<_ /ZY";_ M=-&D8?!C(H@"0F!O[$<&^IL.):W-W*V"?$B1E+F<7AKO7L'^]$VVWXMK(1;Y M;2[<3G53Z:DNL[0!FFQU2;I&T#/B"$\V/8.XR^QF$.NN[;GW9Z^*)@X2E'!Q M&DG484+MIH%A(=[^14H3I1_$7%R[\- VP"F(514_9FJF,N;,NL,#&$TFK/DX^1LV]>Y^]4#3NT7MMD"[J:V^-U)F*? BQ$$*QI'=;+$ M^=,=H/Q),F'39*Z5M2;,4^_E%+_|?"+:IB: >T$@P^Z=QV$W9%%G=:;&]S+R M)J367H]@>SAZN"*[.?/PQ%">_6X%-0A3?_MSC M7N T;AEOZU[$(M%T%Z+/'!#M0I:MW_I"8=W"*$2-SW)- J2^$,=!PPFP0KY'= MS6=A.B%#?5#LEG>'8D:*W$CQCD"Q1IPI:/^><-8+JB/(5!&QI.CK0X874Z9 MAO?% RI.8+"OX7,9)Y3RA$C9_G""F.Z[>*

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|0WH'%^"\R:\EVP(N[MY\0T%U ,\#! M@Z-2(2>PN<|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|? M=^;.]_ZQ9\X^LYZ]SME[K[6>-;//.JY9R+;F\Q3;Y3AK(IJ#C<\9?Q[&)&8RMDMW/6=FG\0;-EWC5W!&=QMU=E&U"H@$ZR\.G[7BF@@,"/FVB^;=@^/%M=Y]^ M\PCW^WJ(=1WIXTX39N]A/M]!LW$;X633D>Z3L=]DL%07,XBN4@Z11)\^2%I MUJJ1J?Z!YW>ISF^J2NB %9.5I8,.&B"*$\<]3KT.Q0G"F%PM/MC7_Z[0EY&7 M3=8V_;_3C0_+]%@/KN5LZMA6.!/KAH ;%V:-U3"E.4'D1"OWI M+WB>>MT-=Y]DWQ&B;,RQO-A^-#/^AY)TJTOZ-:5;3$RLG/W7XC6@*XJ#;$WE M1'V/2Z48[T"BO@2|=Q&:XI2$;!&KW'V$4@VDYH4G+4+IS!!D?!?.MS=ONH6 M5_AFZNQH"C#5U7[^M1)+X "I]L_H,ICS:3 l-$5]2$64:CM/^2$26SC#,%5]0 M",Y;2E;V0M!])?W?K8H%<^B|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|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|M,V9N[[@BMB+I)YH&\#N2YI^;0S3LJBR"2*+Y7L?,N+*C_(GT5F+>>,:*,C>E ME9?_^&^#/|[;SAI"TNFTNTC"=+|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l+$OSMLKU^_[8.8GCZH05PD5IN#BY'YY)2^66@(S|^Y>9NNN7:-^/.M'N%BW)U!-3]% MI:BK<%-=DM/Z9LF,3F -YX?%.<8; :9=>CI3F0O*[PN]8%FBW5XKOO;R7\UX%2?VG.4IE0E=["6J_7 MUK=N.!_FO[YZZ6HF?VB\XK9M/[NA?4?D_$8CI?;''H=2+ T0 YY:*#K82"D/ MRI:FW"4G%]H&WR1_6']G=EU\JOJW0_VXBFFQGA1O0DCH2./KN\LFI(AN :>5 M_"<3P>HE<)&6158?WB(58SSLJ@X>.^$T7NZ;39!\E?-'N[[F&V/@-<.+I&G5 MDDWD58HB5R,(?2W$A1W6&:&Q,OM\/?\CNSBYA;JPKM1E!CRU#6/*MZ$;19 "5,@_AT_A"6"/;Z$XFF$[M,,)"5SZ9WT(X%]ND)EV= M^1"!7WE Z-DV14RSDK.?$_EQ!;E00NYZ2FU-C"_LY1NPS[#OM5N'G^+>,=P1 MNES1LIYY@+Y(%EG*C@RLF*"HYC*I[78X_#T[,.84R MK$44*IW)@=')KF8)]0;W5F"_'IXE29Q91%R=7W6_YTQJMJN MJ7O6#%2IY2?!*W%1_27?=(!L%_@*W']%-D:^F7V=4XVI) MD7&^#^298%KA1@T)7(0%/>X(]DJ2_KN'0E?XSG7ZA[AE3A;K;!T&' KD=)L4M8LSYMV"_L.]"VO]@]<0,FZO(**Q-7/*VVSZ/S/_(AIZXDS)0)I/CU:':?:- M#+^BHA7Z6[@[#?#2("OB]0WZ(G@M&XA83:C<1'JYBT!SGXQC+>)/KVZ)B07+M#CWD4^;= MCJPZ:%^|H%>HEHIO"/+'U01)I/U*T!#RBHQ2J-@9B>|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|\QMNDH;EM/M@FZ%P[^P^#P-7;'(*RV=)?#5=MPC\,LR-;@%S;]BU7 M?Y3%#TH3V3WW]3,(M+Y8O(B(,ELRM=S*]ZZ'Z(<@I8;ZA |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|\WR|

(RLOF=GFMO&(M"V0[HBBWFFLD_@5L_P?8))CP5\1|)[NOZ"<;^2M$Q\@H\K%0#+P$7 ?+T@V M:F94.1_+!5?6[-G>/]],3@?6.%)BD9OLLH? [U%V$VN.XQ'^@ W'#?71L(O!|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|R\49:W6"X-]'9T'P9O+&OQAV>WTV MT;PPTDI5\"P(S M^W6"NUM@R#8#Z?=^=':7:6O@\E5D-H\&P:94D9T8QNW3D^H M!)^"QZMNIBA>G)[&<,6,7F7C9 MRKF^ED7'JC(\ZI5VC)H!7M^SN>W,96S3L-_K_7U<\CB6Q74G$XD-1]WCXW61 MEM?IJDSYH85:9-S*F:"V&ZU&F> ZG"J;CN]WL*EFN:R7],)V$I[+;!$^G\A< M&/9>S-F5RGGQO.U+\-<(+9/G8V=MY/\$FL;PK+BU'9D):S1.OH[^$.\8_2_ M7W^A']=W>IP+-[:IRF*\/+]- Y51:=M3O]D^"*2:M? 07(R!6Z <^#G;S|>S|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|UN-:%!!W&4B&-Z(D]I()ME6>2&"Y+)'2GJCTY52*]IY*YS.> M52Z$$]!$DF"/(&> B-F@]5=:;X>4Y!|WRW]''51$.C%^DS%5E=WNP2Y)DZ^L M!>V@DM_?5[/IL8O($% M?R!_D-Y2451I@F%#W&OH-5?&HIR.[=&6 038;_Z$E!ULJ9* 3XCL]ZQKQ[%Y M%^Z,C(]/BFKEUZ'W*N5FI00I)SC^B=BI4#B*P^,+MGW_[B*7I, MSOT%3@5&>T^ESSL5<#\'Q$L6MM.V M'. [WC.61+$%N]\SC]\&U#).5+O4U %8 7C\)QDIEA_X*^BG1"9M(%"X' ,NU_":K"WO?R0Q4QE,T$: MI.#7!0|ZNDX:(B\SM1!X.T^5SQ7\#I4 _:\BT+K[HCP&@^YP]&W@UGNXE!#$ M6)WP3P+71H=^>M9_T1MO^WR/!'R2],/ MBF^IOZ%#%YX(V*#,W>M4O36 ZLM45-*X&[7&*;H "N'/H+4%LWYQZMHC5*Z] M7$:$\I:Y8V#VK.?^-6?I$4%3MQF88'TM:!-N/W]/7M/7BY!]\DY:8\&GIY^SZ-_?@NXPL&&W/_K&0YO0M="-Z>*3CHZZ MQ|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|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

gaap:RetainedEarningsMember 2024-01-012024-09-30 0001094038 us-gaap:RetainedEarningsMember 2023-07-012023-09-30 0001094038 us-gaap:RetainedEarningsMember 2023-01-012023-09-30 0001094038 mrkr:CpritGrantMember 2024-09-30 0001094038 mrkr:NationalInstitutesOfHealthSmallBusinessInnovationResearchMember 2024-08-31 0001094038 mrkr:NationalInstitutesOfHealthSmallBusinessInnovationResearchMember 2023-05-31 0001094038 mrkr:FdaGrantMember 2022-09-30 0001094038 us-gaap:ServiceMember 2023-01-012023-09-30 0001094038 mrkr:RelatedPartyServiceMember 2023-01-012023-09-30 0001094038 us-gaap:DiscontinuedOperationsDisposedOfBySaleMembermrkr:CellReadyAgreementMember 2023-06-26 0001094038 mrkr:CellReadyAgreementMember 2023-06-26 0001094038 mrkr:ControlledEquityOfferingSalesAgreementMember 2021-08-31 0001094038 srt:MinimumMember 2023-01-26 0001094038 srt:MaximumMember 2023-01-26 0001094038 2023-01-26 0001094038 2023-01-25 0001094038 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember 2023-01-012023-09-30 0001094038 2023-09-30 0001094038 2022-12-31 0001094038 us-gaap:EmployeeStockOptionMember 2024-07-012024-09-30 0001094038 us-gaap:EmployeeStockOptionMember 2024-01-012024-09-30 0001094038 us-gaap:WarrantMember 2023-07-012023-09-30 0001094038 us-gaap:EmployeeStockOptionMember 2023-07-012023-09-30 0001094038 us-gaap:WarrantMember 2023-01-012023-09-30 0001094038 us-gaap:EmployeeStockOptionMember 2023-01-012023-09-30 0001094038 mrkr:LincolnParkMembermrkr:StockPurchaseAgreementMember 2022-12-012022-12-31 0001094038 us-gaap:ResearchAndDevelopmentExpenseMember 2024-07-012024-09-30 0001094038 us-gaap:GeneralAndAdministrativeExpenseMember 2024-07-012024-09-30 0001094038 us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-012024-09-30 0001094038 us-gaap:GeneralAndAdministrativeExpenseMember 2024-01-012024-09-30 0001094038 us-gaap:ResearchAndDevelopmentExpenseMember 2023-07-012023-09-30 0001094038 us-gaap:GeneralAndAdministrativeExpenseMember 2023-07-012023-09-30 0001094038 2023-07-012023-09-30 0001094038 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-012023-09-30 0001094038 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-012023-09-30 0001094038 2023-01-012023-09-30 0001094038 mrkr:NationalInstitutesOfHealthSmallBusinessInnovationResearchMember 2024-07-012024-09-30 0001094038 mrkr:FdaGrantMember 2024-07-012024-09-30 0001094038 us-gaap:GrantMember 2024-07-012024-09-30 0001094038 mrkr:CpritGrantMember 2021-08-012021-08-31 0001094038 mrkr:NationalInstitutesOfHealthSmallBusinessInnovationResearchMember 2024-09-30 0001094038 mrkr:FdaGrantMember 2024-09-30 0001094038 us-gaap:DiscontinuedOperationsDisposedOfBySaleMembermrkr:CellReadyAgreementMember 2023-06-262023-06-26 0001094038 us-gaap:AdditionalPaidInCapitalMember 2023-01-012023-09-30 0001094038 us-gaap:CommonStockMember 2023-01-012023-09-30 0001094038 mrkr:CellReadyAgreementMember 2024-07-012024-09-30 0001094038 mrkr:CellReadyAgreementMember 2024-01-012024-09-30 0001094038 mrkr:NationalInstitutesOfHealthSmallBusinessInnovationResearchMember 2024-08-012024-08-31 0001094038 mrkr:NationalInstitutesOfHealthSmallBusinessInnovationResearchMember 2023-05-012023-05-31 0001094038 mrkr:FdaGrantMember 2022-09-012022-09-30 0001094038 mrkr:NationalInstitutesOfHealthNationalCancerInstituteGrantMember 2024-06-012024-06-30 0001094038 mrkr:NationalInstitutesOfHealthSmallBusinessInnovationResearchForLymphomaGrantMemberus-gaap:SubsequentEventMember 2024-10-012024-10-31 0001094038 mrkr:FdaGrantMemberus-gaap:SubsequentEventMember 2024-10-012024-10-31 0001094038 us-gaap:GrantMember 2024-01-012024-09-30 0001094038 mrkr:NationalInstitutesOfHealthSmallBusinessInnovationResearchMember 2024-01-012024-09-30 0001094038 mrkr:NationalInstitutesOfHealthSmallBusinessInnovationResearchForLymphomaGrantMember 2024-01-012024-09-30 0001094038 mrkr:FdaGrantMember 2024-01-012024-09-30 0001094038 mrkr:NationalInstitutesOfHealthSmallBusinessInnovationResearchMemberus-gaap:SubsequentEventMember 2024-10-012024-10-31 0001094038 mrkr:CantorFitzgeraldCo.AndRbcCapitalMarketsLlcMembermrkr:ControlledEquityOfferingSalesAgreementMember 2021-08-012021-08-31 0001094038 mrkr:LincolnParkMembermrkr:StockPurchaseAgreementMember 2023-01-012023-01-31 0001094038 mrkr:RelatedPartyServiceMembermrkr:WilsonWolfManufacturingCorporationMembermrkr:BindingServicesAgreementMember 2022-04-012022-04-30 0001094038 mrkr:RelatedPartyServiceMembermrkr:WilsonWolfManufacturingCorporationMembermrkr:BindingServicesAgreementMember 2023-03-012023-03-31 0001094038 mrkr:RelatedPartyServiceMembermrkr:WilsonWolfManufacturingCorporationMembermrkr:BindingServicesAgreementMember 2023-05-012023-05-31 0001094038 2024-09-30 0001094038 2023-12-31 0001094038 2024-07-012024-09-30 0001094038 2024-11-07 0001094038 2024-01-012024-09-30 shares iso4217:USD pure mrkr:employee iso4217:USD shareshttp://fasb.org/us-gaap/2024#RelatedPartyMember0001094038--12-31Q3DEhttp://fasb.org/us-gaap/2024#RelatedPartyMember 58501false10-Qtrue2024-09-302024false001-37939MARKER THERAPEUTICS, INC.45-4479412450 Holcombe Blvd, Suite BCM-A, MS: BCM251HoustonTX77021713400-6400Common Stock, par value $0.001 per shareMRKRNASDAQYesYesNon-accelerated Filertruefalsefalse8923490899966415111450116627498812674441010278151091034817127391109103481712739125573351745193903438132963,443179554-4362858637449575140525431091034817127391192602025760643393172254601192602025760643393172254601347121620449808381661779942399873-3200046-7256955-1164358791681218085363264337819-2308192-2981961-6893691-11305768-2922406879442658720202308192-2981961-6893691-5433748-0.26-0.26-0.34-0.34-0.77-0.77-1.29-1.290.670.66-0.26-0.26-0.34-0.34-0.77-0.77-0.62-0.628923170882588189144878782340892317088258818914487883451289226958922450565204-4408713629702764795117001701533025330 2-2308192-2308192892349089234506202064431795547449575889142088914503295154362858631405254381788368943690223892245847758501195320195320-6893691-6893691892349089234506202064431795547449575879917387994495267894305008361903475224774248458084604650736539460239466717504117504 1-2981961-2981961888902088884501810124334827971670710384057718406447641680-4280490491960103727783427710143631014640180410180-1802511825853178534214398321439832-5433748-5433748-113888902088884501810124334827971670710 3-6893691-543374858720206893691-1130576819532071489917814880116-283405-2318691-426217367915812142-159567107530-6207189-8036416-6035961-6207189-1407237718664122186641223690210146405850185342954031099982-611178656917271511145011782172899966417473899 NOTE 1: NATURE OF OPERATIONS Marker Therapeutics, Inc., a Delaware corporation (the "Company" or "we"), is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. The Company's multi tumor associated antigen (multiTAA")-specific T cell technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens, which are tumor targets, and kill tumor cells expressing those targets. These T cells are designed to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. The Company was incorporated in Nevada in 1992 and reincorporated in Delaware in October 2018. Purchase Agreement with Cell Ready On June 26, 2023, the Company completed the previously announced transaction with Cell Ready, LLC ("Cell Ready") pursuant to a Purchase Agreement (the "Cell Ready Purchase Agreement), dated May 1, 2023, by and between the Company and Cell Ready. Mr. John Wilson is a member of the Company's board of directors and is serving as the CEO of Cell Ready, therefore Cell Ready is a related party. Pursuant to the Cell Ready Purchase Agreement, effective as of the Closing Date, the Company (i) assigned to Cell Ready the leases for the Company's two manufacturing facilities in Houston, Texas (the "Manufacturing Facilities"), (ii) sold to Cell Ready all of the equipment and leasehold improvements at the Manufacturing Facilities and (iii) assigned to Cell Ready its rights, title and interest in the Company's Master Services Agreement for Product Supply (the "MSA"), dated April 7, 2023, by and between the Company, Cell Ready and Indapta Therapeutics, Inc., as well as its rights, title and interest in any contracts related to the equipment and Manufacturing Facilities (collectively, the "Purchased Assets"). Cell Ready acquired the Purchased Assets for total consideration of $19.0 million. In connection with the purchase of the Manufacturing Facilities, Cell Ready also extended offers of employment to approximately 50 of the Company's former employees in its manufacturing, development, quality, and regulatory affairs functions. The Purchased Assets constituted a significant disposition. Based upon the magnitude of the disposition and because the Company is exiting certain manufacturing operations, the disposition represents a significant strategic shift that will have a material effect on the Company's operations and financial results. Accordingly, the assets sold meet the definition of a discontinued operation, as defined by Accounting Standards Codification ("ASC") 205-20 – Discontinued Operations, and prior comparative periods have been retroactively adjusted to reflect the current presentation. See additional discussion at Note 7. On February 22, 2024, we entered into a Master Services Agreement for Product Supply (the "MSA") with Cell Ready to provide outsourced services previously performed by the Company prior to its asset sale to Cell Ready. Cell Ready, which is owned by one of our directors and shareholders, Mr. John Wilson, is a contract development and manufacturing organization (CDMO). Under the MSA, it is anticipated Cell Ready will perform a wide variety of services for us, including research and development, and manufacturing in support of our clinical trials. Pursuant to the MSA, the Company may contract with Cell Ready for the provision of various products and services from time to time by entering into work orders with Cell Ready. If the services involve the supply of product, Cell Ready is required to supply such product in conformance with the product requirements set forth in the applicable work order(s). Under the MSA, Cell Ready is to use only personnel with sufficient qualifications and experience to supply the services contemplated by the MSA, provide its personnel with adequate training and assume full responsibility for its personnel's compliance with the MSA. Further, Cell Ready is required to provide the Company with assistance and cooperation in order for the Company to obtain and maintain all necessary regulatory approvals, at the Company's expense. Organizational Changes In 2023, the Company implemented changes to its organizational structure due to the transaction with Cell Ready and to reduce operational costs. In connection with these changes, the Company reduced headcount, including the separation of its former Chief Executive Officer, Peter Hoang, in May 2023, and its former Chief Accounting Officer, Michael Loiacono, in June 2023. During the second quarter of 2023, the Company recorded $0.9 million of severance and termination-related costs. The payments of these

costs were completed in July of 2023. Effective May 1, 2023, the Company's board of directors appointed Dr. Juan Vera as the Company's President and Chief Executive Officer. Effective June 30, 2023, the board of directors appointed Eliot M. Lurier as the Company's Interim Chief Financial Officer, whereby Mr. Lurier provided consulting services to the Company pursuant to a consulting agreement between the Company and Danforth Advisors, LLC ("Danforth") and received no compensation directly from the Company. On November 17, 2023, the Company terminated the consulting agreement between the Company and Danforth, effective January 16, 2024. On November 17, 2023, Mr. Lurier ceased serving as the Company's Interim Chief Financial Officer and Dr. Vera was appointed as the Company's Principal Financial and Accounting Officer. Reverse Stock Split On January 26, 2023, the Company effected a one-for-ten (1-for-10) reverse stock split of its common stock (the "Reverse Stock Split") and a corresponding reduction in the total number of authorized shares of its common stock from 300,000,000 to 30,000,000. The Reverse Stock Split, which was approved by stockholders at an annual stockholder meeting on May 24, 2022, was consummated pursuant to a Certificate of Amendment filed with the Secretary of State of Delaware on January 26, 2023. The Reverse Stock Split was effective on January 26, 2023. All references to common stock, warrants to purchase common stock, options to purchase common stock, share data, per share data and related information contained in the consolidated financial statements have been retrospectively adjusted to reflect the effect of the Reverse Stock Split for all periods presented. 19000000.0509000001-for-1030000000030000000 NOTE 2: BASIS OF PRESENTATION The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with the accounting principles generally accepted in the United States of America ("U.S. GAAP") for interim financial information and pursuant to the instructions to Form 10-Q and Article 8 of Regulation S-X of the Securities and Exchange Commission ("SEC") and on the same basis as the Company prepares its annual audited consolidated financial statements. In the opinion of management, the accompanying unaudited condensed consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation of such interim results (see Note 7 for information on discontinued operations). The results for the unaudited condensed consolidated statement of operations are not necessarily indicative of results to be expected for the year ending December 31, 2024, or for any future interim period. The condensed consolidated balance sheet at December 31, 2023 has been derived from audited financial statements, however, it does not include all of the information and notes required by U.S. GAAP for complete financial statements. The accompanying condensed consolidated financial statements should be read in conjunction with the consolidated financial statements for the year ended December 31, 2023 and notes thereto included in the Company's annual report on Form 10-K filed on March 26, 2024. Certain amounts presented in prior periods have been reclassified to conform to the current period presentation. NOTE 3: LIQUIDITY AND FINANCIAL CONDITION As of September 30, 2024, the Company had cash and cash equivalents of approximately $9.0 million. The Company's activities since inception have consisted principally of acquiring product and technology rights, raising capital, and performing research and development. Successful completion of the Company's development programs and, ultimately, the attainment of profitable operations are dependent on future events, including, among other things, its ability to access potential markets; secure financing; successfully progress its product candidates through preclinical and clinical development; obtain regulatory approval of one or more of its product candidates; maintain and enforce intellectual property rights; develop a customer base; attract, retain and motivate qualified personnel; and develop strategic alliances and collaborations. From inception, the Company has been funded by a combination of equity, debt financings and grants. In August 2021, the Company entered into a Controlled Equity Offering^{SM} Sales Agreement (the "ATM Agreement") with Cantor Fitzgerald & Co. and RBC Capital Markets, LLC (the "Sales Agents"), pursuant to which the Company can offer and sell, from time to time at its sole discretion through the Sales Agents, shares of its common stock having an aggregate offering price of up to $75.0 million. Any shares of its common stock sold will be issued pursuant to the Company's shelf registration statement on Form S-3 (File No. 333-258687), which the SEC declared effective on August 19, 2021. However, our use of the shelf registration statement on Form S-3 will be limited for so long as we are subject to General Instruction I.B.6 of Form S-3, which limits the amounts that we may sell under the registration statement and in accordance with the ATM agreement. The Sales Agents are entitled to compensation under the Sales Agreement at a commission rate equal to 3.0% of the gross sales price per share sold under the ATM Agreement, and we have provided each of the Sales Agents with indemnification and contribution rights. During the nine months ended September 30, 2024, the Company sold 8,178 shares of its common stock under the ATM Agreement for proceeds of $0.04 million. On June 10, 2024, the Company provided notice of its termination of the ATM Agreement with Cantor Fitzgerald & Co. and RBC Capital Markets, LLC. The Company is not subject to any termination penalties related to the termination of the ATM Agreement. The Company is currently considering more effective ways to improve market access to its equity. In August 2021, the Company received notice of a Product Development Research award totaling approximately $13.1 million from the Cancer Prevention and Research Institute of Texas ("CPRIT") to support the Company's clinical investigation of MT-401. Through the date of this filing, the Company has received $9.7 million of funds from the CPRIT grant. The Company recorded $0.9 million and $2.4 million of grant income related to the CPRIT grant as revenue for the three and nine months ended September 30, 2024, respectively. As of September 30, 2024, the Company recorded $0.1 million of grant income receivable, which represented grant income earned in advance of funds to be received from CPRIT. In September 2022, the Company received notice from the U.S. Food and Drug Administration (the "FDA") that it had awarded the Company a $2.0 million grant from the FDA's Orphan Products Grant program to support the Company's clinical investigation of MT-401 for the treatment of post-transplant AML. Through the date of this filing, the Company has received $1.0 million from the FDA grant. The Company recorded $0.02 million and $0.5 million of grant income related to the FDA grant as revenue for the three and nine months ended September 30, 2024, respectively. As of September 30, 2024, the Company recorded $0.02 million of grant income receivable, which represented grant income earned in advance of funds to be received from the FDA. In October 2024, the Company received $0.02 million of funds from the FDA grant. In May 2023, the Company received notice of a $2.0 million grant from the National Institutes of Health Small Business Innovation Research ("SBIR") program to support the development and investigation of MT-401 for the treatment of AML patients following standard-of-care therapy with hypomethylating agents. Through the date of this filing, the Company has received $0.9 million from SBIR. The Company recorded $0.3 million and $0.7 million of grant income related to the SBIR grant as revenue for the three and nine months ended September 30, 2024. As of September 30, 2024, the Company recorded $0.3 million as other receivable, which represented grant income earned in advance of funds to be received from the SBIR. In October 2024, the Company received $0.3 million of funds from the SBIR grant. In June 2024, the Company received notice of a $2.0 million grant over a 2 - year period from the National Institutes of Health - National Cancer Institute to support control over tumor immune escape in pancreatic cancer using a dual T cell product strategy. Through the date of this filing, the Company has not received any funds from this grant. In August 2024, the Company received notice of a $2.0 million grant from the National Institutes of Health Small Business Innovation Research Program to support the clinical investigation of MT-601 in patients with non-Hodgkin's lymphoma (NHL) who have relapsed following anti-CD19 chimeric antigen receptor (CAR) T cell therapy. Through the date of this filing, the Company has received $0.7 million of funds from this grant. The Company recorded $0.7 million of grant income related to this grant as revenue for the three and nine months ended September 30, 2024. As of September 30, 2024, the Company recorded $0.3 million as other receivable, which represented grant income earned in advance of funds to be received from the SBIR. In October 2024, the Company received $0.3 million of funds from the SBIR lymphoma grant. In August 2024, the Company received another $2.0 million grant from the National Institutes of Health SBIR Program to support the advancement of MT-601 in patients with pancreatic cancer. Through the date of this filing, the Company has received an immaterial amount of funds from this grant. As described in Note 1, on June 26, 2023, the Company completed the transaction with Cell Ready pursuant to the Cell Ready Purchase Agreement for total consideration of $19.0 million. On February 22, 2024, the Company entered into a Master Services Agreement for Product Supply (the "MSA") with Cell Ready, a contract development and manufacturing organization (CDMO). Under the MSA, it is anticipated Cell Ready will perform a wide variety of services for us, including research and development, and manufacturing in support of our clinical trials. Pursuant to the MSA, the Company may contract with Cell Ready for the provision of various products and services from time to time by entering into work orders with Cell Ready (See Note 13). The Company expects to continue to incur substantial losses over the next several years during its development phase. Based on the Company's clinical and research and development plans and its timing expectations related to the progress of its programs, the Company anticipates that its cash and cash equivalents as of September 30, 2024, including drawdowns of available grant funds, will enable the Company to fund its operating expenses and capital expenditure requirements into October 2025. This estimate is subject to the Company's ability to effectively manage its costs, raise additional capital, and utilize drawdowns of anticipated grant funds. <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt

0pt;">The Company has based this estimate on assumptions that may prove to be wrong, and the Company could utilize its available capital resources sooner than it currently expects. Furthermore, the Company's operating plan may change, and it may need additional funds sooner than planned in order to meet operational needs and capital requirements for product development and commercialization. Because of the numerous risks and uncertainties associated with the development and commercialization of the Company's product candidates and the extent to which the Company may enter into additional collaborations with third parties to participate in their development and commercialization, the Company is unable to estimate the amounts of increased capital outlays and operating expenditures associated with its current and anticipated clinical trials. The Company's future funding requirements will depend on many factors, as it: <table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">Initiates, continues, or accelerates clinical trials of its product candidates;</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">continues the research and development of its product candidates and seeks to discover additional product candidates;</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">seeks regulatory approvals for any product candidates that successfully complete clinical trials;</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">maintains and enforces intellectual property rights;</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">enters into contract manufacturing arrangements with Cell Ready or other contract manufacturing organizations for clinical manufacturing supply;</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">establishes sales, marketing and distribution infrastructure and scale-up manufacturing capabilities to commercialize any product candidates that may receive regulatory approval; </td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">evaluates strategic transactions the Company may undertake; and</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">enhances operational, financial and information management systems and hires additional personnel, including personnel to support development of product candidates and, if a product candidate is approved, commercialization efforts. </td></tr></table> The Company does not have sufficient sources of revenue to provide incoming cash flows to sustain its future operations. As outlined above, the Company's ability to pursue its long-term planned business activities is dependent upon its successful efforts to raise additional capital and grant income. These factors raise substantial doubt regarding the Company's ability to continue as a going concern. The Company's condensed consolidated financial statements have been prepared on a going concern basis, which implies that the Company will continue to realize its assets and discharge its liabilities in the normal course of business. The Company's financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. In addition to the foregoing, the current macro-economic environment of decades-high inflation and concerns about an economic recession in the United States or other major markets have resulted in, among other things, volatility in the capital markets that may have the effect of reducing the Company's ability to access capital, which could in the future negatively affect the Company's liquidity. In addition, a recession or market correction due to these factors could materially affect the Company's business and the value of its common stock.
9000000.075000000.00.030817840000.00131000009700000900000240000010000020000000.01000000.020000.0050000020000.0020000.00200(style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE 4: SIGNIFICANT ACCOUNTING POLICIES Principles of Consolidation These consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Marker Cell Therapy, Inc. and GeneMax Pharmaceuticals Inc. – a dormant subsidiary that wholly owns GeneMax Pharmaceuticals Canada, Inc. All significant intercompany balances and transactions are eliminated upon consolidation. Use of Estimates Preparation of the Company's consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Accordingly, actual results may differ materially from those estimates. Management considers many factors in selecting appropriate financial accounting policies, controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes, and management must select an amount that falls within that range of reasonable estimates. Estimates are used in the following areas, among others: stock-based compensation expense and income taxes. Cash, Cash Equivalents and Credit Risk The Company considers highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. Cash and cash equivalents at September 30, 2024 consisted of cash and certificates of deposit in institutions in the United States. Balances at certain institutions have exceeded Federal Deposit Insurance Corporation insured limits and U.S. government agency securities. The Company maintains cash in accounts which are in excess of the Federal Deposit Insurance Corporation ("FDIC") insured limits of $250,000. As of September 30, 2024, the Company had approximately $4.1 million in cash at financial institutions and approximately $4.9 million in U.S. government agency securities, for aggregate cash and cash equivalents of $9.0 million. As of December 31, 2023, the Company had approximately $1.4 million in cash at financial institutions and approximately $13.7 million in U.S. government agency securities, for aggregate cash and cash equivalents of $15.1 million. In the event cash is received from grants in advance of incurring qualifying costs, it is recorded as restricted cash until it is earned and recorded to grant income. Discontinued Operations The Purchased Assets sold to Cell Ready pursuant to the Cell Ready Purchase Agreement constituted a significant disposition and as such, the Company concluded that the disposition of its Purchased Assets represented a strategic shift that had a major effect on its operations and financial results. Therefore, the Purchased Assets, related party revenue, service revenue and related expenses are classified as discontinued operations for all periods presented herein. See Note 7 for further information. Recently Issued Accounting Standards Not Yet Adopted Improvements to Reportable Segment Disclosures In November 2023, the Financial Accounting Standards Board (the "FASB") issued Accounting Standards

Update (“ASU”) No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. The ASU requires disclosures to include significant segment expenses that are regularly provided to the chief operating decision maker, among other provisions. Public entities with a single reportable segment, such as the Company, are required to provide the new disclosures and all the disclosures required under ASC 280. The ASU is effective for fiscal year periods beginning after December15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted, and the ASU requires retrospective application to all prior periods presented in the financial statements. The Company is currently evaluating the standard to determine the impact of adoption to its consolidated financial statements and disclosures. Improvements to Income Tax Disclosures In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (ASU 2023-09), which improves the transparency of income tax disclosures by requiring consistent categories and greater disaggregation of information in the effective tax rate reconciliation and income taxes paid disaggregated by jurisdiction. It also includes certain other amendments to improve the effectiveness of income tax disclosures. This guidance will be effective for the annual periods beginning the year ended December 31, 2025. Early adoption is permitted. Upon adoption the guidance can be applied prospectively or retrospectively. We do not expect the adoption of this guidance to have a material impact on the Company’s consolidated financial statements. From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) or other standard setting bodies that the Company adopts as of the specified effective date. Unless otherwise discussed, the Company does not believe that the impact of recently issued standards that are not yet effective will have a material impact on its consolidated financial position or results of operations upon adoption. There have been no material changes in the Company’s significant accounting policies to those previously disclosed in the Annual Report on Form 10-K for the year ended December 31, 2023 filed on March 26, 2024. Principles of Consolidation These consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Marker Cell Therapy, Inc. and GeneMax Pharmaceuticals Inc. – a dormant subsidiary that wholly owns GeneMax Pharmaceuticals Canada, Inc. All significant intercompany balances and transactions are eliminated upon consolidation. Use of Estimates Preparation of the Company’s consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Accordingly, actual results may differ materially from those estimates. Management considers many factors in selecting appropriate financial accounting policies, controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes, and management must select an amount that falls within that range of reasonable estimates. Estimates are used in the following areas, among others: stock-based compensation expense and income taxes. Cash, Cash Equivalents and Credit Risk The Company considers highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. Cash and cash equivalents at September 30, 2024 consisted of cash and certificates of deposit in institutions in the United States. Balances at certain institutions have exceeded Federal Deposit Insurance Corporation insured limits and U.S. government agency securities. The Company maintains cash in accounts which are in excess of the Federal Deposit Insurance Corporation (“FDIC”) insured limits of $250,000. As of September 30, 2024, the Company had approximately $4.1 million in cash at financial institutions and approximately $4.9 million in U.S. government agency securities, for aggregate cash and cash equivalents of $9.0 million. As of December 31, 2023, the Company had approximately $1.4 million in cash at financial institutions and approximately $13.7 million in U.S. government agency securities, for aggregate cash and cash equivalents of $15.1 million. In the event cash is received from grants in advance of incurring qualifying costs, it is recorded as restricted cash until it is earned and recorded to grant income.
41000004900000900000.01400000137000001510000 Discontinued Operations The Purchased Assets sold to Cell Ready pursuant to the Cell Ready Purchase Agreement constituted a significant disposition and as such, the Company concluded that the disposition of its Purchased Assets represented a strategic shift that had a major effect on its operations and financial results. Therefore, the Purchased Assets, related party revenue, service revenue and related expenses are classified as discontinued operations for all periods presented herein. See Note 7 for further information.
Recently Issued Accounting Standards Not Yet Adopted Improvements to Reportable Segment Disclosures In November 2023, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. The ASU requires disclosures to include significant segment expenses that are regularly provided to the chief operating decision maker, among other provisions. Public entities with a single reportable segment, such as the Company, are required to provide the new disclosures and all the disclosures required under ASC 280. The ASU is effective for fiscal year periods beginning after December15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted, and the ASU requires retrospective application to all prior periods presented in the financial statements. The Company is currently evaluating the standard to determine the impact of adoption to its consolidated financial statements and disclosures. Improvements to Income Tax Disclosures In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (ASU 2023-09), which improves the transparency of income tax disclosures by requiring consistent categories and greater disaggregation of information in the effective tax rate reconciliation and income taxes paid disaggregated by jurisdiction. It also includes certain other amendments to improve the effectiveness of income tax disclosures. This guidance will be effective for the annual periods beginning the year ended December 31, 2025. Early adoption is permitted. Upon adoption the guidance can be applied prospectively or retrospectively. We do not expect the adoption of this guidance to have a material impact on the Company’s consolidated financial statements. From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) or other standard setting bodies that the Company adopts as of the specified effective date. Unless otherwise discussed, the Company does not believe that the impact of recently issued standards that are not yet effective will have a material impact on its consolidated financial position or results of operations upon adoption. There have been no material changes in the Company’s significant accounting policies to those previously disclosed in the Annual Report on Form 10-K for the year ended December 31, 2023 filed on March 26, 2024. NOTE 5: NET LOSS PER SHARE Basic loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the reporting period. Diluted loss per common share is computed similarly to basic loss per common share except that it reflects the potential dilution that could occur if dilutive securities or other obligations to issue common stock were exercised or converted into common stock. The following table sets forth the computation of net loss per share for the three and nine months ended September 30, 2024 and 2023, respectively: <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:52.62%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-

align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:52.62%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.55%;margin:0pt;padding:0pt;"> For the Three Months Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.48%;margin:0pt;padding:0pt;"> For the Nine Months Ended </td></tr><tr><td style="vertical-align:bottom;width:52.62%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td></tr><tr><td style="vertical-align:bottom;width:52.62%;margin:0pt;padding:0pt;"> </td><td> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:52.62%;background:#cceeff;margin:0pt;padding:0pt;"> Numerator: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:52.62%;margin:0pt;padding:0pt;"> Loss from continuing operations </td><td style="vertical-align:bottom;white-

space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', 'Times', 'serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,308,192)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', 'Times', 'serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', 'Times', 'serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"> (2,981,961) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', 'Times', 'serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (6,893,691)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', 'Times', 'serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', 'Times', 'serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"> (11,305,768) </td></tr><tr><td style="vertical-align:bottom;width:52.62%;background:#cceeff;margin:0pt;padding:0pt;"> Income from discontinued operations </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', 'Times', 'serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', 'Times', 'serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', 'Times', 'serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', 'Times', 'serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', 'Times', 'serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', 'Times', 'serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 5,872,020 </td></tr><tr><td style="vertical-align:bottom;width:52.62%;margin:0pt;padding:0pt;"> Net loss </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', 'Times', 'serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,308,192)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', 'Times', 'serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', 'Times', 'serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (2,981,961) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', 'Times', 'serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (6,893,691)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', 'Times', 'serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', 'Times', 'serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (5,433,748) </td></tr><tr><td style="vertical-align:bottom;width:52.62%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', 'Times', 'serif';font-

size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:52.62%;margin:0pt;padding:0pt;"> Denominator: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:52.62%;background:#cceeff;margin:0pt;padding:0pt;"> Weighted average common shares outstanding, basic </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 8,923,170 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 8,825,881 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 8,914,487 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 8,782,340 </td></tr><tr><td style="vertical-align:bottom;width:52.62%;margin:0pt;padding:0pt;"> Weighted average common shares outstanding, diluted </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"> 8,923,170 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"> 8,825,881 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"> 8,914,487 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"> 8,834,512 </td></tr><tr><td style="vertical-align:bottom;width:52.62%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:52.62%;margin:0pt;padding:0pt;"> Net earnings (loss) per share: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:52.62%;background:#cceeff;margin:0pt;padding:0pt;"> Loss from continuing operations, basic and diluted </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.26)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (0.34) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.77)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (1.29) </td></tr><tr><td style="vertical-align:bottom;width:52.62%;margin:0pt;padding:0pt;"> Income from discontinued operations, basic </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 0.67 </td></tr><tr><td style="vertical-align:bottom;width:52.62%;background:#cceeff;margin:0pt;padding:0pt;"> Income from discontinued operations, diluted </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.66</p></td></tr><tr><td style="vertical-align:bottom;width:52.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Net loss per share, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (0.26) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.34)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (0.77) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (0.62) </td></tr></table> The following securities, rounded to the nearest thousand, were not included in the diluted net loss per share calculation because their effect was anti-dilutive for the periods presented: <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:52.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:52.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:1.74%;margin:0pt;padding:0pt;"> </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.75%;margin:0pt;padding:0pt;"> For the Three Months Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.25%;margin:0pt;padding:0pt;"> For the Nine Months Ended </td></tr><tr><td style="vertical-align:bottom;width:52.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:1.74%;margin:0pt;padding:0pt;"> </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td></tr><tr><td style="vertical-align:bottom;width:52.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New

Roman', 'Times', 'serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:52.49%;background:#cceeff;margin:0pt;padding:0pt;"> Common stock options </td><td style="vertical-align:bottom;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"> 596,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;background:#cceeff;margin:0pt;padding:0pt;"> 800,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.89%;background:#cceeff;margin:0pt;padding:0pt;"> 596,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"> 748,000 </td></tr><tr><td style="vertical-align:bottom;width:52.49%;margin:0pt;padding:0pt;"> Common stock purchase warrants </td><td style="vertical-align:bottom;width:1.74%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,848,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,848,000 </td></tr><tr><td style="vertical-align:bottom;width:52.49%;background:#cceeff;margin:0pt;padding:0pt;"> Potentially dilutive securities </td><td style="vertical-align:bottom;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 596,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 2,648,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 596,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 2,596,000 </td></tr></table> . . <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:52.62%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div

style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:52.62%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.55%;margin:0pt;padding:0pt;"> For the Three Months Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.48%;margin:0pt;padding:0pt;"> For the Nine Months Ended </td></tr><tr><td style="vertical-align:bottom;width:52.62%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> . </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td></tr><tr><td style="vertical-align:bottom;width:52.62%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:52.62%;background:#cceeff;margin:0pt;padding:0pt;"> Numerator: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:52.62%;margin:0pt;padding:0pt;"> Loss from continuing operations </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,308,192)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"> (2,981,961) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (6,893,691)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"> (11,305,768) </td></tr><tr><td style="vertical-align:bottom;width:52.62%;background:#cceeff;margin:0pt;padding:0pt;"> Income from discontinued operations </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 5,872,020 </td></tr><tr><td style="vertical-align:bottom;width:52.62%;margin:0pt;padding:0pt;"> Net loss </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">(2,308,192)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (2,981,961) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">(6,893,691)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (5,433,748) </td></tr><tr><td style="vertical-align:bottom;width:52.62%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"> - </td></tr><tr><td style="vertical-align:bottom;width:52.62%;margin:0pt;padding:0pt;"> Denominator: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"> - </td></tr><tr><td style="vertical-align:bottom;width:52.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-

size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Weighted average common shares outstanding, basic </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 8,923,170 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 8,825,881 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 8,914,487 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 8,782,340 </td></tr><tr><td style="vertical-align:bottom;width:52.62%;margin:0pt;padding:0pt;"> Weighted average common shares outstanding, diluted </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"> 8,923,170 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"> 8,825,881 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"> 8,914,487 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"> 8,834,512 </td></tr><tr><td style="vertical-align:bottom;width:52.62%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:52.62%;margin:0pt;padding:0pt;"> Net earnings (loss) per share: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-

align:bottom;width:52.62%;background:#cceeff;margin:0pt;padding:0pt;"> Loss from continuing operations, basic and diluted </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.26)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (0.34) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.77)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (1.29) </td></tr><tr><td style="vertical-align:bottom;width:52.62%;margin:0pt;padding:0pt;"> Income from discontinued operations, basic </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 0.67 </td></tr><tr><td style="vertical-align:bottom;width:52.62%;background:#cceeff;margin:0pt;padding:0pt;"> Income from discontinued operations, diluted </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 0.66 </td></tr><tr><td style="vertical-align:bottom;width:52.62%;margin:0pt;padding:0pt;"> Net loss per share, basic and diluted </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.26)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (0.34) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (0.77) </td><td style="vertical-align:bottom;white-

space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (0.62) </td></tr></table> -2308192-2981961-6893691-113057685872020-2308192-2981961-6893691-5433748892317088258818914487878234089231708825881891448788345120.26-0.26-0.34-0.34-0.77-0.77-1.290.670.66-0.26-0.26-0.34-0.34-0.77-0.77-0.62 <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:52.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:52.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:1.74%;margin:0pt;padding:0pt;"> </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.75%;margin:0pt;padding:0pt;"> For the Three Months Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.25%;margin:0pt;padding:0pt;"> For the Nine Months Ended </td></tr><tr><td style="vertical-align:bottom;width:52.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:1.74%;margin:0pt;padding:0pt;"> </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td></tr><tr><td style="vertical-align:bottom;width:52.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:52.49%;background:#cceeff;margin:0pt;padding:0pt;"> Common stock options </td><td style="vertical-align:bottom;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"> 596,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;background:#cceeff;margin:0pt;padding:0pt;"> 800,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.89%;background:#cceeff;margin:0pt;padding:0pt;"> 596,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"> 748,000 </td></tr><tr><td style="vertical-align:bottom;width:52.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-

align:justify;margin:0pt 0pt 0.05pt 0pt;">Common stock purchase warrants </td><td style="vertical-align:bottom;width:1.74%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,848,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,848,000 </td></tr><tr><td style="vertical-align:bottom;width:52.49%;background:#cceeff;margin:0pt;padding:0pt;"> Potentially dilutive securities </td><td style="vertical-align:bottom;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 596,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 2,648,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 596,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 2,596,000 </td></tr></table> 596000800000596007480001848000184800059600026480005960002596000 NOTE 6: OTHER RECEIVABLE Qualifying grant income earned in advance of cash received from grants is recognized as revenue and recorded as other receivable. The Company recorded $0.9 million and $2.4 million of grant income related to the CPRIT grant for the three and nine months ended September 30, 2024, respectively. At September 30, 2024, the Company recorded $0.1 million of grant income receivable related to the CPRIT grant. Additionally, the Company recorded $0.02 million and $1.0 million of grant income related to the FDA and SBIR grants, respectively, for the three months ended September 30, 2024. The Company recorded $0.5 million and $1.4 million of grant income related to the FDA and SBIR grants, respectively, for the nine months ended September 30, 2024. At September 30, 2024, the Company recorded $0.02 million and $0.6 million of grant income receivable related to the FDA and SBIR grants, respectively. In October 2024, the Company received payments of $0.02 million and $0.6 million from the FDA grant and all SBIR grants, respectively. 900000240000010000020000.001000000.050000014000002000 0.00600000020000.00600000 NOTE 7: DISCONTINUED OPERATIONS As discussed in Note 1, on June 26, 2023, the Company completed the previously announced transaction with Cell Ready for cash consideration of $19.0 million, resulting in derecognition of the Purchased Assets and a gain on sale of approximately $8.7 million, net of $63,000 in tax. There were no remaining assets and liabilities classified in discontinued operations as of September 30, 2024 or December 31, 2023. The Company had no activity related to discontinued operations for the three and nine months ended September 30, 2024. Net loss from discontinued operations for the three and nine months ended September 30, 2023, was as follows: . <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.81%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:15.82%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:15.26%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:61.81%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.54%;margin:0pt;padding:0pt;"> For the Three Months </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.93%;margin:0pt;padding:0pt;"> For the Nine Months </td></tr><tr><td style="vertical-align:bottom;width:61.81%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.54%;margin:0pt;padding:0pt;"> Ended September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', 'Times', 'serif';font-size:8pt;text-

align:center;margin:0pt 0pt 0.05pt 0pt;">Ended September 30, </td></tr><tr><td style="vertical-align:bottom;width:61.81%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:61.81%;background:#cceeff;margin:0pt;padding:0pt;"> Revenues: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.82%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.26%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:61.81%;margin:0pt;padding:0pt;"> Service Revenue </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:15.26%;margin:0pt;padding:0pt;"> 816,641 </td></tr><tr><td style="vertical-align:bottom;width:61.81%;background:#cceeff;margin:0pt;padding:0pt;"> Related party service revenue </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 3,500,000 </td></tr><tr><td style="vertical-align:bottom;width:61.81%;margin:0pt;padding:0pt;"> Total revenues </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.82%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.26%;margin:0pt;padding:0pt;"> 4,316,641 </td></tr><tr><td style="vertical-align:bottom;width:61.81%;background:#cceeff;margin:0pt;padding:0pt;"> Operating expenses: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.82%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.26%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:61.81%;margin:0pt;padding:0pt;"> Research and development </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.82%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.26%;margin:0pt;padding:0pt;"> 6,561,957 </td></tr><tr><td style="vertical-align:bottom;width:61.81%;background:#cceeff;margin:0pt;padding:0pt;"> General and administrative </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td

style="vertical-align:bottom;white-space:nowrap;width:15.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 677,090 </td></tr><tr><td style="vertical-align:bottom;width:61.81%;margin:0pt;padding:0pt;"> Total operating expenses </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 7,239,048 </td></tr><tr><td style="vertical-align:bottom;width:61.81%;background:#cceeff;margin:0pt;padding:0pt;"> Loss from discontinued operations </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', 'Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', 'Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', 'Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:15.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (2,922,406) </td></tr></table> The following table summarizes our cash flows related to discontinued operations for the nine months ended September 30, 2023: <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:80.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.26%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:80.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.93%;margin:0pt;padding:0pt;"> For the Nine Months </td></tr><tr><td style="vertical-align:bottom;width:80.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.93%;margin:0pt;padding:0pt;"> Ended September 30, </td></tr><tr><td style="vertical-align:bottom;width:80.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:80.74%;background:#cceeff;margin:0pt;padding:0pt;"> Discontinued operations: </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.26%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:80.74%;margin:0pt;padding:0pt;"> Net cash used in operating activities </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.26%;margin:0pt;padding:0pt;"> (6,036,000) </td></tr><tr><td style="vertical-align:bottom;width:80.74%;background:#cceeff;margin:0pt;padding:0pt;"> Net cash provided by investing activities </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 18,664,000 </td></tr><tr><td style="vertical-align:bottom;width:80.74%;margin:0pt;padding:0pt;"> Net increase (decrease) in cash and cash equivalents </td><td style="vertical-align:bottom;white-

space:nowrap;width:2.32%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:15.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 12,628,000 </td></tr></table>) Related Party Service Revenue In April 2022, the Company entered into a binding services agreement (“Wilson Wolf Agreement”) with Wilson Wolf Manufacturing Corporation (“Wilson Wolf”). Mr. John Wilson is a member of the Company’s board of directors and is serving as the CEO of Wilson Wolf. Wilson Wolf is in the business of creating products and services intended to simplify and expedite the transition of cell therapies and gene-modified cell therapies to mainstream society (the “Wilson Wolf Mission”). Pursuant to the Wilson Wolf Agreement, Wilson Wolf made a cash payment to the Company in the amount of $8.0 million, as consideration for certain training and research services. In March 2023, the Company recognized the final $2.5 million of revenue pursuant to this $8.0 million agreement and an additional $1.0 million because certain agreed milestones were met. Payment of the additional $1.0 million was received in May 2023.
19000000.08700000630003000) <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.81%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:15.82%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:15.26%;margin:0pt;padding:0pt;">) </td></tr><tr><td style="vertical-align:bottom;width:61.81%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.54%;margin:0pt;padding:0pt;"> For the Three Months </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.93%;margin:0pt;padding:0pt;"> For the Nine Months </td></tr><tr><td style="vertical-align:bottom;width:61.81%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;">) </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.54%;margin:0pt;padding:0pt;"> Ended September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;">) </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.93%;margin:0pt;padding:0pt;"> Ended September 30, </td></tr><tr><td style="vertical-align:bottom;width:61.81%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;">) </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;">) </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:61.81%;background:#cceeff;margin:0pt;padding:0pt;"> Revenues: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:15.82%;background:#cceeff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:15.26%;background:#cceeff;margin:0pt;padding:0pt;">) </td></tr><tr><td style="vertical-align:bottom;width:61.81%;margin:0pt;padding:0pt;"> Service Revenue </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-

align:bottom;white-space:nowrap;width:15.26%;margin:0pt;padding:0pt;"> 816,641 </td></tr><tr><td style="vertical-align:bottom;width:61.81%;background:#cceeff;margin:0pt;padding:0pt;"> Related party service revenue </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:15.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:15.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 3,500,000 </td></tr><tr><td style="vertical-align:bottom;width:61.81%;margin:0pt;padding:0pt;"> Total revenues </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.82%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.26%;margin:0pt;padding:0pt;"> 4,316,641 </td></tr><tr><td style="vertical-align:bottom;width:61.81%;background:#cceeff;margin:0pt;padding:0pt;"> Operating expenses: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.82%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.26%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:61.81%;margin:0pt;padding:0pt;"> Research and development </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.82%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.26%;margin:0pt;padding:0pt;"> 6,561,957 </td></tr><tr><td style="vertical-align:bottom;width:61.81%;background:#cceeff;margin:0pt;padding:0pt;"> General and administrative </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:15.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:15.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 677,090 </td></tr><tr><td style="vertical-align:bottom;width:61.81%;margin:0pt;padding:0pt;"> Total operating expenses </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:15.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:15.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 7,239,048 </td></tr><tr><td style="vertical-align:bottom;width:61.81%;background:#cceeff;margin:0pt;padding:0pt;"> Loss from discontinued operations </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:15.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (2,922,406) </td></tr></table> <span

style="margin-bottom:12pt;visibility:hidden;"> <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:80.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.26%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:80.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.93%;margin:0pt;padding:0pt;"> For the Nine Months </td></tr><tr><td style="vertical-align:bottom;width:80.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.93%;margin:0pt;padding:0pt;"> Ended September 30, </td></tr><tr><td style="vertical-align:bottom;width:80.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:80.74%;background:#cceeff;margin:0pt;padding:0pt;"> Discontinued operations: </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.26%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:80.74%;margin:0pt;padding:0pt;"> Net cash used in operating activities </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.26%;margin:0pt;padding:0pt;"> (6,036,000) </td></tr><tr><td style="vertical-align:bottom;width:80.74%;background:#cceeff;margin:0pt;padding:0pt;"> Net cash provided by investing activities </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 18,664,000 </td></tr><tr><td style="vertical-align:bottom;width:80.74%;margin:0pt;padding:0pt;"> Net increase (decrease) in cash and cash equivalents </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:15.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 12,628,000 </td></tr></table>816641350000043166416561957677090723904 8-2922406-6036000186640001262800080000000.025000008000000.01000000.01000000.0 NOTE 8: ACCOUNTS PAYABLE, ACCRUED LIABILITIES AND RELATED PARTY PAYABLE Accounts payable, accrued liabilities, and related party payable consist of the following as of September 30, 2024 and December 31, 2023, respectively: <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-

align:center;margin:0pt 0pt 0.05pt 0pt;">September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"> December 31, </td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"> Accounts payable </td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,904,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"> 961,000 </td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"> Compensation and benefits </td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"> 39,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"> 57,000 </td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"> Professional fees </td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"> 359,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"> 303,000 </td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"> Related party payable </td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"> 903,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"> 1,330,000 </td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"> Tax fees </td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"> 52,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"> 219,000 </td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"> Other </td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 204,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 205,000 </td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-

size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Total accounts payable, accrued liabilities and related party payable </td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,461,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 3,075,000 </td></tr></table> The $0.9 million and $1.3 million related-party payable as of September 30, 2024 and December 31, 2023, respectively, primarily reflects amounts payable to Cell Ready for outsourced product development and manufacturing services. See Note 13: Related Party Transactions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September 30, </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, </p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"> 1,904,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"> 961,000 </td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"> Compensation and benefits </td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"> 39,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"> 57,000 </td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"> Professional fees </td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"> 359,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-

size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"> 303,000 </td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"> Related party payable </td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"> 903,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"> 1,330,000 </td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"> Tax fees </td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"> 52,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"> 219,000 </td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"> Other </td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 204,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 205,000 </td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"> Total accounts payable, accrued liabilities and related party payable </td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,461,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 3,075,000 </td></tr></table>1904000961000390005700035900030300090300013300005200021900020400020500034610003075000900000130000 NOTE 9: STOCKHOLDERS’ EQUITY Reverse Stock Split On January 26, 2023, the Company effected the Reverse Stock Split and a corresponding reduction in the total number of authorized shares of its common stock from 300,000,000 to 30,000,000. The Reverse Stock Split, which was approved by stockholders at an annual stockholder meeting on May 24, 2022, was consummated pursuant to a Certificate of Amendment filed with the Secretary of State of Delaware on January 26, 2023. The Reverse Stock Split was effective on January 26, 2023. All historical share and per share amounts reflected in this report have been adjusted to reflect the Reverse Stock Split. Common Stock Transactions Issuance of Stock Pursuant to ATM Agreement During the nine months ended September 30, 2024, the Company sold 8,178 shares of its common stock under the ATM Agreement for gross proceeds of $37,000. During the nine months ended September 30, 2023, the Company sold 265,334 shares of its common stock under the ATM Agreement for gross proceeds of $1.0 million. On June 10, 2024, the Company provided notice of its termination of the ATM Agreement with Cantor Fitzgerald & Co. and RBC Capital Markets, LLC. The Company is currently considering more effective ways to improve market access to its equity. Stock Purchase Agreement In December 2022, the Company entered into a purchase agreement (the “Purchase Agreement”) with Lincoln Park which provides that, upon the terms and subject to the conditions of the agreement, the Company had the right, but not the obligation, to sell to Lincoln Park up to $25,000,000 of shares of its common stock (the “Purchase Shares”) from time to time over a 24-month term, at a variable price with certain market-based terms as defined in the Purchase Agreement. The Purchase Agreement does not exhibit any of the characteristics for liability classification under ASC Topic 480, Distinguishing Liabilities from Equity. Instead, the purchase agreement was indexed to the Company’s own stock under ASC Subtopic 815-40, Contracts in Entity’s Own Equity, and classified as equity. In January 2023, Lincoln Park was issued 180,410 shares of stock as a commitment fee at a value of $0.5 million. During the nine months ended September 30, 2023, the Company sold 12,500 shares of its common stock under the Purchase Agreement for gross proceeds of approximately $33,000. The Company terminated the Purchase Agreement with Lincoln Park on February 29, 2024, effective March 1, 2024. Exercise of Stock Options During the nine months ended September 30, 2024, certain outstanding options were exercised for 23,892 shares of common stock, providing aggregate proceeds to the Company of approximately $59,000. 3000000003000000081783700026533410000000.025000000P24M1804105000001250033000238923 NOTE 10: STOCK-BASED COMPENSATION Stock Options 2024 Equity Incentive Awards There were no equity incentive awards issued

during the three and nine months ended September 30, 2024. A summary of the Company's stock option activity for the nine months ended September 30, 2024 is as follows: <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:44.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:44.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"> Weighted Average </td></tr><tr><td style="vertical-align:bottom;width:44.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"> Remaining </td></tr><tr><td style="vertical-align:bottom;width:44.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"> Weighted Average </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"><p

style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"> Contractual </td></tr><tr><td style="vertical-align:bottom;width:44.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Number of Shares </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Exercise Price </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Total Intrinsic Value </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Life (in years) </td></tr><tr><td style="vertical-align:bottom;width:44.02%;background:#cceeff;margin:0pt;padding:0pt;"> Outstanding as of January 1, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#cceeff;margin:0pt;padding:0pt;"> 737,895 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 25.42</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"> 1,317,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;background:#cceeff;margin:0pt;padding:0pt;"> 7.6 </td></tr><tr><td style="vertical-align:bottom;width:44.02%;margin:0pt;padding:0pt;"> Exercised </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"> (23,892) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"> 2.45 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:44.02%;background:#cceeff;margin:0pt;padding:0pt;"> Canceled/Expired </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (117,670) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 43.37 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:44.02%;margin:0pt;padding:0pt;"> Outstanding as of September 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 596,333 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-

space:nowrap;width:10.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 22.80 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 291,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7.1</p></td></tr><tr><td style="vertical-align:bottom;width:44.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Options vested and exercisable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 386,062</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;margin:0pt;padding:0pt;"> 33.76 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"> 109,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;background:#cceeff;margin:0pt;padding:0pt;"> 6.4 </td></tr></table> . . The following table sets forth stock-based compensation expenses recorded during the respective periods: . <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:44.16%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:44.16%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.13%;margin:0pt;padding:0pt;"> For the Three Months Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.11%;margin:0pt;padding:0pt;"> For the Nine Months Ended </td></tr><tr><td style="vertical-align:bottom;width:44.16%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"> . </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p

style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td></tr><tr><td style="vertical-align:bottom;width:44.16%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:44.16%;background:#cceeff;margin:0pt;padding:0pt;"> Stock Compensation expenses: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:44.16%;margin:0pt;padding:0pt;"> Research and development </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"> 106,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"> 299,000 </td></tr><tr><td style="vertical-align:bottom;width:44.16%;background:#cceeff;margin:0pt;padding:0pt;"> General and administrative </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 50,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 69,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 182,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New

Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 416,000 </td></tr><tr><td style="vertical-align:bottom;width:44.16%;margin:0pt;padding:0pt;"> Stock compensation in continuing operations </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"> 53,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"> 175,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"> 195,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"> 715,000 </td></tr><tr><td style="vertical-align:bottom;width:44.16%;background:#cceeff;margin:0pt;padding:0pt;"> Stock compensation in discontinued operations </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 725,000 </td></tr><tr><td style="vertical-align:bottom;width:44.16%;margin:0pt;padding:0pt;"> Total stock compensation expenses </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 53,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 175,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 195,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,440,000 </td></tr></table> As of September 30, 2024, the total stock-based compensation cost related to unvested awards not yet recognized was $0.2 million. The expected weighted average period for compensation costs to be recognized was approximately 1.8 years. Future option grants will impact the compensation expense recognized. 0000 <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:44.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> <span style="font-

size:1pt;visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:44.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"> Weighted Average </td></tr><tr><td style="vertical-align:bottom;width:44.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"> Remaining </td></tr><tr><td style="vertical-align:bottom;width:44.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"> Weighted Average </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"> Contractual </td></tr><tr><td style="vertical-align:bottom;width:44.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Number of Shares </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Exercise Price </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New

Roman', 'Times', 'serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Total Intrinsic Value </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Life (in years) </td></tr><tr><td style="vertical-align:bottom;width:44.02%;background:#cceeff;margin:0pt;padding:0pt;"> Outstanding as of January 1, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#cceeff;margin:0pt;padding:0pt;"> 737,895 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', 'Times', 'serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 25.42</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', 'Times', 'serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', 'Times', 'serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"> 1,317,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;background:#cceeff;margin:0pt;padding:0pt;"> 7.6 </td></tr><tr><td style="vertical-align:bottom;width:44.02%;margin:0pt;padding:0pt;"> Exercised </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"> (23,892) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"> 2.45 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:44.02%;background:#cceeff;margin:0pt;padding:0pt;"> Canceled/Expired </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (117,670) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 43.37 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:44.02%;margin:0pt;padding:0pt;"> Outstanding as of September 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 596,333 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', 'Times', 'serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 22.80</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', 'Times', 'serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', 'Times', 'serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 291,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 7.1 </td></tr><tr><td style="vertical-align:bottom;width:44.02%;background:#cceeff;margin:0pt;padding:0pt;"> Options vested and exercisable </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', 'Times', 'serif';font-

size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 386,062 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 33.76</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"> 109,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;background:#cceeff;margin:0pt;padding:0pt;"> 6.4 </td></tr>
</table>73789525.421317000P7Y7M6D238922.4511767043.3759633322.80291000P7Y1M6D38606233.76109000P6Y4M24D <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:44.16%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:44.16%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.13%;margin:0pt;padding:0pt;"> For the Three Months Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.11%;margin:0pt;padding:0pt;"> For the Nine Months Ended </td></tr><tr><td style="vertical-align:bottom;width:44.16%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"> . </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td></tr><tr><td style="vertical-align:bottom;width:44.16%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New

Roman', 'Times', 'serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:44.16%;background:#cceeff;margin:0pt;padding:0pt;"> Stock Compensation expenses: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:44.16%;margin:0pt;padding:0pt;"> Research and development </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', 'Times', 'serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', 'Times', 'serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', 'Times', 'serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"> 106,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', 'Times', 'serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', 'Times', 'serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', 'Times', 'serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"> 299,000 </td></tr><tr><td style="vertical-align:bottom;width:44.16%;background:#cceeff;margin:0pt;padding:0pt;"> General and administrative </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 50,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 69,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 182,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 416,000 </td></tr><tr><td style="vertical-align:bottom;width:44.16%;margin:0pt;padding:0pt;"> Stock compensation in continuing operations </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"> 53,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"> 175,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-

space:nowrap;width:11.03%;margin:0pt;padding:0pt;"> 195,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"> 715,000 </td></tr><tr><td style="vertical-align:bottom;width:44.16%;background:#cceeff;margin:0pt;padding:0pt;"> Stock compensation in discontinued operations </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 725,000 </td></tr><tr><td style="vertical-align:bottom;width:44.16%;margin:0pt;padding:0pt;"> Total stock compensation expenses </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 53,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 175,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 195,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,440,000 </td></tr></table>3000106000130002990005000069000182000416000530001750001950007150007250005300017500019500014400002000000P1Y9M18D NOTE 11: GRANT INCOME CPRIT In August 2021, the Company received notice of a Product Development Research award totaling approximately $13.1 million from CPRIT to support the Company’s clinical investigation of MT-401. If restricted cash is received from grants in advance of incurring qualifying costs, it is recorded as deferred revenue and recognized as revenue when qualifying costs are incurred. There was no restricted cash recorded as of September 30, 2024, and December 31, 2023. If qualifying grant income is earned in advance of cash received from grants, it is recognized as revenue and recorded as other receivable. The Company recorded $0.9 million and $2.4 million of grant income related to the CPRIT grant as revenue for the three and nine months ended September 30, 2024, respectively. As of September 30, 2024, the Company recorded $0.1 million as other receivable, which represented grant income earned in advance of funds to be received from CPRIT. FDA In September 2022, the Company received notice from the FDA that it had awarded the Company a $2.0 million grant from the FDA’s Orphan Products Grant program to support the Company’s clinical investigation of MT-401 for the treatment of post-transplant AML. The Company recorded $0.02 million and $0.5 million of grant income related to the FDA grant as revenue for the three and nine months ended September 30, 2024, respectively. As of September 30, 2024, the Company recorded $0.02 million as other receivable, which represented grant income earned in advance of funds to be received from the FDA. In October 2024, the Company received $0.02 million of funds from the FDA grant. SBIR In May 2023, the Company announced it had received a $2.0 million grant from the National Institutes of Health Small Business Innovation Research program to support the development and investigation of MT-401 for the treatment of AML patients following standard-of-care therapy with hypomethylating agents. The Company recorded $0.3 million and $0.7 million of grant income related to this grant as revenue for the three and nine months ended September 30, 2024, respectively. As of September 30, 2024, the Company recorded $0.3 million as other receivable, which represented grant income earned in advance of funds to be received from the SBIR. In October 2024, the Company received $0.3 million of funds from the SBIR grant. In August 2024, the Company received notice of a $2.0 million grant from the National Institutes of Health Small Business Innovation Research Program to support the clinical investigation of MT-601 in patients with non-Hodgkin’s lymphoma (NHL) who have relapsed following anti-CD19 chimeric antigen receptor (CAR) T cell therapy. The Company recorded $0.7 million of grant income related to this grant as revenue for the three and nine months ended September 30, 2024. As of September 30, 2024, the Company recorded $0.3 million as other receivable, which represented grant income earned in advance of funds to be received from the SBIR. In October 2024, the Company received $0.3 million of funds from the SBIR lymphoma grant. <p style="font-family:'Times

New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">

* 131000000090000024000001000002000000.020000.0050000020000.0020000.002000000.03000007000003000003000002000000.0700000700*

style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">NOTE 12: LEGAL PROCEEDINGS From time to time, the Company may be party to ordinary, routine litigation incidental to their business. The Company knows of no material, active or pending legal proceedings against the Company, nor is the Company involved as a plaintiff in any material proceeding or pending litigation. There are no proceedings in which any of the Company's directors, officers or affiliates, or any registered or beneficial shareholder, is an adverse party or has a material interest adverse to the Company's interest. NOTE 13: RELATED PARTY EXPENSES The following table sets forth related party transaction expenses recorded for the three and nine months ended September 30, 2024 and 2023, respectively. <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:52.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:52.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.84%;margin:0pt;padding:0pt;"> For the Three Months Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.84%;margin:0pt;padding:0pt;"> For the Nine Months Ended </td></tr><tr><td style="vertical-align:bottom;width:52.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td></tr><tr><td style="vertical-align:bottom;width:52.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:middle;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:middle;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:middle;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:52.03%;background:#cceeff;margin:0pt;padding:0pt;"> Baylor College of Medicine </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-

size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"> 13,000 </td></tr><tr><td style="vertical-align:bottom;width:52.03%;margin:0pt;padding:0pt;"> Cell Ready </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"> 1,235,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"> 368,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"> 3,071,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"> 368,000 </td></tr><tr><td style="vertical-align:bottom;width:52.03%;background:#cceeff;margin:0pt;padding:0pt;"> Wilson Wolf Manufacturing Corporation </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 277,000 </td></tr><tr><td style="vertical-align:bottom;width:52.03%;margin:0pt;padding:0pt;"> Total Research and development </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,235,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 368,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,077,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 658,000 </td></tr></table>

$0.9 million of related party transactions are included in accounts payable and accrued liabilities as of September 30, 2024. See Note 8 for additional information. Agreements with The Baylor College of Medicine ("BCM") In November 2018, January 2020 and February 2020, the Company entered in Sponsored Research Agreements with BCM, which provided for the conduct of research for the Company by credentialed personnel at BCM's Center for Cell and Gene Therapy. In September 2019, May 2020 and July 2021, the Company entered into Clinical Supply Agreements with BCM, which provided for BCM to provide to the Company multi tumor antigen specific products. In October 2019, the Company entered in a Workforce Grant Agreement with BCM, which provided for BCM to provide to the Company manpower costs of projects for manufacturing, quality control testing and validation run activities. In August 2020, the Company entered into a Clinical Trial Agreement with BCM, which provided for BCM to provide to the Company investigator-initiated research studies. The Company has also entered into a Clinical Site Agreement with BCM, which provided for BCM to conduct clinical trials for the Company and is a part of continuing operations. BCM owns shares of the Company's common stock. Purchases from Wilson Wolf In 2023, the Company utilized Wilson Wolf for the purchases of cell culture devices called G-Rexes. Mr. John Wilson is a member of the Company's board of directors and is serving as the CEO of Wilson Wolf Manufacturing Corporation. Purchases from Cell Ready, LLC The Company is currently utilizing Cell Ready, LLC for its clinical manufacturing supply and product development. Mr. John Wilson is a member of the Company's board of directors and is serving as the CEO of Cell Ready, LLC. On February 22, 2024, we entered into a 3-year Master Services Agreement for Product Supply (the "MSA") with Cell Ready. Cell Ready, which is owned by one of our directors and shareholders, Mr. John Wilson, is a contract development and manufacturing organization (CDMO). Under the MSA, it is anticipated Cell Ready will perform a wide variety of services for us, including research and development, and manufacturing in support of our clinical trials. Pursuant to the MSA, the Company may contract with Cell Ready for the provision of various products and services from time to time by entering into work orders with Cell Ready. If the services involve the supply of product, Cell Ready is required to supply such product in conformance with the product requirements set forth in the applicable work order(s). Under the MSA, Cell Ready is to use only personnel with sufficient qualifications and experience to supply the services contemplated by the MSA, provide its personnel with adequate training and assume full responsibility for its personnel's compliance with the MSA. Further, Cell Ready is required to provide the Company with assistance and cooperation in order for the Company to obtain and maintain all necessary regulatory approvals, at the Company's expense. During the nine months ended September 30, 2024, the Company entered into Work Order #1 under the MSA, pursuant to which Cell Ready agreed to provide the Company with GMP drug product for Marker MT-401 and/or MT-601. The services include the delivery of final drug product and quality control testing. The Company also requested Cell Ready to provide general support services in connection therewith. During the three and nine months ended September 30, 2024, the Company incurred $1.2 million and $3.1 million, respectively, in expenses related to the services and manufacturing costs and paid $0.5 million and $3.4 million, respectively, for invoices received. Additional Work Orders are expected to be generated for the remainder of 2024. <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:52.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:52.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.84%;margin:0pt;padding:0pt;"> For the Three Months Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.84%;margin:0pt;padding:0pt;"> For the Nine Months Ended </td></tr><tr><td style="vertical-align:bottom;width:52.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td></tr><tr><td style="vertical-align:bottom;width:52.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:middle;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:middle;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:middle;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:52.03%;background:#cceeff;margin:0pt;padding:0pt;"> Baylor College of Medicine </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"> 13,000 </td></tr><tr><td style="vertical-align:bottom;width:52.03%;margin:0pt;padding:0pt;"> Cell Ready </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"> 1,235,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"> 368,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"> 3,071,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"> 368,000 </td></tr><tr><td style="vertical-align:bottom;width:52.03%;background:#cceeff;margin:0pt;padding:0pt;"> Wilson Wolf Manufacturing Corporation </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-

space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 277,000 </td></tr><tr><td style="vertical-align:bottom;width:52.03%;margin:0pt;padding:0pt;"> Total Research and development </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">1,235,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 368,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">3,077,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 658,000 </td></tr></table>600013000123500036800030710003680002770001235000368000307700065800090000012000003100000500000340000 NOTE 14: SUBSEQUENT EVENTS The Company has evaluated subsequent events and transactions that occurred up to the date unaudited condensed consolidated financial statements were issued. Based upon this review, the Company did not identify any subsequent events that would have required adjustment to or disclosure in the unaudited condensed consolidated financial statements. - falsefalsefalsefalse

!;5V)[F MJ'0X^/=73![,A,F#8?)@F#SXU9('SV;5G?S562WP4ZRMK:[N16F/1OR#41;5 M"K8O(]6&7LZ!-]\8MT21H;H'QDK -RKZ,

*'!6YW%6 M 5F=SU%% F%U)D?%A],!69W)604<\'R.*AH-CNH\CBH23@?2ZDS.*N" 9W-4 M0E@(6."7GM4'"W^_Z5,Z);BD/@"7T^[%F/H%F/0W7KH9=6;A\MU___/O_]? MXRT7R8'KZ7P4278@%&#-.;#F#0_ J;&6(V'-6\9W0%O'Z(Y[GD!ZW> ,".Y= MMEZ 2X$P^[@I\]D >0_2O :/+OV+R P*&=BN."2;P ALA7,@E#^#Z0861(!+ MGP:EP*X([(HSI;CS!%)@5P1VQ9D2W'GBTKE9&TTR%A4=%AA8& ')!!;&Z4+I M+\,ER=#PX?]]$[[].EY%SHD3O^CW^;1FX8',',C,9ZLSGR>8_C*N_9*